file,resp_json,data_found,reason,dossier_id,submission_no,date,product_name,medicinal_ingredients,reason_for_submission,species,drug_identification_number_route_form_strength,canadian_reference_product,manufacturer_name,manufacturer_street,manufacturer_city,manufacturer_province,manufacturer_country,manufacturer_postal_code,authorizing_official_name,authorizing_official_title,authorizing_official_division,authorizing_official_directorate
https://pdf.hres.ca/noc_pm/0000000243.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a 'FACT SHEET' for VELCADE detailing its use, mechanism, and indications, but it does not contain the structured Notice of Compliance (NOC) details required (e.g., dossier ID, submission number, manufacturer info, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official). The text only mentions 'Health Canada has approved VELCADE with conditions' under the NOC/c policy, but lacks the specific NOC data fields."",
  ""partial_data"": {}
}",FALSE,"The provided text is a 'FACT SHEET' for VELCADE detailing its use, mechanism, and indications, but it does not contain the structured Notice of Compliance (NOC) details required (e.g., dossier ID, submission number, manufacturer info, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official). The text only mentions 'Health Canada has approved VELCADE with conditions' under the NOC/c policy, but lacks the specific NOC data fields.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000000285.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text does not contain a complete Notice of Compliance (NOC) document with the required structured fields such as dossier_id, submission_no, manufacturer details, date, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, and authorizing_official. It contains only a letter announcing the conditional approval of VELCADE, but lacks the formal NOC details required by the schema."",
  ""partial_data"": {
    ""product_name"": ""VELCADE* (bortezomib mannitol boronic ester) for Injection"",
    ""reason_for_submission"": ""for the treatment of multiple myeloma patients who have relapsed following front-line therapy and are refractory to their most recent therapy"",
    ""species"": ""human"",
    ""date"": ""December 17, 2004"",
    ""manufacturer"": {
      ""name"": ""Janssen-Ortho Inc."",
      ""street"": """",
      ""city"": """",
      ""province"": """",
      ""country"": """",
      ""postal_code"": """"
    },
    ""drug_identification_number_route_form_strength"": """",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": """",
      ""title"": """",
      ""division"": """",
      ""directorate"": """"
    }
  }
}",FALSE,"The provided text does not contain a complete Notice of Compliance (NOC) document with the required structured fields such as dossier_id, submission_no, manufacturer details, date, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, and authorizing_official. It contains only a letter announcing the conditional approval of VELCADE, but lacks the formal NOC details required by the schema.",NA,NA,"December 17, 2004",VELCADE* (bortezomib mannitol boronic ester) for Injection,NA,for the treatment of multiple myeloma patients who have relapsed following front-line therapy and are refractory to their most recent therapy,human,,,Janssen-Ortho Inc.,,,,,,,,,
https://pdf.hres.ca/noc_pm/0000000301.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a fact sheet describing the conditional approval of FEMARA for extended adjuvant therapy, but it does not contain the structured notice of compliance details required (e.g., dossier ID, submission number, manufacturer address, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official). The document lacks the specific regulatory form fields needed to populate the requested JSON schema."",
  ""partial_data"": {}
}",FALSE,"The provided text is a fact sheet describing the conditional approval of FEMARA for extended adjuvant therapy, but it does not contain the structured notice of compliance details required (e.g., dossier ID, submission number, manufacturer address, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official). The document lacks the specific regulatory form fields needed to populate the requested JSON schema.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000000354.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a 'SOMMAIRE DES MOTIFS DE DÉCISION (SMD)' which is a summary of decision rationale, not a Notice of Compliance (NOC). It does not contain the required NOC details such as dossier ID, submission number, manufacturer address, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official information."",
  ""partial_data"": {}
}",FALSE,"The provided text is a 'SOMMAIRE DES MOTIFS DE DÉCISION (SMD)' which is a summary of decision rationale, not a Notice of Compliance (NOC). It does not contain the required NOC details such as dossier ID, submission number, manufacturer address, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official information.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000000357.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text does not contain a complete Notice of Compliance (NOC) document. It only references the NOC (issued March 31, 2005) and includes a Consumer Information Section (Part III) of a Product Monograph. The NOC details such as dossier ID, submission number, manufacturer address, authorizing official, and drug identification number are not present in the text."",
  ""partial_data"": {
    ""dossier_id"": """",
    ""submission_no"": ""087818"",
    ""manufacturer"": {
      ""name"": ""Abbott Laboratories Ltd."",
      ""street"": """",
      ""city"": """",
      ""province"": """",
      ""country"": """",
      ""postal_code"": """"
    },
    ""date"": ""March 31, 2005"",
    ""product_name"": ""ZEMPLAR*"",
    ""medicinal_ingredients"": ""Paricalcitol"",
    ""reason_for_submission"": """",
    ""species"": """",
    ""drug_identification_number_route_form_strength"": ""5 mcg/mL, solution"",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": """",
      ""title"": """",
      ""division"": """",
      ""directorate"": """"
    }
  }
}",FALSE,"The provided text does not contain a complete Notice of Compliance (NOC) document. It only references the NOC (issued March 31, 2005) and includes a Consumer Information Section (Part III) of a Product Monograph. The NOC details such as dossier ID, submission number, manufacturer address, authorizing official, and drug identification number are not present in the text.",,087818,"March 31, 2005",ZEMPLAR*,Paricalcitol,,,"5 mcg/mL, solution",,Abbott Laboratories Ltd.,,,,,,,,,
https://pdf.hres.ca/noc_pm/0000000644.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a consumer information section (part III of the product monograph) for the drug XYREMMD. It does not contain the full Notice of Compliance (NOC) details required by the schema, such as dossier ID, submission number, manufacturer address, date of authorization, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official information. It only states that this version was issued with an NOC dated August 5, 2005, but lacks the specific fields needed to populate the required JSON structure."",
  ""partial_data"": {
    ""product_name"": ""XYREMMD"",
    ""medicinal_ingredients"": ""Oxybate de sodium"",
    ""route_form_strength"": ""500 mg/mL, solution orale"",
    ""date"": ""5 août 2005"",
    ""manufacturer"": {
      ""name"": ""Orphan Medical, Inc.""
    },
    ""drug_identification_number_route_form_strength"": ""N° contrôle de la présentation 088659""
  }
}",FALSE,"The provided text is a consumer information section (part III of the product monograph) for the drug XYREMMD. It does not contain the full Notice of Compliance (NOC) details required by the schema, such as dossier ID, submission number, manufacturer address, date of authorization, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official information. It only states that this version was issued with an NOC dated August 5, 2005, but lacks the specific fields needed to populate the required JSON structure.",NA,NA,5 août 2005,XYREMMD,Oxybate de sodium,NA,NA,N° contrôle de la présentation 088659,NA,"Orphan Medical, Inc.",NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000000722.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""102240"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Shire BioChem Inc."",
    ""street"": """",
    ""city"": """",
    ""province"": """",
    ""country"": ""Canada"",
    ""postal_code"": """"
  },
  ""date"": ""February 19, 2007"",
  ""product_name"": ""FOSRENOL™"",
  ""medicinal_ingredients"": ""lanthanum carbonate hydrate"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""Lanthanum carbonate hydrate, 250 mg, 500 mg, 750 mg, 1000 mg tablets"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,102240,,"February 19, 2007",FOSRENOL™,lanthanum carbonate hydrate,,,"Lanthanum carbonate hydrate, 250 mg, 500 mg, 750 mg, 1000 mg tablets",,Shire BioChem Inc.,,,,Canada,,,,,
https://pdf.hres.ca/noc_pm/0000000821.PDF,"{
  ""data_found"": false,
  ""reason"": ""The document is an 'AVIS D'ADMISSIBILITÉ' (Notice of Admissibility) under Canada's conditional approval policy, not a final 'AVIS DE CONFORMITÉ AVEC CONDITIONS' (Notice of Compliance). It does not contain a final approval or compliance notice, but rather a preliminary determination that the application is admissible for further review under conditional approval. No final compliance details (e.g., dossier ID, submission number, product name with full formulation, drug identification number, authorizing official, etc.) are present in this page."",
  ""partial_data"": {
    ""date"": ""7 juin 2007"",
    ""product_name"": ""SATIVEX® (delta-9-tétrahydrocannabinol [de Tetranabinex® − extrait de Cannabis sativa L.] et cannabidiol [de Nabidiolex® − extrait de Cannabis sativa L.], vaporisateur buccal)"",
    ""drug_identification_number_route_form_strength"": ""109461"",
    ""species"": ""adultes atteints de cancer avancé"",
    ""reason_for_submission"": ""traitement analgésique d’appoint des adultes atteints de cancer avancé qui présentent une douleur modérée ou grave pendant un puissant traitement opioïde administré à la plus forte dose tolérée contre une douleur de fond persistante"",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": ""[nom de l’employé enlevé]"",
      ""title"": ""Directrice de la réglementation"",
      ""division"": ""Produits thérapeutiques"",
      ""directorate"": """"
    },
    ""manufacturer"": {
      ""name"": ""GW Pharmaceuticals Ltd."",
      ""street"": ""Porton Down Science Park"",
      ""city"": ""Salisbury"",
      ""province"": ""Wiltshire"",
      ""country"": ""Royaume-Uni"",
      ""postal_code"": ""SP4 0JQ""
    },
    ""dossier_id"": ""9427-G0846/1-21"",
    ""submission_no"": """"
  }
}",FALSE,"The document is an 'AVIS D'ADMISSIBILITÉ' (Notice of Admissibility) under Canada's conditional approval policy, not a final 'AVIS DE CONFORMITÉ AVEC CONDITIONS' (Notice of Compliance). It does not contain a final approval or compliance notice, but rather a preliminary determination that the application is admissible for further review under conditional approval. No final compliance details (e.g., dossier ID, submission number, product name with full formulation, drug identification number, authorizing official, etc.) are present in this page.",9427-G0846/1-21,,7 juin 2007,"SATIVEX® (delta-9-tétrahydrocannabinol [de Tetranabinex® − extrait de Cannabis sativa L.] et cannabidiol [de Nabidiolex® − extrait de Cannabis sativa L.], vaporisateur buccal)",NA,traitement analgésique d’appoint des adultes atteints de cancer avancé qui présentent une douleur modérée ou grave pendant un puissant traitement opioïde administré à la plus forte dose tolérée contre une douleur de fond persistante,adultes atteints de cancer avancé,109461,,GW Pharmaceuticals Ltd.,Porton Down Science Park,Salisbury,Wiltshire,Royaume-Uni,SP4 0JQ,[nom de l’employé enlevé],Directrice de la réglementation,Produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000000867.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text contains consumer information and a disclaimer about the notice of compliance (NOC) date (June 3, 2005), but it does not contain the structured NOC details required in the schema (e.g., dossier_id, submission_no, manufacturer address, date, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, authorizing_official). The text only states that this consumer information was attached to an NOC, not the NOC itself."",
  ""partial_data"": {
    ""product_name"": ""LYRICA*"",
    ""medicinal_ingredients"": ""Prégabaline"",
    ""drug_identification_number_route_form_strength"": ""25, 50, 75, 100, 150, 200, 225, 300 mg de prégabaline, capsules"",
    ""manufacturer"": {
      ""name"": ""Pfizer Canada Inc."",
      ""street"": """",
      ""city"": """",
      ""province"": """",
      ""country"": """",
      ""postal_code"": """"
    },
    ""date"": ""3 juin 2005"",
    ""reason_for_submission"": """",
    ""species"": """",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": """",
      ""title"": """",
      ""division"": """",
      ""directorate"": """"
    }
  }
}",FALSE,"The provided text contains consumer information and a disclaimer about the notice of compliance (NOC) date (June 3, 2005), but it does not contain the structured NOC details required in the schema (e.g., dossier_id, submission_no, manufacturer address, date, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, authorizing_official). The text only states that this consumer information was attached to an NOC, not the NOC itself.",NA,NA,3 juin 2005,LYRICA*,Prégabaline,,,"25, 50, 75, 100, 150, 200, 225, 300 mg de prégabaline, capsules",,Pfizer Canada Inc.,,,,,,,,,
https://pdf.hres.ca/noc_pm/0000000969.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a Consumer Information section of a Product Monograph, not a Notice of Compliance document. It references the NOC but does not contain the required structured fields (e.g., dossier_id, manufacturer details, date, product_name, medicinal_ingredients, etc.) needed to extract NOC details."",
  ""partial_data"": {
    ""product_name"": ""PrEMEND™ Aprepitant 80 mg and 125 mg, capsules"",
    ""manufacturer"": {
      ""name"": ""Merck Frosst Canada Ltd.""
    },
    ""date"": ""August 20, 2007"",
    ""submission_no"": ""108483""
  }
}",FALSE,"The provided text is a Consumer Information section of a Product Monograph, not a Notice of Compliance document. It references the NOC but does not contain the required structured fields (e.g., dossier_id, manufacturer details, date, product_name, medicinal_ingredients, etc.) needed to extract NOC details.",NA,108483,"August 20, 2007","PrEMEND™ Aprepitant 80 mg and 125 mg, capsules",NA,NA,NA,NA,NA,Merck Frosst Canada Ltd.,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000001034.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a product information sheet (FICHE DE RENSEIGNEMENTS) for VECTIBIXMC, which is an authorization with conditions (AC-C) from Health Canada. However, it does not contain the specific structured notice of compliance details such as dossier ID, submission number, manufacturer information, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official. The text describes the product and its authorization but lacks the required compliance data fields."",
  ""partial_data"": {
    ""product_name"": ""VECTIBIXMC"",
    ""medicinal_ingredients"": ""panitumumab (20 mg/mL), chlorure de sodium, acétate de sodium trihydraté, acide acétique (glacial), eau pour les injections"",
    ""reason_for_submission"": ""Based on promising clinical efficacy data, which require further verification and studies. The product has demonstrated promising benefit, is of high quality, and has an acceptable safety profile, based on risk-benefit assessment."",
    ""species"": ""Human"",
    ""drug_identification_number_route_form_strength"": ""20 mg/mL de concentré pour solution pour perfusion (panitumumab)"",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": ""Santé Canada"",
      ""title"": ""Health Canada"",
      ""division"": """",
      ""directorate"": """"
    }
  }
}",FALSE,"The provided text is a product information sheet (FICHE DE RENSEIGNEMENTS) for VECTIBIXMC, which is an authorization with conditions (AC-C) from Health Canada. However, it does not contain the specific structured notice of compliance details such as dossier ID, submission number, manufacturer information, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official. The text describes the product and its authorization but lacks the required compliance data fields.",NA,NA,NA,VECTIBIXMC,"panitumumab (20 mg/mL), chlorure de sodium, acétate de sodium trihydraté, acide acétique (glacial), eau pour les injections","Based on promising clinical efficacy data, which require further verification and studies. The product has demonstrated promising benefit, is of high quality, and has an acceptable safety profile, based on risk-benefit assessment.",Human,20 mg/mL de concentré pour solution pour perfusion (panitumumab),,NA,NA,NA,NA,NA,NA,Santé Canada,Health Canada,,
https://pdf.hres.ca/noc_pm/0000001050.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is consumer information (part III of the product monograph) and does not contain the full Notice of Compliance (NOC) details required. It references an NOC issued on August 27, 2007, but does not include the required fields such as dossier_id, submission_no, manufacturer address, date, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, or authorizing_official. The text is insufficient to extract a complete NOC record."",
  ""partial_data"": {
    ""product_name"": ""ZELDOX*"",
    ""medicinal_ingredients"": ""chlorhydrate de ziprasidone monohydraté"",
    ""strength"": ""20, 40, 60 et 80 mg/capsule"",
    ""manufacturer"": {
      ""name"": ""Pfizer Canada Inc.""
    },
    ""date"": ""27 août 2007"",
    ""drug_identification_number_route_form_strength"": ""N° de contrôle de la présentation 078188"",
    ""reason_for_submission"": ""Renseignements pour le consommateur (partie III) de la monographie de produit ZELDOX""
  }
}",FALSE,"The provided text is consumer information (part III of the product monograph) and does not contain the full Notice of Compliance (NOC) details required. It references an NOC issued on August 27, 2007, but does not include the required fields such as dossier_id, submission_no, manufacturer address, date, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, or authorizing_official. The text is insufficient to extract a complete NOC record.",NA,NA,27 août 2007,ZELDOX*,chlorhydrate de ziprasidone monohydraté,Renseignements pour le consommateur (partie III) de la monographie de produit ZELDOX,NA,N° de contrôle de la présentation 078188,NA,Pfizer Canada Inc.,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000001260.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text contains consumer information and a disclaimer about the notice of compliance, but does not include the structured notice of compliance details (e.g., dossier ID, submission number, manufacturer address, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official). The only date mentioned (28 octobre 2008) is referenced as the date the notice was issued, but no other required fields are present."",
  ""partial_data"": {
    ""date"": ""28 octobre 2008"",
    ""product_name"": ""OLMETECMD olmésartan médoxomil 5, 20 et 40 mg comprimés"",
    ""manufacturer"": {
      ""name"": ""Schering-Plough Canada Inc.""
    }
  }
}",FALSE,"The provided text contains consumer information and a disclaimer about the notice of compliance, but does not include the structured notice of compliance details (e.g., dossier ID, submission number, manufacturer address, date, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, or authorizing official). The only date mentioned (28 octobre 2008) is referenced as the date the notice was issued, but no other required fields are present.",NA,NA,28 octobre 2008,"OLMETECMD olmésartan médoxomil 5, 20 et 40 mg comprimés",NA,NA,NA,NA,NA,Schering-Plough Canada Inc.,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000001281.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""110853"",
  ""submission_no"": ""9427-G0588/1-25"",
  ""manufacturer"": {
    ""name"": ""Galderma Canada Inc."",
    ""street"": ""105 Commerce Valley Drive West"",
    ""city"": ""Thornhill"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""L3T 7W3""
  },
  ""date"": ""FEB 26 2009"",
  ""product_name"": ""METVIX"",
  ""medicinal_ingredients"": ""methyl aminoolevulinate (supplied as methyl aminoolevulinate hydrochloride)"",
  ""reason_for_submission"": ""Antineoplastic agent"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02232373, Topical, Cream, 168mg/g"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,110853,9427-G0588/1-25,FEB 26 2009,METVIX,methyl aminoolevulinate (supplied as methyl aminoolevulinate hydrochloride),Antineoplastic agent,,"02232373, Topical, Cream, 168mg/g",,Galderma Canada Inc.,105 Commerce Valley Drive West,Thornhill,Ontario,,L3T 7W3,"Supriya Sharma, MD MPH FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000001316.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9460-N0766-020,-521,-522,-523"",
  ""submission_no"": ""2006081A, 2006082A, 2006083A, 2006084A"",
  ""manufacturer"": {
    ""name"": ""Notbrook Laboratories Ltd."",
    ""street"": ""Station Works"",
    ""city"": ""Carrigleagh Road"",
    ""province"": ""Northern Ireland"",
    ""country"": ""BT35 6JP"",
    ""postal_code"": """"
  },
  ""date"": ""March 13, 2009"",
  ""product_name"": ""Norocob"",
  ""medicinal_ingredients"": ""Amoxicillin (as amoxicillin trihydrate) 100 mg/tab. Clavulanate acid (as clavulanate potassium) 50 mg/tab"",
  ""reason_for_submission"": """",
  ""species"": ""Cats (82.5 mg only), dogs (62.5 mg, 125 mg, 250 mg, 375 mg)"",
  ""drug_identification_number_route_form_strength"": ""02323850, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 50 mg/tab. Clavulanate acid (as clavulanate potassium) 12.5 mg/tab 02323899, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 100 mg/tab. Clavulanate acid (as clavulanate potassium) 25 mg/tab 02323877, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 200 mg/tab. Clavulanate acid (as clavulanate potassium) 50 mg/tab 02323893, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 300 mg/tab. Clavulanate acid (as clavulanate potassium) 75 mg/tab"",
  ""canadian_reference_product"": ""Clavimax Tablets, Pfizer Canada Inc., Animal Health Group, Canada"",
  ""authorizing_official"": {
    ""name"": ""D. Ian Alexander, DVM, PhD"",
    ""title"": ""ADirector General, Veterinary Drugs Directorate"",
    ""division"": ""Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,"9460-N0766-020,-521,-522,-523","2006081A, 2006082A, 2006083A, 2006084A","March 13, 2009",Norocob,Amoxicillin (as amoxicillin trihydrate) 100 mg/tab. Clavulanate acid (as clavulanate potassium) 50 mg/tab,,"Cats (82.5 mg only), dogs (62.5 mg, 125 mg, 250 mg, 375 mg)","02323850, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 50 mg/tab. Clavulanate acid (as clavulanate potassium) 12.5 mg/tab 02323899, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 100 mg/tab. Clavulanate acid (as clavulanate potassium) 25 mg/tab 02323877, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 200 mg/tab. Clavulanate acid (as clavulanate potassium) 50 mg/tab 02323893, Oral, Tablet, Amoxicillin (as amoxicillin trihydrate) 300 mg/tab. Clavulanate acid (as clavulanate potassium) 75 mg/tab","Clavimax Tablets, Pfizer Canada Inc., Animal Health Group, Canada",Notbrook Laboratories Ltd.,Station Works,Carrigleagh Road,Northern Ireland,BT35 6JP,,"D. Ian Alexander, DVM, PhD","ADirector General, Veterinary Drugs Directorate",Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000001517.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""130072"",
  ""submission_no"": ""130072"",
  ""manufacturer"": {
    ""name"": ""Paldit Labs Inc."",
    ""street"": ""611 Royalmount Ave."",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""JUN 0 3 2009"",
  ""product_name"": ""LOCACORTEN VIOFORM EARDROPS"",
  ""medicinal_ingredients"": ""Flumethasone Pivalate / Clioquinol"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00074454 (OT DPS, Flumethasone Pivalate 0.02% / Clioquinol 1%)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,130072,130072,JUN 0 3 2009,LOCACORTEN VIOFORM EARDROPS,Flumethasone Pivalate / Clioquinol,Manufacturer Name Change,,"00074454 (OT DPS, Flumethasone Pivalate 0.02% / Clioquinol 1%)",,Paldit Labs Inc.,611 Royalmount Ave.,Montreal,PQ,Canada,H4P 2T4,Supriya Sharma,Director General / Directrice générale,Therapeutic Products,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000001527.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""120534"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Shire Canada Inc."",
    ""street"": """",
    ""city"": """",
    ""province"": """",
    ""country"": ""Canada"",
    ""postal_code"": """"
  },
  ""date"": ""18 mars 2009"",
  ""product_name"": ""VYVANSEMC"",
  ""medicinal_ingredients"": ""dimésylate de lisdexamfétamine"",
  ""reason_for_submission"": ""traitement du trouble déficitaire de l’attention (TDAH) chez les enfants de 6 à 12 ans"",
  ""species"": ""enfants de 6 à 12 ans"",
  ""drug_identification_number_route_form_strength"": ""Dimésylate de lisdexamfétamine, 30 mg et 50 mg, capsules"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Santé Canada"",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,120534,,18 mars 2009,VYVANSEMC,dimésylate de lisdexamfétamine,traitement du trouble déficitaire de l’attention (TDAH) chez les enfants de 6 à 12 ans,enfants de 6 à 12 ans,"Dimésylate de lisdexamfétamine, 30 mg et 50 mg, capsules",,Shire Canada Inc.,,,,Canada,,Santé Canada,,,
https://pdf.hres.ca/noc_pm/0000001624.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""942-M25621-35"",
  ""submission_no"": ""129658"",
  ""manufacturer"": {
    ""name"": ""Mylan Pharmaceuticals LLC"",
    ""street"": ""85 Advance Rd"",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9Z 2S6""
  },
  ""date"": ""JUN 2 9 2009"",
  ""product_name"": ""MYLAN-BECLO AQ"",
  ""medicinal_ingredients"": ""Beclomethasone Dipropionate"",
  ""reason_for_submission"": ""Corticosteroid for Nasal Use"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""G2172712 (NAS,AEM,SUS, 50 mcg/ACT)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara Benning"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,942-M25621-35,129658,JUN 2 9 2009,MYLAN-BECLO AQ,Beclomethasone Dipropionate,Corticosteroid for Nasal Use,,"G2172712 (NAS,AEM,SUS, 50 mcg/ACT)",,Mylan Pharmaceuticals LLC,85 Advance Rd,Etobicoke,ON,Canada,M9Z 2S6,Barbara Benning,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000001663.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""130811"",
  ""submission_no"": ""9427-M2552/1-93"",
  ""manufacturer"": {
    ""name"": ""Mylan Pharmaceuticals ULC"",
    ""street"": ""65 Advance Rd."",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9W 2S6""
  },
  ""date"": ""JUL 0 8 2009"",
  ""product_name"": ""MYLAN-ETIDRONATE"",
  ""medicinal_ingredients"": ""Etidronate Disodium"",
  ""reason_for_submission"": ""Manufacturer and Product Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02245330 (ORL_TAB, 200 mg)"",
  ""canadian_reference_product"": ""Didronel, Proder & Gamble Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,130811,9427-M2552/1-93,JUL 0 8 2009,MYLAN-ETIDRONATE,Etidronate Disodium,Manufacturer and Product Name Change,,"02245330 (ORL_TAB, 200 mg)","Didronel, Proder & Gamble Pharmaceuticals Canada Inc., Canada",Mylan Pharmaceuticals ULC,65 Advance Rd.,Etobicoke,ON,Canada,M9W 2S6,Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000001689.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""089371"",
  ""submission_no"": ""089371"",
  ""manufacturer"": {
    ""name"": ""ratiopharm inc."",
    ""street"": ""17 800 rue Lapicque"",
    ""city"": ""MIRABEL"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7J 1P3""
  },
  ""date"": ""JUL 0 9 2009"",
  ""product_name"": ""RATIO-AMLODIPINE"",
  ""medicinal_ingredients"": ""Amlodipine (supplied as amlodipine besylate)"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02259606 - ORL, TAB, 5mg 02259613 - ORL, TAB, 10mg"",
  ""canadian_reference_product"": ""Norvasc, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,089371,089371,JUL 0 9 2009,RATIO-AMLODIPINE,Amlodipine (supplied as amlodipine besylate),"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"02259606 - ORL, TAB, 5mg 02259613 - ORL, TAB, 10mg","Norvasc, Pfizer Canada Inc., Canada",ratiopharm inc.,17 800 rue Lapicque,MIRABEL,Quebec,Canada,J7J 1P3,"Supriya Sharma, MD MPH FRCP(C)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000001694.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""124448"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Bayer Inc."",
    ""street"": ""77 Bellfield Road"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8W 1G6""
  },
  ""date"": ""JUL 6 7 2009"",
  ""product_name"": ""KOGENATE® FS"",
  ""medicinal_ingredients"": ""Antihemophilic Factor (Recombinant) / Facteur antihémophiliq (Recombina)"",
  ""reason_for_submission"": ""Revision to Product Monograph / Révision à la Monographie du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Lyophilized Powder for Injection, 250 IU/vial / N/A, Intravenous, Lyophilized Powder for Injection, 500 IU/vial / N/A, Intravenous, Lyophilized Powder for Injection, 1000 IU/vial / N/A, Intravenous, Lyophilized Powder for Injection, 2000 IU/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Ewyn Griffith"",
    ""title"": ""Director-General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,124448,,JUL 6 7 2009,KOGENATE® FS,Antihemophilic Factor (Recombinant) / Facteur antihémophiliq (Recombina),Revision to Product Monograph / Révision à la Monographie du produit,,"N/A, Intravenous, Lyophilized Powder for Injection, 250 IU/vial / N/A, Intravenous, Lyophilized Powder for Injection, 500 IU/vial / N/A, Intravenous, Lyophilized Powder for Injection, 1000 IU/vial / N/A, Intravenous, Lyophilized Powder for Injection, 2000 IU/vial",,Bayer Inc.,77 Bellfield Road,Toronto,ON,Canada,M8W 1G6,Ewyn Griffith,Director-General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,NA
https://pdf.hres.ca/noc_pm/0000001957.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-P1912-90"",
  ""submission_no"": ""129774"",
  ""manufacturer"": {
    ""name"": ""ProDac Ltée"",
    ""street"": ""2925 boul Industriel"",
    ""city"": ""Laval PQ"",
    ""province"": ""H7L 3W9"",
    ""country"": """",
    ""postal_code"": """"
  },
  ""date"": ""SEP 2 2 2009"",
  ""product_name"": ""AMOXI-CLAV"",
  ""medicinal_ingredients"": ""Amoxicillin supplied as Amoxicillin Trihydrate / Clavulanic Acid supplied as Potassium Clavulanate"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02328507 (ORL,TAB, Amoxicillin 250mg / Clavulanic Acid 125 mg) 02328515 (ORL,TAB, Amoxicillin 500 mg / Clavulanic Acid 125 mg) 02328523 (ORL,TAB, Amoxicillin 875 mg / Clavulanic Acid 125 mg)"",
  ""canadian_reference_product"": ""Clavulin, SmithKline Beecham Pharma, Division of SmithKline Beecham Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-P1912-90,129774,SEP 2 2 2009,AMOXI-CLAV,Amoxicillin supplied as Amoxicillin Trihydrate / Clavulanic Acid supplied as Potassium Clavulanate,New Manufacturer and Product Name,,"02328507 (ORL,TAB, Amoxicillin 250mg / Clavulanic Acid 125 mg) 02328515 (ORL,TAB, Amoxicillin 500 mg / Clavulanic Acid 125 mg) 02328523 (ORL,TAB, Amoxicillin 875 mg / Clavulanic Acid 125 mg)","Clavulin, SmithKline Beecham Pharma, Division of SmithKline Beecham Inc., Canada",ProDac Ltée,2925 boul Industriel,Laval PQ,H7L 3W9,,,Dr. Supriya Sharma,Director General / Direction générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000002012.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-M2283/1-22"",
  ""submission_no"": ""132913"",
  ""manufacturer"": {
    ""name"": ""MIV Therapeutics Inc."",
    ""street"": ""6111 Royalmount Ave,"",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""OCT 5 2009"",
  ""product_name"": ""AVENTYL"",
  ""medicinal_ingredients"": ""Nortriptyline supplied as Nortriptyline Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00015229 (ORL,CAP, 10 mg) 00015237 (ORL,CAP, 25 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPH FRCPC"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-M2283/1-22,132913,OCT 5 2009,AVENTYL,Nortriptyline supplied as Nortriptyline Hydrochloride,Manufacturer Name Change,,"00015229 (ORL,CAP, 10 mg) 00015237 (ORL,CAP, 25 mg)",,MIV Therapeutics Inc.,"6111 Royalmount Ave,",Montreal,PQ,Canada,H4P 2T4,Supriya Sharma MD MPH FRCPC,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000002087.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""133073"",
  ""submission_no"": ""133073"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Jules-Léger"",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 7K8""
  },
  ""date"": ""OCT 2 1 2009"",
  ""product_name"": ""CIPROFLOXACIN"",
  ""medicinal_ingredients"": ""Ciprofloxacin supplied as Ciprofloxacin Hydrochloride"",
  ""reason_for_submission"": ""Additional Product Name"",
  ""species"": ""Antibacterial Agent"",
  ""drug_identification_number_route_form_strength"": ""02335352 (ORL,TAB, 250 mg) 02335380 (ORL,TAB, 600 mg) 02335379 (ORL,TAB, 750 mg)"",
  ""canadian_reference_product"": ""Ciproby, Bayer AG, Germany"",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Direcctrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,133073,133073,OCT 2 1 2009,CIPROFLOXACIN,Ciprofloxacin supplied as Ciprofloxacin Hydrochloride,Additional Product Name,Antibacterial Agent,"02335352 (ORL,TAB, 250 mg) 02335380 (ORL,TAB, 600 mg) 02335379 (ORL,TAB, 750 mg)","Ciproby, Bayer AG, Germany",Sandoz Canada Inc.,145 Jules-Léger,Boucherville,QC,Canada,J4B 7K8,Dr. SUPRIYA SHARMA,Director General / Direcctrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000002092.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-J0559/4-25"",
  ""submission_no"": ""131627"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1380 Newton, Unit 203"",
    ""city"": ""Boucherville"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 6H2""
  },
  ""date"": ""21 SEP. 2009"",
  ""product_name"": ""JAMP-AMLODIPINE"",
  ""medicinal_ingredients"": ""Amlodipine supplied as Amlodipine Besylate"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02331071 (CRl, TAB, 5 mg) 02331058 (CRl, TAB, 10 mg)"",
  ""canadian_reference_product"": ""Novasc, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-J0559/4-25,131627,21 SEP. 2009,JAMP-AMLODIPINE,Amlodipine supplied as Amlodipine Besylate,New Manufacturer and Product Name,,"02331071 (CRl, TAB, 5 mg) 02331058 (CRl, TAB, 10 mg)","Novasc, Pfizer Canada Inc., Canada",JAMP Pharma Corporation,"1380 Newton, Unit 203",Boucherville,PQ,Canada,J4B 6H2,Dr. SUPRIYA SHARMA,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000002133.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""120462"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""EUSA Pharma SAS"",
    ""street"": ""Les jardins d'Éole"",
    ""city"": ""Limanest"",
    ""province"": """",
    ""country"": ""FRANCE"",
    ""postal_code"": ""99700""
  },
  ""date"": ""APR 17 2003"",
  ""product_name"": ""KIDROLASE"",
  ""medicinal_ingredients"": ""Asparaginase"",
  ""reason_for_submission"": ""Manufacturer Name Change / Changement dans le nom d'un fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01926438 (IM,IV,PWSO, 10000 Unit/Vial)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Elwyn Griffiths"",
    ""title"": ""ADirector General / Directeur général par intérim"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,120462,,APR 17 2003,KIDROLASE,Asparaginase,Manufacturer Name Change / Changement dans le nom d'un fabricant,,"01926438 (IM,IV,PWSO, 10000 Unit/Vial)",,EUSA Pharma SAS,Les jardins d'Éole,Limanest,,FRANCE,99700,Elwyn Griffiths,ADirector General / Directeur général par intérim,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000002162.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""121722"",
  ""submission_no"": ""121722"",
  ""manufacturer"": {
    ""name"": ""Novopharm Ltd."",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K3""
  },
  ""date"": ""JUN 03 2008"",
  ""product_name"": ""NOVO-BENZYDAMINE"",
  ""medicinal_ingredients"": ""Benzylamine Hydrochloride"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": ""Local Anaesthetic"",
  ""drug_identification_number_route_form_strength"": ""02310422 (BUC, ORL, MWH, SOL, 1.5 mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPH FRCPC"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": """"
  }
}",TRUE,NA,121722,121722,JUN 03 2008,NOVO-BENZYDAMINE,Benzylamine Hydrochloride,New Manufacturer and Product Name,Local Anaesthetic,"02310422 (BUC, ORL, MWH, SOL, 1.5 mg/mL)",,Novopharm Ltd.,30 Novopharm Court,Toronto,ON,Canada,M1B 2K3,Supriya Sharma MD MPH FRCPC,Director General / Direction générale,Therapeutic Products Directorate,
https://pdf.hres.ca/noc_pm/0000002296.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-92403-205"",
  ""submission_no"": ""105535"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Luke-Légar"",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 7K8""
  },
  ""date"": ""JUN 06 2008"",
  ""product_name"": ""SANDOZ CLARITHROMYCIN"",
  ""medicinal_ingredients"": ""Clarithromycin"",
  ""reason_for_submission"": ""New manufacturer and product name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02266539 (ORL, TAB, 250mg) 02266547 (ORL, TAB, 500mg)"",
  ""canadian_reference_product"": ""Biaxin BID, Abbott Laboratories, Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-92403-205,105535,JUN 06 2008,SANDOZ CLARITHROMYCIN,Clarithromycin,New manufacturer and product name,,"02266539 (ORL, TAB, 250mg) 02266547 (ORL, TAB, 500mg)","Biaxin BID, Abbott Laboratories, Canada",Sandoz Canada Inc.,145 Luke-Légar,Boucherville,QC,Canada,J4B 7K8,Supriya Sharma,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000002390.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""114887"",
  ""submission_no"": ""114887"",
  ""manufacturer"": {
    ""name"": ""Boehringer Ingelheim (Canada) Ltd."",
    ""street"": ""5190 South Service Road"",
    ""city"": ""Burlington"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""L7L 6H4""
  },
  ""date"": ""Cleared June 10, 2008"",
  ""product_name"": ""Pradaxa"",
  ""medicinal_ingredients"": ""dabigatran etexilate (supplied as dabigatran etexilate mesilate)"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02312433, Oral, Capsule, 75 mg; 02312441, Oral, Capsule, 110 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": """"
  }
}",TRUE,NA,114887,114887,"Cleared June 10, 2008",Pradaxa,dabigatran etexilate (supplied as dabigatran etexilate mesilate),,,"02312433, Oral, Capsule, 75 mg; 02312441, Oral, Capsule, 110 mg",,Boehringer Ingelheim (Canada) Ltd.,5190 South Service Road,Burlington,Ontario,,L7L 6H4,"Supriya Sharma, MD MPH FRCP(C)",Director General,Therapeutic Products Directorate,
https://pdf.hres.ca/noc_pm/0000002430.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""134393"",
  ""submission_no"": ""134393"",
  ""manufacturer"": {
    ""name"": ""Zyma Pharmaceuticals Inc."",
    ""street"": ""5111 Royalmount Ave."",
    ""city"": ""Montreal"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""NOV 2 2009"",
  ""product_name"": ""ZYM-CARVEDILOL"",
  ""medicinal_ingredients"": ""Carvedilol"",
  ""reason_for_submission"": ""Congestive Heart Failure Agent"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02338068 (ORL,TAB, 3.125 mg) 02338092 (ORL,TAB, 6.25 mg) 02338108 (ORL,TAB, 12.5 mg) 02338114 (ORL,TAB, 25 mg)"",
  ""canadian_reference_product"": ""Cong, SmithKline Beecham Pharma, Division of SmithKline Beecham Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,134393,134393,NOV 2 2009,ZYM-CARVEDILOL,Carvedilol,Congestive Heart Failure Agent,,"02338068 (ORL,TAB, 3.125 mg) 02338092 (ORL,TAB, 6.25 mg) 02338108 (ORL,TAB, 12.5 mg) 02338114 (ORL,TAB, 25 mg)","Cong, SmithKline Beecham Pharma, Division of SmithKline Beecham Inc., Canada",Zyma Pharmaceuticals Inc.,5111 Royalmount Ave.,Montreal,QC,Canada,H4P 2T4,Dr. Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000002563.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""135612"",
  ""submission_no"": ""135612"",
  ""manufacturer"": {
    ""name"": ""UCB Canada Inc."",
    ""street"": ""4145 North Service Road, Suite 200"",
    ""city"": ""Burlington"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L7L 6A3""
  },
  ""date"": ""JAN 1 3 2010"",
  ""product_name"": ""KEPPRA"",
  ""medicinal_ingredients"": ""Levetiracetam"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""G2247027 (ORL,TAB, 250 mg) G2247628 (ORL,TAB, 500 mg) G2247628 (ORL,TAB, 750 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPH"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,135612,135612,JAN 1 3 2010,KEPPRA,Levetiracetam,Manufacturer Name Change,,"G2247027 (ORL,TAB, 250 mg) G2247628 (ORL,TAB, 500 mg) G2247628 (ORL,TAB, 750 mg)",,UCB Canada Inc.,"4145 North Service Road, Suite 200",Burlington,ON,Canada,L7L 6A3,Supriya Sharma MD MPH,Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000002679.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""135988"",
  ""submission_no"": ""135988"",
  ""manufacturer"": {
    ""name"": ""Cobalt Pharmaceuticals Inc."",
    ""street"": ""6900 Kiltmot Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 2B8""
  },
  ""date"": ""JAN 2 9 2010"",
  ""product_name"": ""QUETIAPINE"",
  ""medicinal_ingredients"": ""Quetiapine supplied as Quetiapine Fumarate"",
  ""reason_for_submission"": ""Antipsychotic"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""C2342586 (ORL.TAB, 25 mg) C2342518 (ORL.TAB, 100 mg) C2342620 (ORL.TAB, 150 mg) C2342634 (ORL.TAB, 200 mg) C2342642 (ORL.TAB, 300 mg)"",
  ""canadian_reference_product"": ""Seroquel, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,135988,135988,JAN 2 9 2010,QUETIAPINE,Quetiapine supplied as Quetiapine Fumarate,Antipsychotic,,"C2342586 (ORL.TAB, 25 mg) C2342518 (ORL.TAB, 100 mg) C2342620 (ORL.TAB, 150 mg) C2342634 (ORL.TAB, 200 mg) C2342642 (ORL.TAB, 300 mg)","Seroquel, AstraZeneca Canada Inc., Canada",Cobalt Pharmaceuticals Inc.,6900 Kiltmot Road,Mississauga,ON,Canada,L5N 2B8,Barbara J. Sabourin,Director General / Direction générale,Therapeutic Products Directorate,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000002690.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""112852"",
  ""submission_no"": ""112852"",
  ""manufacturer"": {
    ""name"": ""Apotex Incorporated"",
    ""street"": ""150 Signal Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""FEB 04 2010"",
  ""product_name"": ""APO-METFORMIN ER"",
  ""medicinal_ingredients"": ""Metformin Hydrochloride"",
  ""reason_for_submission"": ""Oral Anti-Hyperglycemic Agent"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02305062, Oral, Tablet (Extended-Release), 600 mg"",
  ""canadian_reference_product"": ""Glumetza, Biovail Pharmaceuticals Canada, Division of Biovail Corporation, Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,112852,112852,FEB 04 2010,APO-METFORMIN ER,Metformin Hydrochloride,Oral Anti-Hyperglycemic Agent,,"02305062, Oral, Tablet (Extended-Release), 600 mg","Glumetza, Biovail Pharmaceuticals Canada, Division of Biovail Corporation, Canada",Apotex Incorporated,150 Signal Drive,TORONTO,Ontario,Canada,M9L 1T9,"Supriya Sharma, MD MPH FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000002746.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""136268"",
  ""submission_no"": ""136268"",
  ""manufacturer"": {
    ""name"": ""Cobalt Pharmaceuticals Inc."",
    ""street"": ""6500 Killam Rd."",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 2B8""
  },
  ""date"": ""1 5 2010"",
  ""product_name"": ""AZITHROMYCIN"",
  ""medicinal_ingredients"": ""Azithromycin supplied as Azithromycin Monohydrate"",
  ""reason_for_submission"": ""Antibiotic"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02343347 (ORL,TAB, 250 mg) 02343355 (ORL,TAB, 600 mg)"",
  ""canadian_reference_product"": ""Zithromax, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,136268,136268,1 5 2010,AZITHROMYCIN,Azithromycin supplied as Azithromycin Monohydrate,Antibiotic,,"02343347 (ORL,TAB, 250 mg) 02343355 (ORL,TAB, 600 mg)","Zithromax, Pfizer Canada Inc., Canada",Cobalt Pharmaceuticals Inc.,6500 Killam Rd.,Mississauga,ON,Canada,L5N 2B8,Dr. Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000002754.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""130274"",
  ""submission_no"": ""130274"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signal Drive"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3L 1T9""
  },
  ""date"": ""FEB 1 5 2010"",
  ""product_name"": ""APX-AML0DIPINE"",
  ""medicinal_ingredients"": ""Amlodipine supplied as Amlodipine Besylate"",
  ""reason_for_submission"": ""Antihypertensive / Antianginal Agent"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""G2343274 (ORL, TAB, 5 mg) G2343282 (ORL, TAB, 10 mg)"",
  ""canadian_reference_product"": ""Norvasc, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,130274,130274,FEB 1 5 2010,APX-AML0DIPINE,Amlodipine supplied as Amlodipine Besylate,Antihypertensive / Antianginal Agent,,"G2343274 (ORL, TAB, 5 mg) G2343282 (ORL, TAB, 10 mg)","Norvasc, Pfizer Canada Inc., Canada",Apotex Inc.,150 Signal Drive,Toronto,ON,Canada,M3L 1T9,Dr. Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000002851.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""119609"",
  ""submission_no"": ""119609"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""MAR 1 6 2010"",
  ""product_name"": ""APO-RABEPRAZOLE"",
  ""medicinal_ingredients"": ""rabeprazole sodium"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(c), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02345579, Oral, Tablet (Enteric Coated), 10 mg 02345087, Oral, Tablet (Enteric Coated), 20 mg"",
  ""canadian_reference_product"": ""Pariet, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,119609,119609,MAR 1 6 2010,APO-RABEPRAZOLE,rabeprazole sodium,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(c), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"02345579, Oral, Tablet (Enteric Coated), 10 mg 02345087, Oral, Tablet (Enteric Coated), 20 mg","Pariet, Janssen-Ortho Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Dr. Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000002918.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""137183"",
  ""submission_no"": ""137183"",
  ""manufacturer"": {
    ""name"": ""AlkoPharma"",
    ""street"": ""Rue des Finettes 55"",
    ""city"": ""Martigny"",
    ""province"": ""Switzerland"",
    ""country"": ""Switzerland"",
    ""postal_code"": ""1920""
  },
  ""date"": ""MAR 2 6 2010"",
  ""product_name"": ""SANOREX"",
  ""medicinal_ingredients"": ""Maxidinol; Anorexiant"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00432497 (ORL,TAB, 1 mg) 00285544 (ORL,TAB, 2 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,137183,137183,MAR 2 6 2010,SANOREX,Maxidinol; Anorexiant,Manufacturer Name Change,,"00432497 (ORL,TAB, 1 mg) 00285544 (ORL,TAB, 2 mg)",,AlkoPharma,Rue des Finettes 55,Martigny,Switzerland,Switzerland,1920,Dr. SUPRIYA SHARMA,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000003115.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""129956"",
  ""submission_no"": ""129956"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""2455 Meadowlark Boulevard"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 8L7""
  },
  ""date"": ""MAY 0 5 2010"",
  ""product_name"": ""Rituxan"",
  ""medicinal_ingredients"": ""rituximab"",
  ""reason_for_submission"": ""Addition to the indication for Chronic Lymphocytic Leukemia (CLL); Addition to l'indication de Leucémie lymphoïde chronique (LLC)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": """",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,129956,129956,MAY 0 5 2010,Rituxan,rituximab,Addition to the indication for Chronic Lymphocytic Leukemia (CLL); Addition to l'indication de Leucémie lymphoïde chronique (LLC),,,,Hoffmann-La Roche Limited,2455 Meadowlark Boulevard,Mississauga,ON,Canada,L5N 8L7,,,,
https://pdf.hres.ca/noc_pm/0000003216.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""138009"",
  ""submission_no"": ""9427-5316811-58"",
  ""manufacturer"": {
    ""name"": ""Saris Health Inc."",
    ""street"": ""333 Champlain St., Suite 102"",
    ""city"": ""Dieppe"",
    ""province"": ""NB"",
    ""country"": ""Canada"",
    ""postal_code"": ""E1A 1P2""
  },
  ""date"": ""MAI 25 2010"",
  ""product_name"": ""DOXYCYCLINE TABLETS DOXYCYCLINE CAPSULES"",
  ""medicinal_ingredients"": ""Doxycline supplied as Doxycycline Hydrate"",
  ""reason_for_submission"": ""As a manufacturer, you are further reminded of your obligations under C.08.002(1)(g), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": ""Not specified in the provided text."",
  ""drug_identification_number_route_form_strength"": ""02351242 (ORL_TAB, 100 mg) - Doxycycline Tablets 02351234 (ORL_CAP, 100 mg) - Doxycycline Capsules"",
  ""canadian_reference_product"": ""Not specified in the provided text."",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Not specified in the provided text.""
  }
}",TRUE,NA,138009,9427-5316811-58,MAI 25 2010,DOXYCYCLINE TABLETS DOXYCYCLINE CAPSULES,Doxycline supplied as Doxycycline Hydrate,"As a manufacturer, you are further reminded of your obligations under C.08.002(1)(g), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",Not specified in the provided text.,"02351242 (ORL_TAB, 100 mg) - Doxycycline Tablets 02351234 (ORL_CAP, 100 mg) - Doxycycline Capsules",Not specified in the provided text.,Saris Health Inc.,"333 Champlain St., Suite 102",Dieppe,NB,Canada,E1A 1P2,Dr. SUPRIYA SHARMA,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,Not specified in the provided text.
https://pdf.hres.ca/noc_pm/0000003219.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-S3188/1-62"",
  ""submission_no"": ""138224"",
  ""manufacturer"": {
    ""name"": ""Sans Health Inc."",
    ""street"": ""333 Champlain Street, Suite 102"",
    ""city"": ""Dieppe"",
    ""province"": ""NB"",
    ""country"": ""Canada"",
    ""postal_code"": ""E1A 1P2""
  },
  ""date"": ""MAY 26 2010"",
  ""product_name"": ""FUROSEMIDE"",
  ""medicinal_ingredients"": ""Furosemide"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02351420 (ORL.TAB, 20 mg) 02351439 (ORL.TAB, 40 mg) 02351447 (ORL.TAB, 80 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-S3188/1-62,138224,MAY 26 2010,FUROSEMIDE,Furosemide,New Manufacturer and Product Name,,"02351420 (ORL.TAB, 20 mg) 02351439 (ORL.TAB, 40 mg) 02351447 (ORL.TAB, 80 mg)",,Sans Health Inc.,"333 Champlain Street, Suite 102",Dieppe,NB,Canada,E1A 1P2,Dr. SUPRIYA SHARMA,Director General / Direction générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000003225.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""138681"",
  ""submission_no"": ""138681"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Incorporated"",
    ""street"": ""100 King Street West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5X 1C7""
  },
  ""date"": ""May 27 2010"",
  ""product_name"": ""MIDOCRINE"",
  ""medicinal_ingredients"": ""Midodrine Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer and Product Name Change"",
  ""species"": ""Vasopressor"",
  ""drug_identification_number_route_form_strength"": ""02278677 (ORL,TAB, 2.5 mg) 02278685 (ORL,TAB, 5 mg)"",
  ""canadian_reference_product"": ""Amaline, Shire Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,138681,138681,May 27 2010,MIDOCRINE,Midodrine Hydrochloride,Manufacturer and Product Name Change,Vasopressor,"02278677 (ORL,TAB, 2.5 mg) 02278685 (ORL,TAB, 5 mg)","Amaline, Shire Canada Inc., Canada",AA Pharma Incorporated,100 King Street West,Toronto,ON,Canada,M5X 1C7,Dr. Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000003229.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""138544"",
  ""submission_no"": ""138544"",
  ""manufacturer"": {
    ""name"": ""Mylan Pharmaceuticals ULC"",
    ""street"": ""85 Advance Road"",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8Z 2S6""
  },
  ""date"": ""MAY 2 6 2010"",
  ""product_name"": ""NIFEDIPINE EXTENDED RELEASE"",
  ""medicinal_ingredients"": ""Nifedipine"",
  ""reason_for_submission"": ""Additional Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02351687 (ORAL, TER, 30 mg) 02351688 (ORAL, TER, 60 mg)"",
  ""canadian_reference_product"": ""Adalat XL, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,138544,138544,MAY 2 6 2010,NIFEDIPINE EXTENDED RELEASE,Nifedipine,Additional Product Name,,"02351687 (ORAL, TER, 30 mg) 02351688 (ORAL, TER, 60 mg)","Adalat XL, Bayer Inc., Canada",Mylan Pharmaceuticals ULC,85 Advance Road,Etobicoke,ON,Canada,M8Z 2S6,Dr. SUPRIYA SHARMA,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000003245.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""138152"",
  ""submission_no"": ""138152"",
  ""manufacturer"": {
    ""name"": ""GlaxoSmithKline Inc."",
    ""street"": ""7333 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L4""
  },
  ""date"": ""MAI 0 7 2010"",
  ""product_name"": ""CLINDOXYL GEL"",
  ""medicinal_ingredients"": ""Clindamycin Phosphate, Benzoyl Peroxide"",
  ""reason_for_submission"": ""Topical Acne Therapy"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02243158 (TOP GEL, Clindamycin 10 mg/g / Benzoyl Peroxide 50 mg/g)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,138152,138152,MAI 0 7 2010,CLINDOXYL GEL,"Clindamycin Phosphate, Benzoyl Peroxide",Topical Acne Therapy,,"02243158 (TOP GEL, Clindamycin 10 mg/g / Benzoyl Peroxide 50 mg/g)",,GlaxoSmithKline Inc.,7333 Mississauga Road,Mississauga,ON,Canada,L5N 6L4,Dr. SUPRIYA SHARMA,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000003294.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""126931"",
  ""submission_no"": ""126931"",
  ""manufacturer"": {
    ""name"": ""Hospira Healthcare Corporation"",
    ""street"": ""1111 Dr. Frederick Phillips Blvd, Suite 600"",
    ""city"": ""Saint Laurent"",
    ""province"": ""Quebec"",
    ""country"": ""H4M 2X6"",
    ""postal_code"": ""H4M 2X6""
  },
  ""date"": ""December 09, 2009"",
  ""product_name"": ""Precedex"",
  ""medicinal_ingredients"": ""Dexmedetomidine (supplied as Dexmedetomidine Hydrochloride)"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02339366, Intravenous, Solution, 100mcg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,126931,126931,"December 09, 2009",Precedex,Dexmedetomidine (supplied as Dexmedetomidine Hydrochloride),"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations.",,"02339366, Intravenous, Solution, 100mcg/ml",,Hospira Healthcare Corporation,"1111 Dr. Frederick Phillips Blvd, Suite 600",Saint Laurent,Quebec,H4M 2X6,H4M 2X6,Dr. Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000003350.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-81710-106"",
  ""submission_no"": ""138278"",
  ""manufacturer"": {
    ""name"": ""Boehringer Ingelheim (Canada) Ltd."",
    ""street"": ""5180 South Service Road"",
    ""city"": ""Burlington"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L7L 5H4""
  },
  ""date"": ""JUN 1 6 2010"",
  ""product_name"": ""Cefa-D®"",
  ""medicinal_ingredients"": ""Cephapirin (as cephapirin benzathine)"",
  ""reason_for_submission"": ""Change in ownership"",
  ""species"": ""Dry cows"",
  ""drug_identification_number_route_form_strength"": ""02173255. Intramammary. Gel. 300 mg/10mL."",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": """",
    ""directorate"": ""Veterinary Drugs Directorate""
  }
}",TRUE,NA,OF15-21-81710-106,138278,JUN 1 6 2010,Cefa-D®,Cephapirin (as cephapirin benzathine),Change in ownership,Dry cows,02173255. Intramammary. Gel. 300 mg/10mL.,,Boehringer Ingelheim (Canada) Ltd.,5180 South Service Road,Burlington,ON,Canada,L7L 5H4,Daniel Chaput,"Director General, Veterinary Drugs Directorate",,Veterinary Drugs Directorate
https://pdf.hres.ca/noc_pm/0000003362.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a 'Summary of Decision Motives (SMD)' document, which is not a Notice of Compliance (NOC). It does not contain the required fields such as dossier_id, submission_no, manufacturer details, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, or authorizing_official. The document is a summary of decision rationale, not the official NOC."",
  ""partial_data"": {}
}",FALSE,"The provided text is a 'Summary of Decision Motives (SMD)' document, which is not a Notice of Compliance (NOC). It does not contain the required fields such as dossier_id, submission_no, manufacturer details, product_name, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, or authorizing_official. The document is a summary of decision rationale, not the official NOC.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000003472.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-Z00403-28"",
  ""submission_no"": ""117730"",
  ""manufacturer"": {
    ""name"": ""Zymcan Pharmaceuticals Inc."",
    ""street"": ""8111 Royalwood Ave"",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""JUL 0 9 2008"",
  ""product_name"": ""ZYM-GABAPENTIN"",
  ""medicinal_ingredients"": ""Gabapentin"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": ""Not specified"",
  ""drug_identification_number_route_form_strength"": ""02304775 (ORL, CAP, 100mg) 02304783 (ORL, CAP, 300mg) 02304791 (ORL, CAP, 400mg) 02304805 (ORL, TAB, 600mg) 02304813 (ORL, TAB, 800mg)"",
  ""canadian_reference_product"": ""Nourontin, Parke-Davis, division of Warner Lambert Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Not specified""
  }
}",TRUE,NA,9427-Z00403-28,117730,JUL 0 9 2008,ZYM-GABAPENTIN,Gabapentin,New Manufacturer and Product Name,Not specified,"02304775 (ORL, CAP, 100mg) 02304783 (ORL, CAP, 300mg) 02304791 (ORL, CAP, 400mg) 02304805 (ORL, TAB, 600mg) 02304813 (ORL, TAB, 800mg)","Nourontin, Parke-Davis, division of Warner Lambert Canada Inc., Canada",Zymcan Pharmaceuticals Inc.,8111 Royalwood Ave,Montreal,PQ,Canada,H4P 2T4,Supriya Sharma,Director General / Direction générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,Not specified
https://pdf.hres.ca/noc_pm/0000003510.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""120308"",
  ""submission_no"": ""120308"",
  ""manufacturer"": {
    ""name"": ""Bayer Inc."",
    ""street"": ""77 Bellecliff Road"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9W 1G8""
  },
  ""date"": ""OCT 14 2008"",
  ""product_name"": ""Zevalin®"",
  ""medicinal_ingredients"": ""Ibritumomab tiuxetan"",
  ""reason_for_submission"": ""change in manufacturing - new facility / nouvel emplacement de fabrication"",
  ""species"": ""Therapeutic radiopharmaceutical"",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, LIQ, 3.2 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Elyse Griffiths"",
    ""title"": ""Director General / Directeur général par intérim"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,120308,120308,OCT 14 2008,Zevalin®,Ibritumomab tiuxetan,change in manufacturing - new facility / nouvel emplacement de fabrication,Therapeutic radiopharmaceutical,"N/A, IV, LIQ, 3.2 mg/mL",,Bayer Inc.,77 Bellecliff Road,Toronto,Ontario,Canada,M9W 1G8,Elyse Griffiths,Director General / Directeur général par intérim,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000003573.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""120347"",
  ""submission_no"": ""120347"",
  ""manufacturer"": {
    ""name"": ""Hospice Healthcare Corporation"",
    ""street"": ""1111 Dr. Frederick Philips, Suite 600"",
    ""city"": ""ST.LAURENT"",
    ""province"": ""Quebec"",
    ""country"": ""H4M 2X8"",
    ""postal_code"": ""H4M 2X8""
  },
  ""date"": ""October 14, 2008"",
  ""product_name"": ""0.4% Lidocaine Hydrochloride and 5% Dextrose Injection USP"",
  ""medicinal_ingredients"": ""Lidocaine Hydrochloride and Dextrose"",
  ""reason_for_submission"": ""Addition of alternate manufacturing site for the finished product"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Solution, Lidocaine Hydrochloride, 4 mg/ml. Dextrose, 50 mg/ml."",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD, MPH, FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,120347,120347,"October 14, 2008",0.4% Lidocaine Hydrochloride and 5% Dextrose Injection USP,Lidocaine Hydrochloride and Dextrose,Addition of alternate manufacturing site for the finished product,N/A,"N/A, Intravenous, Solution, Lidocaine Hydrochloride, 4 mg/ml. Dextrose, 50 mg/ml.",,Hospice Healthcare Corporation,"1111 Dr. Frederick Philips, Suite 600",ST.LAURENT,Quebec,H4M 2X8,H4M 2X8,"Supriya Sharma, MD, MPH, FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000003594.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9460-40189-508"",
  ""submission_no"": ""114441"",
  ""manufacturer"": {
    ""name"": ""Alpharma Canada Corporation"",
    ""street"": ""2000 Argentia Rd."",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 1W1""
  },
  ""date"": ""MAR 2 5 2008"",
  ""product_name"": ""Bovatec®"",
  ""medicinal_ingredients"": ""Laxalocid sodium"",
  ""reason_for_submission"": ""Addition of Federated Co-operatives Ltd. for the manufacturing of Co-op Bovatec Paste Cattle Mineral"",
  ""species"": ""Cattle, lambs"",
  ""drug_identification_number_route_form_strength"": ""02242923, Oral, Drug premix, 150 g/kg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Louis Boudry"",
    ""title"": ""A/ Director General, Veterinary Drugs Directorate"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Director General""
  }
}",TRUE,NA,9460-40189-508,114441,MAR 2 5 2008,Bovatec®,Laxalocid sodium,Addition of Federated Co-operatives Ltd. for the manufacturing of Co-op Bovatec Paste Cattle Mineral,"Cattle, lambs","02242923, Oral, Drug premix, 150 g/kg",,Alpharma Canada Corporation,2000 Argentia Rd.,Mississauga,ON,Canada,L5N 1W1,Louis Boudry,"A/ Director General, Veterinary Drugs Directorate",Veterinary Drugs Directorate,Director General
https://pdf.hres.ca/noc_pm/0000003660.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""114004"",
  ""submission_no"": ""9427-A0029-72"",
  ""manufacturer"": {
    ""name"": ""Alcon Canada Incorporated"",
    ""street"": ""2665 Meadowpine Blvd."",
    ""city"": ""MISSISSAUGA"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""L5N 8C7""
  },
  ""date"": ""APR 1 7 2008"",
  ""product_name"": ""NEVANAC OPHTHALMIC SUSPENSION"",
  ""medicinal_ingredients"": ""Nepafenac"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""C2308863, Ophthalmic, Suspension, 0.1%"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,114004,9427-A0029-72,APR 1 7 2008,NEVANAC OPHTHALMIC SUSPENSION,Nepafenac,,,"C2308863, Ophthalmic, Suspension, 0.1%",,Alcon Canada Incorporated,2665 Meadowpine Blvd.,MISSISSAUGA,Ontario,,L5N 8C7,"Supriya Sharma, MD MPH FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000003740.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""101031"",
  ""submission_no"": ""101031"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""180 Signal Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""March 05, 2008"",
  ""product_name"": ""APO-PANTOPRAZOLE"",
  ""medicinal_ingredients"": ""Pantoprazole (supplied as Pantoprazole Sodium) / Pantoprazole (comme Pantoprazole Sodique)"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02292912, Oral, Tablet (Delayed-Release), 20 mg / 02292920, Oral, Tablet (Delayed-Release), 40 mg"",
  ""canadian_reference_product"": ""Pantoloc, Solvay Pharma inc., Canada/Altana Pharma AG, Germany"",
  ""authorizing_official"": {
    ""name"": ""Jacques Bouchard"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,101031,101031,"March 05, 2008",APO-PANTOPRAZOLE,Pantoprazole (supplied as Pantoprazole Sodium) / Pantoprazole (comme Pantoprazole Sodique),,,"02292912, Oral, Tablet (Delayed-Release), 20 mg / 02292920, Oral, Tablet (Delayed-Release), 40 mg","Pantoloc, Solvay Pharma inc., Canada/Altana Pharma AG, Germany",Apotex Inc.,180 Signal Drive,TORONTO,Ontario,Canada,M5L 1T9,Jacques Bouchard,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000003920.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""140577"",
  ""submission_no"": ""140577"",
  ""manufacturer"": {
    ""name"": ""VIV Healthcare Shire Canada"",
    ""street"": ""7333 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L4""
  },
  ""date"": ""Aug 18 2010"",
  ""product_name"": ""COMBIVIR"",
  ""medicinal_ingredients"": ""Lamivudine / Zidovudine"",
  ""reason_for_submission"": ""Antiretroviral Agent"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02239213 (ORL,TAB, Lamivudine 150 mg / Zidovudine 300 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,140577,140577,Aug 18 2010,COMBIVIR,Lamivudine / Zidovudine,Antiretroviral Agent,,"02239213 (ORL,TAB, Lamivudine 150 mg / Zidovudine 300 mg)",,VIV Healthcare Shire Canada,7333 Mississauga Road,Mississauga,ON,Canada,L5N 6L4,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000003990.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""140827"",
  ""submission_no"": ""140827"",
  ""manufacturer"": {
    ""name"": ""Mylan Pharmaceuticals ULC"",
    ""street"": ""85 Advance Road"",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8Z 2S6""
  },
  ""date"": ""25 2010"",
  ""product_name"": ""RANITIDINE"",
  ""medicinal_ingredients"": ""Ranitidine supplied as Ranitidine Hydrochloride"",
  ""reason_for_submission"": ""Histamine H2-Receptor Antagonist"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02296106 (ORL_TAB, 150 mg) 02296114 (ORL_TAB, 300 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPharm"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,140827,140827,25 2010,RANITIDINE,Ranitidine supplied as Ranitidine Hydrochloride,Histamine H2-Receptor Antagonist,,"02296106 (ORL_TAB, 150 mg) 02296114 (ORL_TAB, 300 mg)",,Mylan Pharmaceuticals ULC,85 Advance Road,Etobicoke,ON,Canada,M8Z 2S6,Supriya Sharma MD MPharm,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000004008.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""111362"",
  ""submission_no"": ""9427-9045-43"",
  ""manufacturer"": {
    ""name"": ""Bayer Inc."",
    ""street"": ""77 Belfield Road"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M9W 1G6""
  },
  ""date"": ""DEC 1 1 2007"",
  ""product_name"": ""GLUCOBAY"",
  ""medicinal_ingredients"": ""Acarbose"",
  ""reason_for_submission"": ""Update to the Product Monograph: Warnings and Precautions, Adverse Reactions, Action and Clinical Pharmacology, Clinical Trials."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 50 mg; N/A, Oral, Tablet, 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD, MPh, FRCPC"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,111362,9427-9045-43,DEC 1 1 2007,GLUCOBAY,Acarbose,"Update to the Product Monograph: Warnings and Precautions, Adverse Reactions, Action and Clinical Pharmacology, Clinical Trials.",,"N/A, Oral, Tablet, 50 mg; N/A, Oral, Tablet, 100 mg",,Bayer Inc.,77 Belfield Road,TORONTO,Ontario,,M9W 1G6,"Supriya Sharma, MD, MPh, FRCPC",Director General / Direction générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000004124.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-J05554-42"",
  ""submission_no"": ""141486"",
  ""manufacturer"": {
    ""name"": ""Jamp Pharma Corporation"",
    ""street"": ""1380 - 203 Newton St."",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H2""
  },
  ""date"": ""SEP 2 9 2010"",
  ""product_name"": ""JAMP-FINASTERIDE"",
  ""medicinal_ingredients"": ""Finasteride"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02357224 (ORL,TAB, 5 mg)"",
  ""canadian_reference_product"": ""Proscar, Merck Frosst Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-J05554-42,141486,SEP 2 9 2010,JAMP-FINASTERIDE,Finasteride,New Manufacturer and Product Name,,"02357224 (ORL,TAB, 5 mg)","Proscar, Merck Frosst Canada Ltd., Canada",Jamp Pharma Corporation,1380 - 203 Newton St.,Boucherville,QC,Canada,J4B 5H2,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000004195.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""104754"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Jules-Leger Street"",
    ""city"": ""BOUCHERVILLE"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 7K8""
  },
  ""date"": ""NOV 2 1 2007"",
  ""product_name"": ""Sandoz Cefprozil"",
  ""medicinal_ingredients"": ""Cefprozil"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02202178, Oral, Tablet, 250mg 02202187, Oral, Tablet, 500mg"",
  ""canadian_reference_product"": ""Ceflot, Bristol-Myers Squibb Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPhH FRCPC"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,104754,,NOV 2 1 2007,Sandoz Cefprozil,Cefprozil,,,"02202178, Oral, Tablet, 250mg 02202187, Oral, Tablet, 500mg","Ceflot, Bristol-Myers Squibb Canada Inc., Canada",Sandoz Canada Inc.,145 Jules-Leger Street,BOUCHERVILLE,Quebec,Canada,J4B 7K8,"Supriya Sharma, MD MPhH FRCPC",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000004303.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""104227"",
  ""submission_no"": ""104227"",
  ""manufacturer"": {
    ""name"": ""Cubist Pharmaceuticals, Incorporated"",
    ""street"": ""65 Hayden Avenue"",
    ""city"": ""LEXINGTON"",
    ""province"": ""MA"",
    ""country"": ""USA"",
    ""postal_code"": ""02421""
  },
  ""date"": ""MAR 1 4 2008"",
  ""product_name"": ""CUBICIN"",
  ""medicinal_ingredients"": ""Daptomycin"",
  ""reason_for_submission"": ""New Indication: Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""Intravenous, Powder for Solution, 500 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sugriya Sharma, MD, MPH, FRCP(C)"",
    ""title"": ""Director General / Directeur général par intérim"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,104227,104227,MAR 1 4 2008,CUBICIN,Daptomycin,New Indication: Staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided Staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains.,,"Intravenous, Powder for Solution, 500 mg/vial",,"Cubist Pharmaceuticals, Incorporated",65 Hayden Avenue,LEXINGTON,MA,USA,02421,"Sugriya Sharma, MD, MPH, FRCP(C)",Director General / Directeur général par intérim,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000004313.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-P00067-185"",
  ""submission_no"": ""114625"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17 300 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""JUN 2 1 2007"",
  ""product_name"": ""CARDURA"",
  ""medicinal_ingredients"": ""Doxazosin supplied as Doxazosin Mesylate"",
  ""reason_for_submission"": ""Antihypertensive Agent / Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01958100 (ORL,TAB, 1mg) 01958097 (ORL,TAB, 2mg) 01958119 (ORL,TAB, 4mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Etienne Oulmette"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Supriya Sharma MD MPh FRCPG""
  }
}",TRUE,NA,9427-P00067-185,114625,JUN 2 1 2007,CARDURA,Doxazosin supplied as Doxazosin Mesylate,Antihypertensive Agent / Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH),,"01958100 (ORL,TAB, 1mg) 01958097 (ORL,TAB, 2mg) 01958119 (ORL,TAB, 4mg)",,Pfizer Canada Inc.,17 300 Trans Canada Highway,Kirkland,PQ,Canada,H9J 2M5,Etienne Oulmette,Acting Director General / Directrice générale par intérim,Therapeutic Products Directorate / Direction des produits thérapeutiques,Supriya Sharma MD MPh FRCPG
https://pdf.hres.ca/noc_pm/0000004332.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""105050"",
  ""submission_no"": ""0427-N1085-23"",
  ""manufacturer"": {
    ""name"": ""Novartis Ophthalmics, Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""2235 Argentia Rd, East Tower, Suite 200"",
    ""city"": ""MISSISSAUGA"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""L5N 2X7""
  },
  ""date"": ""04 2007"",
  ""product_name"": ""VOLTAREN OPHTHA"",
  ""medicinal_ingredients"": ""Diclofenac Sodium 0.1%"",
  ""reason_for_submission"": ""Revisions to the Product Monograph. Removal of chronic indication and safety updates."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Ophthalmic, Solution, 1 mg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Supriya Sharma"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,105050,0427-N1085-23,04 2007,VOLTAREN OPHTHA,Diclofenac Sodium 0.1%,Revisions to the Product Monograph. Removal of chronic indication and safety updates.,,"N/A, Ophthalmic, Solution, 1 mg/ml",,"Novartis Ophthalmics, Novartis Pharmaceuticals Canada Inc.","2235 Argentia Rd, East Tower, Suite 200",MISSISSAUGA,Ontario,,L5N 2X7,Dr. Supriya Sharma,Acting Director General / Directrice générale par intérim,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000004483.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9460-V0135-514"",
  ""submission_no"": ""110450, previously 2001034N"",
  ""manufacturer"": {
    ""name"": ""Vetoquinol N.A. inc."",
    ""street"": ""2000 chemin George"",
    ""city"": ""Laval"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J5T 3S5""
  },
  ""date"": ""12 2007"",
  ""product_name"": ""Pillium 150 mg (Imidapril Hydrochloride) (Powder for Oral Solution in Dogs)"",
  ""medicinal_ingredients"": ""Imidapril hydrochloride"",
  ""reason_for_submission"": ""To notify you that pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the regulations."",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""02297280, oral, powder for solution, 0.150 g/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Siddika Mithani, Ph.D."",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,9460-V0135-514,"110450, previously 2001034N",12 2007,Pillium 150 mg (Imidapril Hydrochloride) (Powder for Oral Solution in Dogs),Imidapril hydrochloride,"To notify you that pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the regulations.",Dogs,"02297280, oral, powder for solution, 0.150 g/vial",,Vetoquinol N.A. inc.,2000 chemin George,Laval,QC,Canada,J5T 3S5,"Siddika Mithani, Ph.D.",Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000004487.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""102993"",
  ""submission_no"": ""102993"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5R 1T9""
  },
  ""date"": ""JUN 2 0 2007"",
  ""product_name"": ""Apo-Ibuprofen"",
  ""medicinal_ingredients"": ""Ibuprofen"",
  ""reason_for_submission"": ""New dosage form"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02295970 - ORAL SUSPENSION, 100 mg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,102993,102993,JUN 2 0 2007,Apo-Ibuprofen,Ibuprofen,New dosage form,,"02295970 - ORAL SUSPENSION, 100 mg/ml",,Apotex Inc.,150 Signet Drive,TORONTO,Ontario,Canada,M5R 1T9,"Supriya Sharma, MD MPH FRCP(C)",Acting Director General / Directrice générale par intérim,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000004514.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-MG2852-30"",
  ""submission_no"": ""111170"",
  ""manufacturer"": {
    ""name"": ""Micheli Consumer Healthcare"",
    ""street"": ""88 Mohabb St."",
    ""city"": ""Markham"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L3R 5L2""
  },
  ""date"": ""JAN 2 3 2007"",
  ""product_name"": ""SUDAFED SINUS ADVANCE"",
  ""medicinal_ingredients"": ""Ibuprofen / Pseudoephedrine Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""0242217 (ORL_TAS, Ibuprofen 200mg / Pseudoephedrine Hydrochloride 30mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director-General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-MG2852-30,111170,JAN 2 3 2007,SUDAFED SINUS ADVANCE,Ibuprofen / Pseudoephedrine Hydrochloride,Manufacturer Name Change,,"0242217 (ORL_TAS, Ibuprofen 200mg / Pseudoephedrine Hydrochloride 30mg)",,Micheli Consumer Healthcare,88 Mohabb St.,Markham,ON,Canada,L3R 5L2,Dr. SUPRIYA SHARMA,Director-General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000004545.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""099076"",
  ""submission_no"": ""099076"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Julius-Legge Street"",
    ""city"": ""BOUCHERVILLE"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 7K3""
  },
  ""date"": ""OCT 1 7 2007"",
  ""product_name"": ""SANDOZ LISINOPRIL"",
  ""medicinal_ingredients"": ""Lisinopril (supplied as Lisinopril Dihydrate)"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""G2289100, Oral, Tablet, 5mg; G2289202, Oral, Tablet, 10mg; G2289229, Oral, Tablet, 20mg"",
  ""canadian_reference_product"": ""Prinivil, Merck Frosst Canada & Co., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,099076,099076,OCT 1 7 2007,SANDOZ LISINOPRIL,Lisinopril (supplied as Lisinopril Dihydrate),"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"G2289100, Oral, Tablet, 5mg; G2289202, Oral, Tablet, 10mg; G2289229, Oral, Tablet, 20mg","Prinivil, Merck Frosst Canada & Co., Canada",Sandoz Canada Inc.,145 Julius-Legge Street,BOUCHERVILLE,Quebec,Canada,J4B 7K3,Supriya Sharma,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000004634.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text is a 'NOTICE OF COMPLIANCE WITH CONDITIONS - REQUEST FOR LETTER OF UNDERTAKING', which is a request for additional information to complete an assessment under the NOC/c Policy. It does not contain the final Notice of Compliance (NOC) details such as the actual NOC number, date of issuance, or the final authorization status. The document is an interim communication requesting undertakings, not the final compliance notice itself."",
  ""partial_data"": {
    ""dossier_id"": ""134197"",
    ""submission_no"": ""9427-R0798-167"",
    ""manufacturer"": {
      ""name"": ""ratiopharm inc."",
      ""street"": ""17800 Rue Lapointe"",
      ""city"": ""Mirabel"",
      ""province"": ""Quebec"",
      ""country"": ""Canada"",
      ""postal_code"": ""J7J 1P3""
    },
    ""date"": """",
    ""product_name"": ""ratio-MEMANTINE (Memantine Hydrochloride)"",
    ""medicinal_ingredients"": ""Memantine Hydrochloride"",
    ""reason_for_submission"": ""Supplemental Abbreviated New Drug Submission"",
    ""species"": ""patients with moderate to severe dementia of the Alzheimer’s type"",
    ""drug_identification_number_route_form_strength"": """",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": ""[employee name removed]"",
      ""title"": ""Manager, Post-Marketing Regulatory Affairs"",
      ""division"": ""Therapeutic Product Directorate"",
      ""directorate"": ""Health Canada""
    }
  }
}",FALSE,"The provided text is a 'NOTICE OF COMPLIANCE WITH CONDITIONS - REQUEST FOR LETTER OF UNDERTAKING', which is a request for additional information to complete an assessment under the NOC/c Policy. It does not contain the final Notice of Compliance (NOC) details such as the actual NOC number, date of issuance, or the final authorization status. The document is an interim communication requesting undertakings, not the final compliance notice itself.",134197,9427-R0798-167,,ratio-MEMANTINE (Memantine Hydrochloride),Memantine Hydrochloride,Supplemental Abbreviated New Drug Submission,patients with moderate to severe dementia of the Alzheimer’s type,,,ratiopharm inc.,17800 Rue Lapointe,Mirabel,Quebec,Canada,J7J 1P3,[employee name removed],"Manager, Post-Marketing Regulatory Affairs",Therapeutic Product Directorate,Health Canada
https://pdf.hres.ca/noc_pm/0000004804.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""110485"",
  ""submission_no"": ""9427-N0454-498"",
  ""manufacturer"": {
    ""name"": ""Novopharm Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""JUN 06 2007"",
  ""product_name"": ""NOVO-OLANZAPINE"",
  ""medicinal_ingredients"": ""Olanzapine"",
  ""reason_for_submission"": ""Revisions to the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, Oral, Tablet, 2.5mg\nNIA, Oral, Tablet, 5.0mg\nNIA, Oral, Tablet, 7.5mg\nNIA, Oral, Tablet, 10.0mg\nNIA, Oral, Tablet, 15.0mg"",
  ""canadian_reference_product"": ""Zyprexa, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,110485,9427-N0454-498,JUN 06 2007,NOVO-OLANZAPINE,Olanzapine,Revisions to the Product Monograph,,"NIA, Oral, Tablet, 2.5mg
NIA, Oral, Tablet, 5.0mg
NIA, Oral, Tablet, 7.5mg
NIA, Oral, Tablet, 10.0mg
NIA, Oral, Tablet, 15.0mg","Zyprexa, Eli Lilly Canada Inc., Canada",Novopharm Limited,30 Novopharm Court,TORONTO,Ontario,,M1B 2K9,Supriya Sharma,Acting Director General / Directrice générale par intérim,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000004805.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""114394"",
  ""submission_no"": ""114394"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc"",
    ""street"": ""160 Signet Drive"",
    ""city"": ""Wexford"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""JUN 01 2007"",
  ""product_name"": ""ONDANSETRON INJECTION USP"",
  ""medicinal_ingredients"": ""Ondansetron supplied as Ondansetron Hydrochloride Dihydrate"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above supplement to an abbreviated new drug submission complies with the requirements of sections C.08.003 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.003(1)(c), C.08.007 and C.08.008."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02231703 (IV, SOL, 2 mg/mL) 02231754 (IV, SOL, 2 mg/mL)"",
  ""canadian_reference_product"": ""Zofran, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPharm FRCP(C)"",
    ""title"": ""Acting Director General / Directrice générale adjointe"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,114394,114394,JUN 01 2007,ONDANSETRON INJECTION USP,Ondansetron supplied as Ondansetron Hydrochloride Dihydrate,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above supplement to an abbreviated new drug submission complies with the requirements of sections C.08.003 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.003(1)(c), C.08.007 and C.08.008.",,"02231703 (IV, SOL, 2 mg/mL) 02231754 (IV, SOL, 2 mg/mL)","Zofran, GlaxoSmithKline Inc., Canada",Apotex Inc,160 Signet Drive,Wexford,ON,Canada,M9L 1T9,Supriya Sharma MD MPharm FRCP(C),Acting Director General / Directrice générale adjointe,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000005025.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""105273"",
  ""submission_no"": ""105273"",
  ""manufacturer"": {
    ""name"": ""Abbott Laboratories, Limited"",
    ""street"": ""8401 Trans-Canada Highway"",
    ""city"": ""St-Laurent"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 1Z1""
  },
  ""date"": ""DEC 01 2006"",
  ""product_name"": ""HUMIRA®"",
  ""medicinal_ingredients"": ""adalimumab"",
  ""reason_for_submission"": ""Alternate drug delivery system - HUMIRA® pen"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, SC, Sol, 40 mg/0.8 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Pierre J. Charest"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,105273,105273,DEC 01 2006,HUMIRA®,adalimumab,Alternate drug delivery system - HUMIRA® pen,,"NIA, SC, Sol, 40 mg/0.8 mL",,"Abbott Laboratories, Limited",8401 Trans-Canada Highway,St-Laurent,Quebec,Canada,H4S 1Z1,Pierre J. Charest,Director General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000005127.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-P1672H-48"",
  ""submission_no"": ""060708"",
  ""manufacturer"": {
    ""name"": ""Pharmaceutical Partners of Canada, A Division of Abraxis Bioscience Inc."",
    ""street"": ""45 Voyell Road"",
    ""city"": ""Sault Ste. Marie"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4B 3P6""
  },
  ""date"": ""DEC 1 5 2006"",
  ""product_name"": ""CEFTRIAXONE FOR INJECTION, USP"",
  ""medicinal_ingredients"": ""Ceftriaxone (as Ceftriaxone sodium)"",
  ""reason_for_submission"": ""Antibiotic"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""G2289679, Intramuscular, Intravenous Powder for solution, 0.25 GM/VIAL; G2289657, Intramuscular, Intravenous Powder for solution, 0.50 GM/VIAL; G2289655, Intramuscular, Intravenous Powder for solution, 1.0 GM/VIAL; G2289708, Intramuscular, Intravenous Powder for solution, 2.0 GM/VIAL; G2289717, Intramuscular, Intravenous Powder for solution, 10.0 GM/VIAL"",
  ""canadian_reference_product"": ""Roccepin, Hoffman-LaRoche Limited, Canada"",
  ""authorizing_official"": {
    ""name"": ""Omer Boudreau"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-P1672H-48,060708,DEC 1 5 2006,"CEFTRIAXONE FOR INJECTION, USP",Ceftriaxone (as Ceftriaxone sodium),Antibiotic,,"G2289679, Intramuscular, Intravenous Powder for solution, 0.25 GM/VIAL; G2289657, Intramuscular, Intravenous Powder for solution, 0.50 GM/VIAL; G2289655, Intramuscular, Intravenous Powder for solution, 1.0 GM/VIAL; G2289708, Intramuscular, Intravenous Powder for solution, 2.0 GM/VIAL; G2289717, Intramuscular, Intravenous Powder for solution, 10.0 GM/VIAL","Roccepin, Hoffman-LaRoche Limited, Canada","Pharmaceutical Partners of Canada, A Division of Abraxis Bioscience Inc.",45 Voyell Road,Sault Ste. Marie,Ontario,Canada,L4B 3P6,Omer Boudreau,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000005189.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9460-C1411-904"",
  ""submission_no"": ""2004147A"",
  ""manufacturer"": {
    ""name"": ""Chanelle Pharmaceuticals Manufacturing Ltd."",
    ""street"": ""Loughrea"",
    ""city"": ""County Galway"",
    ""province"": ""Ireland"",
    ""country"": """",
    ""postal_code"": """"
  },
  ""date"": ""March 6, 2006"",
  ""product_name"": ""Clindamycin Tablets 75 mg"",
  ""medicinal_ingredients"": ""clindamycin (as clindamycin hydrochloride)"",
  ""reason_for_submission"": """",
  ""species"": ""dogs"",
  ""drug_identification_number_route_form_strength"": ""02277727, oral, tablets, 75 mg/tab*"",
  ""canadian_reference_product"": ""Anitrobie Capsules 75 mg, Pharmacia Animal Health, Canada"",
  ""authorizing_official"": {
    ""name"": ""Siddika Milican, Ph.D."",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": """",
    ""directorate"": ""Veterinary Drugs Directorate""
  }
}",TRUE,NA,9460-C1411-904,2004147A,"March 6, 2006",Clindamycin Tablets 75 mg,clindamycin (as clindamycin hydrochloride),,dogs,"02277727, oral, tablets, 75 mg/tab*","Anitrobie Capsules 75 mg, Pharmacia Animal Health, Canada",Chanelle Pharmaceuticals Manufacturing Ltd.,Loughrea,County Galway,Ireland,,,"Siddika Milican, Ph.D.","Director General, Veterinary Drugs Directorate",,Veterinary Drugs Directorate
https://pdf.hres.ca/noc_pm/0000005202.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-P0869-107"",
  ""submission_no"": ""110390"",
  ""manufacturer"": {
    ""name"": ""Pharmel Inc."",
    ""street"": ""5111 Royalwood Ave."",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""22 2006"",
  ""product_name"": ""PHL-DOXYCYCLINE"",
  ""medicinal_ingredients"": ""Doxycycline supplied as Doxycycline Hydrate"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02289458 (ORL,TAB, 100mg) 02289431 (ORL,CAP, 100mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Omer Boudreaux"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-P0869-107,110390,22 2006,PHL-DOXYCYCLINE,Doxycycline supplied as Doxycycline Hydrate,New Manufacturer and Product Name,,"02289458 (ORL,TAB, 100mg) 02289431 (ORL,CAP, 100mg)",,Pharmel Inc.,5111 Royalwood Ave.,Montreal,PQ,Canada,H4P 2T4,Omer Boudreaux,Director General / Directeur général,Therapeutic Products Directorate,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000005257.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""094663"",
  ""submission_no"": ""094663"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Jules-Léger Street"",
    ""city"": ""BOUCHERVILLE"",
    ""province"": ""Quebec"",
    ""country"": """",
    ""postal_code"": ""J4B 7K8""
  },
  ""date"": ""JUL 1 8 2007"",
  ""product_name"": ""Pediatric Digoxin injection C.S.D."",
  ""medicinal_ingredients"": ""Digoxin"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02048272, Intramuscular, Intravenous, Liquid, 0.05 mg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Acting Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,094663,094663,JUL 1 8 2007,Pediatric Digoxin injection C.S.D.,Digoxin,,,"02048272, Intramuscular, Intravenous, Liquid, 0.05 mg/ml",,Sandoz Canada Inc.,145 Jules-Léger Street,BOUCHERVILLE,Quebec,,J4B 7K8,Dr. SUPRIYA SHARMA,Acting Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000005420.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""104824"",
  ""submission_no"": ""104824"",
  ""manufacturer"": {
    ""name"": ""Valesant Canada limited"",
    ""street"": ""4787 Levy St"",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 2P9""
  },
  ""date"": ""MAY 9 2006"",
  ""product_name"": ""INFERGEN"",
  ""medicinal_ingredients"": ""Interferon Alfacon-1"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02239832 (SC, SOL, 0.03mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Pierre J. Charest"",
    ""title"": ""Director General"",
    ""division"": ""Biologics and Genetic Therapies"",
    ""directorate"": ""Directorate of Biologics and Genetic Therapies""
  }
}",TRUE,NA,104824,104824,MAY 9 2006,INFERGEN,Interferon Alfacon-1,Manufacturer Name Change,,"02239832 (SC, SOL, 0.03mg/mL)",,Valesant Canada limited,4787 Levy St,Montreal,PQ,Canada,H4R 2P9,Pierre J. Charest,Director General,Biologics and Genetic Therapies,Directorate of Biologics and Genetic Therapies
https://pdf.hres.ca/noc_pm/0000005431.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""104235"",
  ""submission_no"": ""9427-2195-87"",
  ""manufacturer"": {
    ""name"": ""Cobalt Pharmaceuticals Inc."",
    ""street"": ""6500 Kilmart Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 2B8""
  },
  ""date"": ""MAR 2 9 2006"",
  ""product_name"": ""CO SALBUT-IPRAT INHALATION SOLUTION"",
  ""medicinal_ingredients"": ""Ipratropium Bromide (supplied as Ipratropium Bromide Monohydrate) and Salbutamol (supplied as Salbutamol Sulfate)"",
  ""reason_for_submission"": ""Bronchodilator"",
  ""species"": ""Bronchodilator"",
  ""drug_identification_number_route_form_strength"": ""02276348, INH, SOL, 0.5mg/2.5ml - Ipratropium Bromide 2.5mg/2.5ml - Salbutamol"",
  ""canadian_reference_product"": ""Combivent, Boehringer Ingelheim (Canada) Ltd, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,104235,9427-2195-87,MAR 2 9 2006,CO SALBUT-IPRAT INHALATION SOLUTION,Ipratropium Bromide (supplied as Ipratropium Bromide Monohydrate) and Salbutamol (supplied as Salbutamol Sulfate),Bronchodilator,Bronchodilator,"02276348, INH, SOL, 0.5mg/2.5ml - Ipratropium Bromide 2.5mg/2.5ml - Salbutamol","Combivent, Boehringer Ingelheim (Canada) Ltd, Canada",Cobalt Pharmaceuticals Inc.,6500 Kilmart Road,Mississauga,ON,Canada,L5N 2B8,Dr. SUPRIYA SHARMA,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000005475.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""086436"",
  ""submission_no"": ""086436"",
  ""manufacturer"": {
    ""name"": ""Genzyme Canada Inc."",
    ""street"": ""800-2700 Matheson Blvd. East"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 4V9""
  },
  ""date"": ""FEB 17 2006"",
  ""product_name"": ""ALDURAZYME®"",
  ""medicinal_ingredients"": ""Imatinib"",
  ""reason_for_submission"": ""changes to manufacturing facility / changements à l'implantation de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NA, IV, SOL, 0.58 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Pierre J. Chassé"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,086436,086436,FEB 17 2006,ALDURAZYME®,Imatinib,changes to manufacturing facility / changements à l'implantation de fabrication,,"NA, IV, SOL, 0.58 mg/mL",,Genzyme Canada Inc.,800-2700 Matheson Blvd. East,Mississauga,Ontario,Canada,L4W 4V9,Pierre J. Chassé,Director General / Directeur général,Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000005479.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""3427-C0550-26"",
  ""submission_no"": ""110438"",
  ""manufacturer"": {
    ""name"": ""Ovation Pharmaceuticals Inc."",
    ""street"": ""4 Parkway North, Suites 200"",
    ""city"": ""Deerfield"",
    ""province"": ""IL"",
    ""country"": ""USA"",
    ""postal_code"": ""60015""
  },
  ""date"": ""2 2 2006"",
  ""product_name"": ""MUSTARGEN"",
  ""medicinal_ingredients"": ""Mechlorethamine supplied as Mechlorethamine Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00016063 (IP, I.P., I.V., P.I.V.S., 10mg/Vial)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Omer Boudreau"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,3427-C0550-26,110438,2 2 2006,MUSTARGEN,Mechlorethamine supplied as Mechlorethamine Hydrochloride,Manufacturer Name Change,,"00016063 (IP, I.P., I.V., P.I.V.S., 10mg/Vial)",,Ovation Pharmaceuticals Inc.,"4 Parkway North, Suites 200",Deerfield,IL,USA,60015,Omer Boudreau,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000005546.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-T119861-99"",
  ""submission_no"": ""143236"",
  ""manufacturer"": {
    ""name"": ""TEVA Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""DEC 08 2010"",
  ""product_name"": ""TEVA-DORZOTIMOL"",
  ""medicinal_ingredients"": ""Dorzolamide supplied as Dorzolamide Hydrochloride / Timolol Supplied as Timolol Maleate"",
  ""reason_for_submission"": ""Elevated Intraocular Pressure Therapy"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02320525 (OPH-SOL, Dorzolamide 20 mg/mL / Timolol 5 mg/mL)"",
  ""canadian_reference_product"": ""Cosopt, Merck Frosst Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCPC"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-T119861-99,143236,DEC 08 2010,TEVA-DORZOTIMOL,Dorzolamide supplied as Dorzolamide Hydrochloride / Timolol Supplied as Timolol Maleate,Elevated Intraocular Pressure Therapy,,"02320525 (OPH-SOL, Dorzolamide 20 mg/mL / Timolol 5 mg/mL)","Cosopt, Merck Frosst Canada Ltd., Canada",TEVA Canada Limited,30 Novopharm Court,Toronto,ON,Canada,M1B 2K9,"Supriya Sharma, MD MPH FRCPC",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000005756.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""144613"",
  ""submission_no"": ""9427-V07171-23"",
  ""manufacturer"": {
    ""name"": ""Valeant Canada LP/Valeant Canada S.E.C."",
    ""street"": ""4787 Levy St."",
    ""city"": ""Montreal"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H8R 2P9""
  },
  ""date"": ""FEB 1 1 2011"",
  ""product_name"": ""ZYBAN"",
  ""medicinal_ingredients"": ""Bupropion Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02238441 (ORL, TER, 150 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHAZMA"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,144613,9427-V07171-23,FEB 1 1 2011,ZYBAN,Bupropion Hydrochloride,Manufacturer Name Change,,"02238441 (ORL, TER, 150 mg)",,Valeant Canada LP/Valeant Canada S.E.C.,4787 Levy St.,Montreal,QC,Canada,H8R 2P9,Dr. SUPRIYA SHAZMA,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000005848.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""144802"",
  ""submission_no"": ""144802"",
  ""manufacturer"": {
    ""name"": ""Aventra Inc."",
    ""street"": ""10761 29th NE, Suite 110"",
    ""city"": ""Calgary"",
    ""province"": ""AB"",
    ""country"": ""Canada"",
    ""postal_code"": ""T2C 3C2""
  },
  ""date"": ""FEB 2 5 2011"",
  ""product_name"": ""AVA-ONDANSETRON"",
  ""medicinal_ingredients"": ""Ondansetron supplied as Ondansetron Hydrochloride Dihydrate"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02362310 (oral, tablet, 8 mg)"",
  ""canadian_reference_product"": ""Zofran, Glaxo Wellcome GmbH & Co., Germany"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,144802,144802,FEB 2 5 2011,AVA-ONDANSETRON,Ondansetron supplied as Ondansetron Hydrochloride Dihydrate,New Manufacturer and Product Name,,"02362310 (oral, tablet, 8 mg)","Zofran, Glaxo Wellcome GmbH & Co., Germany",Aventra Inc.,"10761 29th NE, Suite 110",Calgary,AB,Canada,T2C 3C2,"Supriya Sharma, MD MPH FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000005885.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""144026"",
  ""submission_no"": ""144026"",
  ""manufacturer"": {
    ""name"": ""Colgate-Palmolive Canada Inc."",
    ""street"": ""Two Morneau Sobeco Centre, 6th Floor"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1W3""
  },
  ""date"": ""MAR 08 2011"",
  ""product_name"": ""COLGATE TOTAL ADVANCED HEALTH GUM DEFENSE"",
  ""medicinal_ingredients"": ""Sodium Fluoride / Triclosan"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.003. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""62364786, Dental, Toothpaste, 0.243% / W/W / 0.300% / W/W"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD, MPH, FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,144026,144026,MAR 08 2011,COLGATE TOTAL ADVANCED HEALTH GUM DEFENSE,Sodium Fluoride / Triclosan,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.003. These obligations are detailed on the reverse of this notice.",,"62364786, Dental, Toothpaste, 0.243% / W/W / 0.300% / W/W",,Colgate-Palmolive Canada Inc.,"Two Morneau Sobeco Centre, 6th Floor",Toronto,Ontario,Canada,M3C 1W3,"Supriya Sharma, MD, MPH, FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000005944.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""107691"",
  ""submission_no"": ""107691"",
  ""manufacturer"": {
    ""name"": ""Genpharm Inc."",
    ""street"": ""85 Advance Rd."",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8Z 2S6""
  },
  ""date"": ""AUG 1 7 2006"",
  ""product_name"": ""METFORMIN"",
  ""medicinal_ingredients"": ""Metformin Hydrochloride"",
  ""reason_for_submission"": ""Additional Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02294782 (ORL,TAB, 500mg) 02294790 (ORL,TAB, 850mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. SUPRIYA SHARMA"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,107691,107691,AUG 1 7 2006,METFORMIN,Metformin Hydrochloride,Additional Product Name,,"02294782 (ORL,TAB, 500mg) 02294790 (ORL,TAB, 850mg)",,Genpharm Inc.,85 Advance Rd.,Etobicoke,ON,Canada,M8Z 2S6,Dr. SUPRIYA SHARMA,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000006014.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""145173"",
  ""submission_no"": ""145173"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""16760 route Transcanadienne"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""MAR 2 1 2011"",
  ""product_name"": ""K-DUR"",
  ""medicinal_ingredients"": ""Potassium Chloride"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00713376 (ORAL EXTENDED-RELEASE TABLET, 1.5 g)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPh FCRCP"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,145173,145173,MAR 2 1 2011,K-DUR,Potassium Chloride,Manufacturer Name Change,,"00713376 (ORAL EXTENDED-RELEASE TABLET, 1.5 g)",,Merck Canada Inc.,16760 route Transcanadienne,Kirkland,QC,Canada,H9H 4M7,Supriya Sharma MD MPh FCRCP,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000006016.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""145174"",
  ""submission_no"": ""145174"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""16750 route Transcanadienne"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""MAR 2 1 2011"",
  ""product_name"": ""ELOCOM"",
  ""medicinal_ingredients"": ""Mometasone Furoate"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(a), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""0087105 (TOPICAL, LOTION, 1 mg/g) 00851744 (TOPICAL, CREAM, 0.1%) 00851736 (TOPICAL, OINTMENT, 0.1%)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma MD MPH FRCPC"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,145174,145174,MAR 2 1 2011,ELOCOM,Mometasone Furoate,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(a), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"0087105 (TOPICAL, LOTION, 1 mg/g) 00851744 (TOPICAL, CREAM, 0.1%) 00851736 (TOPICAL, OINTMENT, 0.1%)",,Merck Canada Inc.,16750 route Transcanadienne,Kirkland,QC,Canada,H9H 4M7,Supriya Sharma MD MPH FRCPC,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000006203.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""106360"",
  ""submission_no"": ""106360"",
  ""manufacturer"": {
    ""name"": ""Dominion Pharmacal"",
    ""street"": ""6111 Royalmount Ave."",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""JUN 2 0 2006"",
  ""product_name"": ""DOM-SIMVASTATIN"",
  ""medicinal_ingredients"": ""Simvastatin"",
  ""reason_for_submission"": ""New Manufacturer and Product Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02281619 (ORL,TAB, 5mg) 02281627 (ORL,TAB, 10mg) 02281635 (ORL,TAB, 20mg) 02281643 (ORL,TAB, 40mg) 02281651 (ORL,TAB, 80mg)"",
  ""canadian_reference_product"": ""Zocor, Merck Frosst Canada & Co., Canada"",
  ""authorizing_official"": {
    ""name"": ""Omer Boudreau"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,106360,106360,JUN 2 0 2006,DOM-SIMVASTATIN,Simvastatin,New Manufacturer and Product Name,,"02281619 (ORL,TAB, 5mg) 02281627 (ORL,TAB, 10mg) 02281635 (ORL,TAB, 20mg) 02281643 (ORL,TAB, 40mg) 02281651 (ORL,TAB, 80mg)","Zocor, Merck Frosst Canada & Co., Canada",Dominion Pharmacal,6111 Royalmount Ave.,Montreal,PQ,Canada,H4P 2T4,Omer Boudreau,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000006215.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""105773"",
  ""submission_no"": ""105773"",
  ""manufacturer"": {
    ""name"": ""sanofi-aventis Canada Inc."",
    ""street"": ""2150 St. Elzear Blvd."",
    ""city"": ""Laval"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 4A9""
  },
  ""date"": ""MAY 1 6 2006"",
  ""product_name"": ""FLUOTIC"",
  ""medicinal_ingredients"": ""Sodium Fluoride"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02098225 (ORL_ECT, 20mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Omer Boudreau"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,105773,105773,MAY 1 6 2006,FLUOTIC,Sodium Fluoride,Manufacturer Name Change,,"02098225 (ORL_ECT, 20mg)",,sanofi-aventis Canada Inc.,2150 St. Elzear Blvd.,Laval,QC,Canada,H7L 4A9,Omer Boudreau,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000006255.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""108014"",
  ""submission_no"": ""108014"",
  ""manufacturer"": {
    ""name"": ""sanofi-aventis Canada inc."",
    ""street"": ""2150 St-Etienne Blvd West"",
    ""city"": ""Laval"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 4A8""
  },
  ""date"": ""SEP 0 5 2006"",
  ""product_name"": ""RHO-TRIAMCINOLONE AQ"",
  ""medicinal_ingredients"": ""Triamcinolone Acetonide"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02236568 (NAS,SPRAY, 55ug/DOSE)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Omer Boudreau"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,108014,108014,SEP 0 5 2006,RHO-TRIAMCINOLONE AQ,Triamcinolone Acetonide,Manufacturer Name Change,,"02236568 (NAS,SPRAY, 55ug/DOSE)",,sanofi-aventis Canada inc.,2150 St-Etienne Blvd West,Laval,PQ,Canada,H7L 4A8,Omer Boudreau,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000006493.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""142308"",
  ""submission_no"": ""142308"",
  ""manufacturer"": {
    ""name"": ""Bristol-Myers Squibb Canada"",
    ""street"": ""234 Alfred-Nobel"",
    ""city"": ""ST. LAURENT"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 0A4""
  },
  ""date"": ""MAY 0 5 2011"",
  ""product_name"": ""REYATAZ"",
  ""medicinal_ingredients"": ""Alazanavir (supplied as atazanavir sulfate)"",
  ""reason_for_submission"": ""Addition of Clinical Trial Data from HIV Infected Pregnant Women Updates to the Post-Market Data, and the Antiretroviral Pregnancy Registry"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, Oral, Capsule, 100 mg NIA, Oral, Capsule, 150 mg NIA, Oral, Capsule, 200 mg NIA, Oral, Capsule, 300 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,142308,142308,MAY 0 5 2011,REYATAZ,Alazanavir (supplied as atazanavir sulfate),"Addition of Clinical Trial Data from HIV Infected Pregnant Women Updates to the Post-Market Data, and the Antiretroviral Pregnancy Registry",,"NIA, Oral, Capsule, 100 mg NIA, Oral, Capsule, 150 mg NIA, Oral, Capsule, 200 mg NIA, Oral, Capsule, 300 mg",,Bristol-Myers Squibb Canada,234 Alfred-Nobel,ST. LAURENT,Quebec,Canada,H4S 0A4,"Supriya Sharma, MD MPH FRCP(C)",Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000006688.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""140974"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Gilead Sciences Inc."",
    ""street"": ""7333 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L4""
  },
  ""date"": ""JUL 1 2011"",
  ""product_name"": ""BOOSTRIX POLIO"",
  ""medicinal_ingredients"": ""diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous hemagglutinin, pertactin, inactivated polio virus type 1, inactivated polio virus type 2, inactivated polio virus type 3"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above supplement to a new drug submission complies with the requirements of sections C.08.003 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.003(1)(a), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NA, IM, SUS, 0.5 mL/single dose"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Ewyn Griffiths"",
    ""title"": ""Director General"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Directorate of Biologics and Genetic Therapies""
  }
}",TRUE,NA,140974,,JUL 1 2011,BOOSTRIX POLIO,"diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous hemagglutinin, pertactin, inactivated polio virus type 1, inactivated polio virus type 2, inactivated polio virus type 3","This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above supplement to a new drug submission complies with the requirements of sections C.08.003 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.003(1)(a), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"NA, IM, SUS, 0.5 mL/single dose",,Gilead Sciences Inc.,7333 Mississauga Road,Mississauga,ON,Canada,L5N 6L4,Ewyn Griffiths,Director General,Biologics and Genetic Therapies Directorate,Directorate of Biologics and Genetic Therapies
https://pdf.hres.ca/noc_pm/0000006728.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""138343"",
  ""submission_no"": ""138343"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L3""
  },
  ""date"": ""JUL 27 2011"",
  ""product_name"": ""ZYTIGA"",
  ""medicinal_ingredients"": ""abiraterone acetate"",
  ""reason_for_submission"": ""As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""62371065, Oral, Tablet, 250 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCP(C)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,138343,138343,JUL 27 2011,ZYTIGA,abiraterone acetate,"As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008.",,"62371065, Oral, Tablet, 250 mg",,Janssen Inc.,19 Green Belt Drive,TORONTO,Ontario,Canada,M3C 1L3,"Supriya Sharma, MD MPH FRCP(C)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000006760.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-A23851-24"",
  ""submission_no"": ""147760"",
  ""manufacturer"": {
    ""name"": ""Angita Pharma Inc."",
    ""street"": ""1380 Newton St."",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H2""
  },
  ""date"": ""AUG 2 2 2011"",
  ""product_name"": ""AG-RISPERIDONE"",
  ""medicinal_ingredients"": ""Risperidone"",
  ""reason_for_submission"": ""New Manufacturer and Product Name / Nouveau nom de fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02369079 (ORAL TABLET, 0.25 mg) 02365087 (ORAL TABLET, 0.5 mg) 02365085 (ORAL TABLET, 1 mg) 02369117 (ORAL TABLET, 2 mg) 02369125 (ORAL TABLET, 3 mg) 02369133 (ORAL TABLET, 4 mg)"",
  ""canadian_reference_product"": ""Risperdal, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Supriya Sharma, MD MPH FRCPC"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-A23851-24,147760,AUG 2 2 2011,AG-RISPERIDONE,Risperidone,New Manufacturer and Product Name / Nouveau nom de fabricant et du produit,,"02369079 (ORAL TABLET, 0.25 mg) 02365087 (ORAL TABLET, 0.5 mg) 02365085 (ORAL TABLET, 1 mg) 02369117 (ORAL TABLET, 2 mg) 02369125 (ORAL TABLET, 3 mg) 02369133 (ORAL TABLET, 4 mg)","Risperdal, Janssen-Ortho Inc., Canada",Angita Pharma Inc.,1380 Newton St.,Boucherville,QC,Canada,J4B 5H2,"Supriya Sharma, MD MPH FRCPC",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000006856.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""142198"",
  ""submission_no"": ""9427-C0015-48"",
  ""manufacturer"": {
    ""name"": ""Colgate-Palmolive Canada Inc."",
    ""street"": ""Two Nunneau Sobeco Centre"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M3C 1W3""
  },
  ""date"": ""SEP 20 2011"",
  ""product_name"": ""COLGATE TOTAL ADVANCED HEALTH SENSITIVE"",
  ""medicinal_ingredients"": ""Sodium Fluoride / Triclosan / Silicon Dioxide"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02373254, Dental, Toothpaste, 0.243% / W/W / 0.3% / W/W / 5% / W/W"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,142198,9427-C0015-48,SEP 20 2011,COLGATE TOTAL ADVANCED HEALTH SENSITIVE,Sodium Fluoride / Triclosan / Silicon Dioxide,,,"02373254, Dental, Toothpaste, 0.243% / W/W / 0.3% / W/W / 5% / W/W",,Colgate-Palmolive Canada Inc.,Two Nunneau Sobeco Centre,Toronto,Ontario,,M3C 1W3,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000006945.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-V0135-128141465"",
  ""submission_no"": ""141465"",
  ""manufacturer"": {
    ""name"": ""Vetoquinol N.A. Inc."",
    ""street"": """",
    ""city"": ""Lavaltrie"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J5T 3S5""
  },
  ""date"": ""OCT 1 2011"",
  ""product_name"": ""Narketan"",
  ""medicinal_ingredients"": ""Ketamine (as Ketamine HCl)"",
  ""reason_for_submission"": ""New drug submission"",
  ""species"": ""Cats"",
  ""drug_identification_number_route_form_strength"": ""02374904, intramuscular, Solution, 100mg/ml"",
  ""canadian_reference_product"": ""Ketaset (Pfizer Canada Inc., Animal Health Group) DIN# 02173239"",
  ""authorizing_official"": {
    ""name"": ""Daniel Chapel"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction générale des produits de santé et des aliments""
  }
}",TRUE,NA,OF15-21-V0135-128141465,141465,OCT 1 2011,Narketan,Ketamine (as Ketamine HCl),New drug submission,Cats,"02374904, intramuscular, Solution, 100mg/ml","Ketaset (Pfizer Canada Inc., Animal Health Group) DIN# 02173239",Vetoquinol N.A. Inc.,,Lavaltrie,QC,Canada,J5T 3S5,Daniel Chapel,Director General,Veterinary Drugs Directorate,Direction générale des produits de santé et des aliments
https://pdf.hres.ca/noc_pm/0000007041.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-M26151-27"",
  ""submission_no"": ""150514"",
  ""manufacturer"": {
    ""name"": ""Marcan Pharmaceuticals Inc."",
    ""street"": ""77 Auriga Drive, Unit #4"",
    ""city"": ""Ottawa"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""K2E 7Z7""
  },
  ""date"": ""NOV 1 6 2011"",
  ""product_name"": ""MAR-SIMVASTATIN"",
  ""medicinal_ingredients"": ""Simvastatin"",
  ""reason_for_submission"": ""New manufacturer and product name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02375036 (oral, tablet, 5 mg) 02375044 (oral, tablet, 10 mg) 02375052 (oral, tablet, 20 mg) 02375080 (oral, tablet, 40 mg) 02375079 (oral, tablet, 80 mg)"",
  ""canadian_reference_product"": ""Zocor, Merck Frost Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-M26151-27,150514,NOV 1 6 2011,MAR-SIMVASTATIN,Simvastatin,New manufacturer and product name,,"02375036 (oral, tablet, 5 mg) 02375044 (oral, tablet, 10 mg) 02375052 (oral, tablet, 20 mg) 02375080 (oral, tablet, 40 mg) 02375079 (oral, tablet, 80 mg)","Zocor, Merck Frost Canada Ltd., Canada",Marcan Pharmaceuticals Inc.,"77 Auriga Drive, Unit #4",Ottawa,ON,Canada,K2E 7Z7,Barbara J. Sabourin,Acting Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000007062.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-L0857-103/148483"",
  ""submission_no"": ""148483"",
  ""manufacturer"": {
    ""name"": ""LLOYD, Inc. of Iowa"",
    ""street"": ""P.O. Box 130"",
    ""city"": ""Sherando"",
    ""province"": ""USA"",
    ""country"": ""USA"",
    ""postal_code"": ""51661-6150""
  },
  ""date"": ""NOV 2 6 2011"",
  ""product_name"": ""Anased®"",
  ""medicinal_ingredients"": ""Xylazine (as xylazine hydrochloride)"",
  ""reason_for_submission"": ""Change in ownership"",
  ""species"": ""Horses"",
  ""drug_identification_number_route_form_strength"": ""C0582233, Intramuscular, intravenous, Solution, 100 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,OF15-21-L0857-103/148483,148483,NOV 2 6 2011,Anased®,Xylazine (as xylazine hydrochloride),Change in ownership,Horses,"C0582233, Intramuscular, intravenous, Solution, 100 mg/mL",,"LLOYD, Inc. of Iowa",P.O. Box 130,Sherando,USA,USA,51661-6150,Daniel Chaput,"Director General, Veterinary Drugs Directorate",Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000007102.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""128639"",
  ""submission_no"": ""128639"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8L 1T9""
  },
  ""date"": ""NOV 3 0 2011"",
  ""product_name"": ""APO-MYCOPHENOLATE"",
  ""medicinal_ingredients"": ""Mycophenolate Mofetil"",
  ""reason_for_submission"": ""Immunosuppressive Agent"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02352559, Oral, Capsule, 250 mg; 02352567, Oral, Tablet, 500 mg"",
  ""canadian_reference_product"": ""Cellcept, Hoffmann-La Roche Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,128639,128639,NOV 3 0 2011,APO-MYCOPHENOLATE,Mycophenolate Mofetil,Immunosuppressive Agent,,"02352559, Oral, Capsule, 250 mg; 02352567, Oral, Tablet, 500 mg","Cellcept, Hoffmann-La Roche Ltd., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M8L 1T9,Barbara J. Sabourin,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007132.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""093486"",
  ""submission_no"": ""DEC 14 2011"",
  ""manufacturer"": {
    ""name"": ""Teva Cabada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""DEC 14 2011"",
  ""product_name"": ""Teva-Clopidogrel"",
  ""medicinal_ingredients"": ""Clopidogrel (supplied as Clopidogrel Bisulfate)"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02293161, Oral, Tablet, 75 mg"",
  ""canadian_reference_product"": ""Plavix, Sanofi-Synthelabo Canada inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,093486,DEC 14 2011,DEC 14 2011,Teva-Clopidogrel,Clopidogrel (supplied as Clopidogrel Bisulfate),,,"02293161, Oral, Tablet, 75 mg","Plavix, Sanofi-Synthelabo Canada inc., Canada",Teva Cabada Limited,30 Novopharm Court,TORONTO,Ontario,Canada,M1B 2K9,Barbara J. Sabourin,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007232.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""151834"",
  ""submission_no"": ""151834"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""JAN 1 3 2012"",
  ""product_name"": ""TEVA-NARATRIPTAN"",
  ""medicinal_ingredients"": ""Naratriptan supplied as Naratriptan Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer and product name change / Changement du nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02314290 (oral, tablet, 1 mg) 02314304 (oral, tablet, 2.5 mg)"",
  ""canadian_reference_product"": ""Amerega, GlaxoSmithKline inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,151834,151834,JAN 1 3 2012,TEVA-NARATRIPTAN,Naratriptan supplied as Naratriptan Hydrochloride,Manufacturer and product name change / Changement du nom du fabricant et du produit,,"02314290 (oral, tablet, 1 mg) 02314304 (oral, tablet, 2.5 mg)","Amerega, GlaxoSmithKline inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,ON,Canada,M1B 2K9,Barbara J. Sabourin,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007267.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-N140311-83"",
  ""submission_no"": ""151641"",
  ""manufacturer"": {
    ""name"": ""NT Pharma Canada Ltd."",
    ""street"": ""5901 Main Street"",
    ""city"": ""Stouffville"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4A 1H5""
  },
  ""date"": ""JAN 1 8 2012"",
  ""product_name"": ""NTP-MONTELUKAST"",
  ""medicinal_ingredients"": ""Montelukast supplied as Montelukast Sodium"",
  ""reason_for_submission"": ""New manufacturer and product name / Nouveau nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02376822 (oral, chewable tablet, 4 mg) 02376830 (oral, chewable tablet, 5 mg) 02376849 (oral, tablet, 10 mg)"",
  ""canadian_reference_product"": ""Singular, Merck Frosst Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director-General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-N140311-83,151641,JAN 1 8 2012,NTP-MONTELUKAST,Montelukast supplied as Montelukast Sodium,New manufacturer and product name / Nouveau nom du fabricant et du produit,,"02376822 (oral, chewable tablet, 4 mg) 02376830 (oral, chewable tablet, 5 mg) 02376849 (oral, tablet, 10 mg)","Singular, Merck Frosst Canada Ltd., Canada",NT Pharma Canada Ltd.,5901 Main Street,Stouffville,ON,Canada,L4A 1H5,Barbara J. Sabourin,Acting Director-General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007285.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-A23831-84"",
  ""submission_no"": ""145370"",
  ""manufacturer"": {
    ""name"": ""Avanstra Inc."",
    ""street"": ""10761 - 29th NE, Suite 110"",
    ""city"": ""Calgary"",
    ""province"": ""AB"",
    ""country"": ""Canada"",
    ""postal_code"": ""T2C 3C2""
  },
  ""date"": ""JAN 3 0 2012"",
  ""product_name"": ""AVA-PAROXETINE"",
  ""medicinal_ingredients"": ""Paroxetine supplied as Paroxetine Hydrochloride"",
  ""reason_for_submission"": ""New manufacturer and product name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02365103 (oral, tablet, 10 mg) 02365111 (oral, tablet, 20 mg) 02365138 (oral, tablet, 50 mg)"",
  ""canadian_reference_product"": ""Pauli, SmithKline Beecham Pharma, Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-A23831-84,145370,JAN 3 0 2012,AVA-PAROXETINE,Paroxetine supplied as Paroxetine Hydrochloride,New manufacturer and product name,,"02365103 (oral, tablet, 10 mg) 02365111 (oral, tablet, 20 mg) 02365138 (oral, tablet, 50 mg)","Pauli, SmithKline Beecham Pharma, Canada",Avanstra Inc.,"10761 - 29th NE, Suite 110",Calgary,AB,Canada,T2C 3C2,Barbara J. Sabourin,Acting Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000007357.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""148332"",
  ""submission_no"": ""148332"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signal Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""FEB 1 0 2012"",
  ""product_name"": ""LORATADINE SOFT GEL CAPSULE"",
  ""medicinal_ingredients"": ""Loratadine"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02379481, Oral, Capsule, 10mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,148332,148332,FEB 1 0 2012,LORATADINE SOFT GEL CAPSULE,Loratadine,,,"02379481, Oral, Capsule, 10mg",,Apotex Inc.,150 Signal Drive,TORONTO,Ontario,,M5L 1T9,Barbara J. Sabourin,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007379.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-81716-100146251"",
  ""submission_no"": ""146261"",
  ""manufacturer"": {
    ""name"": ""Boehringer Ingelheim (Canada) Ltd."",
    ""street"": ""5180 South Service Road"",
    ""city"": ""Burlington"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L7L 5H4""
  },
  ""date"": ""FEB 2 2012"",
  ""product_name"": ""Metcasan® Oral Suspension for Cats"",
  ""medicinal_ingredients"": ""Meloxicam"",
  ""reason_for_submission"": ""Additional claim"",
  ""species"": ""Cats"",
  ""drug_identification_number_route_form_strength"": ""02360489, Oral, Suspension, 0.5 mg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chapel"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Director General, Direction des médicaments vétérinaires""
  }
}",TRUE,NA,OF15-21-81716-100146251,146261,FEB 2 2012,Metcasan® Oral Suspension for Cats,Meloxicam,Additional claim,Cats,"02360489, Oral, Suspension, 0.5 mg/ml",,Boehringer Ingelheim (Canada) Ltd.,5180 South Service Road,Burlington,ON,Canada,L7L 5H4,Daniel Chapel,"Director General, Veterinary Drugs Directorate",Veterinary Drugs Directorate,"Director General, Direction des médicaments vétérinaires"
https://pdf.hres.ca/noc_pm/0000007588.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""153002"",
  ""submission_no"": ""153002"",
  ""manufacturer"": {
    ""name"": ""Insight Pharmaceuticals LLC"",
    ""street"": ""1175 Wheeler Way"",
    ""city"": ""Langhorne"",
    ""province"": ""PA"",
    ""country"": ""USA"",
    ""postal_code"": ""19047-1749""
  },
  ""date"": ""APR 05 2012"",
  ""product_name"": ""MONICURE COMBO"",
  ""medicinal_ingredients"": ""Fluconazole / Miconazole Nitrate"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02382628, Oral/Topical, Capsule/Cream/Kit, 150 MG / 2%"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,153002,153002,APR 05 2012,MONICURE COMBO,Fluconazole / Miconazole Nitrate,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"02382628, Oral/Topical, Capsule/Cream/Kit, 150 MG / 2%",,Insight Pharmaceuticals LLC,1175 Wheeler Way,Langhorne,PA,USA,19047-1749,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007934.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""155891"",
  ""submission_no"": ""155891"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Jules-Léger Street"",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 7K8""
  },
  ""date"": ""JUN 2 1 2012"",
  ""product_name"": ""SANDOZ OFLOXACIN"",
  ""medicinal_ingredients"": ""Ofloxacin"",
  ""reason_for_submission"": ""Manufacturer and product name change / Changement du nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02247189 (ophthalmic, solution, 0.3%)"",
  ""canadian_reference_product"": ""Ocullux, Allergan Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,155891,155891,JUN 2 1 2012,SANDOZ OFLOXACIN,Ofloxacin,Manufacturer and product name change / Changement du nom du fabricant et du produit,,"02247189 (ophthalmic, solution, 0.3%)","Ocullux, Allergan Inc., Canada",Sandoz Canada Inc.,145 Jules-Léger Street,Boucherville,QC,Canada,J4B 7K8,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000007952.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""152290"",
  ""submission_no"": ""152290"",
  ""manufacturer"": {
    ""name"": ""Jansen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""MEX 11.9"",
    ""postal_code"": """"
  },
  ""date"": ""JUN 2 7 2012"",
  ""product_name"": ""VELCADE"",
  ""medicinal_ingredients"": ""bortezomib (supplied as bortezomib marmitol koranic ester)"",
  ""reason_for_submission"": ""Addition of an alternate manufacturing, packaging and testing site."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Powder for Solution, 3.5 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General/Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,152290,152290,JUN 2 7 2012,VELCADE,bortezomib (supplied as bortezomib marmitol koranic ester),"Addition of an alternate manufacturing, packaging and testing site.",,"N/A, Intravenous, Powder for Solution, 3.5 mg/vial",,Jansen Inc.,19 Green Belt Drive,TORONTO,Ontario,MEX 11.9,,Barbara J. Sabourin,Director General/Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008053.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""143070"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Accord Healthcare Inc."",
    ""street"": ""3100 Steeles Avenue East"",
    ""city"": ""Markham"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6A 6T3""
  },
  ""date"": ""JUL 2 4 2012"",
  ""product_name"": ""AH! TEMOZOLOMIDE CAPSULES"",
  ""medicinal_ingredients"": ""Temozolomide"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""G2389819, Oral, Capsule, 20 mg; G2389827, Oral, Capsule, 100 mg; G2389835, Oral, Capsule, 140 mg; G2389843, Oral, Capsule, 180 mg; G2389851, Oral, Capsule, 250 mg"",
  ""canadian_reference_product"": ""Temodal, Schering-Plough, Belgium"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,143070,,JUL 2 4 2012,AH! TEMOZOLOMIDE CAPSULES,Temozolomide,,,"G2389819, Oral, Capsule, 20 mg; G2389827, Oral, Capsule, 100 mg; G2389835, Oral, Capsule, 140 mg; G2389843, Oral, Capsule, 180 mg; G2389851, Oral, Capsule, 250 mg","Temodal, Schering-Plough, Belgium",Accord Healthcare Inc.,3100 Steeles Avenue East,Markham,ON,Canada,L6A 6T3,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000008156.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""150121"",
  ""submission_no"": ""150121"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""16750 Trans Canada Highway"",
    ""city"": ""KIRKLAND"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""AUG 07 2012"",
  ""product_name"": ""JANUVIA"",
  ""medicinal_ingredients"": ""sitagliptin (supplied as sitagliptin phosphate monohydrate)"",
  ""reason_for_submission"": ""New Indication: As add-on combination therapy with premixed or long/intermediate acting insulin (with or without metformin) in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when diet and exercise, and therapy with premixed or long/intermediate acting insulin (with or without metformin) do not provide adequate glycemic control."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Oral, Tablet, 100 mg"",
  ""canadian_reference_product"": ""N/A"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General/Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,150121,150121,AUG 07 2012,JANUVIA,sitagliptin (supplied as sitagliptin phosphate monohydrate),"New Indication: As add-on combination therapy with premixed or long/intermediate acting insulin (with or without metformin) in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control when diet and exercise, and therapy with premixed or long/intermediate acting insulin (with or without metformin) do not provide adequate glycemic control.",N/A,"Oral, Tablet, 100 mg",N/A,Merck Canada Inc.,16750 Trans Canada Highway,KIRKLAND,Quebec,Canada,H9H 4M7,Barbara J. Sabourin,Director General/Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008266.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""157200"",
  ""submission_no"": ""157200"",
  ""manufacturer"": {
    ""name"": ""GenMed, a division of Pfizer Canada Inc."",
    ""street"": ""17,300 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""SEP 06 2012"",
  ""product_name"": ""GD-SILDENAFIL R"",
  ""medicinal_ingredients"": ""Sildenafil supplied as sildenafil citrate"",
  ""reason_for_submission"": ""New manufacturer and product name / Nouveau nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02392682 (oral, tablet, 23 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,157200,157200,SEP 06 2012,GD-SILDENAFIL R,Sildenafil supplied as sildenafil citrate,New manufacturer and product name / Nouveau nom du fabricant et du produit,,"02392682 (oral, tablet, 23 mg)",,"GenMed, a division of Pfizer Canada Inc.","17,300 Trans Canada Highway",Kirkland,QC,Canada,H9J 2M5,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008395.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-PC00617-164"",
  ""submission_no"": ""146250"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17300 Trans-Canada Highway"",
    ""city"": ""KIRKLAND"",
    ""province"": ""Quebec"",
    ""country"": ""H9J 2M5"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""OCT 0 4 2012"",
  ""product_name"": ""Champix"",
  ""medicinal_ingredients"": ""Varenicline (supplied as varenicline tartrate)"",
  ""reason_for_submission"": ""Modification of specification and testing method before packaging."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 1 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-PC00617-164,146250,OCT 0 4 2012,Champix,Varenicline (supplied as varenicline tartrate),Modification of specification and testing method before packaging.,,"N/A, Oral, Tablet, 1 mg",,Pfizer Canada Inc.,17300 Trans-Canada Highway,KIRKLAND,Quebec,H9J 2M5,H9J 2M5,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008440.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""150966"",
  ""submission_no"": ""JANUVA"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""90750 Trans Canada Highway"",
    ""city"": ""KIRKLAND"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""OCT 1 0 2012"",
  ""product_name"": ""JANUVA"",
  ""medicinal_ingredients"": ""sitaliptin (supplied as sitagliptin phosphate monohydrate)"",
  ""reason_for_submission"": ""New Indication: In combination with pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, plus pioglitazone do not provide adequate glycemic control. New Indication: In combination with metformin and pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, and dual therapy with these agents, do not provide adequate glycemic control."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 25 mg; N/A, Oral, Tablet, 50 mg; N/A, Oral, Tablet, 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General/Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,150966,JANUVA,OCT 1 0 2012,JANUVA,sitaliptin (supplied as sitagliptin phosphate monohydrate),"New Indication: In combination with pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, plus pioglitazone do not provide adequate glycemic control. New Indication: In combination with metformin and pioglitazone in adult patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise, and dual therapy with these agents, do not provide adequate glycemic control.",,"N/A, Oral, Tablet, 25 mg; N/A, Oral, Tablet, 50 mg; N/A, Oral, Tablet, 100 mg",,Merck Canada Inc.,90750 Trans Canada Highway,KIRKLAND,Quebec,Canada,H9H 4M7,Barbara J. Sabourin,Director General/Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008514.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""116834"",
  ""submission_no"": ""116834"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave."",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""OCT 25 2012"",
  ""product_name"": ""pms-ANASTROZOLE"",
  ""medicinal_ingredients"": ""Anastrozole"",
  ""reason_for_submission"": ""Non-Steroidal Aromatase Inhibitor"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02320738, Oral, Tablet, 1 mg"",
  ""canadian_reference_product"": ""Arimidex, Astra Zeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,116834,116834,OCT 25 2012,pms-ANASTROZOLE,Anastrozole,Non-Steroidal Aromatase Inhibitor,,"02320738, Oral, Tablet, 1 mg","Arimidex, Astra Zeneca Canada Inc., Canada",Pharmascience Inc.,6111 Royalmount Ave.,Montreal,Quebec,Canada,H4P 2T4,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008604.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""154201"",
  ""submission_no"": ""154201"",
  ""manufacturer"": {
    ""name"": ""Sanofi Pasteur Limited"",
    ""street"": ""1755 Sheeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9R 3T4""
  },
  ""date"": ""NOV 0 1 2012"",
  ""product_name"": ""Vivaxim"",
  ""medicinal_ingredients"": ""Salmonella typhi VI capsular polysaccharide vaccine/ Vaccin polysaccharidique capsulaire VI purifié contre Salmonella typhi, inactivated hepatitis A virus/ vaccin anti-hépatite A inactivé"",
  ""reason_for_submission"": ""New intermediate seed lots and working seed lot de semence intermédiaire et nouveau lot de travail"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NA, IM, Salmonella typhi VI capsular polysaccharide vaccine/ Vaccin polysaccharidique capsulaire VI purifié contre Salmonella typhi 25µg/0.5ml, inactivated hepatitis A virus/ vaccin anti-hépatite A inactivé 150 units/0.5ml."",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Cushman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,154201,154201,NOV 0 1 2012,Vivaxim,"Salmonella typhi VI capsular polysaccharide vaccine/ Vaccin polysaccharidique capsulaire VI purifié contre Salmonella typhi, inactivated hepatitis A virus/ vaccin anti-hépatite A inactivé",New intermediate seed lots and working seed lot de semence intermédiaire et nouveau lot de travail,,"NA, IM, Salmonella typhi VI capsular polysaccharide vaccine/ Vaccin polysaccharidique capsulaire VI purifié contre Salmonella typhi 25µg/0.5ml, inactivated hepatitis A virus/ vaccin anti-hépatite A inactivé 150 units/0.5ml.",,Sanofi Pasteur Limited,1755 Sheeles Avenue West,Toronto,ON,Canada,M9R 3T4,Dr. Robert Cushman,Director General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000008622.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-A2443/1-38"",
  ""submission_no"": ""158346"",
  ""manufacturer"": {
    ""name"": ""AbbVie Corporation"",
    ""street"": ""9401 Trans Canada Highway"",
    ""city"": ""Saint-Laurent"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 1Z1""
  },
  ""date"": ""NOV 01 2012"",
  ""product_name"": ""NIMBEK"",
  ""medicinal_ingredients"": ""Cisatracurium supplied as Cisatracurium Besylate"",
  ""reason_for_submission"": ""Manufacturer name change / Changement du nom du fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02229422 (intravenous, liquid, 2 mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-A2443/1-38,158346,NOV 01 2012,NIMBEK,Cisatracurium supplied as Cisatracurium Besylate,Manufacturer name change / Changement du nom du fabricant,,"02229422 (intravenous, liquid, 2 mg/mL)",,AbbVie Corporation,9401 Trans Canada Highway,Saint-Laurent,QC,Canada,H4R 1Z1,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008687.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""159558"",
  ""submission_no"": ""159558"",
  ""manufacturer"": {
    ""name"": ""Aptex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""NOV 0 9 2012"",
  ""product_name"": ""ATORVASTATIN"",
  ""medicinal_ingredients"": ""Atorvastatin supplied as atorvastatin calcium propylene glycol solvate"",
  ""reason_for_submission"": ""Additional product name / Nom du produit additionnel"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02396424 (oral, tablet, 10 mg) 02396432 (oral, tablet, 20 mg) 02396440 (oral, tablet, 40 mg) 02396459 (oral, tablet, 80 mg)"",
  ""canadian_reference_product"": ""Liptor, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,159558,159558,NOV 0 9 2012,ATORVASTATIN,Atorvastatin supplied as atorvastatin calcium propylene glycol solvate,Additional product name / Nom du produit additionnel,,"02396424 (oral, tablet, 10 mg) 02396432 (oral, tablet, 20 mg) 02396440 (oral, tablet, 40 mg) 02396459 (oral, tablet, 80 mg)","Liptor, Pfizer Canada Inc., Canada",Aptex Inc.,150 Signet Drive,Toronto,ON,Canada,M9L 1T9,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008875.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""149115"",
  ""submission_no"": ""149115"",
  ""manufacturer"": {
    ""name"": ""Ranbaxy Pharmaceuticals Canada Inc."",
    ""street"": ""2080 Matheson Blvd. E."",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 5A5""
  },
  ""date"": ""Dec 17 2012"",
  ""product_name"": ""Ran-Fenofibrate S"",
  ""medicinal_ingredients"": ""Fenofibrate"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02391309, Oral, Tablet, 100 mg\n02391317, Oral, Tablet, 150 mg"",
  ""canadian_reference_product"": ""Lipid Supra, Fournier Pharma Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,149115,149115,Dec 17 2012,Ran-Fenofibrate S,Fenofibrate,,,"02391309, Oral, Tablet, 100 mg
02391317, Oral, Tablet, 150 mg","Lipid Supra, Fournier Pharma Inc., Canada",Ranbaxy Pharmaceuticals Canada Inc.,2080 Matheson Blvd. E.,Mississauga,Ontario,Canada,L4W 5A5,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008944.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-G1024-56"",
  ""submission_no"": ""159530"",
  ""manufacturer"": {
    ""name"": ""GenMed, a division of Pfizer Canada Inc."",
    ""street"": ""17,300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""JAN - 8 2013"",
  ""product_name"": ""GD-LISINOPRIL"",
  ""medicinal_ingredients"": ""Lisinopril supplied as Lisinopril Dihydrate"",
  ""reason_for_submission"": ""New manufacturer and product"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02398907 (oral, tablet, 5 mg); 02398915 (oral, tablet, 10 mg); 02398931 (oral, tablet, 20 mg)"",
  ""canadian_reference_product"": ""Zestril, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-G1024-56,159530,JAN - 8 2013,GD-LISINOPRIL,Lisinopril supplied as Lisinopril Dihydrate,New manufacturer and product,,"02398907 (oral, tablet, 5 mg); 02398915 (oral, tablet, 10 mg); 02398931 (oral, tablet, 20 mg)","Zestril, AstraZeneca Canada Inc., Canada","GenMed, a division of Pfizer Canada Inc.","17,300 Trans-Canada Highway",Kirkland,QC,Canada,H9J 2M5,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000008966.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-A2260/2-28"",
  ""submission_no"": ""160684"",
  ""manufacturer"": {
    ""name"": ""Accel Pharma Inc."",
    ""street"": ""99 Place Fontenac"",
    ""city"": ""Pointe-Claire"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9R 4Z7""
  },
  ""date"": ""JAN - 7 2013"",
  ""product_name"": ""ACCEL-AMLIDIPINE"",
  ""medicinal_ingredients"": ""Amlodipine supplied as Amlodipine Besylate"",
  ""reason_for_submission"": ""New manufacturer and product name / Nouveau nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02398788 (oral, tablet, 2.5 mg)"",
  ""canadian_reference_product"": ""Norvasc, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-A2260/2-28,160684,JAN - 7 2013,ACCEL-AMLIDIPINE,Amlodipine supplied as Amlodipine Besylate,New manufacturer and product name / Nouveau nom du fabricant et du produit,,"02398788 (oral, tablet, 2.5 mg)","Norvasc, Pfizer Canada Inc., Canada",Accel Pharma Inc.,99 Place Fontenac,Pointe-Claire,QC,Canada,H9R 4Z7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000009016.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""148320"",
  ""submission_no"": ""148320"",
  ""manufacturer"": {
    ""name"": ""Grifols Therapeutics Inc."",
    ""street"": ""8308 US 79 Business Highway West"",
    ""city"": ""Clayton"",
    ""province"": ""NC"",
    ""country"": ""USA"",
    ""postal_code"": ""27520""
  },
  ""date"": ""JAN 29 2013"",
  ""product_name"": ""Gamunex®"",
  ""medicinal_ingredients"": ""Immune Globulin (Human) / Immunoglobuline (Humaine)"",
  ""reason_for_submission"": ""New Indication for Guillain-Barré Syndrome (GBS) / Nouvelle Indication pour le Syndrome de Guillain-Barré"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NA. IV / SC, SOL, 10 g/100 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Gushman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,148320,148320,JAN 29 2013,Gamunex®,Immune Globulin (Human) / Immunoglobuline (Humaine),New Indication for Guillain-Barré Syndrome (GBS) / Nouvelle Indication pour le Syndrome de Guillain-Barré,,"NA. IV / SC, SOL, 10 g/100 mL",,Grifols Therapeutics Inc.,8308 US 79 Business Highway West,Clayton,NC,USA,27520,Dr. Robert Gushman,Director General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000009140.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""160897"",
  ""submission_no"": ""0427-C30561-21"",
  ""manufacturer"": {
    ""name"": ""Correvio (UK) Ltd."",
    ""street"": ""266 Strand"",
    ""city"": ""London"",
    ""province"": ""UNITED KINGDOM"",
    ""country"": ""UNITED KINGDOM"",
    ""postal_code"": ""WC2R 1BH""
  },
  ""date"": ""FEB 0 5 2013"",
  ""product_name"": ""AGGRATAT"",
  ""medicinal_ingredients"": ""Tirofiban supplied as tirofban hydrochloride"",
  ""reason_for_submission"": ""Manufacturer name change / Changement du nom du fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02240705 (intravenous, liquid, 0.25 mg/mL) 02240706 (intravenous, solution, 5 mg/100mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,160897,0427-C30561-21,FEB 0 5 2013,AGGRATAT,Tirofiban supplied as tirofban hydrochloride,Manufacturer name change / Changement du nom du fabricant,,"02240705 (intravenous, liquid, 0.25 mg/mL) 02240706 (intravenous, solution, 5 mg/100mL)",,Correvio (UK) Ltd.,266 Strand,London,UNITED KINGDOM,UNITED KINGDOM,WC2R 1BH,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000009223.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""153557"",
  ""submission_no"": ""153557"",
  ""manufacturer"": {
    ""name"": ""Ferring Inc."",
    ""street"": ""200 Yorktown Boulevard, Suite 800"",
    ""city"": ""NORTH YORK"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2J 5C1""
  },
  ""date"": ""FEB 1 3 2013"",
  ""product_name"": ""LYSTEDA"",
  ""medicinal_ingredients"": ""tranexamic acid"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02401959, Oral, Table, 650 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General/Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,153557,153557,FEB 1 3 2013,LYSTEDA,tranexamic acid,,,"02401959, Oral, Table, 650 mg",,Ferring Inc.,"200 Yorktown Boulevard, Suite 800",NORTH YORK,Ontario,Canada,M2J 5C1,Barbara J. Sabourin,Director General/Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000009258.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""161591"",
  ""submission_no"": ""161591"",
  ""manufacturer"": {
    ""name"": ""Accord Healthcare Inc."",
    ""street"": ""3100 Steeles Avenue East"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L3R 6T3""
  },
  ""date"": ""FEB 1 4 2013"",
  ""product_name"": ""CIPROFLOXACIN TABLETS"",
  ""medicinal_ingredients"": ""Ciprofloxacin supplied as Ciprofloxacin Hydrochloride"",
  ""reason_for_submission"": ""New manufacturer and product name / Nouveau nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02400766 (oral, tablet, 250 mg) 02400547 (oral, tablet, 500 mg) 02400555 (oral, tablet, 750 mg)"",
  ""canadian_reference_product"": ""Cipro, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,161591,161591,FEB 1 4 2013,CIPROFLOXACIN TABLETS,Ciprofloxacin supplied as Ciprofloxacin Hydrochloride,New manufacturer and product name / Nouveau nom du fabricant et du produit,,"02400766 (oral, tablet, 250 mg) 02400547 (oral, tablet, 500 mg) 02400555 (oral, tablet, 750 mg)","Cipro, Bayer Inc., Canada",Accord Healthcare Inc.,3100 Steeles Avenue East,Mississauga,Ontario,Canada,L3R 6T3,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000009282.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""157668"",
  ""submission_no"": ""157668"",
  ""manufacturer"": {
    ""name"": ""Genzyme Canada Inc. a division of sanofi-aventis Canada Inc."",
    ""street"": ""800-2700 Matheson Blvd E"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 4V9""
  },
  ""date"": ""FEB 22 2013"",
  ""product_name"": ""Fabrazyme"",
  ""medicinal_ingredients"": ""agalsidase beta"",
  ""reason_for_submission"": ""New manufacturing facility / Nouvel emplacement de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, PWSO, 5 mg/vial; N/A, IV, PWSO, 35 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Cushman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,157668,157668,FEB 22 2013,Fabrazyme,agalsidase beta,New manufacturing facility / Nouvel emplacement de fabrication,,"N/A, IV, PWSO, 5 mg/vial; N/A, IV, PWSO, 35 mg/vial",,Genzyme Canada Inc. a division of sanofi-aventis Canada Inc.,800-2700 Matheson Blvd E,Mississauga,ON,Canada,L4W 4V9,Dr. Robert Cushman,Director General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,NA
https://pdf.hres.ca/noc_pm/0000009285.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""152179"",
  ""submission_no"": ""152179"",
  ""manufacturer"": {
    ""name"": ""Jamp Pharma Corporation"",
    ""street"": ""1380 Newton"",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H2""
  },
  ""date"": ""FEB 2 2 2013"",
  ""product_name"": ""JAMP-GABAPENTIN TABLETS"",
  ""medicinal_ingredients"": ""Gabapentin"",
  ""reason_for_submission"": ""New manufacturer and product name / Nouveau nom du fabricant et du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02402289 (oral, tablet, 600 mg) 02402297 (oral, tablet, 600 mg)"",
  ""canadian_reference_product"": ""Neurontin, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,152179,152179,FEB 2 2 2013,JAMP-GABAPENTIN TABLETS,Gabapentin,New manufacturer and product name / Nouveau nom du fabricant et du produit,,"02402289 (oral, tablet, 600 mg) 02402297 (oral, tablet, 600 mg)","Neurontin, Pfizer Canada Inc., Canada",Jamp Pharma Corporation,1380 Newton,Boucherville,QC,Canada,J4B 5H2,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000009414.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""155655"",
  ""submission_no"": ""155655"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M3C 1L8""
  },
  ""date"": ""MAR 0 5 2013"",
  ""product_name"": ""DORIBAX"",
  ""medicinal_ingredients"": ""Doripenem supplied as Doripenem Monohydrate"",
  ""reason_for_submission"": ""Updates to the Warnings & Precautions, and the Dosage & Administration sections of the Product Monograph"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Intravenous, Powder for solution, 500 mg / Vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""John-Patrick Stewart"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,155655,155655,MAR 0 5 2013,DORIBAX,Doripenem supplied as Doripenem Monohydrate,"Updates to the Warnings & Precautions, and the Dosage & Administration sections of the Product Monograph",N/A,"Intravenous, Powder for solution, 500 mg / Vial",,Janssen Inc.,19 Green Belt Drive,TORONTO,Ontario,,M3C 1L8,John-Patrick Stewart,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000009620.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""2002659N"",
  ""submission_no"": ""2002659N"",
  ""manufacturer"": {
    ""name"": ""Bayer Inc., Bayer Healthcare, Animal Health Division"",
    ""street"": ""77 Bellfield Road"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9W 1G5""
  },
  ""date"": ""JAN 1 7 2005"",
  ""product_name"": ""Advantage Multi 100 (imidacloprid + Moxidectin) (Topical Parasiticide for Dogs)"",
  ""medicinal_ingredients"": ""Imidacloprid, Moxidectin"",
  ""reason_for_submission"": ""This is to notify you that pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations."",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""02263564, Topical, Solution, 400mg/4 mL, 100mg/4 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""D.C. Anikarica"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,2002659N,2002659N,JAN 1 7 2005,Advantage Multi 100 (imidacloprid + Moxidectin) (Topical Parasiticide for Dogs),"Imidacloprid, Moxidectin","This is to notify you that pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations.",Dogs,"02263564, Topical, Solution, 400mg/4 mL, 100mg/4 mL",,"Bayer Inc., Bayer Healthcare, Animal Health Division",77 Bellfield Road,Toronto,ON,Canada,M9W 1G5,D.C. Anikarica,"Director General, Veterinary Drugs Directorate",Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000009718.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""073239"",
  ""submission_no"": ""073239"",
  ""manufacturer"": {
    ""name"": ""AltMed Pharma Inc., a Division of Technilab Pharma Inc"",
    ""street"": ""17800 Lapointe"",
    ""city"": ""Mirabel"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7J 1P3""
  },
  ""date"": ""0 9 2001"",
  ""product_name"": ""ALTI-AMOXI CLAV-125F"",
  ""medicinal_ingredients"": ""Amoxicillin as Amoxicillin Trihydrate Clavulanic Acid as Clavulanate Potassium"",
  ""reason_for_submission"": ""Therapeutic Classification/Classification Thérapeutique"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02244646 (SUS, ORL, 125mg/5mL, amoxicillin, 31.25mg/mL, clavulanic acid) - Alt-Amoxi Clav-125F"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., Ph.D., M.P.H."",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,073239,073239,0 9 2001,ALTI-AMOXI CLAV-125F,Amoxicillin as Amoxicillin Trihydrate Clavulanic Acid as Clavulanate Potassium,Therapeutic Classification/Classification Thérapeutique,,"02244646 (SUS, ORL, 125mg/5mL, amoxicillin, 31.25mg/mL, clavulanic acid) - Alt-Amoxi Clav-125F",,"AltMed Pharma Inc., a Division of Technilab Pharma Inc",17800 Lapointe,Mirabel,PQ,Canada,J7J 1P3,"Robert G. Peterson, M.D., Ph.D., M.P.H.",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000009985.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""065818"",
  ""submission_no"": ""065818"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signal Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""N8V 0 9 2001"",
  ""product_name"": ""APO-FLAVOXATE Tablet"",
  ""medicinal_ingredients"": ""Flavoxate Hydrochloride"",
  ""reason_for_submission"": ""Urinary Tract Anti-spasmodic"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02244842 - 200mg"",
  ""canadian_reference_product"": ""Urispas"",
  ""authorizing_official"": {
    ""name"": ""Lynn Bernard"",
    ""title"": ""Original Signed By"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,065818,065818,N8V 0 9 2001,APO-FLAVOXATE Tablet,Flavoxate Hydrochloride,Urinary Tract Anti-spasmodic,,02244842 - 200mg,Urispas,Apotex Inc.,150 Signal Drive,TORONTO,Ontario,Canada,M5L 1T9,Lynn Bernard,Original Signed By,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000010027.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""2000125S"",
  ""submission_no"": ""9460-J0471-532"",
  ""manufacturer"": {
    ""name"": ""Intervet Canada Ltd."",
    ""street"": ""250 Water Street"",
    ""city"": ""Windsor"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L7N 9T5""
  },
  ""date"": ""MAR 2 7 2001"",
  ""product_name"": ""PANACUR PASTE 10%"",
  ""medicinal_ingredients"": ""Fenbendazole 100 mg/g"",
  ""reason_for_submission"": ""Treatment of equine larval cyathostomosis induced by encysted larvae (third and fourth stage) of cyathostomes."",
  ""species"": ""Horses"",
  ""drug_identification_number_route_form_strength"": ""02113163"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""D.C. Kirkpatrick"",
    ""title"": ""Visiting Executive, Veterinary Drug Program"",
    ""division"": ""Cadre supérieur invité"",
    ""directorate"": ""programme des médicaments vétérinaires""
  }
}",TRUE,NA,2000125S,9460-J0471-532,MAR 2 7 2001,PANACUR PASTE 10%,Fenbendazole 100 mg/g,Treatment of equine larval cyathostomosis induced by encysted larvae (third and fourth stage) of cyathostomes.,Horses,02113163,,Intervet Canada Ltd.,250 Water Street,Windsor,ON,Canada,L7N 9T5,D.C. Kirkpatrick,"Visiting Executive, Veterinary Drug Program",Cadre supérieur invité,programme des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000010045.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""064762"",
  ""submission_no"": ""064762"",
  ""manufacturer"": {
    ""name"": ""Novopharm Ltd."",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K3""
  },
  ""date"": ""SÉR. 2 1 2001"",
  ""product_name"": ""NOVO-GABAPENTIN Capsules"",
  ""medicinal_ingredients"": ""Gabapentin"",
  ""reason_for_submission"": ""the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations"",
  ""species"": ""Artileptic Agent"",
  ""drug_identification_number_route_form_strength"": ""02244513-100mg, 02244514-300mg, 02244515-400mg"",
  ""canadian_reference_product"": ""Neurontin Parke-Davis Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,064762,064762,SÉR. 2 1 2001,NOVO-GABAPENTIN Capsules,Gabapentin,the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations,Artileptic Agent,"02244513-100mg, 02244514-300mg, 02244515-400mg",Neurontin Parke-Davis Canada,Novopharm Ltd.,30 Novopharm Court,TORONTO,Ontario,Canada,M1B 2K3,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000010117.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""061071"",
  ""submission_no"": ""061071"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signal Drive"",
    ""city"": ""WESTON"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T3""
  },
  ""date"": ""JUN 1 1 2001"",
  ""product_name"": ""APO-LORATADINE Tablet"",
  ""medicinal_ingredients"": ""Loratadine"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02243880 - 10mg"",
  ""canadian_reference_product"": ""Claritin Schering Canada Inc. Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,061071,061071,JUN 1 1 2001,APO-LORATADINE Tablet,Loratadine,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations.",,02243880 - 10mg,Claritin Schering Canada Inc. Canada,Apotex Inc.,150 Signal Drive,WESTON,Ontario,Canada,M9L 1T3,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000010354.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""070158"",
  ""submission_no"": ""070158"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""2455 Meadowpine Blvd"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L7""
  },
  ""date"": ""FEB 1 3 2001"",
  ""product_name"": ""FORTOVASE ROCHE"",
  ""medicinal_ingredients"": ""Saquinavir"",
  ""reason_for_submission"": ""Product Name Change from Fortovase"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02239083 (CAP, ORL, 200mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Programme / Programme des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,070158,070158,FEB 1 3 2001,FORTOVASE ROCHE,Saquinavir,Product Name Change from Fortovase,,"02239083 (CAP, ORL, 200mg)",,Hoffmann-La Roche Limited,2455 Meadowpine Blvd,Mississauga,ON,Canada,L5N 6L7,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Programme / Programme des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000010411.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-G0833-04"",
  ""submission_no"": ""072559"",
  ""manufacturer"": {
    ""name"": ""GlasSmithKline Inc"",
    ""street"": ""7333 Mississauga Road N."",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L4""
  },
  ""date"": ""April 15 2001"",
  ""product_name"": ""PARNATE"",
  ""medicinal_ingredients"": ""Tranylcypromine as Tranylcypromine Sulfate"",
  ""reason_for_submission"": ""Change in Manufacturer Name"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01919598 (TAB,ORL, 10mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-G0833-04,072559,April 15 2001,PARNATE,Tranylcypromine as Tranylcypromine Sulfate,Change in Manufacturer Name,,"01919598 (TAB,ORL, 10mg)",,GlasSmithKline Inc,7333 Mississauga Road N.,Mississauga,ON,Canada,L5N 6L4,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000010452.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""064195"",
  ""submission_no"": ""064195"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc"",
    ""street"": ""6111 Royalmount Avenue"",
    ""city"": ""MONTREAL"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H3P 2T4""
  },
  ""date"": ""MAR 1 1 2002"",
  ""product_name"": ""PMS-AMIODARONE for Injection BP"",
  ""medicinal_ingredients"": ""Amiodarone hydrochloride"",
  ""reason_for_submission"": ""New Dosage Form"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02245371 - 50 mg/ml"",
  ""canadian_reference_product"": ""Cordarone Intravenous Wyeth-Ayerst Canada Inc. Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,064195,064195,MAR 1 1 2002,PMS-AMIODARONE for Injection BP,Amiodarone hydrochloride,New Dosage Form,,02245371 - 50 mg/ml,Cordarone Intravenous Wyeth-Ayerst Canada Inc. Canada,Pharmascience Inc,6111 Royalmount Avenue,MONTREAL,Quebec,Canada,H3P 2T4,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000010489.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""079683"",
  ""submission_no"": ""079683"",
  ""manufacturer"": {
    ""name"": ""lyco Healthcare"",
    ""street"": ""7500 Trans Canada Highway"",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9R 5H8""
  },
  ""date"": ""6 SEP 2002"",
  ""product_name"": ""ISOJEX SYRINGÉS I 125"",
  ""medicinal_ingredients"": ""Albumin Radioiodated I 125"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Julia Hill"",
    ""title"": ""Acting Director General"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,079683,079683,6 SEP 2002,ISOJEX SYRINGÉS I 125,Albumin Radioiodated I 125,Manufacturer Name Change,,N/A,,lyco Healthcare,7500 Trans Canada Highway,Montreal,PQ,Canada,H9R 5H8,Julia Hill,Acting Director General,Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000010492.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-R0798-85"",
  ""submission_no"": ""080356"",
  ""manufacturer"": {
    ""name"": ""rallipharma inc."",
    ""street"": ""17800 Lapointe"",
    ""city"": ""Mirabel"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7J 1P3""
  },
  ""date"": ""OCT 2 4 2002"",
  ""product_name"": ""RATIO-ACYCLOVIR"",
  ""medicinal_ingredients"": ""Acyclovir"",
  ""reason_for_submission"": ""Manufacturer and Product Name Change"",
  ""species"": ""Antiviral Agent"",
  ""drug_identification_number_route_form_strength"": ""02078627 (TAB.ORL., 200mg) 02078635 (TAB.ORL., 400mg) 02078651 (TAB.ORL., 800mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-R0798-85,080356,OCT 2 4 2002,RATIO-ACYCLOVIR,Acyclovir,Manufacturer and Product Name Change,Antiviral Agent,"02078627 (TAB.ORL., 200mg) 02078635 (TAB.ORL., 400mg) 02078651 (TAB.ORL., 800mg)",,rallipharma inc.,17800 Lapointe,Mirabel,PQ,Canada,J7J 1P3,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000010526.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""20010105"",
  ""submission_no"": ""20010105"",
  ""manufacturer"": {
    ""name"": ""Ayent Veterinary Laboratories"",
    ""street"": ""400 Michener Road"",
    ""city"": ""Guelph"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""N1K 1E4""
  },
  ""date"": ""APR 1 7 2002"",
  ""product_name"": ""TORBUTROL TABLETS 1 MG"",
  ""medicinal_ingredients"": ""Butorphanol (as butorphanol tartrate) 1 mg/tab"",
  ""reason_for_submission"": ""Alternate source of active ingredient"",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""00844977"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""D.C. Kirpatrick"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": """",
    ""directorate"": ""Veterinary Drugs Directorate""
  }
}",TRUE,NA,20010105,20010105,APR 1 7 2002,TORBUTROL TABLETS 1 MG,Butorphanol (as butorphanol tartrate) 1 mg/tab,Alternate source of active ingredient,Dogs,00844977,,Ayent Veterinary Laboratories,400 Michener Road,Guelph,ON,Canada,N1K 1E4,D.C. Kirpatrick,"Director General, Veterinary Drugs Directorate",,Veterinary Drugs Directorate
https://pdf.hres.ca/noc_pm/0000010603.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-A1563-58"",
  ""submission_no"": ""069551"",
  ""manufacturer"": {
    ""name"": ""Aventis Pharma Inc."",
    ""street"": ""2150 St. Elzear Blvd. West"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 4A8""
  },
  ""date"": ""Feb 19 2002"",
  ""product_name"": ""Taxotere, Concentrate for injection"",
  ""medicinal_ingredients"": ""docetaxel"",
  ""reason_for_submission"": ""New Indication: Monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen."",
  ""species"": ""Antineoplastic Agent"",
  ""drug_identification_number_route_form_strength"": ""N/A"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D. Ph.D. MPH"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,9427-A1563-58,069551,Feb 19 2002,"Taxotere, Concentrate for injection",docetaxel,New Indication: Monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.,Antineoplastic Agent,N/A,,Aventis Pharma Inc.,2150 St. Elzear Blvd. West,Laval,Quebec,Canada,H7L 4A8,"Robert G. Peterson, M.D. Ph.D. MPH",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000010610.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-R0798-54"",
  ""submission_no"": ""077371"",
  ""manufacturer"": {
    ""name"": ""cillipharm inc."",
    ""street"": ""17800 Lapointe"",
    ""city"": ""Mirabel PQ"",
    ""province"": """",
    ""country"": """",
    ""postal_code"": ""J7J 1P3""
  },
  ""date"": ""MAY 0 8 2002"",
  ""product_name"": ""RATIO-DOXYCYCLINE"",
  ""medicinal_ingredients"": ""Doxycline as Doxycycline Hydrate"",
  ""reason_for_submission"": ""Manufacturer and Product Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02091232 (TAB, ORL, 100mg) 02053103 (CAP, ORL, 100mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., M.P.H."",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-R0798-54,077371,MAY 0 8 2002,RATIO-DOXYCYCLINE,Doxycline as Doxycycline Hydrate,Manufacturer and Product Name Change,,"02091232 (TAB, ORL, 100mg) 02053103 (CAP, ORL, 100mg)",,cillipharm inc.,17800 Lapointe,Mirabel PQ,,,J7J 1P3,"Robert G. Peterson, M.D., M.P.H.",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000010629.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""077775"",
  ""submission_no"": ""9427-R0798-76"",
  ""manufacturer"": {
    ""name"": ""ratipharma inc."",
    ""street"": ""17800 Lapointe"",
    ""city"": ""Mirabel"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7J 1P3""
  },
  ""date"": ""JUN 0 2002"",
  ""product_name"": ""RATIO-DESIPRAMINE"",
  ""medicinal_ingredients"": ""Desipramine Hydrochloride"",
  ""reason_for_submission"": ""Manufacturer and Product Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01948775 (TAB,ORL, 10mg), 01948784 (TAB,ORL, 25mg), 01948792 (TAB,ORL, 50mg), 01948800 (TAB,ORL, 75mg), 01948814 (TAB,ORL, 100mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,077775,9427-R0798-76,JUN 0 2002,RATIO-DESIPRAMINE,Desipramine Hydrochloride,Manufacturer and Product Name Change,,"01948775 (TAB,ORL, 10mg), 01948784 (TAB,ORL, 25mg), 01948792 (TAB,ORL, 50mg), 01948800 (TAB,ORL, 75mg), 01948814 (TAB,ORL, 100mg)",,ratipharma inc.,17800 Lapointe,Mirabel,PQ,Canada,J7J 1P3,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000010680.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""069123"",
  ""submission_no"": ""069123"",
  ""manufacturer"": {
    ""name"": ""Genpharm Inc."",
    ""street"": ""85 Advance Road"",
    ""city"": ""ETOBICOKE"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9Z 2S9""
  },
  ""date"": ""JUN 0 5 2002"",
  ""product_name"": ""GEN-FLUCONAZOLE Capsule"",
  ""medicinal_ingredients"": ""Fluconazole"",
  ""reason_for_submission"": ""Drug Identification Number/Identification Numérique de drogue: 02249597 - 150 mg"",
  ""species"": ""Antifungal Agent"",
  ""drug_identification_number_route_form_strength"": ""02249597 - 150 mg"",
  ""canadian_reference_product"": ""Diflucan-150 Pfizer Canada Inc. Canaca"",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., Ph.D., MPH"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,069123,069123,JUN 0 5 2002,GEN-FLUCONAZOLE Capsule,Fluconazole,Drug Identification Number/Identification Numérique de drogue: 02249597 - 150 mg,Antifungal Agent,02249597 - 150 mg,Diflucan-150 Pfizer Canada Inc. Canaca,Genpharm Inc.,85 Advance Road,ETOBICOKE,Ontario,Canada,M9Z 2S9,"Robert G. Peterson, M.D., Ph.D., MPH",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000010688.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""076008"",
  ""submission_no"": ""076008"",
  ""manufacturer"": {
    ""name"": ""Bristol-Myers Squibb Canada Inc"",
    ""street"": ""2365 Cote de Lisse"",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4N 2M7""
  },
  ""date"": ""Feb. 15 2002"",
  ""product_name"": ""GALLIUM CITRATE Ga 67 INJECTION"",
  ""medicinal_ingredients"": ""Gallium 67"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,076008,076008,Feb. 15 2002,GALLIUM CITRATE Ga 67 INJECTION,Gallium 67,Manufacturer Name Change,N/A,N/A,,Bristol-Myers Squibb Canada Inc,2365 Cote de Lisse,Montreal,PQ,Canada,H4N 2M7,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000010780.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""076158"",
  ""submission_no"": ""076158"",
  ""manufacturer"": {
    ""name"": ""Bertex Canada Inc"",
    ""street"": ""2250 32nd Ave"",
    ""city"": ""Lachine"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H8T 3H4""
  },
  ""date"": ""FEB 27 2002"",
  ""product_name"": ""REFLUDAN"",
  ""medicinal_ingredients"": ""Lepridin"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02240996 (PWSO/IV, 50mg/Vial)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,076158,076158,FEB 27 2002,REFLUDAN,Lepridin,Manufacturer Name Change,,"02240996 (PWSO/IV, 50mg/Vial)",,Bertex Canada Inc,2250 32nd Ave,Lachine,PQ,Canada,H8T 3H4,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000010844.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""060418"",
  ""submission_no"": ""060418"",
  ""manufacturer"": {
    ""name"": ""Mayne Pharma (Canada) Inc."",
    ""street"": ""16100 aut. Transcanadienne"",
    ""city"": ""Montreal"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 4A1""
  },
  ""date"": ""OCT 2 4 2002"",
  ""product_name"": ""METHOTREXATE SODIUM INJECTION USP"",
  ""medicinal_ingredients"": ""Methotrexate as Methotrexate Sodium"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02182555 (SOL.IAR,IM,INT,IV, 25mg/mL), 02182547 (SOL.IAR,IM,INT,IV, 10mg/mL), 02182777 (SOL.IAR,IM,INT,IV, 25mg/mL), 02182971 (SOL.IV, 25mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,060418,060418,OCT 2 4 2002,METHOTREXATE SODIUM INJECTION USP,Methotrexate as Methotrexate Sodium,Manufacturer Name Change,,"02182555 (SOL.IAR,IM,INT,IV, 25mg/mL), 02182547 (SOL.IAR,IM,INT,IV, 10mg/mL), 02182777 (SOL.IAR,IM,INT,IV, 25mg/mL), 02182971 (SOL.IV, 25mg/mL)",,Mayne Pharma (Canada) Inc.,16100 aut. Transcanadienne,Montreal,PQ,Canada,H9J 4A1,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000010982.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""071940"",
  ""submission_no"": ""071940"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""2455 Meadowvale Boulevard"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L7""
  },
  ""date"": ""6 NOV 2002"",
  ""product_name"": ""Rituxan®"",
  ""medicinal_ingredients"": ""rituximab"",
  ""reason_for_submission"": ""New Indication - for use in the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Julia Hill"",
    ""title"": ""Acting Director General / Directeur général par intérim"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""La Direction des produits biologiques et des thérapies génétiques""
  }
}",TRUE,NA,071940,071940,6 NOV 2002,Rituxan®,rituximab,"New Indication - for use in the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy",N/A,N/A,,Hoffmann-La Roche Limited,2455 Meadowvale Boulevard,Mississauga,Ontario,Canada,L5N 6L7,Julia Hill,Acting Director General / Directeur général par intérim,Biologics and Genetic Therapies Directorate,La Direction des produits biologiques et des thérapies génétiques
https://pdf.hres.ca/noc_pm/0000011071.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9460-80284-28"",
  ""submission_no"": ""2000074S"",
  ""manufacturer"": {
    ""name"": ""Bio Agri Mix 1998 Inc."",
    ""street"": ""P.O. Box 399"",
    ""city"": ""NKK 1N0"",
    ""province"": """",
    ""country"": ""Canada"",
    ""postal_code"": """"
  },
  ""date"": ""JUN 2 5 2002"",
  ""product_name"": ""TYLOSIN 10 PREMIX"",
  ""medicinal_ingredients"": ""Tylosin (as tylosin phosphate) 22 g/kg"",
  ""reason_for_submission"": ""New zero-day withdrawal time when fed to swine at 110 mg tylosin per kg of complete feed (in the absence of concurrent tylosin use in drinking water)."",
  ""species"": ""Beef cattle, Swine"",
  ""drug_identification_number_route_form_strength"": ""00713481"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""D.C. Kirkpatrick"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Direction générale des produits de santé et des aliments"",
    ""directorate"": ""Directorat général des médicaments vétérinaires""
  }
}",TRUE,NA,9460-80284-28,2000074S,JUN 2 5 2002,TYLOSIN 10 PREMIX,Tylosin (as tylosin phosphate) 22 g/kg,New zero-day withdrawal time when fed to swine at 110 mg tylosin per kg of complete feed (in the absence of concurrent tylosin use in drinking water).,"Beef cattle, Swine",00713481,,Bio Agri Mix 1998 Inc.,P.O. Box 399,NKK 1N0,,Canada,,D.C. Kirkpatrick,"Director General, Veterinary Drugs Directorate",Direction générale des produits de santé et des aliments,Directorat général des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000011131.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""083279"",
  ""submission_no"": ""083279"",
  ""manufacturer"": {
    ""name"": ""Wyeth Canada"",
    ""street"": ""1025 Blvd. Marcel Laurin"",
    ""city"": ""St. Laurent"",
    ""province"": ""PQ"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 1J6""
  },
  ""date"": ""Apr 1 4 2003"",
  ""product_name"": ""AMICAR"",
  ""medicinal_ingredients"": ""E Aminocaproic Acid"",
  ""reason_for_submission"": ""Antifibrinolytic Agent"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""02169746 (I.V. 250mg/mL) 02169754 (T.A.B., 500mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,083279,083279,Apr 1 4 2003,AMICAR,E Aminocaproic Acid,Antifibrinolytic Agent,Human,"02169746 (I.V. 250mg/mL) 02169754 (T.A.B., 500mg)",,Wyeth Canada,1025 Blvd. Marcel Laurin,St. Laurent,PQ,Canada,H4R 1J6,Robert G. Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000011175.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""067185"",
  ""submission_no"": ""067185"",
  ""manufacturer"": {
    ""name"": ""Gernpharm Inc."",
    ""street"": ""85 Advance Rd"",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8Z 2S9""
  },
  ""date"": ""FEB 1 9 2003"",
  ""product_name"": ""GEN-CLOZAPINE"",
  ""medicinal_ingredients"": ""Clozapine"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02247243 - TAB, ORAL, 25mg / 02247244 - TAB, ORAL, 100mg"",
  ""canadian_reference_product"": ""Cizaril - Sandos Canada Inc. Canada"",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., Ph.D., M.P.H."",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Therapeutic Products Directorate""
  }
}",TRUE,NA,067185,067185,FEB 1 9 2003,GEN-CLOZAPINE,Clozapine,,,"02247243 - TAB, ORAL, 25mg / 02247244 - TAB, ORAL, 100mg",Cizaril - Sandos Canada Inc. Canada,Gernpharm Inc.,85 Advance Rd,Etobicoke,ON,Canada,M8Z 2S9,"Robert G. Peterson, M.D., Ph.D., M.P.H.",Director General,Therapeutic Products Directorate,Therapeutic Products Directorate
https://pdf.hres.ca/noc_pm/0000011177.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""071365"",
  ""submission_no"": ""071365"",
  ""manufacturer"": {
    ""name"": ""Serono Canada Inc."",
    ""street"": ""1075 North Service Road West"",
    ""city"": ""Oakville"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6M 2G2""
  },
  ""date"": ""Aug 1 3 2003"",
  ""product_name"": ""CETROTIDE"",
  ""medicinal_ingredients"": ""Cetrorelix Acetate"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02247766, SC, PWSO, 0.25 mg/vial; 02247767, SC, PWSO, 3.0 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., M.PH."",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,071365,071365,Aug 1 3 2003,CETROTIDE,Cetrorelix Acetate,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"02247766, SC, PWSO, 0.25 mg/vial; 02247767, SC, PWSO, 3.0 mg/vial",,Serono Canada Inc.,1075 North Service Road West,Oakville,Ontario,Canada,L6M 2G2,"Robert G. Peterson, M.D., M.PH.",Director General / Directeur général,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000011258.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""075470"",
  ""submission_no"": ""075470"",
  ""manufacturer"": {
    ""name"": ""Scheering Canada Inc."",
    ""street"": ""3535 Trans Canada Highway"",
    ""city"": ""POINTE-CLAIRE"",
    ""province"": ""Québec"",
    ""country"": ""H9R 1S4"",
    ""postal_code"": ""H9R 1S4""
  },
  ""date"": ""2003"",
  ""product_name"": ""AERIUS"",
  ""medicinal_ingredients"": ""Desloratadine"",
  ""reason_for_submission"": ""New Indication - Allergic Rhinitis"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, ORL, TAB, 5mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., PhD, MPH"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,075470,075470,2003,AERIUS,Desloratadine,New Indication - Allergic Rhinitis,,"NIA, ORL, TAB, 5mg",,Scheering Canada Inc.,3535 Trans Canada Highway,POINTE-CLAIRE,Québec,H9R 1S4,H9R 1S4,"Robert G. Peterson, M.D., PhD, MPH",Director General / Directeur général,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000011274.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""088536"",
  ""submission_no"": ""088536"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc"",
    ""street"": ""17,300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""SEP 1 5 2003"",
  ""product_name"": ""ARTHROTEC 50 ARTHROTEC 75"",
  ""medicinal_ingredients"": ""Diclofenac Sodium / Misoprostol"",
  ""reason_for_submission"": ""Manufacturer Name Change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01917058 (ORL,TAB, 50mg Diclofenac Sodium / 200mcg Misoprostol) - Arthrotec 50 02229637 (ORL,TAB, 75mg Diclofenac Sodium / 200mcg Misoprostol) - Arthrotec 75"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Therapeutic Products Directorate""
  }
}",TRUE,NA,088536,088536,SEP 1 5 2003,ARTHROTEC 50 ARTHROTEC 75,Diclofenac Sodium / Misoprostol,Manufacturer Name Change,,"01917058 (ORL,TAB, 50mg Diclofenac Sodium / 200mcg Misoprostol) - Arthrotec 50 02229637 (ORL,TAB, 75mg Diclofenac Sodium / 200mcg Misoprostol) - Arthrotec 75",,Pfizer Canada Inc,"17,300 Trans-Canada Highway",Kirkland,QC,Canada,H9J 2M5,Dr. Robert Peterson,Director General,Therapeutic Products Directorate,Therapeutic Products Directorate
https://pdf.hres.ca/noc_pm/0000011286.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9460-L10991-501"",
  ""submission_no"": ""2002124G"",
  ""manufacturer"": {
    ""name"": ""LEO Pharma Inc."",
    ""street"": ""123 Commerce Valley Drive East"",
    ""city"": ""Thornhill"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L3T 7W8""
  },
  ""date"": ""AUG 26 2003"",
  ""product_name"": ""Canavural (Ear Drops)"",
  ""medicinal_ingredients"": ""Dihydroxyamine lactate 5 mg/g\nFramycetin sulfate 5 mg/g\nNystatin 100,000 U/g\nPrednisolone 2.5 mg/g"",
  ""reason_for_submission"": ""To notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the regulations."",
  ""species"": ""Dogs, Cats"",
  ""drug_identification_number_route_form_strength"": ""00727709"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""C.C. Kirkpatrick"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Director General, Direction des médicaments vétérinaires""
  }
}",TRUE,NA,9460-L10991-501,2002124G,AUG 26 2003,Canavural (Ear Drops),"Dihydroxyamine lactate 5 mg/g
Framycetin sulfate 5 mg/g
Nystatin 100,000 U/g
Prednisolone 2.5 mg/g","To notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the regulations.","Dogs, Cats",00727709,,LEO Pharma Inc.,123 Commerce Valley Drive East,Thornhill,ON,Canada,L3T 7W8,C.C. Kirkpatrick,"Director General, Veterinary Drugs Directorate",Veterinary Drugs Directorate,"Director General, Direction des médicaments vétérinaires"
https://pdf.hres.ca/noc_pm/0000011293.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""075409"",
  ""submission_no"": ""075409"",
  ""manufacturer"": {
    ""name"": ""Aventis Pharma Inc."",
    ""street"": ""2150 St. Elzear Blvd. West"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 4A8""
  },
  ""date"": ""FEB 28 2003"",
  ""product_name"": ""Lovenox, Lovenox HP"",
  ""medicinal_ingredients"": ""Enoxaparin Sodium"",
  ""reason_for_submission"": ""Revisions to the Product Monograph including reduced dosage regimen for patients with severe renal impairment"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Liq. SC - 100 mg/ml; N/A, Liq. SC - 150 mg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,075409,075409,FEB 28 2003,"Lovenox, Lovenox HP",Enoxaparin Sodium,Revisions to the Product Monograph including reduced dosage regimen for patients with severe renal impairment,,"N/A, Liq. SC - 100 mg/ml; N/A, Liq. SC - 150 mg/ml",,Aventis Pharma Inc.,2150 St. Elzear Blvd. West,Laval,Quebec,Canada,H7L 4A8,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000011378.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""081287"",
  ""submission_no"": ""081287"",
  ""manufacturer"": {
    ""name"": ""Bayer Corporation"",
    ""street"": ""1884 Miles Avenue"",
    ""city"": ""Elkhart"",
    ""province"": ""Indiana"",
    ""country"": ""USA"",
    ""postal_code"": ""46514""
  },
  ""date"": ""25 SEP 2003"",
  ""product_name"": ""Gamimune® N, 5% and Gamimune® N, 10%"",
  ""medicinal_ingredients"": ""immune globulin intravenous (human) passive immunizing agent"",
  ""reason_for_submission"": ""new sterile filling facility"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 5 gm/100mL, N/A, IV, SOL, 10 gm/100 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Julia Hill"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,081287,081287,25 SEP 2003,"Gamimune® N, 5% and Gamimune® N, 10%",immune globulin intravenous (human) passive immunizing agent,new sterile filling facility,,"N/A, IV, SOL, 5 gm/100mL, N/A, IV, SOL, 10 gm/100 mL",,Bayer Corporation,1884 Miles Avenue,Elkhart,Indiana,USA,46514,Julia Hill,Director General / Directeur général,Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000011455.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-P1489-333"",
  ""submission_no"": ""060640"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Avenue"",
    ""city"": ""MONTREAL"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""N.S. 0 6 2003"",
  ""product_name"": ""pms-MELOXICAM"",
  ""medicinal_ingredients"": ""meloxicam"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02248267 - ORL, TAB, 7.5mg\n02248268 - ORL, TAB, 15mg"",
  ""canadian_reference_product"": ""Motibocox, Boehringer Ingelheim (Canada) Ltd, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-P1489-333,060640,N.S. 0 6 2003,pms-MELOXICAM,meloxicam,,,"02248267 - ORL, TAB, 7.5mg
02248268 - ORL, TAB, 15mg","Motibocox, Boehringer Ingelheim (Canada) Ltd, Canada",Pharmascience Inc.,6111 Royalmount Avenue,MONTREAL,Quebec,Canada,H4P 2T4,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000011580.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""083858"",
  ""submission_no"": ""083858"",
  ""manufacturer"": {
    ""name"": ""Insight Pharmaceuticals Corporation"",
    ""street"": ""550 Township Line Rd."",
    ""city"": ""Blue Bell"",
    ""province"": ""PA"",
    ""country"": ""USA"",
    ""postal_code"": ""19422""
  },
  ""date"": ""APR 3 0 2003"",
  ""product_name"": ""NIX CREME RINSE"",
  ""medicinal_ingredients"": ""Permethrin"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00771368 (CRM,TOP, 1%)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., Ph.D., M.P.H."",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,083858,083858,APR 3 0 2003,NIX CREME RINSE,Permethrin,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"00771368 (CRM,TOP, 1%)",,Insight Pharmaceuticals Corporation,550 Township Line Rd.,Blue Bell,PA,USA,19422,"Robert G. Peterson, M.D., Ph.D., M.P.H.",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000011673.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-P07621-22"",
  ""submission_no"": ""063806"",
  ""manufacturer"": {
    ""name"": ""Prempharm Inc."",
    ""street"": ""85 Advance Road"",
    ""city"": ""Etobicoke"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9Z 2S9""
  },
  ""date"": ""3 0 2003"",
  ""product_name"": ""SIMVASTATIN"",
  ""medicinal_ingredients"": ""SIMVASTATIN"",
  ""reason_for_submission"": ""Administrative ANDS for a Cross-Referenced Submission"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""G2247521 (TAB, ORL, 5mg) G2247532 (TAB, ORL, 10mg) G2247533 (TAB, ORL, 20mg) G2247534 (TAB, ORL, 40mg) G2247535 (TAB, ORL, 80mg)"",
  ""canadian_reference_product"": ""ZOCOR Merck Frosst Canada & Co. Canada"",
  ""authorizing_official"": {
    ""name"": ""Robert G. Peterson, M.D., Ph.D., MPH"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-P07621-22,063806,3 0 2003,SIMVASTATIN,SIMVASTATIN,Administrative ANDS for a Cross-Referenced Submission,Human,"G2247521 (TAB, ORL, 5mg) G2247532 (TAB, ORL, 10mg) G2247533 (TAB, ORL, 20mg) G2247534 (TAB, ORL, 40mg) G2247535 (TAB, ORL, 80mg)",ZOCOR Merck Frosst Canada & Co. Canada,Prempharm Inc.,85 Advance Road,Etobicoke,ON,Canada,M9Z 2S9,"Robert G. Peterson, M.D., Ph.D., MPH",Director General / Directeur général,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000011775.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""148299"",
  ""submission_no"": ""148299"",
  ""manufacturer"": {
    ""name"": ""AMO Canada Company"",
    ""street"": ""80 Whitehall Drive, Unit 2"",
    ""city"": ""Markham"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L3R 0P3""
  },
  ""date"": ""MAY 9 2013"",
  ""product_name"": ""REVITALENS OCUTEC MULTI-PURPOSE SOLUTION"",
  ""medicinal_ingredients"": ""Alexidine Dihydrochloride / Polyquaternium 1"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02405784, Disinfectant, Solution, 0.00016 %/W/W / 0.0003 %/W/W"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,148299,148299,MAY 9 2013,REVITALENS OCUTEC MULTI-PURPOSE SOLUTION,Alexidine Dihydrochloride / Polyquaternium 1,,,"02405784, Disinfectant, Solution, 0.00016 %/W/W / 0.0003 %/W/W",,AMO Canada Company,"80 Whitehall Drive, Unit 2",Markham,Ontario,Canada,L3R 0P3,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000011852.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-P23931-100164003"",
  ""submission_no"": ""164603"",
  ""manufacturer"": {
    ""name"": ""Pfizer Animal Health Canada Inc."",
    ""street"": ""17300 TransCanada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""MAY 2 2013"",
  ""product_name"": ""M-Elosyn"",
  ""medicinal_ingredients"": ""Meloxicam"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement between two companies"",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""00408403, Oral, Suspension, 1.5 mg/mL"",
  ""canadian_reference_product"": ""Meloxicam Oral Suspension (DIN 0237715), Boehringer Ingelheim Vetmedica, Europe"",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,OF15-21-P23931-100164003,164603,MAY 2 2013,M-Elosyn,Meloxicam,Administrative: Licensing Agreement between two companies,Dogs,"00408403, Oral, Suspension, 1.5 mg/mL","Meloxicam Oral Suspension (DIN 0237715), Boehringer Ingelheim Vetmedica, Europe",Pfizer Animal Health Canada Inc.,17300 TransCanada Highway,Kirkland,QC,Canada,H9J 2M5,Daniel Chaput,Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000011899.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""159405"",
  ""submission_no"": ""9427-B1878-109"",
  ""manufacturer"": {
    ""name"": ""Bayer Inc."",
    ""street"": ""77 Belfield Road"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9W 1C6""
  },
  ""date"": ""JUN 07 2013"",
  ""product_name"": ""YAZ PLUS"",
  ""medicinal_ingredients"": ""drospirenone, ethinyl estradiol, levomefolate calcium, and levomefolate calcium"",
  ""reason_for_submission"": ""Change in synthesis of drug substance."",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 3.0 mg, 0.02 mg, 0.451 mg and 0.451 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,159405,9427-B1878-109,JUN 07 2013,YAZ PLUS,"drospirenone, ethinyl estradiol, levomefolate calcium, and levomefolate calcium",Change in synthesis of drug substance.,Human,"N/A, Oral, Tablet, 3.0 mg, 0.02 mg, 0.451 mg and 0.451 mg",,Bayer Inc.,77 Belfield Road,TORONTO,Ontario,Canada,M9W 1C6,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012116.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""9427-M25521-211"",
  ""submission_no"": ""147842"",
  ""manufacturer"": {
    ""name"": ""Mylan Pharmaceuticals ULC"",
    ""street"": ""85 Advance Road"",
    ""city"": ""Etobicoke"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9Z 2S9""
  },
  ""date"": ""JUL - 5 2013"",
  ""product_name"": ""Mylan-Rabeprazole"",
  ""medicinal_ingredients"": ""Rabeprazole Sodium"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02408382, Oral, Tablet (delayed-release), 10 mg 02409408, Oral, Tablet (delayed-release), 20 mg"",
  ""canadian_reference_product"": ""Pariet, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,9427-M25521-211,147842,JUL - 5 2013,Mylan-Rabeprazole,Rabeprazole Sodium,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"02408382, Oral, Tablet (delayed-release), 10 mg 02409408, Oral, Tablet (delayed-release), 20 mg","Pariet, Janssen-Ortho Inc., Canada",Mylan Pharmaceuticals ULC,85 Advance Road,Etobicoke,Ontario,Canada,M9Z 2S9,Barbara J. Sabourin,Director General / Direction générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012118.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF-15-21-B1716-114/106673"",
  ""submission_no"": ""169373"",
  ""manufacturer"": {
    ""name"": ""Boehringer Ingelheim (Canada) Ltd."",
    ""street"": ""5180 South Service Road"",
    ""city"": ""Burlington"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L7L 0H4""
  },
  ""date"": ""JUL 1 0 2013"",
  ""product_name"": ""Metacam 20 mg/mL Solution for Injection"",
  ""medicinal_ingredients"": ""Meloxicam"",
  ""reason_for_submission"": ""Additional claim"",
  ""species"": ""Cattle"",
  ""drug_identification_number_route_form_strength"": ""62230059, Subcutaneous, Intravenous, Solution, 20mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chepil"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Directorat des médicaments vétérinaires""
  }
}",TRUE,NA,OF-15-21-B1716-114/106673,169373,JUL 1 0 2013,Metacam 20 mg/mL Solution for Injection,Meloxicam,Additional claim,Cattle,"62230059, Subcutaneous, Intravenous, Solution, 20mg/mL",,Boehringer Ingelheim (Canada) Ltd.,5180 South Service Road,Burlington,ON,Canada,L7L 0H4,Daniel Chepil,Director General,Veterinary Drugs Directorate,Directorat des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000012215.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""165851"",
  ""submission_no"": ""165851"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""JUL 1 9 2013"",
  ""product_name"": ""NTP-AMIODARONE"",
  ""medicinal_ingredients"": ""Amiodarone Hydrochloride"",
  ""reason_for_submission"": ""Administrative: merger - buyout / Administratif: fusion - rachat"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02361280 (oral, tablet, 200 mg)"",
  ""canadian_reference_product"": ""Cordarone, Wyeth Ayerst Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,165851,165851,JUL 1 9 2013,NTP-AMIODARONE,Amiodarone Hydrochloride,Administrative: merger - buyout / Administratif: fusion - rachat,,"02361280 (oral, tablet, 200 mg)","Cordarone, Wyeth Ayerst Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,ON,Canada,M1B 2K9,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012419.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""158863"",
  ""submission_no"": ""158863"",
  ""manufacturer"": {
    ""name"": ""Aicon Canada Incorporated"",
    ""street"": ""2805 Meadowpine Blvd"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 9C7""
  },
  ""date"": ""AUG 2 2 2013"",
  ""product_name"": ""ILEVRO"",
  ""medicinal_ingredients"": ""Napafenac"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02411393, Ophthalmic, Suspension, 0.3 % W/V"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,158863,158863,AUG 2 2 2013,ILEVRO,Napafenac,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Regulations.",,"02411393, Ophthalmic, Suspension, 0.3 % W/V",,Aicon Canada Incorporated,2805 Meadowpine Blvd,Mississauga,Ontario,Canada,L5N 9C7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012432.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""166986"",
  ""submission_no"": ""166986"",
  ""manufacturer"": {
    ""name"": ""Ranbaxy Pharmaceuticals Canada Inc."",
    ""street"": ""2680 Matheson Blvd. E., Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 0A5""
  },
  ""date"": ""AUG 2 1 2013"",
  ""product_name"": ""CANDESARTAN Cilexetil"",
  ""medicinal_ingredients"": ""Angiotensin II AT1 Receptor Blocker / Angiotensin II Receptor Blocker"",
  ""reason_for_submission"": ""Administrative - additional product name / Administratif - nom du produit additionnel"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02410478 (oral, tablet, 4 mg) 02410486 (oral, tablet, 8 mg) 02410494 (oral, tablet, 16 mg) 02410508 (oral, tablet, 32 mg)"",
  ""canadian_reference_product"": ""Atacand, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,166986,166986,AUG 2 1 2013,CANDESARTAN Cilexetil,Angiotensin II AT1 Receptor Blocker / Angiotensin II Receptor Blocker,Administrative - additional product name / Administratif - nom du produit additionnel,,"02410478 (oral, tablet, 4 mg) 02410486 (oral, tablet, 8 mg) 02410494 (oral, tablet, 16 mg) 02410508 (oral, tablet, 32 mg)","Atacand, AstraZeneca Canada Inc., Canada",Ranbaxy Pharmaceuticals Canada Inc.,"2680 Matheson Blvd. E., Suite 200",Mississauga,ON,Canada,L4W 0A5,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012539.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""167451"",
  ""submission_no"": ""167451"",
  ""manufacturer"": {
    ""name"": ""Sivern Pharmaceuticals ULC"",
    ""street"": ""4705 Dobrin Street"",
    ""city"": ""Saint-Laurent"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 2P7""
  },
  ""date"": ""SEP 11 2013"",
  ""product_name"": ""OMEPAZOLE-20"",
  ""medicinal_ingredients"": ""Omeprazole"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02411857 (oral, delayed-release capsules, 20 mg)"",
  ""canadian_reference_product"": ""Losec, Astra Pharma Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,167451,167451,SEP 11 2013,OMEPAZOLE-20,Omeprazole,Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés,,"02411857 (oral, delayed-release capsules, 20 mg)","Losec, Astra Pharma Inc., Canada",Sivern Pharmaceuticals ULC,4705 Dobrin Street,Saint-Laurent,QC,Canada,H4R 2P7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012760.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""154088"",
  ""submission_no"": ""154088"",
  ""manufacturer"": {
    ""name"": ""Allergan Inc"",
    ""street"": ""65 Enterprise Blvd"",
    ""city"": ""Markham"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L3G 0B5""
  },
  ""date"": ""OCT 10 2013"",
  ""product_name"": ""BOTOX®"",
  ""medicinal_ingredients"": ""OnabotulinumtoxinA"",
  ""reason_for_submission"": ""New indication: for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of anticholinergic medication."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NA, IM, PWSO, 50 Units/vial, 100 Units/vial, 200 Units/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Cushman"",
    ""title"": ""Director, Biologics and Genetic Therapies"",
    ""division"": ""Biologics and Genetic Therapies"",
    ""directorate"": ""Directorate of Biologics and Genetic Therapies""
  }
}",TRUE,NA,154088,154088,OCT 10 2013,BOTOX®,OnabotulinumtoxinA,"New indication: for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of anticholinergic medication.",,"NA, IM, PWSO, 50 Units/vial, 100 Units/vial, 200 Units/vial",,Allergan Inc,65 Enterprise Blvd,Markham,Ontario,Canada,L3G 0B5,Dr. Robert Cushman,"Director, Biologics and Genetic Therapies",Biologics and Genetic Therapies,Directorate of Biologics and Genetic Therapies
https://pdf.hres.ca/noc_pm/0000012766.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e162151"",
  ""submission_no"": ""162151"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""OCT 1 0 2013"",
  ""product_name"": ""Apo-Latanoprost-Timop"",
  ""medicinal_ingredients"": ""Timolol (supplied as timolol maleate 6.83 mg/mL)"",
  ""reason_for_submission"": ""Elevated Intraocular Pressure Therapy"",
  ""species"": ""Prostaglandin F2a analogue and beta-adrenergic receptor blocker"",
  ""drug_identification_number_route_form_strength"": ""02414155, Ophthalmic, Solution, 50 µg/mL / 5 mg/mL"",
  ""canadian_reference_product"": ""Xalacom, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e162151,162151,OCT 1 0 2013,Apo-Latanoprost-Timop,Timolol (supplied as timolol maleate 6.83 mg/mL),Elevated Intraocular Pressure Therapy,Prostaglandin F2a analogue and beta-adrenergic receptor blocker,"02414155, Ophthalmic, Solution, 50 µg/mL / 5 mg/mL","Xalacom, Pfizer Canada Inc., Canada",Apotex Inc.,150 Signet Drive,TORONTO,ON,Canada,M5L 1T9,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000012910.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""168228"",
  ""submission_no"": ""168228"",
  ""manufacturer"": {
    ""name"": ""Pro Doc Limitée"",
    ""street"": ""2925, boul. Industriel"",
    ""city"": ""Laval"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 3W9""
  },
  ""date"": ""OCT 3 1 2013"",
  ""product_name"": ""CARBAMAZEPINE CR"",
  ""medicinal_ingredients"": ""Carbamazepine"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02413590 (oral, extended-release tablet, 200 mg) 02413604 (oral, extended-release tablet, 400 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,168228,168228,OCT 3 1 2013,CARBAMAZEPINE CR,Carbamazepine,Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés,,"02413590 (oral, extended-release tablet, 200 mg) 02413604 (oral, extended-release tablet, 400 mg)",,Pro Doc Limitée,"2925, boul. Industriel",Laval,QC,Canada,H7L 3W9,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000013027.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""168206"",
  ""submission_no"": ""168206"",
  ""manufacturer"": {
    ""name"": ""TEVA Pharmaceuticals Inc."",
    ""street"": ""10001 N. 10th Street"",
    ""city"": ""Maven"",
    ""province"": ""PA"",
    ""country"": ""USA"",
    ""postal_code"": ""19325""
  },
  ""date"": ""NOV 2 1 2013"",
  ""product_name"": ""Frovatriptan"",
  ""medicinal_ingredients"": ""5-HT1 Receptor Subtype Agonist, Migraine Therapy / Agoniste des récepteurs de sous-type 5-HT1, Antimigraineux"",
  ""reason_for_submission"": ""Frovatriptan supplied as Frovatriptan Succinate"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""02415944 (oral, tablet, 2.5 mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Babara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,168206,168206,NOV 2 1 2013,Frovatriptan,"5-HT1 Receptor Subtype Agonist, Migraine Therapy / Agoniste des récepteurs de sous-type 5-HT1, Antimigraineux",Frovatriptan supplied as Frovatriptan Succinate,Human,"02415944 (oral, tablet, 2.5 mg)",,TEVA Pharmaceuticals Inc.,10001 N. 10th Street,Maven,PA,USA,19325,Babara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000013042.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""18400"",
  ""submission_no"": ""9427-7488-596"",
  ""manufacturer"": {
    ""name"": ""Pharmadex Inc."",
    ""street"": ""100 Avenue"",
    ""city"": ""Montreal"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9P 2T4""
  },
  ""date"": ""NOV 2 6 2013"",
  ""product_name"": ""ALLERGY CONTROL DESORATADINE"",
  ""medicinal_ingredients"": ""Desloratadine"",
  ""reason_for_submission"": ""Administrative - additional product name /Administratif - nom additionnel du produit"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""02415771 (oral, tablet, 5 mg)"",
  ""canadian_reference_product"": ""Aero, Schering Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director, Therapeutic Products Directorate"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,18400,9427-7488-596,NOV 2 6 2013,ALLERGY CONTROL DESORATADINE,Desloratadine,Administrative - additional product name /Administratif - nom additionnel du produit,Human,"02415771 (oral, tablet, 5 mg)","Aero, Schering Canada Inc., Canada",Pharmadex Inc.,100 Avenue,Montreal,QC,Canada,H9P 2T4,Barbara J. Sabourin,"Director, Therapeutic Products Directorate",Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000013637.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""171120"",
  ""submission_no"": ""171120"",
  ""manufacturer"": {
    ""name"": ""GlaxoSmithKline"",
    ""street"": ""Prometheus Rd"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L4""
  },
  ""date"": ""FEB 1 2014"",
  ""product_name"": ""Typherix"",
  ""medicinal_ingredients"": ""Vi Capsular polysaccharide of Salmonella Typhi / Vi polysaccharide Capsulaire de Salmonella Typhi"",
  ""reason_for_submission"": ""Update format of Product Monograph / mise à jour le format de Monographie de Produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IM, PWSO, Vi Capsular polysaccharide of Salmonella Typhi / Vi polysaccharide Capsulaire de Salmonella Typhi 300Units/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Cushman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,171120,171120,FEB 1 2014,Typherix,Vi Capsular polysaccharide of Salmonella Typhi / Vi polysaccharide Capsulaire de Salmonella Typhi,Update format of Product Monograph / mise à jour le format de Monographie de Produit,,"N/A, IM, PWSO, Vi Capsular polysaccharide of Salmonella Typhi / Vi polysaccharide Capsulaire de Salmonella Typhi 300Units/vial",,GlaxoSmithKline,Prometheus Rd,Mississauga,ON,Canada,L5N 6L4,Dr. Robert Cushman,Director General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000013710.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF-15-21-2015011-1821169006"",
  ""submission_no"": ""189096"",
  ""manufacturer"": {
    ""name"": ""Zoetis Canada Inc."",
    ""street"": ""17300 TransCanada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""FEB 13 2014"",
  ""product_name"": ""Zeniquin®"",
  ""medicinal_ingredients"": ""Marbofloxacin"",
  ""reason_for_submission"": ""Administrative - Transfer of Drug Identification Number (DIN) Holder"",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""02241413, Oral, Tablets, 100 mg/tab"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": """",
    ""directorate"": ""Veterinary Drugs Directorate""
  }
}",TRUE,NA,OF-15-21-2015011-1821169006,189096,FEB 13 2014,Zeniquin®,Marbofloxacin,Administrative - Transfer of Drug Identification Number (DIN) Holder,Dogs,"02241413, Oral, Tablets, 100 mg/tab",,Zoetis Canada Inc.,17300 TransCanada Highway,Kirkland,QC,Canada,H9J 2M5,Daniel Chaput,"Director General, Veterinary Drugs Directorate",,Veterinary Drugs Directorate
https://pdf.hres.ca/noc_pm/0000013767.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-201601-1511167719"",
  ""submission_no"": ""167719"",
  ""manufacturer"": {
    ""name"": ""Zoetis Canada Inc."",
    ""street"": ""17300 TransCanada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""FEB 2 2014"",
  ""product_name"": ""Ketaset®"",
  ""medicinal_ingredients"": ""Ketamine (as ketamine hydrochloride)"",
  ""reason_for_submission"": ""Administrative - Transfer of Drug Identification Number (DIN) Holder"",
  ""species"": ""Cats"",
  ""drug_identification_number_route_form_strength"": ""02173239. Intramuscular, Solution, 100 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Charet"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,OF15-21-201601-1511167719,167719,FEB 2 2014,Ketaset®,Ketamine (as ketamine hydrochloride),Administrative - Transfer of Drug Identification Number (DIN) Holder,Cats,"02173239. Intramuscular, Solution, 100 mg/mL",,Zoetis Canada Inc.,17300 TransCanada Highway,Kirkland,QC,Canada,H9J 2M5,Daniel Charet,Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000013925.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p18370"",
  ""submission_no"": ""181370"",
  ""manufacturer"": {
    ""name"": ""Mint Pharmaceuticals Inc."",
    ""street"": ""Unit 1"",
    ""city"": ""MISSISSAUGA"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5T 1J8""
  },
  ""date"": ""MAR - 7 2014"",
  ""product_name"": ""Min-Latanoprost"",
  ""medicinal_ingredients"": ""Latanoprost"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above product is confirmed as meeting the requirements of sections C.08.002 and C.08.003.1 of the Food and Drug Regulations, and that your obligations under C.08.002(1)(b), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""0242127, Ophthalmic Solution, 50 mg/mL"",
  ""canadian_reference_product"": ""Kala, Pfizer Canada Inc. Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Secorim"",
    ""title"": ""Director General, Directorate of Therapeutic Products"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Directorate of Therapeutic Products""
  }
}",TRUE,NA,p18370,181370,MAR - 7 2014,Min-Latanoprost,Latanoprost,"This is to notify you that, pursuant to section C.08.004 of the Food and Drug Regulations, the above product is confirmed as meeting the requirements of sections C.08.002 and C.08.003.1 of the Food and Drug Regulations, and that your obligations under C.08.002(1)(b), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"0242127, Ophthalmic Solution, 50 mg/mL","Kala, Pfizer Canada Inc. Canada",Mint Pharmaceuticals Inc.,Unit 1,MISSISSAUGA,ON,Canada,L5T 1J8,Barbara J. Secorim,"Director General, Directorate of Therapeutic Products",Therapeutic Products Directorate,Directorate of Therapeutic Products
https://pdf.hres.ca/noc_pm/0000013938.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""145771"",
  ""submission_no"": ""145771"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 3G6""
  },
  ""date"": ""MAR 1 0 2014"",
  ""product_name"": ""Ciprofloxacin (Sodium) as Ciprofloxacin Hydrochloride"",
  ""medicinal_ingredients"": ""Ciprofloxacin (Sodium) as Ciprofloxacin Hydrochloride"",
  ""reason_for_submission"": ""Extension of the shelf life"",
  ""species"": ""Antibacterial Agent"",
  ""drug_identification_number_route_form_strength"": ""NA, Oral, Tablet, 250 mg"",
  ""canadian_reference_product"": ""NA, Oral, Tablet, 500 mg"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director, Generic Drug Directorate"",
    ""division"": ""Directorate of Generic Drugs"",
    ""directorate"": ""Directorate of Therapeutic Products""
  }
}",TRUE,NA,145771,145771,MAR 1 0 2014,Ciprofloxacin (Sodium) as Ciprofloxacin Hydrochloride,Ciprofloxacin (Sodium) as Ciprofloxacin Hydrochloride,Extension of the shelf life,Antibacterial Agent,"NA, Oral, Tablet, 250 mg","NA, Oral, Tablet, 500 mg",Auro Pharma Inc.,3700 Steeles Avenue West,Mississauga,ON,Canada,L4W 3G6,Barbara J. Sabourin,"Director, Generic Drug Directorate",Directorate of Generic Drugs,Directorate of Therapeutic Products
https://pdf.hres.ca/noc_pm/0000013953.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF-15-21-20150/2-210/171152"",
  ""submission_no"": ""171152"",
  ""manufacturer"": {
    ""name"": ""Zoetis Canada Inc."",
    ""street"": ""16740 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""MAR 4 2014"",
  ""product_name"": ""Aureomycin® 220 G"",
  ""medicinal_ingredients"": ""Chlortetracycline hydrochloride (as chlortetracycline calcium complex)"",
  ""reason_for_submission"": ""Administrative - Transfer of Drug Identification Number (DIN) Holder"",
  ""species"": ""Chickens, turkeys, lambs, swine, cattle, mink"",
  ""drug_identification_number_route_form_strength"": ""02242693, Oral, Drug Premix, 220 g/kg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Direction Générale des Produits de Santé et des Aliments"",
    ""directorate"": ""Director General, Veterinary Drugs Directorate""
  }
}",TRUE,NA,OF-15-21-20150/2-210/171152,171152,MAR 4 2014,Aureomycin® 220 G,Chlortetracycline hydrochloride (as chlortetracycline calcium complex),Administrative - Transfer of Drug Identification Number (DIN) Holder,"Chickens, turkeys, lambs, swine, cattle, mink","02242693, Oral, Drug Premix, 220 g/kg",,Zoetis Canada Inc.,16740 Trans-Canada Highway,Kirkland,QC,Canada,H9H 4M7,Daniel Chaput,"Director General, Veterinary Drugs Directorate",Direction Générale des Produits de Santé et des Aliments,"Director General, Veterinary Drugs Directorate"
https://pdf.hres.ca/noc_pm/0000014072.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""121486"",
  ""submission_no"": ""187141"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Norquay Court"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2A9""
  },
  ""date"": ""MAR 2 5 2014"",
  ""product_name"": ""Teva-Quetiapine XR"",
  ""medicinal_ingredients"": ""Quetiapine (leopoldine)"",
  ""reason_for_submission"": ""Additional Drug Product Manufacturing Site"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""NA, Oral, Tablet (extended-release) 50 mg; NA, Oral, Tablet (extended-release) 150 mg; NA, Oral, Tablet (extended-release) 200 mg; NA, Oral, Tablet (extended-release) 400 mg"",
  ""canadian_reference_product"": ""Seroquel XR, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Béatrice J. Saborin"",
    ""title"": ""Director, Therapeutic Products Directorate"",
    ""division"": ""Directorate of Therapeutic Products"",
    ""directorate"": ""Therapeutic Products Directorate""
  }
}",TRUE,NA,121486,187141,MAR 2 5 2014,Teva-Quetiapine XR,Quetiapine (leopoldine),Additional Drug Product Manufacturing Site,Human,"NA, Oral, Tablet (extended-release) 50 mg; NA, Oral, Tablet (extended-release) 150 mg; NA, Oral, Tablet (extended-release) 200 mg; NA, Oral, Tablet (extended-release) 400 mg","Seroquel XR, AstraZeneca Canada Inc., Canada",Teva Canada Limited,30 Norquay Court,Mississauga,Ontario,Canada,M1B 2A9,Béatrice J. Saborin,"Director, Therapeutic Products Directorate",Directorate of Therapeutic Products,Therapeutic Products Directorate
https://pdf.hres.ca/noc_pm/0000014178.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""147300"",
  ""submission_no"": ""M19 203"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""10000 100 Street"",
    ""city"": ""Edmonton"",
    ""province"": ""Alberta"",
    ""country"": ""Canada"",
    ""postal_code"": ""T5J 0A6""
  },
  ""date"": ""MAR 31 2014"",
  ""product_name"": ""Voriconazole"",
  ""medicinal_ingredients"": ""Voriconazole"",
  ""reason_for_submission"": ""Antifungal Agent"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""0238566, Oral, Tablet, 50 mg; 0238574, Oral, Tablet, 200 mg"",
  ""canadian_reference_product"": ""Vfend, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Product Information Division""
  }
}",TRUE,NA,147300,M19 203,MAR 31 2014,Voriconazole,Voriconazole,Antifungal Agent,Human,"0238566, Oral, Tablet, 50 mg; 0238574, Oral, Tablet, 200 mg","Vfend, Pfizer Canada Inc., Canada",Teva Canada Limited,10000 100 Street,Edmonton,Alberta,Canada,T5J 0A6,Barbara J. Sabourin,Director General,Therapeutic Products Directorate,Product Information Division
https://pdf.hres.ca/noc_pm/0000014379.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""179234"",
  ""submission_no"": ""179234"",
  ""manufacturer"": {
    ""name"": ""Mesoblast International Sàrl"",
    ""street"": ""505 Fifth Avenue"",
    ""city"": ""New York"",
    ""province"": ""NY"",
    ""country"": ""United States"",
    ""postal_code"": ""10017""
  },
  ""date"": ""MAY 0 2 2014"",
  ""product_name"": ""Prochymal"",
  ""medicinal_ingredients"": ""remestemcel-L"",
  ""reason_for_submission"": ""Administrative – Manufacturer name change"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02386380, IV, SOL, 100 x 10^6 MSCs / 15 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Cushman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genomic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,179234,179234,MAY 0 2 2014,Prochymal,remestemcel-L,Administrative – Manufacturer name change,,"02386380, IV, SOL, 100 x 10^6 MSCs / 15 mL",,Mesoblast International Sàrl,505 Fifth Avenue,New York,NY,United States,10017,Dr. Robert Cushman,Director General / Directeur général,Biologics and Genomic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000014768.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""14-233"",
  ""submission_no"": ""14-233"",
  ""manufacturer"": {
    ""name"": ""Sarot Synthetique Canada Inc."",
    ""street"": """",
    ""city"": """",
    ""province"": """",
    ""country"": ""Canada"",
    ""postal_code"": """"
  },
  ""date"": ""JUN 2 4 2014"",
  ""product_name"": ""MILRONEACETATE INJECTION"",
  ""medicinal_ingredients"": ""Milroneacétate"",
  ""reason_for_submission"": ""New drug submission"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""02883519 intravenous solution. 1 (mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Absorin"",
    ""title"": ""Director, Therapeutic Products"",
    ""division"": ""Directorate of Therapeutic Products"",
    ""directorate"": ""Directorate of Therapeutic Products""
  }
}",TRUE,NA,14-233,14-233,JUN 2 4 2014,MILRONEACETATE INJECTION,Milroneacétate,New drug submission,Human,02883519 intravenous solution. 1 (mg/mL),,Sarot Synthetique Canada Inc.,,,,Canada,,Barbara J. Absorin,"Director, Therapeutic Products",Directorate of Therapeutic Products,Directorate of Therapeutic Products
https://pdf.hres.ca/noc_pm/0000014781.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided PDF text is incomplete and lacks sufficient detail to extract all required notice of compliance fields. It contains only partial information such as the date (JUN 2 6 2014), product name (RISPERIDONE), and some manufacturer details (Silver Pharmaceutics ULC). Critical fields like dossier_id, submission_no, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, and authorizing_official are either missing or not clearly visible in the text provided. The text appears to be truncated or poorly scanned."",
  ""partial_data"": {
    ""date"": ""JUN 2 6 2014"",
    ""product_name"": ""RISPERIDONE"",
    ""manufacturer"": {
      ""name"": ""Silver Pharmaceutics ULC"",
      ""street"": ""4710 Dablin"",
      ""city"": ""Ottawa"",
      ""province"": ""ON"",
      ""country"": ""Canada"",
      ""postal_code"": ""K1G 2P7""
    }
  }
}",FALSE,"The provided PDF text is incomplete and lacks sufficient detail to extract all required notice of compliance fields. It contains only partial information such as the date (JUN 2 6 2014), product name (RISPERIDONE), and some manufacturer details (Silver Pharmaceutics ULC). Critical fields like dossier_id, submission_no, medicinal_ingredients, reason_for_submission, species, drug_identification_number_route_form_strength, canadian_reference_product, and authorizing_official are either missing or not clearly visible in the text provided. The text appears to be truncated or poorly scanned.",NA,NA,JUN 2 6 2014,RISPERIDONE,NA,NA,NA,NA,NA,Silver Pharmaceutics ULC,4710 Dablin,Ottawa,ON,Canada,K1G 2P7,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000014925.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-D27971-101/175389"",
  ""submission_no"": ""175389"",
  ""manufacturer"": {
    ""name"": ""Dechra Veterinary Products A/S"",
    ""street"": ""Mekuvej 9"",
    ""city"": ""Uldum"",
    ""province"": ""Denmark"",
    ""country"": ""DK"",
    ""postal_code"": ""7171""
  },
  ""date"": ""JUL 1 2014"",
  ""product_name"": ""Isaithal Eye Gel"",
  ""medicinal_ingredients"": ""Fusidic acid"",
  ""reason_for_submission"": ""Administrative - Licensing agreement between two companies"",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""02427869, Ophthalmic, Gel, 10 mg/g"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Director General, Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,OF15-21-D27971-101/175389,175389,JUL 1 2014,Isaithal Eye Gel,Fusidic acid,Administrative - Licensing agreement between two companies,Dogs,"02427869, Ophthalmic, Gel, 10 mg/g",,Dechra Veterinary Products A/S,Mekuvej 9,Uldum,Denmark,DK,7171,Daniel Chaput,"Director General, Veterinary Drugs Directorate","Director General, Direction des médicaments vétérinaires",
https://pdf.hres.ca/noc_pm/0000015487.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided PDF text is incomplete and lacks sufficient detail to extract all required notice of compliance fields. It contains partial information such as the manufacturer name, date, product name, and some drug identification numbers, but lacks critical fields like submission number, medicinal ingredients, reason for submission, species, and the full authorizing official details. The text is also fragmented and does not present a complete block of NOC information."",
  ""partial_data"": {
    ""dossier_id"": ""177200"",
    ""submission_no"": ""J46 3R2"",
    ""manufacturer"": {
      ""name"": ""Janssen Pharmaceuticals Inc."",
      ""street"": """",
      ""city"": ""Boucherville, QC"",
      ""province"": """",
      ""country"": """",
      ""postal_code"": """"
    },
    ""date"": ""SEP 0 9 2014"",
    ""product_name"": ""CITALOPRAM"",
    ""medicinal_ingredients"": ""Citalopram hydrobromide"",
    ""reason_for_submission"": ""Administered according to the label directions"",
    ""species"": """",
    ""drug_identification_number_route_form_strength"": ""02430517 (oral tablet, 10 mg) 02430541 (oral tablet, 20 mg) 02430568 (oral tablet, 40 mg)"",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": ""Bartlett J. Saezourin"",
      ""title"": ""Director General / Directeur général"",
      ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
      ""directorate"": ""Product Monograph""
    }
  }
}",FALSE,"The provided PDF text is incomplete and lacks sufficient detail to extract all required notice of compliance fields. It contains partial information such as the manufacturer name, date, product name, and some drug identification numbers, but lacks critical fields like submission number, medicinal ingredients, reason for submission, species, and the full authorizing official details. The text is also fragmented and does not present a complete block of NOC information.",177200,J46 3R2,SEP 0 9 2014,CITALOPRAM,Citalopram hydrobromide,Administered according to the label directions,,"02430517 (oral tablet, 10 mg) 02430541 (oral tablet, 20 mg) 02430568 (oral tablet, 40 mg)",,Janssen Pharmaceuticals Inc.,,"Boucherville, QC",,,,Bartlett J. Saezourin,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Product Monograph
https://pdf.hres.ca/noc_pm/0000015615.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""177298"",
  ""submission_no"": ""177298"",
  ""manufacturer"": {
    ""name"": ""Sanofi Health Inc."",
    ""street"": ""333 Carenalin Street"",
    ""city"": ""St. John's"",
    ""province"": ""NL"",
    ""country"": ""Canada"",
    ""postal_code"": ""A1B 1P2""
  },
  ""date"": ""SEP 1 7 2014"",
  ""product_name"": ""GABAPENTIN"",
  ""medicinal_ingredients"": ""Gabapentin"",
  ""reason_for_submission"": ""Administrative accord of agreement between two companies / Accord administratif de l'agrément entre deux sociétés"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""02431289 (oral tablet 600 mg)"",
  ""canadian_reference_product"": ""Neurontin, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Director General / Directeur général"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Product Monograph""
  }
}",TRUE,NA,177298,177298,SEP 1 7 2014,GABAPENTIN,Gabapentin,Administrative accord of agreement between two companies / Accord administratif de l'agrément entre deux sociétés,Human,02431289 (oral tablet 600 mg),"Neurontin, Pfizer Canada Inc., Canada",Sanofi Health Inc.,333 Carenalin Street,St. John's,NL,Canada,A1B 1P2,Director General / Directeur général,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Product Monograph
https://pdf.hres.ca/noc_pm/0000015657.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""054174"",
  ""submission_no"": ""054174"",
  ""manufacturer"": {
    ""name"": ""Cobalt Pharmaceuticals Inc."",
    ""street"": ""6500 Kilmart Road"",
    ""city"": ""MISSISSAUGA"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 2B8""
  },
  ""date"": ""24 2004"",
  ""product_name"": ""Co-Metformin"",
  ""medicinal_ingredients"": ""Metformin Hydrochloride"",
  ""reason_for_submission"": ""This is to notify you that, pursuant to section C.09.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.05.002 and C.06.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02257738, ORL, TAB, 500MG 02257734, ORL, TAB, 850MG"",
  ""canadian_reference_product"": ""Glucophage, Aventis Pharma Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Peterson"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,054174,054174,24 2004,Co-Metformin,Metformin Hydrochloride,"This is to notify you that, pursuant to section C.09.004 of the Food and Drug Regulations, the above abbreviated new drug submission complies with the requirements of sections C.05.002 and C.06.005.1 of the Regulations. As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008. These obligations are detailed on the reverse of this notice.",,"02257738, ORL, TAB, 500MG 02257734, ORL, TAB, 850MG","Glucophage, Aventis Pharma Inc., Canada",Cobalt Pharmaceuticals Inc.,6500 Kilmart Road,MISSISSAUGA,Ontario,Canada,L5N 2B8,Dr. Robert Peterson,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000015661.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""OF15-21-M23242-104140691"",
  ""submission_no"": ""149591"",
  ""manufacturer"": {
    ""name"": ""Modern Veterinary Therapeutics LLC"",
    ""street"": ""18001 Old Cutler Road"",
    ""city"": ""Miami"",
    ""province"": ""FL"",
    ""country"": ""USA"",
    ""postal_code"": ""33157""
  },
  ""date"": ""SEP 2 9 2014"",
  ""product_name"": ""HYMATIL"",
  ""medicinal_ingredients"": ""Tilmicosin"",
  ""reason_for_submission"": ""new drug submission"",
  ""species"": ""Cattle, Sheep"",
  ""drug_identification_number_route_form_strength"": ""02431912, Subcutaneous, Solution, 300 mg/mL"",
  ""canadian_reference_product"": ""Micotil (Elanco Animal Health, DIN 00857602)"",
  ""authorizing_official"": {
    ""name"": ""Daniel Chaput"",
    ""title"": ""Director General, Veterinary Drugs Directorate"",
    ""division"": ""Director General, Veterinary Drugs Directorate"",
    ""directorate"": ""Director General, Veterinary Drugs Directorate""
  }
}",TRUE,NA,OF15-21-M23242-104140691,149591,SEP 2 9 2014,HYMATIL,Tilmicosin,new drug submission,"Cattle, Sheep","02431912, Subcutaneous, Solution, 300 mg/mL","Micotil (Elanco Animal Health, DIN 00857602)",Modern Veterinary Therapeutics LLC,18001 Old Cutler Road,Miami,FL,USA,33157,Daniel Chaput,"Director General, Veterinary Drugs Directorate","Director General, Veterinary Drugs Directorate","Director General, Veterinary Drugs Directorate"
https://pdf.hres.ca/noc_pm/0000015962.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""108551"",
  ""submission_no"": ""108551"",
  ""manufacturer"": {
    ""name"": ""Octapharma Pharmazeutika Produktionsges.m.b.H."",
    ""street"": ""Oberlaaer Strasse 235"",
    ""city"": ""Vienna"",
    ""province"": ""Austria"",
    ""country"": ""Austria"",
    ""postal_code"": ""A-1100""
  },
  ""date"": ""October 23, 2014"",
  ""product_name"": ""Nuviq"",
  ""medicinal_ingredients"": ""Antihemophilic Factor (Recombinant, B-domain deleted) / Facteur antihémophilique (recombinant et dépourvu du domaine B)"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02432951, IV, PWSO, 250 IU/vial; 02432978, IV, PWSO, 500 IU/vial; 02432968, IV, PWSO, 1000 IU/vial; 02432994, IV, PWSO, 2000 IU/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Robert Cushman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,108551,108551,"October 23, 2014",Nuviq,"Antihemophilic Factor (Recombinant, B-domain deleted) / Facteur antihémophilique (recombinant et dépourvu du domaine B)",,,"02432951, IV, PWSO, 250 IU/vial; 02432978, IV, PWSO, 500 IU/vial; 02432968, IV, PWSO, 1000 IU/vial; 02432994, IV, PWSO, 2000 IU/vial",,Octapharma Pharmazeutika Produktionsges.m.b.H.,Oberlaaer Strasse 235,Vienna,Austria,Austria,A-1100,Dr. Robert Cushman,Director General / Directeur général,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000016167.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""176910"",
  ""submission_no"": ""9427-A25171-21"",
  ""manufacturer"": {
    ""name"": ""Asgiri Pharma Canada Inc."",
    ""street"": ""665 Millway Avenue"",
    ""city"": ""Concord"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 3T6""
  },
  ""date"": ""NOV 21 2014"",
  ""product_name"": ""SEPTRA INJECTION"",
  ""medicinal_ingredients"": ""Sulfamethoxazole, Trimethoprim"",
  ""reason_for_submission"": ""Administrative - manufacturer name change / Administratif - changement du nom du fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00550086 (intravenous, solution, sulfamethoxazole 80 mg/mL, trimethoprim 16 mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,176910,9427-A25171-21,NOV 21 2014,SEPTRA INJECTION,"Sulfamethoxazole, Trimethoprim",Administrative - manufacturer name change / Administratif - changement du nom du fabricant,,"00550086 (intravenous, solution, sulfamethoxazole 80 mg/mL, trimethoprim 16 mg/mL)",,Asgiri Pharma Canada Inc.,665 Millway Avenue,Concord,ON,Canada,L4K 3T6,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000016222.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""178134"",
  ""submission_no"": ""94/27-0739V1-47"",
  ""manufacturer"": {
    ""name"": ""Vane Pharmaceuticals Inc."",
    ""street"": ""11782 River Road, Building-162"",
    ""city"": ""Richmond"",
    ""province"": ""BC"",
    ""country"": ""Canada"",
    ""postal_code"": ""V6X 1Z7""
  },
  ""date"": ""NOV 2 8 2014"",
  ""product_name"": ""VAN-TELMISARTAN-HCTZ"",
  ""medicinal_ingredients"": ""Telmisartan, Hydrochlorothiazide"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02434067 (oral, tablet, telmisartan 80 mg, hydrochlorothiazide 12.5 mg) 02434075 (oral, tablet, telmisartan 80 mg, hydrochlorothiazide 25 mg)"",
  ""canadian_reference_product"": ""Micardis Plus, Boehringer Ingelheim (Canada) Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,178134,94/27-0739V1-47,NOV 2 8 2014,VAN-TELMISARTAN-HCTZ,"Telmisartan, Hydrochlorothiazide",Administrative - licensing agreement between two companies,,"02434067 (oral, tablet, telmisartan 80 mg, hydrochlorothiazide 12.5 mg) 02434075 (oral, tablet, telmisartan 80 mg, hydrochlorothiazide 25 mg)","Micardis Plus, Boehringer Ingelheim (Canada) Ltd., Canada",Vane Pharmaceuticals Inc.,"11782 River Road, Building-162",Richmond,BC,Canada,V6X 1Z7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000016470.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""180251"",
  ""submission_no"": ""DEC 3.0 2014"",
  ""manufacturer"": {
    ""name"": ""Active Pharma Company"",
    ""street"": ""6733 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 1C6""
  },
  ""date"": ""DEC 3.0 2014"",
  ""product_name"": ""ACT Cardietaratan"",
  ""medicinal_ingredients"": ""Cardietaratan (Crestel)"",
  ""reason_for_submission"": ""New indication"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 4 mg; N/A, Oral, Tablet, 18 mg; N/A, Oral, Tablet, 32 mg"",
  ""canadian_reference_product"": ""AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Secord"",
    ""title"": ""Director"",
    ""division"": ""Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,180251,DEC 3.0 2014,DEC 3.0 2014,ACT Cardietaratan,Cardietaratan (Crestel),New indication,Human,"N/A, Oral, Tablet, 4 mg; N/A, Oral, Tablet, 18 mg; N/A, Oral, Tablet, 32 mg","AstraZeneca Canada Inc., Canada",Active Pharma Company,6733 Mississauga Road,Mississauga,Ontario,Canada,L5N 1C6,Barbara J. Secord,Director,Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000016825.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""172836"",
  ""submission_no"": ""172836"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5C 1L9""
  },
  ""date"": ""FEB 1 9 2015"",
  ""product_name"": ""STELARA"",
  ""medicinal_ingredients"": ""ustekinumab"",
  ""reason_for_submission"": ""Product monograph update / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, SC, SOL, 45 mg/0.5mL; NIA, SC, SOL, 90 mg/1.0mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Acting Director General / Directrice générale adjointe"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,172836,172836,FEB 1 9 2015,STELARA,ustekinumab,Product monograph update / Mise à jour de la monographie de produit,,"NIA, SC, SOL, 45 mg/0.5mL; NIA, SC, SOL, 90 mg/1.0mL",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M5C 1L9,Catherine Parker,Acting Director General / Directrice générale adjointe,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000016957.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p144773"",
  ""submission_no"": ""181576"",
  ""manufacturer"": {
    ""name"": ""Presentus Kabi Canada Ltd"",
    ""street"": ""41 Vogell Road, Suite 200"",
    ""city"": ""Richmond Hill"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4B 3P6""
  },
  ""date"": ""MAR 05 2015"",
  ""product_name"": ""VANCAMYCIN HYDROCHLORIDE CAPSULES, USP"",
  ""medicinal_ingredients"": ""Vancomycin supplied as Vancomycin Hydrochloride"",
  ""reason_for_submission"": ""Administrative - manufacturer name change / Administratif - changement du nom du fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02377470 (oral, capsule, 125 mg) 02377489 (oral, capsule, 250 mg)"",
  ""canadian_reference_product"": ""Vancocin, Inko International LP, Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p144773,181576,MAR 05 2015,"VANCAMYCIN HYDROCHLORIDE CAPSULES, USP",Vancomycin supplied as Vancomycin Hydrochloride,Administrative - manufacturer name change / Administratif - changement du nom du fabricant,,"02377470 (oral, capsule, 125 mg) 02377489 (oral, capsule, 250 mg)","Vancocin, Inko International LP, Canada",Presentus Kabi Canada Ltd,"41 Vogell Road, Suite 200",Richmond Hill,ON,Canada,L4B 3P6,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000016958.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p44773"",
  ""submission_no"": ""181577"",
  ""manufacturer"": {
    ""name"": ""Fresenius Kabi Canada Ltd"",
    ""street"": ""45 Vogel Road, Suite 200"",
    ""city"": ""Richmond Hill"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4B 3P4""
  },
  ""date"": ""MAR 05 2015"",
  ""product_name"": ""VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP"",
  ""medicinal_ingredients"": ""Vancomycin supplied as Vancomycin Hydrochloride"",
  ""reason_for_submission"": ""Administrative - manufacturer name change / Administratif - changement du nom du fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""O2139375 (intravenous, powder for solution, 500 mg/vial) O2139383 (intravenous, powder for solution, 1 g/vial) O2139243 (intravenous, powder for solution, 5 g/vial) O2241807 (intravenous, powder for solution, 10 g/vial)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p44773,181577,MAR 05 2015,"VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP",Vancomycin supplied as Vancomycin Hydrochloride,Administrative - manufacturer name change / Administratif - changement du nom du fabricant,,"O2139375 (intravenous, powder for solution, 500 mg/vial) O2139383 (intravenous, powder for solution, 1 g/vial) O2139243 (intravenous, powder for solution, 5 g/vial) O2241807 (intravenous, powder for solution, 10 g/vial)",,Fresenius Kabi Canada Ltd,"45 Vogel Road, Suite 200",Richmond Hill,ON,Canada,L4B 3P4,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000017295.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""183666"",
  ""submission_no"": ""183666"",
  ""manufacturer"": {
    ""name"": ""Fresenius Kabi Canada Ltd"",
    ""street"": ""10000 Highway 7"",
    ""city"": ""Richmond Hill"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4B 3P4""
  },
  ""date"": ""APR 1 7 2015"",
  ""product_name"": ""INTRALIPID 10%"",
  ""medicinal_ingredients"": ""Intralipid"",
  ""reason_for_submission"": ""Amendment - transfer of Drug Identification Number(s) / Requisition - transfer of identification number(s) (drug(s))"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""O2065681 (Intravenous, emulsion, 2.5%) O2216175 (Intravenous, emulsion, 10%)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Cynthia G. Boudreau"",
    ""title"": ""Director, General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Division des produits thérapeutiques""
  }
}",TRUE,NA,183666,183666,APR 1 7 2015,INTRALIPID 10%,Intralipid,Amendment - transfer of Drug Identification Number(s) / Requisition - transfer of identification number(s) (drug(s)),Human,"O2065681 (Intravenous, emulsion, 2.5%) O2216175 (Intravenous, emulsion, 10%)",,Fresenius Kabi Canada Ltd,10000 Highway 7,Richmond Hill,ON,Canada,L4B 3P4,Cynthia G. Boudreau,"Director, General / Directrice générale",Therapeutic Products Directorate,Division des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000017556.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""pf123979"",
  ""submission_no"": ""183703"",
  ""manufacturer"": {
    ""name"": ""Fresenius Kabi Canada Ltd."",
    ""street"": ""45 Vogel Road, Suite 200"",
    ""city"": ""Richmond Hill"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4B 3P6""
  },
  ""date"": ""MAY 19 2015"",
  ""product_name"": ""TOPOTECAN FOR INJECTION"",
  ""medicinal_ingredients"": ""Topotecan supplied as Topotecan Hydrochloride"",
  ""reason_for_submission"": ""Administrative - manufacturer name change / Administratif - changement du nom du fabricant"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02346656 (Intravenous, powder for solution, 4 mg/vial)"",
  ""canadian_reference_product"": ""Hycamtin, GlaxoSmithKline inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sakkour"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,pf123979,183703,MAY 19 2015,TOPOTECAN FOR INJECTION,Topotecan supplied as Topotecan Hydrochloride,Administrative - manufacturer name change / Administratif - changement du nom du fabricant,,"02346656 (Intravenous, powder for solution, 4 mg/vial)","Hycamtin, GlaxoSmithKline inc., Canada",Fresenius Kabi Canada Ltd.,"45 Vogel Road, Suite 200",Richmond Hill,ON,Canada,L4B 3P6,Barbara J. Sakkour,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000018088.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e162597"",
  ""submission_no"": ""184946"",
  ""manufacturer"": {
    ""name"": ""Ranbaxy Pharmaceuticals Canada Inc"",
    ""street"": ""2680 Matheson Blvd. E., Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 0A5""
  },
  ""date"": ""JUL 27 2015"",
  ""product_name"": ""RAN-LANSOPRAZOLE"",
  ""medicinal_ingredients"": ""Lansoprazole"",
  ""reason_for_submission"": ""Administrative – update to the Product Monograph, new indication"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, (oral, delayed-release capsule, 15 mg) / N/A, (oral, delayed-release capsule, 30 mg)"",
  ""canadian_reference_product"": ""Prevacid, Takeda Pharmaceuticals America Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e162597,184946,JUL 27 2015,RAN-LANSOPRAZOLE,Lansoprazole,"Administrative – update to the Product Monograph, new indication",N/A,"N/A, (oral, delayed-release capsule, 15 mg) / N/A, (oral, delayed-release capsule, 30 mg)","Prevacid, Takeda Pharmaceuticals America Inc., Canada",Ranbaxy Pharmaceuticals Canada Inc,"2680 Matheson Blvd. E., Suite 200",Mississauga,ON,Canada,L4W 0A5,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000018137.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p185281"",
  ""submission_no"": ""185281"",
  ""manufacturer"": {
    ""name"": ""Sivem Pharmaceuticals ULC"",
    ""street"": ""4700 rue Doba"",
    ""city"": ""St. Laurent"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 2P7""
  },
  ""date"": ""JUL 3 1 2015"",
  ""product_name"": ""ENALAPRIL"",
  ""medicinal_ingredients"": ""Enalapril Sodium"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""Q2442957 (oral, tablet, 2 mg) Q2442965 (oral, tablet, 4 mg) Q2442973 (oral, tablet, 8 mg) Q2442981 (oral, tablet, 16 mg)"",
  ""canadian_reference_product"": ""Vasotec, Merck Frosst Canada Ltd, Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p185281,185281,JUL 3 1 2015,ENALAPRIL,Enalapril Sodium,Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés,,"Q2442957 (oral, tablet, 2 mg) Q2442965 (oral, tablet, 4 mg) Q2442973 (oral, tablet, 8 mg) Q2442981 (oral, tablet, 16 mg)","Vasotec, Merck Frosst Canada Ltd, Canada",Sivem Pharmaceuticals ULC,4700 rue Doba,St. Laurent,QC,Canada,H4R 2P7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000018276.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e131781"",
  ""submission_no"": ""185046"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""16750, rue Transcanadienne"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""AUG 10 2015"",
  ""product_name"": ""ZEMURON"",
  ""medicinal_ingredients"": ""Rocuronium Bromide"",
  ""reason_for_submission"": ""Revision of the wording, font, and layout of the outer carton label and inner vial labels."",
  ""species"": ""Non-depolarizing Skeletal Neuromuscular Blocking Agent"",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Solution for injection, 10 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,e131781,185046,AUG 10 2015,ZEMURON,Rocuronium Bromide,"Revision of the wording, font, and layout of the outer carton label and inner vial labels.",Non-depolarizing Skeletal Neuromuscular Blocking Agent,"N/A, Intravenous, Solution for injection, 10 mg/mL",,Merck Canada Inc.,"16750, rue Transcanadienne",Kirkland,Quebec,Canada,H9H 4M7,Barbara J. Sabourin,Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000018414.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p186085"",
  ""submission_no"": ""186085"",
  ""manufacturer"": {
    ""name"": ""Vanc Pharmaceuticals Inc."",
    ""street"": ""2630 Viking Way, Unit 210"",
    ""city"": ""Richmond"",
    ""province"": ""BC"",
    ""country"": ""Canada"",
    ""postal_code"": ""V6V 3B7""
  },
  ""date"": ""AUG 28 2015"",
  ""product_name"": ""VAN-TOPIRAMATE"",
  ""medicinal_ingredients"": ""Topiramate"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02444283 (oral, tablet, 25 mg) 02444291 (oral, tablet, 100 mg) 02444305 (oral, tablet, 200 mg)"",
  ""canadian_reference_product"": ""Topamax, Janssen-Cilag Ltd., UK"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p186085,186085,AUG 28 2015,VAN-TOPIRAMATE,Topiramate,Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés,,"02444283 (oral, tablet, 25 mg) 02444291 (oral, tablet, 100 mg) 02444305 (oral, tablet, 200 mg)","Topamax, Janssen-Cilag Ltd., UK",Vanc Pharmaceuticals Inc.,"2630 Viking Way, Unit 210",Richmond,BC,Canada,V6V 3B7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000018697.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e154167"",
  ""submission_no"": ""167295"",
  ""manufacturer"": {
    ""name"": ""Apotex incorporated"",
    ""street"": ""150 Signal Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T3""
  },
  ""date"": ""OCT 1 4 2015"",
  ""product_name"": ""Apo-Tadalafil PAH"",
  ""medicinal_ingredients"": ""Tadalafil"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02421933, Oral, Tablet, 20 mg"",
  ""canadian_reference_product"": ""Adcirca, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e154167,167295,OCT 1 4 2015,Apo-Tadalafil PAH,Tadalafil,,,"02421933, Oral, Tablet, 20 mg","Adcirca, Eli Lilly Canada Inc., Canada",Apotex incorporated,150 Signal Drive,Toronto,Ontario,Canada,M5L 1T3,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000018720.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p186214"",
  ""submission_no"": ""186214"",
  ""manufacturer"": {
    ""name"": ""Rimneri Pharma"",
    ""street"": ""6990, Côte de Liesse, suite 100"",
    ""city"": ""Ville Mont-Royal"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4T 1E2""
  },
  ""date"": ""OCT 1 4 2015"",
  ""product_name"": ""BIO-VALACYCLOVIR"",
  ""medicinal_ingredients"": ""Valacyclovir supplied as Valacyclovir Hydrochloride"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02444860 (oral, tablet, 500 mg)"",
  ""canadian_reference_product"": ""Valtrex, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p186214,186214,OCT 1 4 2015,BIO-VALACYCLOVIR,Valacyclovir supplied as Valacyclovir Hydrochloride,Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés,,"02444860 (oral, tablet, 500 mg)","Valtrex, GlaxoSmithKline Inc., Canada",Rimneri Pharma,"6990, Côte de Liesse, suite 100",Ville Mont-Royal,QC,Canada,H4T 1E2,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000018858.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e159755"",
  ""submission_no"": ""187888"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""NOV 04 2015"",
  ""product_name"": ""Tigecycline"",
  ""medicinal_ingredients"": ""Tigecycline"",
  ""reason_for_submission"": ""Revisions to product monograph"",
  ""species"": ""NIA, Intravenous, Powder for Solution, 50 mg / vial"",
  ""drug_identification_number_route_form_strength"": """",
  ""canadian_reference_product"": ""Tygacil, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e159755,187888,NOV 04 2015,Tigecycline,Tigecycline,Revisions to product monograph,"NIA, Intravenous, Powder for Solution, 50 mg / vial",,"Tygacil, Pfizer Canada Inc., Canada",Apotex Inc.,150 Signet Drive,TORONTO,Ontario,Canada,M5L 1T9,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000019186.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""166864"",
  ""submission_no"": ""165864"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""145 Jules-Léger Street"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 7N6""
  },
  ""date"": ""DEC 1 6 2015"",
  ""product_name"": ""Oxalplat in Injection"",
  ""medicinal_ingredients"": ""Oxalplat in"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02438957, Intravenous, Solution, 5 mg/mL"",
  ""canadian_reference_product"": ""Eloxatin, sanofi-aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,166864,165864,DEC 1 6 2015,Oxalplat in Injection,Oxalplat in,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02438957, Intravenous, Solution, 5 mg/mL","Eloxatin, sanofi-aventis Canada Inc., Canada",Sandoz Canada Inc.,145 Jules-Léger Street,Boucherville,Québec,Canada,J4B 7N6,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000019330.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""182878"",
  ""submission_no"": ""182878"",
  ""manufacturer"": {
    ""name"": ""Sanofi Pasteur Limited"",
    ""street"": ""1755 Steeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2R 3T4""
  },
  ""date"": ""DEC 1 8 2015"",
  ""product_name"": ""ADACEL POLIO"",
  ""medicinal_ingredients"": ""Perfussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, diphtheria toxoid, tetanus toxoid, inactivated poliomyelitis vaccine type 1 (Mahoney), inactivated poliomyelitis vaccine type 2 (M.E.F.1), inactivated poliomyelitis vaccine type 3 (Saukett)"",
  ""reason_for_submission"": ""Changes to the manufacturing facility / modification a l'emplace ment de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IM, SUS, 0.5ml, dose: Pertussis toxoid - 2.5ug Filamentous haemagglutinin - 5ug Pertactin - 3 ug Fimbriae types 2 and 3 - 5 ug Diphtheria toxoid - 2LF Tetanus toxoid - 5LF Inactivated Poliomyelitis Vaccine Type 1 (Mahoney) - 40 DU Inactivated Poliomyelitis Vaccine Type 2 (M.E.F.1) - 8 DU Inactivated Poliomyelitis Vaccine Type 3 (Saukett) - 32 DU"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,182878,182878,DEC 1 8 2015,ADACEL POLIO,"Perfussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, diphtheria toxoid, tetanus toxoid, inactivated poliomyelitis vaccine type 1 (Mahoney), inactivated poliomyelitis vaccine type 2 (M.E.F.1), inactivated poliomyelitis vaccine type 3 (Saukett)",Changes to the manufacturing facility / modification a l'emplace ment de fabrication,,"N/A, IM, SUS, 0.5ml, dose: Pertussis toxoid - 2.5ug Filamentous haemagglutinin - 5ug Pertactin - 3 ug Fimbriae types 2 and 3 - 5 ug Diphtheria toxoid - 2LF Tetanus toxoid - 5LF Inactivated Poliomyelitis Vaccine Type 1 (Mahoney) - 40 DU Inactivated Poliomyelitis Vaccine Type 2 (M.E.F.1) - 8 DU Inactivated Poliomyelitis Vaccine Type 3 (Saukett) - 32 DU",,Sanofi Pasteur Limited,1755 Steeles Avenue West,Toronto,ON,Canada,M2R 3T4,Catherine Parker,Director General,Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000019531.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e161886"",
  ""submission_no"": ""190520"",
  ""manufacturer"": {
    ""name"": ""Marcan Pharmaceuticals Inc"",
    ""street"": ""77 Autiga Drive, Unit #4"",
    ""city"": ""Ottawa"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""K2E 7Z7""
  },
  ""date"": ""JAN 1 9 2016"",
  ""product_name"": ""IPG-PAROXETINE"",
  ""medicinal_ingredients"": ""Paroxetine supplied as Paroxetine Hydrochloride Hemihydrate"",
  ""reason_for_submission"": ""Adminitrative: merger - buyout / Administratif: fusion - rachat"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02410834 (oral, tablet, 10 mg) 02410842 (oral, tablet, 20 mg) 02410850 (oral, tablet, 30 mg)"",
  ""canadian_reference_product"": ""Paxil, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e161886,190520,JAN 1 9 2016,IPG-PAROXETINE,Paroxetine supplied as Paroxetine Hydrochloride Hemihydrate,Adminitrative: merger - buyout / Administratif: fusion - rachat,,"02410834 (oral, tablet, 10 mg) 02410842 (oral, tablet, 20 mg) 02410850 (oral, tablet, 30 mg)","Paxil, GlaxoSmithKline Inc., Canada",Marcan Pharmaceuticals Inc,"77 Autiga Drive, Unit #4",Ottawa,ON,Canada,K2E 7Z7,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000019694.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e123059"",
  ""submission_no"": ""190886"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""8111 Royalmount Avenue, Suite 100"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""FEB 11 2016"",
  ""product_name"": ""pms-Clopidogrel"",
  ""medicinal_ingredients"": ""Clopidogrel Bisulfate"",
  ""reason_for_submission"": ""Updates to the product monograph and labels"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Oral, Tablet, 75 mg"",
  ""canadian_reference_product"": ""Plavix, Sanofi-Aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Barbara J. Sabourin"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e123059,190886,FEB 11 2016,pms-Clopidogrel,Clopidogrel Bisulfate,Updates to the product monograph and labels,N/A,"Oral, Tablet, 75 mg","Plavix, Sanofi-Aventis Canada Inc., Canada",Pharmascience Inc.,"8111 Royalmount Avenue, Suite 100",Montreal,Quebec,Canada,H4P 2T4,Barbara J. Sabourin,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000019841.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""6136222"",
  ""submission_no"": ""178874"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Avenue"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""FEB 2 5 2016"",
  ""product_name"": ""pms-Esomeprazole DR"",
  ""medicinal_ingredients"": ""Esomeprazole Magnesium Dihydrate"",
  ""reason_for_submission"": ""To propose an alternate mode of administration"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Delayed-Release Capsule, 20 mg\nN/A, Oral, Delayed-Release Capsule, 40 mg"",
  ""canadian_reference_product"": ""Nexium, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,6136222,178874,FEB 2 5 2016,pms-Esomeprazole DR,Esomeprazole Magnesium Dihydrate,To propose an alternate mode of administration,,"N/A, Oral, Delayed-Release Capsule, 20 mg
N/A, Oral, Delayed-Release Capsule, 40 mg","Nexium, AstraZeneca Canada Inc., Canada",Pharmascience Inc.,6111 Royalmount Avenue,Montreal,Quebec,Canada,H4P 2T4,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000019843.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e133596"",
  ""submission_no"": ""180937"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""FEB 25 2016"",
  ""product_name"": ""Teva-Olanzapine ODT"",
  ""medicinal_ingredients"": ""Olanzapine"",
  ""reason_for_submission"": ""Change in manufacturing site for the drug product\nChange in formulation\nChange in manufacturing process"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet (Orally Disintegrating), 6 mg\nN/A, Oral, Tablet (Orally Disintegrating), 10 mg"",
  ""canadian_reference_product"": ""Zyprexa Zydus, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Merion Levy"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e133596,180937,FEB 25 2016,Teva-Olanzapine ODT,Olanzapine,"Change in manufacturing site for the drug product
Change in formulation
Change in manufacturing process",,"N/A, Oral, Tablet (Orally Disintegrating), 6 mg
N/A, Oral, Tablet (Orally Disintegrating), 10 mg","Zyprexa Zydus, Eli Lilly Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Merion Levy,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000020292.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""193104"",
  ""submission_no"": ""193104"",
  ""manufacturer"": {
    ""name"": ""Baxter Corporation"",
    ""street"": ""7125 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 0C2""
  },
  ""date"": ""APR 18 2016"",
  ""product_name"": ""Artiss"",
  ""medicinal_ingredients"": ""Sealer Protein (Human), Aprotinin (synthetic), Thrombin (Human), Calcium Chloride / Cole protéinée (Humaine), Aprotinine (synthétique), Thrombine (Humaine), Chloride de Calcium."",
  ""reason_for_submission"": ""Update to Product Monograph"",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""N/A, TOP, KIT, Sealer Protein (Human): 96-125 mg/mL; Aprotinin (synthetic): 3000 KIU/mL; Thrombin (Human): 4 IU/mL; Calcium Chloride: 40 µmol/mL."",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies"",
    ""directorate"": ""Directorate / Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,193104,193104,APR 18 2016,Artiss,"Sealer Protein (Human), Aprotinin (synthetic), Thrombin (Human), Calcium Chloride / Cole protéinée (Humaine), Aprotinine (synthétique), Thrombine (Humaine), Chloride de Calcium.",Update to Product Monograph,Human,"N/A, TOP, KIT, Sealer Protein (Human): 96-125 mg/mL; Aprotinin (synthetic): 3000 KIU/mL; Thrombin (Human): 4 IU/mL; Calcium Chloride: 40 µmol/mL.",,Baxter Corporation,7125 Mississauga Road,Mississauga,Ontario,Canada,L5N 0C2,Catherine Parker,Director General / Directrice générale,Biologics and Genetic Therapies,Directorate / Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000020458.PDF,"{
  ""data_found"": true,
  ""dossier_id"": """",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Bristol-Myers Squibb Canada"",
    ""street"": """",
    ""city"": """",
    ""province"": """",
    ""country"": """",
    ""postal_code"": """"
  },
  ""date"": ""29 avril 2016"",
  ""product_name"": ""OPDIVO™"",
  ""medicinal_ingredients"": ""nivolumab"",
  ""reason_for_submission"": ""pour le traitement par perfusion intraveineuse du mélanome non résécable ou métastatique chez les patients dont la maladie a progressé après un traitement par l'ipilimumab et, en cas de présence d'une mutation BRAF V600, après un traitement par un inhibiteur de BRAF."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""flacons de 40 mg/4 mL (10 mg/mL) ou de 100 mg/10 mL (10 mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,,,29 avril 2016,OPDIVO™,nivolumab,"pour le traitement par perfusion intraveineuse du mélanome non résécable ou métastatique chez les patients dont la maladie a progressé après un traitement par l'ipilimumab et, en cas de présence d'une mutation BRAF V600, après un traitement par un inhibiteur de BRAF.",,flacons de 40 mg/4 mL (10 mg/mL) ou de 100 mg/10 mL (10 mg/mL),,Bristol-Myers Squibb Canada,,,,,,,,,
https://pdf.hres.ca/noc_pm/0000020501.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""161910"",
  ""submission_no"": ""161910"",
  ""manufacturer"": {
    ""name"": ""Ranbaxy Pharmaceuticals Canada Inc."",
    ""street"": ""125 East Drive"",
    ""city"": ""Brantford"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L3T 1C1""
  },
  ""date"": ""MAY 02 2016"",
  ""product_name"": ""RAN-Duloxetine"",
  ""medicinal_ingredients"": ""Duloxetine (supplied as duloxetine hydrochloride)"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02438259, Oral, Capsule (delayed-release), 30 mg; 02438267, Oral, Capsule (delayed-release), 60 mg"",
  ""canadian_reference_product"": ""Cymbalta, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,161910,161910,MAY 02 2016,RAN-Duloxetine,Duloxetine (supplied as duloxetine hydrochloride),"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02438259, Oral, Capsule (delayed-release), 30 mg; 02438267, Oral, Capsule (delayed-release), 60 mg","Cymbalta, Eli Lilly Canada Inc., Canada",Ranbaxy Pharmaceuticals Canada Inc.,125 East Drive,Brantford,Ontario,Canada,L3T 1C1,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000020683.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""184584"",
  ""submission_no"": ""184584"",
  ""manufacturer"": {
    ""name"": ""CELLTRION HEALTHCARE Co. Ltd."",
    ""street"": ""19, Academy-ro 51 beon-gil, 4th Floor"",
    ""city"": ""Incheon"",
    ""province"": ""Yeonsu-gu"",
    ""country"": ""South Korea"",
    ""postal_code"": ""406-840""
  },
  ""date"": ""June 10, 2016"",
  ""product_name"": ""INFLECTRA®"",
  ""medicinal_ingredients"": ""Infliximab"",
  ""reason_for_submission"": ""New Indications: INFLECTRA® (infliximab) is indicated for: reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing and reduction of corticosteroid use in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to a corticosteroid and/or amino salicylates. INFLECTRA® can be used alone or in combination with conventional therapy. treatment of Reliabing Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment. reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing, and reduction or elimination of corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy (i.e., aminosalicylate and/or an immunosuppressant)."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": """",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,184584,184584,"June 10, 2016",INFLECTRA®,Infliximab,"New Indications: INFLECTRA® (infliximab) is indicated for: reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing and reduction of corticosteroid use in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to a corticosteroid and/or amino salicylates. INFLECTRA® can be used alone or in combination with conventional therapy. treatment of Reliabing Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment. reduction of signs and symptoms, induction and maintenance of clinical remission and mucosal healing, and reduction or elimination of corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy (i.e., aminosalicylate and/or an immunosuppressant).",,,,CELLTRION HEALTHCARE Co. Ltd.,"19, Academy-ro 51 beon-gil, 4th Floor",Incheon,Yeonsu-gu,South Korea,406-840,,,,
https://pdf.hres.ca/noc_pm/0000020721.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e177637"",
  ""submission_no"": ""183534"",
  ""manufacturer"": {
    ""name"": ""Ferring Inc."",
    ""street"": ""200 Yorkland Boulevard"",
    ""city"": ""North York"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3J 1S1""
  },
  ""date"": ""JUN 20 2016"",
  ""product_name"": ""CORTIMENT"",
  ""medicinal_ingredients"": ""Budesonide"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02455889, Oral, Delayed and Extended Release Tablet, 9 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e177637,183534,JUN 20 2016,CORTIMENT,Budesonide,"This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02455889, Oral, Delayed and Extended Release Tablet, 9 mg",,Ferring Inc.,200 Yorkland Boulevard,North York,Ontario,Canada,M3J 1S1,Marion Law,Director General / Direction générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000020803.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p186476"",
  ""submission_no"": ""186476"",
  ""manufacturer"": {
    ""name"": ""Diomed Pharma"",
    ""street"": ""5950, Côte de Liesse, suite 100"",
    ""city"": ""Ville Mont Royal"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4T 1E2""
  },
  ""date"": ""JUL 1 8 2016"",
  ""product_name"": ""BIO-CLOPIDOGREL"",
  ""medicinal_ingredients"": ""Clopidogrel supplied as Clopidogrel Bisulfate"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02444895 (oral, tablet, 75 mg)"",
  ""canadian_reference_product"": ""Plavix, sanofi-aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p186476,186476,JUL 1 8 2016,BIO-CLOPIDOGREL,Clopidogrel supplied as Clopidogrel Bisulfate,Administrative - licensing agreement between two companies,,"02444895 (oral, tablet, 75 mg)","Plavix, sanofi-aventis Canada Inc., Canada",Diomed Pharma,"5950, Côte de Liesse, suite 100",Ville Mont Royal,QC,Canada,H4T 1E2,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000020948.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""101087"",
  ""submission_no"": ""101087"",
  ""manufacturer"": {
    ""name"": ""sanofi-aventis Canada Inc."",
    ""street"": ""2905 Place Louis-R.-Renaud"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7V 0A3""
  },
  ""date"": ""AUG 23 2016"",
  ""product_name"": ""Tussionex"",
  ""medicinal_ingredients"": ""Hydrocodone Bitartrate/Phenyltoloxamine Citrate"",
  ""reason_for_submission"": ""Changes to the hydrocodone bitartrate drug substance manufacturing process and manufacturing, release testing, and packaging stability testing sites."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Suspension, 5 mg/10 mg per 5 mL. N/A, Oral, Tablet (controlled release) 5 mg/10 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kimby N. Eberts"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,101087,101087,AUG 23 2016,Tussionex,Hydrocodone Bitartrate/Phenyltoloxamine Citrate,"Changes to the hydrocodone bitartrate drug substance manufacturing process and manufacturing, release testing, and packaging stability testing sites.",N/A,"N/A, Oral, Suspension, 5 mg/10 mg per 5 mL. N/A, Oral, Tablet (controlled release) 5 mg/10 mg",,sanofi-aventis Canada Inc.,2905 Place Louis-R.-Renaud,Laval,Quebec,Canada,H7V 0A3,Kimby N. Eberts,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000020962.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""196112"",
  ""submission_no"": ""196112"",
  ""manufacturer"": {
    ""name"": ""Sanofi Pasteur Limited"",
    ""street"": ""1755 Steeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2R 3T4""
  },
  ""date"": ""AUG 1 9 2016"",
  ""product_name"": ""MOVAX POLIO"",
  ""medicinal_ingredients"": ""Inactivated poliomyelitis vaccine type 1 (Mahoney), inactivated poliomyelitis vaccine type 2 (M.E.F.1), inactivated poliomyelitis vaccine type 3 (Saukett)"",
  ""reason_for_submission"": ""Changes to the manufacturing facility / modification a l'implantation de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N.A. SC. SUS. 0.5ml dose: Inactivated Poliomyelitis Vaccine Type 1 (Mahoney) – 40 DU Inactivated Poliomyelitis Vaccine Type 2 (M.E.F.1) – 8 DU Inactivated Poliomyelitis Vaccine Type 3 (Saukett) – 32 DU"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,196112,196112,AUG 1 9 2016,MOVAX POLIO,"Inactivated poliomyelitis vaccine type 1 (Mahoney), inactivated poliomyelitis vaccine type 2 (M.E.F.1), inactivated poliomyelitis vaccine type 3 (Saukett)",Changes to the manufacturing facility / modification a l'implantation de fabrication,,N.A. SC. SUS. 0.5ml dose: Inactivated Poliomyelitis Vaccine Type 1 (Mahoney) – 40 DU Inactivated Poliomyelitis Vaccine Type 2 (M.E.F.1) – 8 DU Inactivated Poliomyelitis Vaccine Type 3 (Saukett) – 32 DU,,Sanofi Pasteur Limited,1755 Steeles Avenue West,Toronto,ON,Canada,M2R 3T4,Catherine Parker,Director General / Directrice générale,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000020971.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p190659"",
  ""submission_no"": ""196877"",
  ""manufacturer"": {
    ""name"": ""Laboratoire Riva Inc."",
    ""street"": ""660 Bou. Industriel"",
    ""city"": ""Blainville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7C 3V4""
  },
  ""date"": ""AUG 18 2016"",
  ""product_name"": ""RIVA-MOXIFLOXACIN"",
  ""medicinal_ingredients"": ""Moxifloxacin, supplied as Moxifloxacin Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Update to Product Monograph to be in line with CRP / Administratif: Mise à jour de la monographie de produit pour qu'elle corresponde à celle du produit de référence canadien"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02450976 (oral, tablet, 400 mg)"",
  ""canadian_reference_product"": ""AVELOX, Bayer Inc."",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p190659,196877,AUG 18 2016,RIVA-MOXIFLOXACIN,"Moxifloxacin, supplied as Moxifloxacin Hydrochloride",Administrative: Update to Product Monograph to be in line with CRP / Administratif: Mise à jour de la monographie de produit pour qu'elle corresponde à celle du produit de référence canadien,,"02450976 (oral, tablet, 400 mg)","AVELOX, Bayer Inc.",Laboratoire Riva Inc.,660 Bou. Industriel,Blainville,Quebec,Canada,J7C 3V4,Marion Law,Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021060.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""103306"",
  ""submission_no"": """",
  ""manufacturer"": {
    ""name"": ""Gilead Sciences Inc."",
    ""street"": ""7333 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6L4""
  },
  ""date"": ""SEP 08 2016"",
  ""product_name"": ""BENLYSTA"",
  ""medicinal_ingredients"": ""Belimumab"",
  ""reason_for_submission"": ""Product Monograph update"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, LPWSO, 120mg/vial / N/A, IV, LPWSO, 400mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,103306,,SEP 08 2016,BENLYSTA,Belimumab,Product Monograph update,,"N/A, IV, LPWSO, 120mg/vial / N/A, IV, LPWSO, 400mg/vial",,Gilead Sciences Inc.,7333 Mississauga Road,Mississauga,Ontario,Canada,L5N 6L4,Catherine Parker,Director General,Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000021118.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""192563"",
  ""submission_no"": ""192563"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signal Drive"",
    ""city"": ""TORONTO"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""SEP 23 2016"",
  ""product_name"": ""NIGHTTIME COLD COUGH & FLU"",
  ""medicinal_ingredients"": ""Bupropion. Diphenhydramine hydrochloride"",
  ""reason_for_submission"": ""As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008."",
  ""species"": ""Human"",
  ""drug_identification_number_route_form_strength"": ""62457946, Oral, Liquid Gel Capsule, 700 mg Bupropion / 25 mg Diphenhydramine Hydrochloride"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Bruce Randall"",
    ""title"": ""Acting Director General / Directeur Général par Intérim"",
    ""division"": ""Natural and Non-prescription Health Products Directorate"",
    ""directorate"": ""Direction des produits de santé naturels et sans ordonnance""
  }
}",TRUE,NA,192563,192563,SEP 23 2016,NIGHTTIME COLD COUGH & FLU,Bupropion. Diphenhydramine hydrochloride,"As a manufacturer, you are further reminded of your obligations under C.08.002(1)(d), C.08.007 and C.08.008.",Human,"62457946, Oral, Liquid Gel Capsule, 700 mg Bupropion / 25 mg Diphenhydramine Hydrochloride",,Apotex Inc.,150 Signal Drive,TORONTO,ON,Canada,M9L 1T9,Bruce Randall,Acting Director General / Directeur Général par Intérim,Natural and Non-prescription Health Products Directorate,Direction des produits de santé naturels et sans ordonnance
https://pdf.hres.ca/noc_pm/0000021172.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""192678"",
  ""submission_no"": ""192678"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L9""
  },
  ""date"": ""OCT 1 1 2016"",
  ""product_name"": ""RISPERDAL CONSTA"",
  ""medicinal_ingredients"": ""Risperidone"",
  ""reason_for_submission"": ""Change to the drug product manufacturing process."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 12.5 mg/vial; N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 25 mg/vial; N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 37.5 mg/vial; N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 50 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,192678,192678,OCT 1 1 2016,RISPERDAL CONSTA,Risperidone,Change to the drug product manufacturing process.,,"N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 12.5 mg/vial; N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 25 mg/vial; N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 37.5 mg/vial; N/A, Intramuscular, Kit, Powder for Suspension (Sustained-Release), 50 mg/vial",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M3C 1L9,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021257.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E167884"",
  ""submission_no"": ""175512"",
  ""manufacturer"": {
    ""name"": ""Pfizer Consumer Healthcare, a division of Pfizer Canada Inc."",
    ""street"": ""5975 Whistle Road"",
    ""city"": ""MISSISSAUGA"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4Z 3M6""
  },
  ""date"": ""AUG 0 4 2016"",
  ""product_name"": ""NEXIUM 24HR"",
  ""medicinal_ingredients"": ""Esomeprazole"",
  ""reason_for_submission"": ""Proton Pump Inhibitor Acid Reducer"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02444712, Oral, Capsule (Delayed-release), 20mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Bruce Randall"",
    ""title"": ""Acting Director General"",
    ""division"": ""Natural and Non-prescription Health Products Directorate"",
    ""directorate"": ""Direction des produits de santé naturels et sans ordonnance""
  }
}",TRUE,NA,E167884,175512,AUG 0 4 2016,NEXIUM 24HR,Esomeprazole,Proton Pump Inhibitor Acid Reducer,,"02444712, Oral, Capsule (Delayed-release), 20mg",,"Pfizer Consumer Healthcare, a division of Pfizer Canada Inc.",5975 Whistle Road,MISSISSAUGA,ON,Canada,L4Z 3M6,Bruce Randall,Acting Director General,Natural and Non-prescription Health Products Directorate,Direction des produits de santé naturels et sans ordonnance
https://pdf.hres.ca/noc_pm/0000021331.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e197876"",
  ""submission_no"": ""197876"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Raymount Avenue"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""OCT 28 2016"",
  ""product_name"": ""PMS-CHOLESTYRAMINE"",
  ""medicinal_ingredients"": ""Cholestyramine Resin"",
  ""reason_for_submission"": ""Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02458365 (oral, powder for suspension, 4g/5g) 02458373 (oral, powder for suspension, 4g/5g)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e197876,197876,OCT 28 2016,PMS-CHOLESTYRAMINE,Cholestyramine Resin,Administrative - licensing agreement between two companies / Administratif - accord de licence entre deux sociétés,,"02458365 (oral, powder for suspension, 4g/5g) 02458373 (oral, powder for suspension, 4g/5g)",,Pharmascience Inc.,6111 Raymount Avenue,Montreal,Quebec,Canada,H4P 2T4,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021438.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p128681"",
  ""submission_no"": ""194642"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 5M6""
  },
  ""date"": ""DEC 02 2016"",
  ""product_name"": ""CYTOVENE"",
  ""medicinal_ingredients"": ""Ganciclovir (supplied as Ganciclovir Sodium)"",
  ""reason_for_submission"": ""Addition of new drug product manufacturing and QC testing site"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Intravenous, Powder for Solution, 500 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marian Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p128681,194642,DEC 02 2016,CYTOVENE,Ganciclovir (supplied as Ganciclovir Sodium),Addition of new drug product manufacturing and QC testing site,N/A,"Intravenous, Powder for Solution, 500 mg/vial",,Hoffmann-La Roche Limited,7070 Mississauga Road,Mississauga,Ontario,Canada,L5N 5M6,Marian Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021446.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p176992"",
  ""submission_no"": ""199104"",
  ""manufacturer"": {
    ""name"": ""Stem Pharmaceuticals ULC"",
    ""street"": ""4705 Dobbie Street"",
    ""city"": ""St. Laurent"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 2P7""
  },
  ""date"": ""NOV 29 2016"",
  ""product_name"": ""TRAMADOL / ACETAMINOPHEN"",
  ""medicinal_ingredients"": ""Acetaminophen, Tramadol Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02429969 (oral, tablet, acetaminophen 325mg, tramadol hydrochloride 37.5mg)"",
  ""canadian_reference_product"": ""Tramacet, Janssen Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p176992,199104,NOV 29 2016,TRAMADOL / ACETAMINOPHEN,"Acetaminophen, Tramadol Hydrochloride",Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés,,"02429969 (oral, tablet, acetaminophen 325mg, tramadol hydrochloride 37.5mg)","Tramacet, Janssen Inc., Canada",Stem Pharmaceuticals ULC,4705 Dobbie Street,St. Laurent,Quebec,Canada,H4R 2P7,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021452.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e129280"",
  ""submission_no"": ""109398"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave."",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""DEC 0 1 2016"",
  ""product_name"": ""ASA DAILY LOW DOSE"",
  ""medicinal_ingredients"": ""Acetylsalicylic Acid"",
  ""reason_for_submission"": ""Product Monograph update to match the innovator's Product Monograph / Administratif. Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02394790 (oral, chewable tablet, 81mg)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e129280,109398,DEC 0 1 2016,ASA DAILY LOW DOSE,Acetylsalicylic Acid,Product Monograph update to match the innovator's Product Monograph / Administratif. Mise à jour de la monographie de produit pour égaler la monographie de produit de l'innovateur,,"02394790 (oral, chewable tablet, 81mg)",,Pharmascience Inc.,6111 Royalmount Ave.,Montreal,Quebec,Canada,H4P 2T4,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021468.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""190732"",
  ""submission_no"": ""190732"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L9""
  },
  ""date"": ""DEC 1 2 2016"",
  ""product_name"": ""STELARA"",
  ""medicinal_ingredients"": ""Ustekinumab"",
  ""reason_for_submission"": ""New Indication: STELARA® (ustekinumab) is indicated for the treatment of adult patients with moderately to severely active Crohn's disease, who have had an inadequate response, loss of response to, or were intolerant to either immunomodulators or one or more tumour necrosis factor-alpha (TNFα) antagonists, or have had an inadequate response, intolerance or demonstrated dependence on corticosteroids."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02419671 – IV, SOL, 5 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,190732,190732,DEC 1 2 2016,STELARA,Ustekinumab,"New Indication: STELARA® (ustekinumab) is indicated for the treatment of adult patients with moderately to severely active Crohn's disease, who have had an inadequate response, loss of response to, or were intolerant to either immunomodulators or one or more tumour necrosis factor-alpha (TNFα) antagonists, or have had an inadequate response, intolerance or demonstrated dependence on corticosteroids.",,"02419671 – IV, SOL, 5 mg/mL",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M3C 1L9,,,,
https://pdf.hres.ca/noc_pm/0000021517.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v187515"",
  ""submission_no"": ""191572"",
  ""manufacturer"": {
    ""name"": ""Bio Agri Mix Limited Partnership"",
    ""street"": ""11 Ellena Street"",
    ""city"": ""Mitchell"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""N0K 1N0""
  },
  ""date"": ""DEC 2 2016"",
  ""product_name"": ""CHLOR 100"",
  ""medicinal_ingredients"": ""Chlortetracycline (as chlortetracycline hydrochloride)"",
  ""reason_for_submission"": ""Removal of growth promotion claim\nAdditional indications (turkeys and lambs)"",
  ""species"": ""Swine, Cattle, Turkey, Lambs"",
  ""drug_identification_number_route_form_strength"": ""00698210, Oral, Medicated Premix, 220 g/kg"",
  ""canadian_reference_product"": ""Aureomycin 220 G (Zoetis Canada Inc., DIN 02242693)"",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v187515,191572,DEC 2 2016,CHLOR 100,Chlortetracycline (as chlortetracycline hydrochloride),"Removal of growth promotion claim
Additional indications (turkeys and lambs)","Swine, Cattle, Turkey, Lambs","00698210, Oral, Medicated Premix, 220 g/kg","Aureomycin 220 G (Zoetis Canada Inc., DIN 02242693)",Bio Agri Mix Limited Partnership,11 Ellena Street,Mitchell,ON,Canada,N0K 1N0,Dr. Mary Jane Ireland,Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000021529.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p190858"",
  ""submission_no"": ""190858"",
  ""manufacturer"": {
    ""name"": ""SteriMax Inc."",
    ""street"": ""2770 Portland Drive"",
    ""city"": ""Oakville"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6H 9F4""
  },
  ""date"": ""DEC 2 2 2016"",
  ""product_name"": ""Levofloxacin in 5% Dextrose Injection"",
  ""medicinal_ingredients"": ""Levofloxacin"",
  ""reason_for_submission"": ""This is to notify that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02490122, Intravenous, Solution, 5 mg/mL"",
  ""canadian_reference_product"": ""Levofloxacin in 5% Dextrose Injection, Hospira Healthcare Corporation, Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p190858,190858,DEC 2 2 2016,Levofloxacin in 5% Dextrose Injection,Levofloxacin,"This is to notify that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02490122, Intravenous, Solution, 5 mg/mL","Levofloxacin in 5% Dextrose Injection, Hospira Healthcare Corporation, Canada",SteriMax Inc.,2770 Portland Drive,Oakville,Ontario,Canada,L6H 9F4,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000021897.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""163785"",
  ""submission_no"": ""163785"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5M 5N8""
  },
  ""date"": ""MAR 1 0 2017"",
  ""product_name"": ""KADCYLA"",
  ""medicinal_ingredients"": ""Trastuzumab emtansine"",
  ""reason_for_submission"": ""Update to the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, PVSQ, 20 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General"",
    ""division"": ""Biologics and Genetic Therapies"",
    ""directorate"": ""Directorate / Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,163785,163785,MAR 1 0 2017,KADCYLA,Trastuzumab emtansine,Update to the Product Monograph,,"N/A, IV, PVSQ, 20 mg/mL",,Hoffmann-La Roche Limited,7070 Mississauga Road,Mississauga,ON,Canada,L5M 5N8,Catherine Parker,Director General,Biologics and Genetic Therapies,Directorate / Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000021958.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e174396"",
  ""submission_no"": ""196769"",
  ""manufacturer"": {
    ""name"": ""Basilea Pharmaceutica International AG"",
    ""street"": ""Grazacherstrasse 487"",
    ""city"": ""Basel"",
    ""province"": ""Switzerland"",
    ""country"": ""Switzerland"",
    ""postal_code"": ""CH-4005""
  },
  ""date"": ""FEB 07 2017"",
  ""product_name"": ""ZEVTERA"",
  ""medicinal_ingredients"": ""Ceftobiprole (supplied as ceftobiprole mecloxacil sodium)"",
  ""reason_for_submission"": ""To increase the drug product's shelf life specifications for two individual and total degradation products"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Powder for Solution, 500 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,e174396,196769,FEB 07 2017,ZEVTERA,Ceftobiprole (supplied as ceftobiprole mecloxacil sodium),To increase the drug product's shelf life specifications for two individual and total degradation products,,"N/A, Intravenous, Powder for Solution, 500 mg/vial",,Basilea Pharmaceutica International AG,Grazacherstrasse 487,Basel,Switzerland,Switzerland,CH-4005,Marion Law,Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000021991.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e156618"",
  ""submission_no"": ""202290"",
  ""manufacturer"": {
    ""name"": ""Taro Pharmaceuticals Inc."",
    ""street"": ""130 East Drive"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6T 1C1""
  },
  ""date"": ""MAR 14 2017"",
  ""product_name"": ""Taro-Testosterone"",
  ""medicinal_ingredients"": ""Testosterone Undecanoate"",
  ""reason_for_submission"": ""Revisions to the labels"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Capsule, 40 mg"",
  ""canadian_reference_product"": ""Andriol, Organon Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,e156618,202290,MAR 14 2017,Taro-Testosterone,Testosterone Undecanoate,Revisions to the labels,,"N/A, Oral, Capsule, 40 mg","Andriol, Organon Canada Ltd., Canada",Taro Pharmaceuticals Inc.,130 East Drive,Brampton,Ontario,Canada,L6T 1C1,Marion Law,Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000022040.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E133862"",
  ""submission_no"": ""200730"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17,300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2N5""
  },
  ""date"": ""MAR 06 2017"",
  ""product_name"": ""METHOTREXATE"",
  ""medicinal_ingredients"": ""Methotrexate (supplied as methotrexate disodium)"",
  ""reason_for_submission"": ""To remove information pertaining to the injection formulation from the Product Monograph as this format is no longer marketed and the DIN has been cancelled."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 2.5 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E133862,200730,MAR 06 2017,METHOTREXATE,Methotrexate (supplied as methotrexate disodium),To remove information pertaining to the injection formulation from the Product Monograph as this format is no longer marketed and the DIN has been cancelled.,,"N/A, Oral, Tablet, 2.5 mg",,Pfizer Canada Inc.,"17,300 Trans-Canada Highway",Kirkland,Quebec,Canada,H9J 2N5,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022055.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e125722"",
  ""submission_no"": ""202905"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""385 Bouchard Blvd."",
    ""city"": ""Dorval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""APR 03 2017"",
  ""product_name"": ""CILOXAN"",
  ""medicinal_ingredients"": ""Ciprofloxacin Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Transfer of Drug Identification Numbers / Administratif: Transfert d'identification numérique des drogues"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01945270 (ophthalmic, solution, 0.3%) 02200864 (ophthalmic, ointment, 0.3%)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e125722,202905,APR 03 2017,CILOXAN,Ciprofloxacin Hydrochloride,Administrative: Transfer of Drug Identification Numbers / Administratif: Transfert d'identification numérique des drogues,,"01945270 (ophthalmic, solution, 0.3%) 02200864 (ophthalmic, ointment, 0.3%)",,Novartis Pharmaceuticals Canada Inc.,385 Bouchard Blvd.,Dorval,Quebec,Canada,H9S 1A9,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022185.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E144901"",
  ""submission_no"": ""198311"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""19750 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4W7""
  },
  ""date"": ""MAY 03 2017"",
  ""product_name"": ""DIPROSONE"",
  ""medicinal_ingredients"": ""Betamethasone dipropionate"",
  ""reason_for_submission"": ""Change in the drug product manufacturing and testing site."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Topical, Cream, 0.05%"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,E144901,198311,MAY 03 2017,DIPROSONE,Betamethasone dipropionate,Change in the drug product manufacturing and testing site.,N/A,"Topical, Cream, 0.05%",,Merck Canada Inc.,19750 Trans-Canada Highway,Kirkland,Quebec,Canada,H9H 4W7,Marion Law,Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000022200.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p199867"",
  ""submission_no"": ""199889"",
  ""manufacturer"": {
    ""name"": ""Jamp Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H5""
  },
  ""date"": ""APR 1 1 2017"",
  ""product_name"": ""JAMP-TACROLIMUS"",
  ""medicinal_ingredients"": ""Tacrolimus"",
  ""reason_for_submission"": ""Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02460238 (oral, immediate-release capsule, 0.5mg)"",
  ""canadian_reference_product"": ""Prograf, Astellas Pharma Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p199867,199889,APR 1 1 2017,JAMP-TACROLIMUS,Tacrolimus,Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés,,"02460238 (oral, immediate-release capsule, 0.5mg)","Prograf, Astellas Pharma Canada Inc., Canada",Jamp Pharma Corporation,1310 rue Nobel,Boucherville,Quebec,Canada,J4B 5H5,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022217.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""P124075"",
  ""submission_no"": ""201597"",
  ""manufacturer"": {
    ""name"": ""Actavis Pharma Company"",
    ""street"": ""6735 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6J5""
  },
  ""date"": ""APR 1 2 2017"",
  ""product_name"": ""ACT ETIDROCIAL"",
  ""medicinal_ingredients"": ""Etidronate disodium / Calcium carbonate"",
  ""reason_for_submission"": ""Update to the Product Monograph regarding Osteonecrosis of the Jaw (ONJ) in response to an Advertisement Letter."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Oral, Tablet, 400 mg / 1250 mg"",
  ""canadian_reference_product"": ""Didrocal, Procter and Gamble Pharmaceuticals Canada, Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,P124075,201597,APR 1 2 2017,ACT ETIDROCIAL,Etidronate disodium / Calcium carbonate,Update to the Product Monograph regarding Osteonecrosis of the Jaw (ONJ) in response to an Advertisement Letter.,N/A,"Oral, Tablet, 400 mg / 1250 mg","Didrocal, Procter and Gamble Pharmaceuticals Canada, Inc., Canada",Actavis Pharma Company,6735 Mississauga Road,Mississauga,Ontario,Canada,L5N 6J5,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022331.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""203141"",
  ""submission_no"": ""203141"",
  ""manufacturer"": {
    ""name"": ""Fresenius Kabi Canada Ltd."",
    ""street"": ""165 Gaxxy Blvd, Suite 100"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9W 0C8""
  },
  ""date"": ""MAY 1 2 2017"",
  ""product_name"": ""INTRALIPID 10% INTRALIPID 20% INTRALIPID 30%"",
  ""medicinal_ingredients"": ""Soybean Oil"",
  ""reason_for_submission"": ""To add a Patient Medication Information Section to the Product Monograph and Package Insert."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Emulsion, 10% / WV N/A, Intravenous, Emulsion, 20% / WV N/A, Intravenous, Emulsion, 30% / WV"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,203141,203141,MAY 1 2 2017,INTRALIPID 10% INTRALIPID 20% INTRALIPID 30%,Soybean Oil,To add a Patient Medication Information Section to the Product Monograph and Package Insert.,,"N/A, Intravenous, Emulsion, 10% / WV N/A, Intravenous, Emulsion, 20% / WV N/A, Intravenous, Emulsion, 30% / WV",,Fresenius Kabi Canada Ltd.,"165 Gaxxy Blvd, Suite 100",Toronto,Ontario,Canada,M9W 0C8,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000022420.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v175167"",
  ""submission_no"": ""201435"",
  ""manufacturer"": {
    ""name"": ""Intervet Canada Corp."",
    ""street"": ""16750 Trans Canada Hwy"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""MAY 2 6 2017"",
  ""product_name"": ""SALIX"",
  ""medicinal_ingredients"": ""Furosemide"",
  ""reason_for_submission"": ""Manufacturing Changes"",
  ""species"": ""Dogs, Cats, Horses, Cattle"",
  ""drug_identification_number_route_form_strength"": ""00116238, Intravenous, Intramuscular, Solution, 50 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v175167,201435,MAY 2 6 2017,SALIX,Furosemide,Manufacturing Changes,"Dogs, Cats, Horses, Cattle","00116238, Intravenous, Intramuscular, Solution, 50 mg/mL",,Intervet Canada Corp.,16750 Trans Canada Hwy,Kirkland,QC,Canada,H9H 4M7,Dr. Mary Jane Ireland,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,NA
https://pdf.hres.ca/noc_pm/0000022454.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e158636"",
  ""submission_no"": ""201180"",
  ""manufacturer"": {
    ""name"": ""AstraZeneca Canada Inc."",
    ""street"": ""1004 Middlegate Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4Y 1N4""
  },
  ""date"": ""JUN 20 2017"",
  ""product_name"": ""MOVANTIK"",
  ""medicinal_ingredients"": ""Naloxegol (supplied as naloxegol oxalate)"",
  ""reason_for_submission"": ""Additional alternate manufacturing and testing site for the drug substance"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 12.5 mg; N/A, Oral, Tablet, 25 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kimby N. Barton"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e158636,201180,JUN 20 2017,MOVANTIK,Naloxegol (supplied as naloxegol oxalate),Additional alternate manufacturing and testing site for the drug substance,N/A,"N/A, Oral, Tablet, 12.5 mg; N/A, Oral, Tablet, 25 mg",,AstraZeneca Canada Inc.,1004 Middlegate Road,Mississauga,Ontario,Canada,L4Y 1N4,Kimby N. Barton,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022491.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e153424"",
  ""submission_no"": ""205473"",
  ""manufacturer"": {
    ""name"": ""Jamp Pharma Corporation"",
    ""street"": ""1310 Rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 6H3""
  },
  ""date"": ""JUN 16 2017"",
  ""product_name"": ""JAMP-RIZATRIPTAN ODT"",
  ""medicinal_ingredients"": ""Rizatriptan, supplied as Rizatriptan Benzoate"",
  ""reason_for_submission"": ""Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02465086 (oral, orally disintegrating tablet, 5mg) 02465094 (oral, orally disintegrating tablet, 10mg)"",
  ""canadian_reference_product"": ""Maxalt Smolt, Merck Sharp & Dohme BV, The Netherlands"",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e153424,205473,JUN 16 2017,JAMP-RIZATRIPTAN ODT,"Rizatriptan, supplied as Rizatriptan Benzoate",Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés,,"02465086 (oral, orally disintegrating tablet, 5mg) 02465094 (oral, orally disintegrating tablet, 10mg)","Maxalt Smolt, Merck Sharp & Dohme BV, The Netherlands",Jamp Pharma Corporation,1310 Rue Nobel,Boucherville,Quebec,Canada,J4B 6H3,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022523.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e186636"",
  ""submission_no"": ""186636"",
  ""manufacturer"": {
    ""name"": ""Mint Pharmaceuticals Inc."",
    ""street"": ""1093 Myerside Drive, Unit #1"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5T 1K6""
  },
  ""date"": ""JUN 21 2017"",
  ""product_name"": ""Mint-Fenofibrate E"",
  ""medicinal_ingredients"": ""Fenofibrate"",
  ""reason_for_submission"": """",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02465167, Oral, Tablet, 145 mg"",
  ""canadian_reference_product"": ""Lipidil EZ, Fournier Pharma Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kimby N. Barton"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e186636,186636,JUN 21 2017,Mint-Fenofibrate E,Fenofibrate,,,"02465167, Oral, Tablet, 145 mg","Lipidil EZ, Fournier Pharma Inc., Canada",Mint Pharmaceuticals Inc.,"1093 Myerside Drive, Unit #1",Mississauga,Ontario,Canada,L5T 1K6,Kimby N. Barton,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022559.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""201500"",
  ""submission_no"": ""201500"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""JUL 10 2017"",
  ""product_name"": ""Docetaxel Injection USP"",
  ""medicinal_ingredients"": ""Docetaxel"",
  ""reason_for_submission"": ""Alternate drug substance manufacturing site"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, Intravenous, Solution, 10 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kimby N. Barton"",
    ""title"": ""Acting Director General / Directrice générale intérimaire"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,201500,201500,JUL 10 2017,Docetaxel Injection USP,Docetaxel,Alternate drug substance manufacturing site,,"NIA, Intravenous, Solution, 10 mg/mL",,Pfizer Canada Inc.,17300 Trans-Canada Highway,Kirkland,Quebec,Canada,H9J 2M5,Kimby N. Barton,Acting Director General / Directrice générale intérimaire,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022718.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e151693"",
  ""submission_no"": ""198372"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novoeham Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""JUL 26 2017"",
  ""product_name"": ""Teva-Efavirenz/Emtricitabine/Tenofovir"",
  ""medicinal_ingredients"": ""Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate"",
  ""reason_for_submission"": ""Change in the drug substance supplier"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 600 mg/ 200 mg/ 300 mg"",
  ""canadian_reference_product"": ""Atripla, Bristol-Myers Squibb & Gilead Sciences, LLC., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e151693,198372,JUL 26 2017,Teva-Efavirenz/Emtricitabine/Tenofovir,Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,Change in the drug substance supplier,,"N/A, Oral, Tablet, 600 mg/ 200 mg/ 300 mg","Atripla, Bristol-Myers Squibb & Gilead Sciences, LLC., Canada",Teva Canada Limited,30 Novoeham Court,Toronto,Ontario,Canada,M1B 2K9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022724.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E157762"",
  ""submission_no"": ""199318"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""JUL 20 2017"",
  ""product_name"": ""DUAVIVE"",
  ""medicinal_ingredients"": ""Conjugated estrogens and bazedoxifene (supplied as bazedoxifene acetate)"",
  ""reason_for_submission"": ""Update to the Product Monograph reflecting the results of a drug-drug interaction (DDI) study."",
  ""species"": ""NIA"",
  ""drug_identification_number_route_form_strength"": ""Oral, Tablet, 0.45 mg and 20 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E157762,199318,JUL 20 2017,DUAVIVE,Conjugated estrogens and bazedoxifene (supplied as bazedoxifene acetate),Update to the Product Monograph reflecting the results of a drug-drug interaction (DDI) study.,NIA,"Oral, Tablet, 0.45 mg and 20 mg",,Pfizer Canada Inc.,17300 Trans-Canada Highway,Kirkland,Quebec,Canada,H9J 2M5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000022849.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e120541"",
  ""submission_no"": ""207276"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17300 \""Tenn-Carada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""AUG 1 1 2017"",
  ""product_name"": ""PACLITAXEL FOR INJECTION"",
  ""medicinal_ingredients"": ""Paclitaxel"",
  ""reason_for_submission"": ""Administrative: Merger - buyout / Administratif: Fusion - rachat"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02296624 (intravenous, solution, 6 mg/ml)"",
  ""canadian_reference_product"": ""Taxol, Bristol-Myers Squibb Canada, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e120541,207276,AUG 1 1 2017,PACLITAXEL FOR INJECTION,Paclitaxel,Administrative: Merger - buyout / Administratif: Fusion - rachat,,"02296624 (intravenous, solution, 6 mg/ml)","Taxol, Bristol-Myers Squibb Canada, Canada",Pfizer Canada Inc.,"17300 ""Tenn-Carada Highway",Kirkland,Quebec,Canada,H9J 2M5,"Dr. J Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000022980.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e113071"",
  ""submission_no"": ""208703"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""SEP 2 0 2017"",
  ""product_name"": ""LMD 10% IN 0.9% SODIUM CHLORIDE"",
  ""medicinal_ingredients"": ""Dextran, Sodium Chloride"",
  ""reason_for_submission"": ""Administrative: Merger - buyout / Administratif: Fusion - rachat"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00224227 (intravenous, solution, dextran 10 %, sodium chloride 0.9 %)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e113071,208703,SEP 2 0 2017,LMD 10% IN 0.9% SODIUM CHLORIDE,"Dextran, Sodium Chloride",Administrative: Merger - buyout / Administratif: Fusion - rachat,,"00224227 (intravenous, solution, dextran 10 %, sodium chloride 0.9 %)",,Pfizer Canada Inc.,17300 Trans-Canada Highway,Kirkland,Quebec,Canada,H9J 2M5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023031.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E120824"",
  ""submission_no"": ""208150"",
  ""manufacturer"": {
    ""name"": ""EMD Serono, A Division of EMD Inc. Canada"",
    ""street"": ""2695 North Sheridan Way, Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5K 2N6""
  },
  ""date"": ""SEP 27 2017"",
  ""product_name"": ""CETROTIDE"",
  ""medicinal_ingredients"": ""Cetrorelix (supplied as cetrorelix octate)"",
  ""reason_for_submission"": ""Update the Product Monograph and Package Insert to remove references to the discontinued 3 mg strength formulation."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Subcutaneous, Powder for Solution, 0.25 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E120824,208150,SEP 27 2017,CETROTIDE,Cetrorelix (supplied as cetrorelix octate),Update the Product Monograph and Package Insert to remove references to the discontinued 3 mg strength formulation.,N/A,"Subcutaneous, Powder for Solution, 0.25 mg/vial",,"EMD Serono, A Division of EMD Inc. Canada","2695 North Sheridan Way, Suite 200",Mississauga,Ontario,Canada,L5K 2N6,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023035.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""208547"",
  ""submission_no"": ""208547"",
  ""manufacturer"": {
    ""name"": ""Jamp Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H5""
  },
  ""date"": ""SEP 2 2017"",
  ""product_name"": ""JAMP-ESCIATALOPRAM"",
  ""medicinal_ingredients"": ""Escitalopram, supplied as Escitalopram Oxalate"",
  ""reason_for_submission"": ""Administrative: Licensing agreement between two companies"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02429780 (oral, tablet, 10mg) 02429799 (oral, tablet, 20mg)"",
  ""canadian_reference_product"": ""Cipralex, Lundbeck Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,208547,208547,SEP 2 2017,JAMP-ESCIATALOPRAM,"Escitalopram, supplied as Escitalopram Oxalate",Administrative: Licensing agreement between two companies,,"02429780 (oral, tablet, 10mg) 02429799 (oral, tablet, 20mg)","Cipralex, Lundbeck Canada Inc., Canada",Jamp Pharma Corporation,1310 rue Nobel,boucherville,Quebec,Canada,J4B 5H5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023077.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p108249"",
  ""submission_no"": ""108249"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Neweham Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2N9""
  },
  ""date"": ""OCT 0 5 2017"",
  ""product_name"": ""Teva-Doxylamine/Pyrdoxine DR"",
  ""medicinal_ingredients"": ""Doxylamine Succinate / Pyridoxine Hydrochloride"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02304503, Oral, Tablet (delayed-release) 10 mg/10 mg"",
  ""canadian_reference_product"": ""Diclectin, Duchesnay Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCPP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p108249,108249,OCT 0 5 2017,Teva-Doxylamine/Pyrdoxine DR,Doxylamine Succinate / Pyridoxine Hydrochloride,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02304503, Oral, Tablet (delayed-release) 10 mg/10 mg","Diclectin, Duchesnay Inc., Canada",Teva Canada Limited,30 Neweham Court,Toronto,Ontario,Canada,M1B 2N9,"Dr. J. Patrick Stewart, MD, CCPP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023095.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E162920"",
  ""submission_no"": ""201361"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""385 Bauchard Boulevard"",
    ""city"": ""Dorval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""OCT 2 0 2017"",
  ""product_name"": ""CERITINIB"",
  ""medicinal_ingredients"": ""Ceritinib"",
  ""reason_for_submission"": ""Final report for study CLDK378X2101 ss per the commitment in the Letter of Undertaking (LOU) dated March 20, 2015."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Capsule, 150 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E162920,201361,OCT 2 0 2017,CERITINIB,Ceritinib,"Final report for study CLDK378X2101 ss per the commitment in the Letter of Undertaking (LOU) dated March 20, 2015.",,"N/A, Oral, Capsule, 150 mg",,Novartis Pharmaceuticals Canada Inc.,385 Bauchard Boulevard,Dorval,Quebec,Canada,H9S 1A9,"Dr. J. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023265.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""204251"",
  ""submission_no"": ""204251"",
  ""manufacturer"": {
    ""name"": ""Hoffman-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 5M8""
  },
  ""date"": ""NOV 1 4 2017"",
  ""product_name"": ""ACTEMRA"",
  ""medicinal_ingredients"": ""tocilizumab"",
  ""reason_for_submission"": ""For the treatment of giant cell arteritis (GCA) in adult patients/"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA. SC. SOL. 162 mg/0.9mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director, General"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,204251,204251,NOV 1 4 2017,ACTEMRA,tocilizumab,For the treatment of giant cell arteritis (GCA) in adult patients/,,NIA. SC. SOL. 162 mg/0.9mL,,Hoffman-La Roche Limited,7070 Mississauga Road,Mississauga,ON,Canada,L5N 5M8,Catherine Parker,"Director, General",Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000023307.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e133219"",
  ""submission_no"": ""205519"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signal Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""NOV 2 8 2017"",
  ""product_name"": ""APO-NORTIPTYLINE"",
  ""medicinal_ingredients"": ""Nortriptyline hydrochloride"",
  ""reason_for_submission"": ""Change in specifications"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Capsule, 10 mg; N/A, Oral, Capsule, 25 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(F)EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e133219,205519,NOV 2 8 2017,APO-NORTIPTYLINE,Nortriptyline hydrochloride,Change in specifications,N/A,"N/A, Oral, Capsule, 10 mg; N/A, Oral, Capsule, 25 mg",,Apotex Inc.,150 Signal Drive,Toronto,Ontario,Canada,M5L 1T9,"Dr. J. Patrick Stewart, MD, CCP(F)EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023379.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e125489"",
  ""submission_no"": ""210015"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Inc."",
    ""street"": ""1105 Circulstone Road, Unit #1"",
    ""city"": ""Vaughan"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 4N7""
  },
  ""date"": ""NOV 1 4 2017"",
  ""product_name"": ""Moclobemide"",
  ""medicinal_ingredients"": ""Moclobemide"",
  ""reason_for_submission"": ""Labelling Assessment and Administrative – Transfer of Drug Identification Number (DIN)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02232148, Oral, Tablet, 100 mg; 02232150, Oral, Tablet, 150 mg; 02240456, Oral, Tablet, 300 mg"",
  ""canadian_reference_product"": ""Manerix, Hoffmann-La Roche Limited, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e125489,210015,NOV 1 4 2017,Moclobemide,Moclobemide,Labelling Assessment and Administrative – Transfer of Drug Identification Number (DIN),,"02232148, Oral, Tablet, 100 mg; 02232150, Oral, Tablet, 150 mg; 02240456, Oral, Tablet, 300 mg","Manerix, Hoffmann-La Roche Limited, Canada",AA Pharma Inc.,"1105 Circulstone Road, Unit #1",Vaughan,Ontario,Canada,L4K 4N7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023380.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e208443"",
  ""submission_no"": ""210071"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Rayeimount Avenue"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""NOV 15 2017"",
  ""product_name"": ""PHARMA-AMLODIPINE"",
  ""medicinal_ingredients"": ""Amlodipine, supplied as Amlodipine Besylate"",
  ""reason_for_submission"": ""Licensing agreement between two companies"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02469022 (oral, tablet, 2.5 mg) 02469030 (oral, tablet, 5 mg) 02469049 (oral, tablet, 10 mg)"",
  ""canadian_reference_product"": ""Norvasc, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e208443,210071,NOV 15 2017,PHARMA-AMLODIPINE,"Amlodipine, supplied as Amlodipine Besylate",Licensing agreement between two companies,,"02469022 (oral, tablet, 2.5 mg) 02469030 (oral, tablet, 5 mg) 02469049 (oral, tablet, 10 mg)","Norvasc, Pfizer Canada Inc., Canada",Pharmascience Inc.,6111 Rayeimount Avenue,Montreal,Quebec,Canada,H4P 2T4,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000023544.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E142326"",
  ""submission_no"": ""202700"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17,300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M6""
  },
  ""date"": ""DEC 15 2017"",
  ""product_name"": ""TOVI AZ"",
  ""medicinal_ingredients"": ""Fesoterodine fumarate"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph based on a Pediatric Pharmacokinetic Study"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablets (Extended-Release), 4 mg; N/A, Oral, Tablets (Extended-Release) 8 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,E142326,202700,DEC 15 2017,TOVI AZ,Fesoterodine fumarate,Safety updates to the Product Monograph based on a Pediatric Pharmacokinetic Study,,"N/A, Oral, Tablets (Extended-Release), 4 mg; N/A, Oral, Tablets (Extended-Release) 8 mg",,Pfizer Canada Inc.,"17,300 Trans-Canada Highway",Kirkland,Quebec,Canada,H9J 2M6,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000023568.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p211793"",
  ""submission_no"": ""211793"",
  ""manufacturer"": {
    ""name"": ""Menira Pharma Inc."",
    ""street"": ""4606-B boul. Lapiniere"",
    ""city"": ""Brossard"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4Z 3T5""
  },
  ""date"": ""DEC 2 8 2017"",
  ""product_name"": ""M-VENLAFAXINE XR"",
  ""medicinal_ingredients"": ""Venlafaxine, supplied as Venlafaxine Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02471280 (oral, extended release capsule, 37.5 mg) 02471299 (oral, extended release capsule, 75 mg) 02471302 (oral, extended release capsule, 150 mg)"",
  ""canadian_reference_product"": ""Effexor XR, Wyeth Canada, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p211793,211793,DEC 2 8 2017,M-VENLAFAXINE XR,"Venlafaxine, supplied as Venlafaxine Hydrochloride",Administrative: Licensing agreement between two companies / Administratif: Accord de licence entre deux sociétés,,"02471280 (oral, extended release capsule, 37.5 mg) 02471299 (oral, extended release capsule, 75 mg) 02471302 (oral, extended release capsule, 150 mg)","Effexor XR, Wyeth Canada, Canada",Menira Pharma Inc.,4606-B boul. Lapiniere,Brossard,Quebec,Canada,J4Z 3T5,"Dr. J. Patrick Stewart, MD, CFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000024567.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e185484"",
  ""submission_no"": ""214192"",
  ""manufacturer"": {
    ""name"": ""Shire Pharma Canada ULC"",
    ""street"": ""22 Adelaide Street West"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5H 4E3""
  },
  ""date"": ""APR 1 0 2010"",
  ""product_name"": ""ONIVYDE"",
  ""medicinal_ingredients"": ""Irinotecan Hydrochloride supplied as Irinotecan Sucrose Octasulfate"",
  ""reason_for_submission"": ""Administrative: Merger/Buy-out / Administratif: Fusion/rachat"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02467135 (intravenous, suspension, +3 mg/10 mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e185484,214192,APR 1 0 2010,ONIVYDE,Irinotecan Hydrochloride supplied as Irinotecan Sucrose Octasulfate,Administrative: Merger/Buy-out / Administratif: Fusion/rachat,,"02467135 (intravenous, suspension, +3 mg/10 mL)",,Shire Pharma Canada ULC,22 Adelaide Street West,Toronto,Ontario,Canada,M5H 4E3,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000024923.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e120247"",
  ""submission_no"": ""205004"",
  ""manufacturer"": {
    ""name"": ""Pendopharm, Division of Pharmascience Inc."",
    ""street"": ""6111 Royalmount Avenue"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""MAY 15 2018"",
  ""product_name"": ""Entrophen"",
  ""medicinal_ingredients"": ""Acetylsalicylic Acid"",
  ""reason_for_submission"": ""Alternate manufacturing site for the finished product"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet (Delayed-Release), 81 mg"",
  ""canadian_reference_product"": ""Coated Aspirin Daily Low Dose 81 mg, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e120247,205004,MAY 15 2018,Entrophen,Acetylsalicylic Acid,Alternate manufacturing site for the finished product,,"N/A, Oral, Tablet (Delayed-Release), 81 mg","Coated Aspirin Daily Low Dose 81 mg, Bayer Inc., Canada","Pendopharm, Division of Pharmascience Inc.",6111 Royalmount Avenue,Montreal,Quebec,Canada,H4P 2T4,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000025039.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e122069"",
  ""submission_no"": ""215901"",
  ""manufacturer"": {
    ""name"": ""Actavis Pharma Company"",
    ""street"": ""6733 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6J5""
  },
  ""date"": ""MAY 29 2018"",
  ""product_name"": ""ACT PIOGLITAZONE"",
  ""medicinal_ingredients"": ""Pioglitazone hydrochloride"",
  ""reason_for_submission"": ""Revisions to the product monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 15 mg\nN/A, Oral, Tablet, 30 mg\nN/A, Oral, Tablet, 45 mg"",
  ""canadian_reference_product"": ""Actos, Takeda Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,e122069,215901,MAY 29 2018,ACT PIOGLITAZONE,Pioglitazone hydrochloride,Revisions to the product monograph,,"N/A, Oral, Tablet, 15 mg
N/A, Oral, Tablet, 30 mg
N/A, Oral, Tablet, 45 mg","Actos, Takeda Canada Inc., Canada",Actavis Pharma Company,6733 Mississauga Road,Mississauga,Ontario,Canada,L5N 6J5,"Dr. J. Patrick Stewart, MD, CFP(EM)",Director General / Directeur général,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000025061.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e208976"",
  ""submission_no"": ""208976"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""MAY 3 1 2018"",
  ""product_name"": ""Auro-Olmesartan HCTZ"",
  ""medicinal_ingredients"": ""Olmesartan Medoxomil and Hydrochlorothiazide"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02476487, Oral, Tablet, 20 mg/12.5 mg\n02476495, Oral, Tablet, 40 mg/12.5 mg\n02476509, Oral, Tablet, 40 mg/25 mg"",
  ""canadian_reference_product"": ""Olmetec Plus, Merck Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e208976,208976,MAY 3 1 2018,Auro-Olmesartan HCTZ,Olmesartan Medoxomil and Hydrochlorothiazide,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02476487, Oral, Tablet, 20 mg/12.5 mg
02476495, Oral, Tablet, 40 mg/12.5 mg
02476509, Oral, Tablet, 40 mg/25 mg","Olmetec Plus, Merck Canada Inc., Canada",Auro Pharma Inc.,3700 Steeles Avenue West,Woodbridge,Ontario,Canada,L4L 8K8,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000025140.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e215532"",
  ""submission_no"": ""215532"",
  ""manufacturer"": {
    ""name"": ""Mint Pharmaceuticals Inc."",
    ""street"": ""1093 Meyerside Drive, Unit 1"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5T 1J6""
  },
  ""date"": ""JUN 04 2010"",
  ""product_name"": ""Mint-Perindopril"",
  ""medicinal_ingredients"": ""Perindopril Erbumine"",
  ""reason_for_submission"": ""Licensing agreement between two companies and revisions to the labels"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02476762, Oral, Tablet, 2 mg; 02470770, Oral, Tablet, 4 mg; 02476789, Oral, Tablet, 8 mg"",
  ""canadian_reference_product"": ""Coversyl, Servier Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP (EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e215532,215532,JUN 04 2010,Mint-Perindopril,Perindopril Erbumine,Licensing agreement between two companies and revisions to the labels,,"02476762, Oral, Tablet, 2 mg; 02470770, Oral, Tablet, 4 mg; 02476789, Oral, Tablet, 8 mg","Coversyl, Servier Canada Inc., Canada",Mint Pharmaceuticals Inc.,"1093 Meyerside Drive, Unit 1",Mississauga,Ontario,Canada,L5T 1J6,"Dr. J. Patrick Stewart, MD, CCP (EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000025347.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E174228"",
  ""submission_no"": ""213240"",
  ""manufacturer"": {
    ""name"": ""Pharmaceuticals Inc."",
    ""street"": ""6111 Royalmount Ave."",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""MAR 15 2018"",
  ""product_name"": ""PMS-ZOLPIDEM ODT"",
  ""medicinal_ingredients"": ""Zolpidem Tartrate"",
  ""reason_for_submission"": ""Revised labels"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Oral / Sublingual, Tablet (orally disintegrating), 5 mg\nOral / Sublingual, Tablet (orally disintegrating), 10 mg"",
  ""canadian_reference_product"": ""Sublinox, Media Valeant Pharma Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director general"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,E174228,213240,MAR 15 2018,PMS-ZOLPIDEM ODT,Zolpidem Tartrate,Revised labels,N/A,"Oral / Sublingual, Tablet (orally disintegrating), 5 mg
Oral / Sublingual, Tablet (orally disintegrating), 10 mg","Sublinox, Media Valeant Pharma Canada Inc., Canada",Pharmaceuticals Inc.,6111 Royalmount Ave.,Montreal,Quebec,Canada,H4P 2T4,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director general,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000025502.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e131745"",
  ""submission_no"": ""210088"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada Inc."",
    ""street"": ""17,300 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M6""
  },
  ""date"": ""JUN 2 5 2018"",
  ""product_name"": ""DALACIN C FLAVOURED GRANULES"",
  ""medicinal_ingredients"": ""Clindamycin Palmitate Hydrochloride"",
  ""reason_for_submission"": ""Updates to the action and clinical pharmacology and microbiology sections of the pm."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Powder for solution, 75 mg / 5 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e131745,210088,JUN 2 5 2018,DALACIN C FLAVOURED GRANULES,Clindamycin Palmitate Hydrochloride,Updates to the action and clinical pharmacology and microbiology sections of the pm.,,"N/A, Oral, Powder for solution, 75 mg / 5 mL",,Pfizer Canada Inc.,"17,300 Trans Canada Highway",Kirkland,Quebec,Canada,H9J 2M6,"Dr. J. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000025529.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""6149894"",
  ""submission_no"": ""216323"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Sigel Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 1T9""
  },
  ""date"": ""JUN 29 2018"",
  ""product_name"": ""Apo-Abacavir-Lamivudine"",
  ""medicinal_ingredients"": ""Abacavir Sulfate, Lamivudine"",
  ""reason_for_submission"": ""Update to the Product Monograph"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Oral, Tablet, 600 mg/300 mg"",
  ""canadian_reference_product"": ""Kivexa, GlaxoSmithKline Shire Canada, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,6149894,216323,JUN 29 2018,Apo-Abacavir-Lamivudine,"Abacavir Sulfate, Lamivudine",Update to the Product Monograph,N/A,"Oral, Tablet, 600 mg/300 mg","Kivexa, GlaxoSmithKline Shire Canada, Canada",Apotex Inc.,150 Sigel Drive,Toronto,Ontario,Canada,M5L 1T9,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000025598.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""211996"",
  ""submission_no"": ""211996"",
  ""manufacturer"": {
    ""name"": ""sanofi-aventis Canada Inc."",
    ""street"": ""2905 Place Louis-R.-Renaud"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7V 0A3""
  },
  ""date"": ""JUL 1 6 2018"",
  ""product_name"": ""Lantus"",
  ""medicinal_ingredients"": ""insulin glargine"",
  ""reason_for_submission"": ""New manufacturing area and manufacturing scale-up / nouvel emplacement de fabrication et nouvelle échelle de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA - SC, SOL, 100 Unit/ml, (10 mL vial)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,211996,211996,JUL 1 6 2018,Lantus,insulin glargine,New manufacturing area and manufacturing scale-up / nouvel emplacement de fabrication et nouvelle échelle de fabrication,,"NIA - SC, SOL, 100 Unit/ml, (10 mL vial)",,sanofi-aventis Canada Inc.,2905 Place Louis-R.-Renaud,Laval,Quebec,Canada,H7V 0A3,Catherine Parker,Director General / Directrice générale,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000025755.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e155671"",
  ""submission_no"": ""217251"",
  ""manufacturer"": {
    ""name"": ""Alembic Pharmaceuticals Limited, India"",
    ""street"": ""Alembic Road"",
    ""city"": ""Vadodara"",
    ""province"": ""Gujarat"",
    ""country"": ""India"",
    ""postal_code"": ""390003""
  },
  ""date"": ""JUL 23 2018"",
  ""product_name"": ""ALEMBIC-TELMISARTAN"",
  ""medicinal_ingredients"": ""Teknisartan"",
  ""reason_for_submission"": ""Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02428245 (oral, tablet, 40 mg) 02428253 (oral, tablet, 80 mg)"",
  ""canadian_reference_product"": ""Micardis, Boehringer Ingelheim (Canada) Ltd"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e155671,217251,JUL 23 2018,ALEMBIC-TELMISARTAN,Teknisartan,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,,"02428245 (oral, tablet, 40 mg) 02428253 (oral, tablet, 80 mg)","Micardis, Boehringer Ingelheim (Canada) Ltd","Alembic Pharmaceuticals Limited, India",Alembic Road,Vadodara,Gujarat,India,390003,"Dr. J. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000025864.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""214191"",
  ""submission_no"": ""214191"",
  ""manufacturer"": {
    ""name"": ""Eli Lilly Canada Inc."",
    ""street"": ""3650 Danforth Avenue"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M4N 2E9""
  },
  ""date"": ""AUG 2 2018"",
  ""product_name"": ""LARTRUVO"",
  ""medicinal_ingredients"": ""olaratumab"",
  ""reason_for_submission"": ""New presentation / nouvelle présentation"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02480271, IV, SOL, 190mg/19mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,214191,214191,AUG 2 2018,LARTRUVO,olaratumab,New presentation / nouvelle présentation,,"02480271, IV, SOL, 190mg/19mL",,Eli Lilly Canada Inc.,3650 Danforth Avenue,Toronto,ON,Canada,M4N 2E9,Catherine Parker,Director General / Directrice générale,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000026082.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""208730"",
  ""submission_no"": ""208730"",
  ""manufacturer"": {
    ""name"": ""Ipsen Biopharmaceuticals Canada Inc."",
    ""street"": ""5060 Spectrum Way, Suite 502"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 5N6""
  },
  ""date"": ""OCT 12 2018"",
  ""product_name"": ""XERMELO"",
  ""medicinal_ingredients"": ""Trelotristat ethyl (supplied as trelotristat etiprate)"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.004 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02481553, Oral, Tablet, 250 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,208730,208730,OCT 12 2018,XERMELO,Trelotristat ethyl (supplied as trelotristat etiprate),"This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.004 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02481553, Oral, Tablet, 250 mg",,Ipsen Biopharmaceuticals Canada Inc.,"5060 Spectrum Way, Suite 502",Mississauga,Ontario,Canada,L4W 5N6,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000026126.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p100422"",
  ""submission_no"": ""219109"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Incorporated"",
    ""street"": ""110 rue de Lauson"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E5""
  },
  ""date"": ""OCT - 9 2018"",
  ""product_name"": ""FLUCONAZOLE INJECTION and FLUCONAZOLE INJECTION SDZ"",
  ""medicinal_ingredients"": ""Fluconazole"",
  ""reason_for_submission"": ""Updates to product monograph"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Intravenous, Solution, 2 mg / mL"",
  ""canadian_reference_product"": ""Diffucan, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,p100422,219109,OCT - 9 2018,FLUCONAZOLE INJECTION and FLUCONAZOLE INJECTION SDZ,Fluconazole,Updates to product monograph,N/A,"Intravenous, Solution, 2 mg / mL","Diffucan, Pfizer Canada Inc., Canada",Sandoz Canada Incorporated,110 rue de Lauson,Boucherville,Québec,Canada,J4B 1E5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000026333.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""212299"",
  ""submission_no"": ""212299"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 5M8""
  },
  ""date"": ""NOV 28 2010"",
  ""product_name"": ""Actemra"",
  ""medicinal_ingredients"": ""tocilizumab"",
  ""reason_for_submission"": ""new presentation / nouvelle presentation"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02463327, SC, SOL, 162 mg / 0.9 mL (autoinjector)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,212299,212299,NOV 28 2010,Actemra,tocilizumab,new presentation / nouvelle presentation,,"02463327, SC, SOL, 162 mg / 0.9 mL (autoinjector)",,Hoffmann-La Roche Limited,7070 Mississauga Road,Mississauga,Ontario,Canada,L5N 5M8,Catherine Parker,Director General / Directrice générale,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000026538.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""215950"",
  ""submission_no"": ""215950"",
  ""manufacturer"": {
    ""name"": ""Jubilant DraxImage Inc."",
    ""street"": ""16751 TransCanada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4J4""
  },
  ""date"": ""DEC 2 1 2018"",
  ""product_name"": ""Ruby-Fill"",
  ""medicinal_ingredients"": ""Rubidium Rb-82 Generator"",
  ""reason_for_submission"": ""An alternative source of Strontium (Sr-82) chloride"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A – IV, SOL, 3.7 GBq"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,215950,215950,DEC 2 1 2018,Ruby-Fill,Rubidium Rb-82 Generator,An alternative source of Strontium (Sr-82) chloride,,"N/A – IV, SOL, 3.7 GBq",,Jubilant DraxImage Inc.,16751 TransCanada Highway,Kirkland,Quebec,Canada,H9H 4J4,Catherine Parker,Director General / Directrice générale,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000026626.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e128001"",
  ""submission_no"": ""222182"",
  ""manufacturer"": {
    ""name"": ""Sunovion Pharmaceuticals Canada Inc."",
    ""street"": ""7025 Langer Drive"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 0E8""
  },
  ""date"": ""JAN 24 2019"",
  ""product_name"": ""APTIOM"",
  ""medicinal_ingredients"": ""Eslicarbazepine Acetate"",
  ""reason_for_submission"": ""Addition of new labels with Increased size"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 200 mg; N/A, Oral, Tablet, 400 mg; N/A, Oral, Tablet, 600 mg; N/A, Oral, Tablet, 800 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e128001,222182,JAN 24 2019,APTIOM,Eslicarbazepine Acetate,Addition of new labels with Increased size,N/A,"N/A, Oral, Tablet, 200 mg; N/A, Oral, Tablet, 400 mg; N/A, Oral, Tablet, 600 mg; N/A, Oral, Tablet, 800 mg",,Sunovion Pharmaceuticals Canada Inc.,7025 Langer Drive,Mississauga,Ontario,Canada,L5N 0E8,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000026695.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e128647"",
  ""submission_no"": ""221068"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Siget Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""JAN 22 2019"",
  ""product_name"": ""CIPROFLOXACIN INTRAVENOUS INFUSION, BP"",
  ""medicinal_ingredients"": ""Ciprofloxacin"",
  ""reason_for_submission"": ""To updated the Product Monograph with new Safety Information"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""Cipro I.V. Mini Bags, Bayer Inc., Canada"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e128647,221068,JAN 22 2019,"CIPROFLOXACIN INTRAVENOUS INFUSION, BP",Ciprofloxacin,To updated the Product Monograph with new Safety Information,N/A,"Cipro I.V. Mini Bags, Bayer Inc., Canada",,Apotex Inc.,150 Siget Drive,Toronto,Ontario,Canada,M9L 1T9,"Dr. J. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000026698.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e163054"",
  ""submission_no"": ""221785"",
  ""manufacturer"": {
    ""name"": ""Ranbaxy Pharmaceuticals Canada Inc."",
    ""street"": ""126 East Drive"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6T 1C1""
  },
  ""date"": ""NOV 28 2018"",
  ""product_name"": ""RAN-FENTANYL MATRIX PATCH"",
  ""medicinal_ingredients"": ""Fentanyl"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A (transdermal, patch, 12 mcg/hour) / N/A (transdermal, patch, 25 mcg/hour) / N/A (transdermal, patch, 50 mcg/hour) / N/A (transdermal, patch, 75 mcg/hour) / N/A (transdermal, patch, 100 mcg/hour)"",
  ""canadian_reference_product"": ""Duragesic, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(F)EM"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e163054,221785,NOV 28 2018,RAN-FENTANYL MATRIX PATCH,Fentanyl,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A (transdermal, patch, 12 mcg/hour) / N/A (transdermal, patch, 25 mcg/hour) / N/A (transdermal, patch, 50 mcg/hour) / N/A (transdermal, patch, 75 mcg/hour) / N/A (transdermal, patch, 100 mcg/hour)","Duragesic, Janssen-Ortho Inc., Canada",Ranbaxy Pharmaceuticals Canada Inc.,126 East Drive,Brampton,Ontario,Canada,L6T 1C1,"Dr. J. Patrick Stewart, MD, CCP(F)EM",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000026768.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v161303"",
  ""submission_no"": ""223856"",
  ""manufacturer"": {
    ""name"": ""Vétoquinol N.-A. Inc."",
    ""street"": ""2000 chemin Georges"",
    ""city"": ""Lavaltrie"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J5T 3S5""
  },
  ""date"": ""JAN 2 5 2019"",
  ""product_name"": ""OvuGel"",
  ""medicinal_ingredients"": ""Triptorelin (as triptorelin acetate)"",
  ""reason_for_submission"": ""Administrative - Change in Product Ownership"",
  ""species"": ""Sows"",
  ""drug_identification_number_route_form_strength"": ""02424150, Intravaginal, Gel, 100 µg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v161303,223856,JAN 2 5 2019,OvuGel,Triptorelin (as triptorelin acetate),Administrative - Change in Product Ownership,Sows,"02424150, Intravaginal, Gel, 100 µg/mL",,Vétoquinol N.-A. Inc.,2000 chemin Georges,Lavaltrie,QC,Canada,J5T 3S5,Dr. Mary Jane Ireland,Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000026898.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""202488"",
  ""submission_no"": ""202488"",
  ""manufacturer"": {
    ""name"": ""Endo Ventures Ltd."",
    ""street"": ""First Floor, Minerva House"",
    ""city"": ""Dublin"",
    ""province"": ""Ireland"",
    ""country"": ""Ireland"",
    ""postal_code"": ""4""
  },
  ""date"": ""JAN 0 2 2019"",
  ""product_name"": ""XIAFLEX"",
  ""medicinal_ingredients"": ""collagenase clostridium histolyticum"",
  ""reason_for_submission"": ""New indication: For the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy / nouvelle indication: Pour le traitement des hommes ayant la maladie de La Peyronie présentant une plaque palpable et avec une déformation de la courbure d'au moins 30 degrés au début du traitement."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, IL, PWSO, 0.9 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Catherine Parker"",
    ""title"": ""Director General"",
    ""division"": ""Biologics and Genetic Therapies Directorate"",
    ""directorate"": ""Direction des produits biologiques et thérapies génétiques""
  }
}",TRUE,NA,202488,202488,JAN 0 2 2019,XIAFLEX,collagenase clostridium histolyticum,New indication: For the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy / nouvelle indication: Pour le traitement des hommes ayant la maladie de La Peyronie présentant une plaque palpable et avec une déformation de la courbure d'au moins 30 degrés au début du traitement.,,"NIA, IL, PWSO, 0.9 mg/vial",,Endo Ventures Ltd.,"First Floor, Minerva House",Dublin,Ireland,Ireland,4,Catherine Parker,Director General,Biologics and Genetic Therapies Directorate,Direction des produits biologiques et thérapies génétiques
https://pdf.hres.ca/noc_pm/0000027048.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""p219836"",
  ""submission_no"": ""219836"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""MAR 1 1 2019"",
  ""product_name"": ""SANDOZ FINGOLIMOD"",
  ""medicinal_ingredients"": ""Fingolimod (supplied as fingolimod hydrochloride)"",
  ""reason_for_submission"": ""New Product Labels and Product Monograph"",
  ""species"": ""Two Companies"",
  ""drug_identification_number_route_form_strength"": ""02482606, Oral, Capsule, 0.5 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,p219836,219836,MAR 1 1 2019,SANDOZ FINGOLIMOD,Fingolimod (supplied as fingolimod hydrochloride),New Product Labels and Product Monograph,Two Companies,"02482606, Oral, Capsule, 0.5 mg",,Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Quebec,Canada,J4B 1E6,"Dr. Patrick Stewart, MD, CCP(EM)",Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000027060.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e198972"",
  ""submission_no"": ""198972"",
  ""manufacturer"": {
    ""name"": ""Bard Pharmaceuticals (1990) Inc."",
    ""street"": ""560 Granite Court"",
    ""city"": ""Pickering"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L1W 3W8""
  },
  ""date"": ""JAN 2 0 2017"",
  ""product_name"": ""BAR-HYDROMorphone HCl"",
  ""medicinal_ingredients"": ""Hydromorphone hydrochloride"",
  ""reason_for_submission"": ""Administrative – Licensing Agreement Between Two Companies"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02460777, Oral, Extended-Release Capsule, 3 mg; 02460785, Oral, Extended-Release Capsule, 4.5 mg; 02460793, Oral, Extended-Release Capsule, 6 mg; 02460807, Oral, Extended-Release Capsule, 9 mg; 02460815, Oral, Extended-Release Capsule, 12 mg; 02460823, Oral, Extended-Release Capsule, 18 mg; 02460831, Oral, Extended-Release Capsule, 24 mg; 02460858, Oral, Extended-Release Capsule, 30 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marion Law"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e198972,198972,JAN 2 0 2017,BAR-HYDROMorphone HCl,Hydromorphone hydrochloride,Administrative – Licensing Agreement Between Two Companies,,"02460777, Oral, Extended-Release Capsule, 3 mg; 02460785, Oral, Extended-Release Capsule, 4.5 mg; 02460793, Oral, Extended-Release Capsule, 6 mg; 02460807, Oral, Extended-Release Capsule, 9 mg; 02460815, Oral, Extended-Release Capsule, 12 mg; 02460823, Oral, Extended-Release Capsule, 18 mg; 02460831, Oral, Extended-Release Capsule, 24 mg; 02460858, Oral, Extended-Release Capsule, 30 mg",,Bard Pharmaceuticals (1990) Inc.,560 Granite Court,Pickering,Ontario,Canada,L1W 3W8,Marion Law,Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000027271.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""206854"",
  ""submission_no"": ""206854"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada ULC"",
    ""street"": ""17, 300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""APR 02 2019"",
  ""product_name"": ""CELEBREX"",
  ""medicinal_ingredients"": ""celecoxib"",
  ""reason_for_submission"": ""Update to the Product Monograph."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Capsules, 100 mg; N/A, Oral, Capsules, 200 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,206854,206854,APR 02 2019,CELEBREX,celecoxib,Update to the Product Monograph.,N/A,"N/A, Oral, Capsules, 100 mg; N/A, Oral, Capsules, 200 mg",,Pfizer Canada ULC,"17, 300 Trans-Canada Highway",Kirkland,Quebec,Canada,H9J 2M5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000027344.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""216208"",
  ""submission_no"": ""216208"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada ULC"",
    ""street"": ""17,300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""APR 1 5 2019"",
  ""product_name"": ""Pneuvan 13"",
  ""medicinal_ingredients"": ""Pneumococcal polysaccharide serotype 1* Pneumococcal polysaccharide serotype 3* Pneumococcal polysaccharide serotype 4* Pneumococcal polysaccharide serotype 5* Pneumococcal polysaccharide serotype 6A* Pneumococcal polysaccharide serotype 6B* Pneumococcal polysaccharide serotype 7F* Pneumococcal polysaccharide serotype 9V* Pneumococcal polysaccharide serotype 14* Pneumococcal polysaccharide serotype 18C* Pneumococcal polysaccharide serotype 19A* Pneumococcal polysaccharide serotype 19F* Pneumococcal polysaccharide serotype 23F* *conjugated to Diphtheria CRM197/protein"",
  ""reason_for_submission"": ""Extension of an indication. Pneuvan 13 is indicated for active immunization of infants and children from 6 weeks to 5 years of age (prior to the 6th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) and acute otitis media caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": """",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,216208,216208,APR 1 5 2019,Pneuvan 13,Pneumococcal polysaccharide serotype 1* Pneumococcal polysaccharide serotype 3* Pneumococcal polysaccharide serotype 4* Pneumococcal polysaccharide serotype 5* Pneumococcal polysaccharide serotype 6A* Pneumococcal polysaccharide serotype 6B* Pneumococcal polysaccharide serotype 7F* Pneumococcal polysaccharide serotype 9V* Pneumococcal polysaccharide serotype 14* Pneumococcal polysaccharide serotype 18C* Pneumococcal polysaccharide serotype 19A* Pneumococcal polysaccharide serotype 19F* Pneumococcal polysaccharide serotype 23F* *conjugated to Diphtheria CRM197/protein,"Extension of an indication. Pneuvan 13 is indicated for active immunization of infants and children from 6 weeks to 5 years of age (prior to the 6th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) and acute otitis media caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.",,,,Pfizer Canada ULC,"17,300 Trans-Canada Highway",Kirkland,Quebec,Canada,H9J 2M5,,,,
https://pdf.hres.ca/noc_pm/0000027374.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""d226311"",
  ""submission_no"": ""226311"",
  ""manufacturer"": {
    ""name"": ""Mantra Pharma Inc."",
    ""street"": ""9150 boul. Leduc, bur. 201"",
    ""city"": ""Brossard"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4Y 6E3""
  },
  ""date"": ""MAY 03 2019"",
  ""product_name"": ""M-MONTELUKAST"",
  ""medicinal_ingredients"": ""Montelukast supplied as Montelukast Sodium"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02488167 (oral, tablet chewable, 4 mg) 02488175 (oral, tablet chewable, 5 mg) 02488183 (oral, tablet, 10 mg)"",
  ""canadian_reference_product"": ""SINGULAIR - MERCK SHARP & DOHME CORP., USA (4mg and 5mg) SINGULAIR - MERCK SHARP & DOHME LIMITED, GERMANY (10mg)"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,d226311,226311,MAY 03 2019,M-MONTELUKAST,Montelukast supplied as Montelukast Sodium,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02488167 (oral, tablet chewable, 4 mg) 02488175 (oral, tablet chewable, 5 mg) 02488183 (oral, tablet, 10 mg)","SINGULAIR - MERCK SHARP & DOHME CORP., USA (4mg and 5mg) SINGULAIR - MERCK SHARP & DOHME LIMITED, GERMANY (10mg)",Mantra Pharma Inc.,"9150 boul. Leduc, bur. 201",Brossard,Quebec,Canada,J4Y 6E3,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000027488.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v158519"",
  ""submission_no"": ""209224"",
  ""manufacturer"": {
    ""name"": ""Elanco, Division Eli Lilly Canada Inc."",
    ""street"": ""150 Research Lane"",
    ""city"": ""Guelph"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""N1G 4T2""
  },
  ""date"": ""JAN 0 8 2010"",
  ""product_name"": ""Component TE-5 Implants with Tylan"",
  ""medicinal_ingredients"": ""Trenbolone Acetate, Estradiol, Tylosin Tartrate"",
  ""reason_for_submission"": ""Change to Prescription Status, Labelling updates"",
  ""species"": ""Feedlot steers"",
  ""drug_identification_number_route_form_strength"": ""02245745, Subcutaneous, Implant, Trenbolone Acetate 120 mg/implant, Estradiol 24 mg/implant, Tylosin Tartrate 29 mg/implant"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v158519,209224,JAN 0 8 2010,Component TE-5 Implants with Tylan,"Trenbolone Acetate, Estradiol, Tylosin Tartrate","Change to Prescription Status, Labelling updates",Feedlot steers,"02245745, Subcutaneous, Implant, Trenbolone Acetate 120 mg/implant, Estradiol 24 mg/implant, Tylosin Tartrate 29 mg/implant",,"Elanco, Division Eli Lilly Canada Inc.",150 Research Lane,Guelph,ON,Canada,N1G 4T2,Dr. Mary Jane Ireland,Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000027656.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""212191"",
  ""submission_no"": ""212191"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Inc."",
    ""street"": ""1195 Creditstone Road"",
    ""city"": ""Vaughan"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 4N7""
  },
  ""date"": ""FEB 08 2018"",
  ""product_name"": ""Norfloxacin"",
  ""medicinal_ingredients"": ""Norfloxacin"",
  ""reason_for_submission"": ""Labelling Assessment and Administrative – Transfer of Drug Identification Number (DIN)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02226524, Oral, Tablet, 400 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,212191,212191,FEB 08 2018,Norfloxacin,Norfloxacin,Labelling Assessment and Administrative – Transfer of Drug Identification Number (DIN),,"02226524, Oral, Tablet, 400 mg",,AA Pharma Inc.,1195 Creditstone Road,Vaughan,Ontario,Canada,L4K 4N7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000027672.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v154547"",
  ""submission_no"": ""213181"",
  ""manufacturer"": {
    ""name"": ""Elanco Canada Limited"",
    ""street"": ""190 Research Lane, Suite 120"",
    ""city"": ""Guelph"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""N1G 4T2""
  },
  ""date"": ""FEB 1 4 2018"",
  ""product_name"": ""Component TE-100 Implants with Tylosin"",
  ""medicinal_ingredients"": ""Trenbolone Acetate, Estradiol, Tylosin Tartrate"",
  ""reason_for_submission"": ""Merger/Buyout"",
  ""species"": ""Feedlot steers and heifers"",
  ""drug_identification_number_route_form_strength"": ""02368916, Subcutaneous, Implant, Trenbolone Acetate 100 mg/implant, Estradiol 10 mg/implant, Tylosin Tartrate 20 mg/implant"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v154547,213181,FEB 1 4 2018,Component TE-100 Implants with Tylosin,"Trenbolone Acetate, Estradiol, Tylosin Tartrate",Merger/Buyout,Feedlot steers and heifers,"02368916, Subcutaneous, Implant, Trenbolone Acetate 100 mg/implant, Estradiol 10 mg/implant, Tylosin Tartrate 20 mg/implant",,Elanco Canada Limited,"190 Research Lane, Suite 120",Guelph,ON,Canada,N1G 4T2,Dr. Mary Jane Ireland,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,NA
https://pdf.hres.ca/noc_pm/0000027883.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v148503"",
  ""submission_no"": ""214620"",
  ""manufacturer"": {
    ""name"": ""Elanco Canada Limited"",
    ""street"": ""150 Research Lane, Suite 120"",
    ""city"": ""Guelph"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""N1G 4T2""
  },
  ""date"": ""15Mar2018"",
  ""product_name"": ""Comfortis"",
  ""medicinal_ingredients"": ""Spinosad"",
  ""reason_for_submission"": ""Administrative - Merger/Buyout"",
  ""species"": ""Dogs, Cats"",
  ""drug_identification_number_route_form_strength"": ""0232483, Oral, Chewable Tablet, 140 mg/tab"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General / Direction générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v148503,214620,15Mar2018,Comfortis,Spinosad,Administrative - Merger/Buyout,"Dogs, Cats","0232483, Oral, Chewable Tablet, 140 mg/tab",,Elanco Canada Limited,"150 Research Lane, Suite 120",Guelph,ON,Canada,N1G 4T2,Dr. Mary Jane Ireland,Director General / Direction générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,NA
https://pdf.hres.ca/noc_pm/0000028101.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e223549"",
  ""submission_no"": ""226749"",
  ""manufacturer"": {
    ""name"": ""MINT Pharmaceuticals Inc."",
    ""street"": ""1093 Meyerside Drive"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5T 1J6""
  },
  ""date"": ""MAY 1 3 2019"",
  ""product_name"": ""MINT-TELMISARTAN"",
  ""medicinal_ingredients"": ""Telmisartan"",
  ""reason_for_submission"": ""Administrative: Labelling Update (la Match License) / Administratif: Mise à jour de l'étiquetage pour correspondre au concédant)"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A (oral, tablet, 40 mg)"",
  ""canadian_reference_product"": ""Micards, Boehringer Ingelheim (Canada) Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e223549,226749,MAY 1 3 2019,MINT-TELMISARTAN,Telmisartan,Administrative: Labelling Update (la Match License) / Administratif: Mise à jour de l'étiquetage pour correspondre au concédant),N/A,"N/A (oral, tablet, 40 mg)","Micards, Boehringer Ingelheim (Canada) Ltd., Canada",MINT Pharmaceuticals Inc.,1093 Meyerside Drive,Mississauga,Ontario,Canada,L5T 1J6,"Dr. J. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000028152.PDF,"{
  ""data_found"": false,
  ""reason"": ""The provided text contains only a partial view of the notice of compliance document, with significant portions of the required fields (such as manufacturer address, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, and authorizing official details) either missing or obscured. The visible text is insufficient to extract a complete and valid JSON object as required."",
  ""partial_data"": {
    ""dossier_id"": ""177702"",
    ""submission_no"": ""02431173"",
    ""manufacturer"": {
      ""name"": ""Saris Health Inc."",
      ""street"": ""332 Changpen Street"",
      ""city"": ""Suite 102"",
      ""province"": """",
      ""country"": """",
      ""postal_code"": ""E1A 1P2""
    },
    ""date"": ""SEP 1 8 2014"",
    ""product_name"": ""ESOMEPRAZOLE"",
    ""medicinal_ingredients"": ""Esomeprazole succinate"",
    ""reason_for_submission"": ""Therapeutic Classification: Classification thérapeutique: 1H+-K+-ATPase inhibitor / inhibiteur de l'H+-K+-ATPase"",
    ""species"": """",
    ""drug_identification_number_route_form_strength"": ""02431173 (oral, delayed-release tablet 40 mg)"",
    ""canadian_reference_product"": """",
    ""authorizing_official"": {
      ""name"": """",
      ""title"": """",
      ""division"": """",
      ""directorate"": """"
    }
  }
}",FALSE,"The provided text contains only a partial view of the notice of compliance document, with significant portions of the required fields (such as manufacturer address, product name, medicinal ingredients, reason for submission, species, drug identification number, Canadian reference product, and authorizing official details) either missing or obscured. The visible text is insufficient to extract a complete and valid JSON object as required.",177702,02431173,SEP 1 8 2014,ESOMEPRAZOLE,Esomeprazole succinate,Therapeutic Classification: Classification thérapeutique: 1H+-K+-ATPase inhibitor / inhibiteur de l'H+-K+-ATPase,,"02431173 (oral, delayed-release tablet 40 mg)",,Saris Health Inc.,332 Changpen Street,Suite 102,,,E1A 1P2,,,,
https://pdf.hres.ca/noc_pm/0000028736.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""171179"",
  ""submission_no"": ""228711"",
  ""manufacturer"": {
    ""name"": ""MDA Inc"",
    ""street"": ""205-2401 Bristol Circle"",
    ""city"": ""Oakville"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6H 5S9""
  },
  ""date"": ""JUL 19 2019"",
  ""product_name"": ""ZOLEDRONIC ACID FOR INJECTION"",
  ""medicinal_ingredients"": ""Zoledronic Acid (Supplied as Zoledronic Acid Monohydrate)"",
  ""reason_for_submission"": ""Revisions to the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""NIA, Intravenous, Solution, 4 mg / 5 mL"",
  ""canadian_reference_product"": ""ZOMETAB® Concentrate, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCPF (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,171179,228711,JUL 19 2019,ZOLEDRONIC ACID FOR INJECTION,Zoledronic Acid (Supplied as Zoledronic Acid Monohydrate),Revisions to the Product Monograph,,"NIA, Intravenous, Solution, 4 mg / 5 mL","ZOMETAB® Concentrate, Novartis Pharmaceuticals Canada Inc., Canada",MDA Inc,205-2401 Bristol Circle,Oakville,Ontario,Canada,L6H 5S9,"Dr. J. Patrick Stewart, MD, CCPF (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000028791.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""Dp227544"",
  ""submission_no"": ""228333"",
  ""manufacturer"": {
    ""name"": ""Sanis Health Inc."",
    ""street"": ""1 President's Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""JUL 25 2019"",
  ""product_name"": ""DULOXETINE"",
  ""medicinal_ingredients"": ""Duloxetine (supplied as duloxetine hydrochloride)"",
  ""reason_for_submission"": ""New labelling documents AND Licensing Agreement Between Two Companies"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02490889, Oral, Capsule (delayed-release), 30 mg 02460897, Oral, Capsule (delayed-release), 60 mg"",
  ""canadian_reference_product"": ""Cymbalta, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,Dp227544,228333,JUL 25 2019,DULOXETINE,Duloxetine (supplied as duloxetine hydrochloride),New labelling documents AND Licensing Agreement Between Two Companies,,"02490889, Oral, Capsule (delayed-release), 30 mg 02460897, Oral, Capsule (delayed-release), 60 mg","Cymbalta, Eli Lilly Canada Inc., Canada",Sanis Health Inc.,1 President's Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029014.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e115011"",
  ""submission_no"": ""224301"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Inc."",
    ""street"": ""1155 Creditstone Road"",
    ""city"": ""Vougnre"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 4N7""
  },
  ""date"": ""AUG 16 2019"",
  ""product_name"": ""BENAZEPRIL"",
  ""medicinal_ingredients"": ""Benazepril Hydrochloride"",
  ""reason_for_submission"": ""Addition of a drug substance manufacturer"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 5 mg; N/A, Oral, Tablet, 10 mg; N/A, Oral, Tablet, 20 mg"",
  ""canadian_reference_product"": ""Lotensin, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCPR (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e115011,224301,AUG 16 2019,BENAZEPRIL,Benazepril Hydrochloride,Addition of a drug substance manufacturer,N/A,"N/A, Oral, Tablet, 5 mg; N/A, Oral, Tablet, 10 mg; N/A, Oral, Tablet, 20 mg","Lotensin, Novartis Pharmaceuticals Canada Inc., Canada",AA Pharma Inc.,1155 Creditstone Road,Vougnre,Ontario,Canada,L4K 4N7,"Dr. J. Patrick Stewart, MD, CCPR (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029045.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e115391"",
  ""submission_no"": ""224689"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2N9""
  },
  ""date"": ""AUG 0 8 2019"",
  ""product_name"": ""TEVA-PANTOPRAZOLE"",
  ""medicinal_ingredients"": ""Pantoprazole (as pantoprazole sodium sesquihydrate)"",
  ""reason_for_submission"": ""Change in manufacturing process"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet (Delayed-Release), 20 mg; N/A, Oral, Tablet (Delayed-Release), 40 mg"",
  ""canadian_reference_product"": ""PANTOLOIC, SOLVAY PHARMA INC., CANADA / ALTANA PHARMA A.G., GERMANY, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(F) (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e115391,224689,AUG 0 8 2019,TEVA-PANTOPRAZOLE,Pantoprazole (as pantoprazole sodium sesquihydrate),Change in manufacturing process,N/A,"N/A, Oral, Tablet (Delayed-Release), 20 mg; N/A, Oral, Tablet (Delayed-Release), 40 mg","PANTOLOIC, SOLVAY PHARMA INC., CANADA / ALTANA PHARMA A.G., GERMANY, Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2N9,"Dr. J. Patrick Stewart, MD, CCP(F) (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029387.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""229358"",
  ""submission_no"": ""229358"",
  ""manufacturer"": {
    ""name"": ""BWXT ITG Canada, Inc."",
    ""street"": ""4004 Westrock Mall"",
    ""city"": ""Vancouver"",
    ""province"": ""BC"",
    ""country"": ""Canada"",
    ""postal_code"": ""V6T 2A3""
  },
  ""date"": ""SEP 1 9 2019"",
  ""product_name"": ""Sodium Iodide I-123 Oral Solution"",
  ""medicinal_ingredients"": ""Sodium Iodide I-123"",
  ""reason_for_submission"": ""Administrative – Transfer of Drug Identification Number (DIN); Labelling updates / Administratif – transfert d'identification numérique de drogue (DIN); Mise à jour des étiquettes"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""ORL, SOL, 74 MBq/0.08mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Laurence, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques"",
    ""directorate"": """"
  }
}",TRUE,NA,229358,229358,SEP 1 9 2019,Sodium Iodide I-123 Oral Solution,Sodium Iodide I-123,Administrative – Transfer of Drug Identification Number (DIN); Labelling updates / Administratif – transfert d'identification numérique de drogue (DIN); Mise à jour des étiquettes,N/A,"ORL, SOL, 74 MBq/0.08mL",,"BWXT ITG Canada, Inc.",4004 Westrock Mall,Vancouver,BC,Canada,V6T 2A3,"Celia Laurence, Ph.D.",Director General / Directrice générale,Biologics and Genetic Therapies Directorate / Direction des produits biologiques et thérapies génétiques,
https://pdf.hres.ca/noc_pm/0000029793.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e131292"",
  ""submission_no"": ""226362"",
  ""manufacturer"": {
    ""name"": ""Purdue Pharma"",
    ""street"": ""575 Granite Court"",
    ""city"": ""Pickering"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L1W 3W8""
  },
  ""date"": ""DEC 1 3 2019"",
  ""product_name"": ""ZYTRAM XL"",
  ""medicinal_ingredients"": ""Tramadol Hydrochloride"",
  ""reason_for_submission"": ""Increase the amount of drug product coating for the 150 mg, 200 mg, 300 mg and 400 mg tablet strengths."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet (extended-release), 75 mg; N/A, Oral, Tablet (extended-release), 100 mg; N/A, Oral, Tablet (extended-release), 150 mg; N/A, Oral, Tablet (extended-release), 200 mg; N/A, Oral, Tablet (extended-release), 300 mg; N/A, Oral, Tablet (extended-release), 400 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. A. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e131292,226362,DEC 1 3 2019,ZYTRAM XL,Tramadol Hydrochloride,"Increase the amount of drug product coating for the 150 mg, 200 mg, 300 mg and 400 mg tablet strengths.",N/A,"N/A, Oral, Tablet (extended-release), 75 mg; N/A, Oral, Tablet (extended-release), 100 mg; N/A, Oral, Tablet (extended-release), 150 mg; N/A, Oral, Tablet (extended-release), 200 mg; N/A, Oral, Tablet (extended-release), 300 mg; N/A, Oral, Tablet (extended-release), 400 mg",,Purdue Pharma,575 Granite Court,Pickering,Ontario,Canada,L1W 3W8,"Dr. A. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029825.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e137419"",
  ""submission_no"": ""207994"",
  ""manufacturer"": {
    ""name"": ""GW Pharma Limited"",
    ""street"": ""Sovereign House"",
    ""city"": ""Cambridge"",
    ""province"": ""UK"",
    ""country"": ""UK"",
    ""postal_code"": ""CB24 9BZ""
  },
  ""date"": ""DEC 1 2 2019"",
  ""product_name"": ""SATIVEX"",
  ""medicinal_ingredients"": ""delta-9-tetrahydrocannabinol / cannabidiol"",
  ""reason_for_submission"": ""To remove the cancer pain indication and neuropathic pain indication approved under the NCCc policy"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Buccal, Spray, 27 mg / 25 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e137419,207994,DEC 1 2 2019,SATIVEX,delta-9-tetrahydrocannabinol / cannabidiol,To remove the cancer pain indication and neuropathic pain indication approved under the NCCc policy,,"N/A, Buccal, Spray, 27 mg / 25 mg",,GW Pharma Limited,Sovereign House,Cambridge,UK,UK,CB24 9BZ,"Dr. J. Patrick Stewart, MD, CCP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029852.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""2209006"",
  ""submission_no"": ""222846"",
  ""manufacturer"": {
    ""name"": ""Virbac Animal Health Inc."",
    ""street"": ""3200 Meacham Blvd"",
    ""city"": ""Fort Worth"",
    ""province"": ""TX"",
    ""country"": ""USA"",
    ""postal_code"": ""76137""
  },
  ""date"": ""JAN 0 2 2020"",
  ""product_name"": ""EVICTO"",
  ""medicinal_ingredients"": ""Selamectin"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": ""Dogs, Cats"",
  ""drug_identification_number_route_form_strength"": ""02465260, Topical, Solution, 15 mg/0.25 mL (dog, cat) 02465279, Topical, Solution, 30 mg/0.25 mL (dog) 02465287, Topical, Solution, 45 mg/0.75 mL (cat) 02465295, Topical, Solution, 60 mg/0.5 mL (dog) 02465309, Topical, Solution, 60 mg/mL (cat) 02465317, Topical, Solution, 120 mg/mL (dog) 02465325, Topical, Solution, 240 mg/2 mL (dog) 02465333, Topical, Solution, 360 mg/3 mL (dog)"",
  ""canadian_reference_product"": ""Revolution – Zoetis Canada Inc. (DIN # 02242045, 02242046, 02243047, 02242048, 02242049, 02279336, 02367343)"",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General"",
    ""division"": ""Veterinary Drugs Directorate"",
    ""directorate"": ""Direction des médicaments vétérinaires""
  }
}",TRUE,NA,2209006,222846,JAN 0 2 2020,EVICTO,Selamectin,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.","Dogs, Cats","02465260, Topical, Solution, 15 mg/0.25 mL (dog, cat) 02465279, Topical, Solution, 30 mg/0.25 mL (dog) 02465287, Topical, Solution, 45 mg/0.75 mL (cat) 02465295, Topical, Solution, 60 mg/0.5 mL (dog) 02465309, Topical, Solution, 60 mg/mL (cat) 02465317, Topical, Solution, 120 mg/mL (dog) 02465325, Topical, Solution, 240 mg/2 mL (dog) 02465333, Topical, Solution, 360 mg/3 mL (dog)","Revolution – Zoetis Canada Inc. (DIN # 02242045, 02242046, 02243047, 02242048, 02242049, 02279336, 02367343)",Virbac Animal Health Inc.,3200 Meacham Blvd,Fort Worth,TX,USA,76137,Dr. Mary Jane Ireland,Director General,Veterinary Drugs Directorate,Direction des médicaments vétérinaires
https://pdf.hres.ca/noc_pm/0000029949.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E165693"",
  ""submission_no"": ""165693"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 NovoHarm Court"",
    ""city"": ""TORONTO"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""JAN 28 2020"",
  ""product_name"": ""TEVA-BETAMETHASONE/CALCIPOTRIOL"",
  ""medicinal_ingredients"": ""betamethasone (supplied as betamethasone dipropionate) / calcipotriol"",
  ""reason_for_submission"": ""new drug submission"",
  ""species"": ""human"",
  ""drug_identification_number_route_form_strength"": ""02427419, Topical, Ointment, 0.5 mg/g / 50 mcg/g"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCP(F) (EM)"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E165693,165693,JAN 28 2020,TEVA-BETAMETHASONE/CALCIPOTRIOL,betamethasone (supplied as betamethasone dipropionate) / calcipotriol,new drug submission,human,"02427419, Topical, Ointment, 0.5 mg/g / 50 mcg/g",,Teva Canada Limited,30 NovoHarm Court,TORONTO,Ontario,Canada,M1B 2K9,"Dr. J. Patrick Stewart, MD, CCP(F) (EM)",Director General / Directrice générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029965.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""235263"",
  ""submission_no"": ""e217858"",
  ""manufacturer"": {
    ""name"": ""Laboratoire Riva Inc."",
    ""street"": ""680 Industriel Blvd."",
    ""city"": ""Bisinville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7C 3V4""
  },
  ""date"": ""JAN 31 2020"",
  ""product_name"": ""RIVA-PYRIDOSTIGMINE"",
  ""medicinal_ingredients"": ""Pyridostigmine Bromide"",
  ""reason_for_submission"": ""Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02495643, oral, tablet, 60 mg"",
  ""canadian_reference_product"": ""Mestinon, Valeant Pharmaceuticals North America LLC, USA"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,235263,e217858,JAN 31 2020,RIVA-PYRIDOSTIGMINE,Pyridostigmine Bromide,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,,"02495643, oral, tablet, 60 mg","Mestinon, Valeant Pharmaceuticals North America LLC, USA",Laboratoire Riva Inc.,680 Industriel Blvd.,Bisinville,Quebec,Canada,J7C 3V4,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000029995.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""C118904"",
  ""submission_no"": ""226144"",
  ""manufacturer"": {
    ""name"": ""Bristol-Myers Squibb Canada"",
    ""street"": ""2344 Alfred-Nobel, Suite 300"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 0A4""
  },
  ""date"": ""FEB 10 2020"",
  ""product_name"": ""HYDREA"",
  ""medicinal_ingredients"": ""Hydroxyurea"",
  ""reason_for_submission"": ""Update to the product monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Capsule, 500 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,C118904,226144,FEB 10 2020,HYDREA,Hydroxyurea,Update to the product monograph,,"N/A, Oral, Capsule, 500 mg",,Bristol-Myers Squibb Canada,"2344 Alfred-Nobel, Suite 300",Montreal,Quebec,Canada,H4S 0A4,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000030060.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e227027"",
  ""submission_no"": ""227027"",
  ""manufacturer"": {
    ""name"": ""Nativo Pharma (Canada) Inc."",
    ""street"": ""2000 Argentia Road, Plaza 1, Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 1P7""
  },
  ""date"": ""FEB 21 2020"",
  ""product_name"": ""NAT-CETIRIZINE"",
  ""medicinal_ingredients"": ""Cetirizine Hydrochloride"",
  ""reason_for_submission"": ""This is to notify that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02498461, Oral, Tablet, 10 mg (non-prescription) (02498468, Oral, Tablet, 20 mg (prescription))"",
  ""canadian_reference_product"": ""REACTINE, McNeil Consumer Healthcare, division of Johnson & Johnson Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General"",
    ""division"": ""Therapeutic Products Directorate"",
    ""directorate"": ""Direction des produits thérapeutiques""
  }
}",TRUE,NA,e227027,227027,FEB 21 2020,NAT-CETIRIZINE,Cetirizine Hydrochloride,"This is to notify that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02498461, Oral, Tablet, 10 mg (non-prescription) (02498468, Oral, Tablet, 20 mg (prescription))","REACTINE, McNeil Consumer Healthcare, division of Johnson & Johnson Inc., Canada",Nativo Pharma (Canada) Inc.,"2000 Argentia Road, Plaza 1, Suite 200",Mississauga,Ontario,Canada,L5N 1P7,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General,Therapeutic Products Directorate,Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000030177.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e155181"",
  ""submission_no"": ""235993"",
  ""manufacturer"": {
    ""name"": ""Chiesi Canada Corp."",
    ""street"": ""200 Berman Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5L 2Z7""
  },
  ""date"": ""MAR 1 2 2020"",
  ""product_name"": ""FERRIPROX"",
  ""medicinal_ingredients"": ""Deferiprone"",
  ""reason_for_submission"": ""Change in Product Ownership / Administratif: Changement de propriété du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02436531, oral, tablet, 500 mg; 02436558, oral, tablet, 1000 mg; 02436523, oral, solution, 100 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCPP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e155181,235993,MAR 1 2 2020,FERRIPROX,Deferiprone,Change in Product Ownership / Administratif: Changement de propriété du produit,,"02436531, oral, tablet, 500 mg; 02436558, oral, tablet, 1000 mg; 02436523, oral, solution, 100 mg/mL",,Chiesi Canada Corp.,200 Berman Drive,Toronto,Ontario,Canada,M5L 2Z7,"Dr. J. Patrick Stewart, MD, CCPP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000030187.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""23268"",
  ""submission_no"": ""23268"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc"",
    ""street"": ""385 Bouchard Blvd"",
    ""city"": ""Donval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""MAR 1 3 2020"",
  ""product_name"": ""Kynriah"",
  ""medicinal_ingredients"": ""Tisagenlecleucel"",
  ""reason_for_submission"": ""New manufacturing process / Nouveau procédé de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SUS, 2.0x10^6 to 6.0x10^6 CAR positive viable T cells/ lymphocytes T CAR-positifs viables"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,23268,23268,MAR 1 3 2020,Kynriah,Tisagenlecleucel,New manufacturing process / Nouveau procédé de fabrication,,"N/A, IV, SUS, 2.0x10^6 to 6.0x10^6 CAR positive viable T cells/ lymphocytes T CAR-positifs viables",,Novartis Pharmaceuticals Canada Inc,385 Bouchard Blvd,Donval,Quebec,Canada,H9S 1A9,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,
https://pdf.hres.ca/noc_pm/0000030234.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""212895"",
  ""submission_no"": ""212895"",
  ""manufacturer"": {
    ""name"": ""Taro Pharmaceuticals Inc."",
    ""street"": ""130 East Drive"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6T 1C1""
  },
  ""date"": ""MAR 24 2020"",
  ""product_name"": ""TARO-CLONIPRAMINE"",
  ""medicinal_ingredients"": ""Clomipramine hydrochloride"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.09.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02497506, Oral, Capsule, 25 mg; 02497514, Oral, Capsule, 50 mg"",
  ""canadian_reference_product"": ""Anafranil, AA Pharma Inc., Canada (25 mg) Anafranil, Aspir Pharma Canada Inc., Canada (50 mg)"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,212895,212895,MAR 24 2020,TARO-CLONIPRAMINE,Clomipramine hydrochloride,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.09.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02497506, Oral, Capsule, 25 mg; 02497514, Oral, Capsule, 50 mg","Anafranil, AA Pharma Inc., Canada (25 mg) Anafranil, Aspir Pharma Canada Inc., Canada (50 mg)",Taro Pharmaceuticals Inc.,130 East Drive,Brampton,Ontario,Canada,L6T 1C1,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000030320.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e149286"",
  ""submission_no"": ""238025"",
  ""manufacturer"": {
    ""name"": ""Strides Pharma Canada Inc."",
    ""street"": ""1565, Boul. Lionel-Boulet"",
    ""city"": ""Varennes"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J3X 1P7""
  },
  ""date"": ""May 19, 2020"",
  ""product_name"": ""EPIRUBICIN HYDROCHLORIDE INJECTION"",
  ""medicinal_ingredients"": ""Epirubicin Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02413221, intravenous, solution, 2 mg/mL"",
  ""canadian_reference_product"": ""Pharmorubicin PFS, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e149286,238025,"May 19, 2020",EPIRUBICIN HYDROCHLORIDE INJECTION,Epirubicin Hydrochloride,Administrative: Change in Product Ownership / Administratif: Changement de propriété du produit,,"02413221, intravenous, solution, 2 mg/mL","Pharmorubicin PFS, Pfizer Canada Inc., Canada",Strides Pharma Canada Inc.,"1565, Boul. Lionel-Boulet",Varennes,Quebec,Canada,J3X 1P7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000030345.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v196113"",
  ""submission_no"": ""238187"",
  ""manufacturer"": {
    ""name"": ""Intervet Canada Corp."",
    ""street"": ""16750 Trans Canada Hwy"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""May 26, 2020"",
  ""product_name"": ""Paracillin SP"",
  ""medicinal_ingredients"": ""Amoxicillin trihydrate"",
  ""reason_for_submission"": ""Addition of drug substance supplier"",
  ""species"": ""Poultry: Chicken, Swine"",
  ""drug_identification_number_route_form_strength"": ""02281376, Oral, Powder for solution, 800 mg/g"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v196113,238187,"May 26, 2020",Paracillin SP,Amoxicillin trihydrate,Addition of drug substance supplier,"Poultry: Chicken, Swine","02281376, Oral, Powder for solution, 800 mg/g",,Intervet Canada Corp.,16750 Trans Canada Hwy,Kirkland,QC,Canada,H9H 4M7,Dr. Mary Jane Ireland,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000030388.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v209003"",
  ""submission_no"": ""226414"",
  ""manufacturer"": {
    ""name"": ""Virbac Animal Health Inc."",
    ""street"": ""3200 Meacham Boulevard"",
    ""city"": ""Fort Worth"",
    ""province"": ""TX"",
    ""country"": ""USA"",
    ""postal_code"": ""76137""
  },
  ""date"": ""June 3, 2020"",
  ""product_name"": ""Eradia"",
  ""medicinal_ingredients"": ""Metronidazole"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": ""Dogs"",
  ""drug_identification_number_route_form_strength"": ""02499819, Oral, Suspension, 125 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v209003,226414,"June 3, 2020",Eradia,Metronidazole,This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations.,Dogs,"02499819, Oral, Suspension, 125 mg/mL",,Virbac Animal Health Inc.,3200 Meacham Boulevard,Fort Worth,TX,USA,76137,Dr. Mary Jane Ireland,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,NA
https://pdf.hres.ca/noc_pm/0000030416.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E205780"",
  ""submission_no"": ""235295"",
  ""manufacturer"": {
    ""name"": ""Seattle Genetics Inc."",
    ""street"": ""21823 - 30th Drive Southeast"",
    ""city"": ""Bothell"",
    ""province"": ""Washington"",
    ""country"": ""United States"",
    ""postal_code"": ""98021""
  },
  ""date"": ""June 5, 2020"",
  ""product_name"": ""TUKYSA"",
  ""medicinal_ingredients"": ""Tucatinib"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02499827, Oral, Tablet, 50 mg; 02499835, Oral, Tablet, 150 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E205780,235295,"June 5, 2020",TUKYSA,Tucatinib,"This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02499827, Oral, Tablet, 50 mg; 02499835, Oral, Tablet, 150 mg",,Seattle Genetics Inc.,21823 - 30th Drive Southeast,Bothell,Washington,United States,98021,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000030464.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e150554"",
  ""submission_no"": ""239276"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""June 15, 2020"",
  ""product_name"": ""ACT OLOPATADINE 0.2%"",
  ""medicinal_ingredients"": ""Olopatadine supplied as Olopatadine Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Merger/Buy-out"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02404095, ophthalmic, solution, 0.2 % w/v"",
  ""canadian_reference_product"": ""Pataday, Alcon Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e150554,239276,"June 15, 2020",ACT OLOPATADINE 0.2%,Olopatadine supplied as Olopatadine Hydrochloride,Administrative: Merger/Buy-out,,"02404095, ophthalmic, solution, 0.2 % w/v","Pataday, Alcon Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000030492.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v159534"",
  ""submission_no"": ""227003"",
  ""manufacturer"": {
    ""name"": ""Elanco Canada Limited"",
    ""street"": ""150 Research Lane, Suite 120"",
    ""city"": ""Guelph"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""N1G 4T2""
  },
  ""date"": ""June 17, 2020"",
  ""product_name"": ""Component TE-H Implants with Tylan"",
  ""medicinal_ingredients"": ""Trenbolone Acetate, Estradiol, Tylosin Tartrate"",
  ""reason_for_submission"": ""Addition of a new drug product manufacturing and testing site"",
  ""species"": ""Feedlot heifers"",
  ""drug_identification_number_route_form_strength"": ""02245665, Subcutaneous, Implant, Trenbolone Acetate 140 mg/implant, Estradiol 14 mg/implant, Tylosin Tartrate 29 mg/implant"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. Mary Jane Ireland"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v159534,227003,"June 17, 2020",Component TE-H Implants with Tylan,"Trenbolone Acetate, Estradiol, Tylosin Tartrate",Addition of a new drug product manufacturing and testing site,Feedlot heifers,"02245665, Subcutaneous, Implant, Trenbolone Acetate 140 mg/implant, Estradiol 14 mg/implant, Tylosin Tartrate 29 mg/implant",,Elanco Canada Limited,"150 Research Lane, Suite 120",Guelph,ON,Canada,N1G 4T2,Dr. Mary Jane Ireland,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000030759.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""231268"",
  ""submission_no"": ""231268"",
  ""manufacturer"": {
    ""name"": ""Sanofi-aventis Canada Inc."",
    ""street"": ""2905 Place Louis-R-Renaud"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7V0A3""
  },
  ""date"": ""August 12, 2020"",
  ""product_name"": ""Dupixent"",
  ""medicinal_ingredients"": ""dupilumab"",
  ""reason_for_submission"": ""New Indication: Dupixent is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A - SC, SOL, 150 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,231268,231268,"August 12, 2020",Dupixent,dupilumab,New Indication: Dupixent is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.,,"N/A - SC, SOL, 150 mg/mL",,Sanofi-aventis Canada Inc.,2905 Place Louis-R-Renaud,Laval,Quebec,Canada,H7V0A3,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000030942.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E133862"",
  ""submission_no"": ""236541"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave., Suite 100"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": """",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""April 20, 2020"",
  ""product_name"": ""PMS-METHOTREXATE"",
  ""medicinal_ingredients"": ""Methotrexate sodium"",
  ""reason_for_submission"": ""Changes to box label, foil and package insert."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 2.5 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,E133862,236541,"April 20, 2020",PMS-METHOTREXATE,Methotrexate sodium,"Changes to box label, foil and package insert.",,"N/A, Oral, Tablet, 2.5 mg",,Pharmascience Inc.,"6111 Royalmount Ave., Suite 100",Montreal,Quebec,,H4P 2T4,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000030960.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e134897"",
  ""submission_no"": ""236789"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite #402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""April 30, 2020"",
  ""product_name"": ""PIPERACILLIN AND TAZOBACTAM FOR INJECTION"",
  ""medicinal_ingredients"": ""Piperacillin (supplied as piperacillin sodium)\nTazobactam (supplied as tazobactam sodium)"",
  ""reason_for_submission"": ""Update to labels"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Powder for Solution, 4 g/vial / 0.5 g / vial\nN/A, Intravenous, Powder for Solution, 3 g/vial / 0.375 g / vial\nN/A, Intravenous, Powder for Solution, 2 g/vial / 0.25 g / vial"",
  ""canadian_reference_product"": ""Tazocin, Wyeth Canada, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e134897,236789,"April 30, 2020",PIPERACILLIN AND TAZOBACTAM FOR INJECTION,"Piperacillin (supplied as piperacillin sodium)
Tazobactam (supplied as tazobactam sodium)",Update to labels,,"N/A, Intravenous, Powder for Solution, 4 g/vial / 0.5 g / vial
N/A, Intravenous, Powder for Solution, 3 g/vial / 0.375 g / vial
N/A, Intravenous, Powder for Solution, 2 g/vial / 0.25 g / vial","Tazocin, Wyeth Canada, Canada",Auro Pharma Inc.,"3700 Steeles Avenue West, Suite #402",Woodbridge,Ontario,Canada,L4L 8K8,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000030967.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e137506"",
  ""submission_no"": ""236909"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""385 Bouchard Blvd."",
    ""city"": ""Dorval"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""May 12, 2020"",
  ""product_name"": ""FORADIL"",
  ""medicinal_ingredients"": ""Formoterol fumarate"",
  ""reason_for_submission"": ""Change of the leaflet to outsert format"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Inhalation, Capsule, 12 mcg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e137506,236909,"May 12, 2020",FORADIL,Formoterol fumarate,Change of the leaflet to outsert format,,"N/A, Inhalation, Capsule, 12 mcg",,Novartis Pharmaceuticals Canada Inc.,385 Bouchard Blvd.,Dorval,Québec,Canada,H9S 1A9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031044.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E127055"",
  ""submission_no"": ""238997"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""September 1, 2020"",
  ""product_name"": ""TEVA-FINASTERIDE"",
  ""medicinal_ingredients"": ""finasteride"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 5 mg"",
  ""canadian_reference_product"": ""PROSCAR, Merck Frosst Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Leslie Vrooman, M.Sc."",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E127055,238997,"September 1, 2020",TEVA-FINASTERIDE,finasteride,Safety updates to the Product Monograph.,,"N/A, Oral, Tablet, 5 mg","PROSCAR, Merck Frosst Canada Ltd., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,"Leslie Vrooman, M.Sc.",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000031046.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E201196"",
  ""submission_no"": ""239817"",
  ""manufacturer"": {
    ""name"": ""ViiV Healthcare ULC"",
    ""street"": ""245 Boulevard Armand-Frappier"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7V 4A7""
  },
  ""date"": ""August 24, 2020"",
  ""product_name"": ""JULUCA"",
  ""medicinal_ingredients"": ""Dolutegravir (supplied as dolutegravir sodium) / Rilpivirine (supplied as rilpivirine hydrochloride)"",
  ""reason_for_submission"": ""To change the labelling from an Outer Carton to an Extended Content Label (ECL) with affixed patient insert/leaflet."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 50 MG / 25 MG"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E201196,239817,"August 24, 2020",JULUCA,Dolutegravir (supplied as dolutegravir sodium) / Rilpivirine (supplied as rilpivirine hydrochloride),To change the labelling from an Outer Carton to an Extended Content Label (ECL) with affixed patient insert/leaflet.,,"N/A, Oral, Tablet, 50 MG / 25 MG",,ViiV Healthcare ULC,245 Boulevard Armand-Frappier,Laval,Quebec,Canada,H7V 4A7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000031114.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e159078"",
  ""submission_no"": ""239200"",
  ""manufacturer"": {
    ""name"": ""Mint Pharmaceuticals Inc."",
    ""street"": ""6575 Davand Drive"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5T 2M3""
  },
  ""date"": ""September 11, 2020"",
  ""product_name"": ""MINT-ALENDRONATE"",
  ""medicinal_ingredients"": ""Alendronic Acid supplied as Alendronate Sodium"",
  ""reason_for_submission"": ""Updating Labelling and the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 5 mg; N/A, Oral, Tablet, 70 mg"",
  ""canadian_reference_product"": ""FOSAMAX, Merck Frosst Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e159078,239200,"September 11, 2020",MINT-ALENDRONATE,Alendronic Acid supplied as Alendronate Sodium,Updating Labelling and the Product Monograph,,"N/A, Oral, Tablet, 5 mg; N/A, Oral, Tablet, 70 mg","FOSAMAX, Merck Frosst Canada Ltd., Canada",Mint Pharmaceuticals Inc.,6575 Davand Drive,Mississauga,Ontario,Canada,L5T 2M3,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031142.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""241231"",
  ""submission_no"": ""241231"",
  ""manufacturer"": {
    ""name"": ""ID Biomedical Corporation of Quebec"",
    ""street"": ""2323 du Parc Technologique Blvd"",
    ""city"": ""Quebec"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""G1P 4R8""
  },
  ""date"": ""September 11, 2020"",
  ""product_name"": ""FluLaval Tetra"",
  ""medicinal_ingredients"": ""Haemagglutinin – strain A (H1N1) / hémagglutinine – souche A (H1N1)\nHaemagglutinin – strain A (H3N2) / hémagglutinine – souche A (H3N2)\nHaemagglutinin – strain B (Victoria) / hémagglutinine – souche B (Victoria)\nHaemagglutinin – strain B (Yamagata) / hémagglutinine – souche B (Yamagata)"",
  ""reason_for_submission"": ""Annual update – strain changes / Mise à jour annuelle – changements de souches virales"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A - IM, SUS, 15 µg/strain/0.5 mL / 15 µg/souche/0,5 mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,241231,241231,"September 11, 2020",FluLaval Tetra,"Haemagglutinin – strain A (H1N1) / hémagglutinine – souche A (H1N1)
Haemagglutinin – strain A (H3N2) / hémagglutinine – souche A (H3N2)
Haemagglutinin – strain B (Victoria) / hémagglutinine – souche B (Victoria)
Haemagglutinin – strain B (Yamagata) / hémagglutinine – souche B (Yamagata)",Annual update – strain changes / Mise à jour annuelle – changements de souches virales,,"N/A - IM, SUS, 15 µg/strain/0.5 mL / 15 µg/souche/0,5 mL",,ID Biomedical Corporation of Quebec,2323 du Parc Technologique Blvd,Quebec,QC,Canada,G1P 4R8,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000031212.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""220103"",
  ""submission_no"": ""220103"",
  ""manufacturer"": {
    ""name"": ""Sanofi Pasteur Limited"",
    ""street"": ""1755 Steeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2R 3T4""
  },
  ""date"": ""September 25, 2020"",
  ""product_name"": ""Adacel"",
  ""medicinal_ingredients"": ""Tetanus Toxoid, Diphtheria Toxoid, Acellular Pertussis (Pertussis Toxoid, Filamentous Haemagglutinin, Pertactin, Fimbriae Types 2 and 3)"",
  ""reason_for_submission"": ""Vaccination during pregnancy for passive immunization against pertussis disease in young infants."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IM, SUS, 5Lf / 0.5mL Tetanus Toxoid, 2Lf / 0.5mL Diphtheria Toxoid, Acellular Pertussis (2.5mcg / 0.5mL Pertussis Toxoid, 5mcg / 0.5mL Filamentous Haemagglutinin, 3mcg / 0.5mL Pertactin, 5mcg / 0.5mL Fimbriae Types 2 and 3)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,220103,220103,"September 25, 2020",Adacel,"Tetanus Toxoid, Diphtheria Toxoid, Acellular Pertussis (Pertussis Toxoid, Filamentous Haemagglutinin, Pertactin, Fimbriae Types 2 and 3)",Vaccination during pregnancy for passive immunization against pertussis disease in young infants.,,"N/A, IM, SUS, 5Lf / 0.5mL Tetanus Toxoid, 2Lf / 0.5mL Diphtheria Toxoid, Acellular Pertussis (2.5mcg / 0.5mL Pertussis Toxoid, 5mcg / 0.5mL Filamentous Haemagglutinin, 3mcg / 0.5mL Pertactin, 5mcg / 0.5mL Fimbriae Types 2 and 3)",,Sanofi Pasteur Limited,1755 Steeles Avenue West,Toronto,ON,Canada,M2R 3T4,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000031287.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E216035"",
  ""submission_no"": ""232761"",
  ""manufacturer"": {
    ""name"": ""Celgene Inc."",
    ""street"": ""6755 Mississauga Road, Suite 600"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""L5N 7Y2""
  },
  ""date"": ""October 2, 2020"",
  ""product_name"": ""ZEPOSIA"",
  ""medicinal_ingredients"": ""Ozanimod (Supplied as Ozanimod hydrochloride)"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02506009, Oral, Capsule (Kit), 0.23 mg / 0.46 mg; 02505991, Oral, Capsule, 0.92mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,E216035,232761,"October 2, 2020",ZEPOSIA,Ozanimod (Supplied as Ozanimod hydrochloride),This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations.,,"02506009, Oral, Capsule (Kit), 0.23 mg / 0.46 mg; 02505991, Oral, Capsule, 0.92mg",,Celgene Inc.,"6755 Mississauga Road, Suite 600",Mississauga,Ontario,,L5N 7Y2,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031494.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E195768"",
  ""submission_no"": ""234362"",
  ""manufacturer"": {
    ""name"": ""AbbVie Corporation"",
    ""street"": ""8401 Trans Canada Highway"",
    ""city"": ""Saint-Laurent"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 1Z1""
  },
  ""date"": ""October 30, 2020"",
  ""product_name"": ""MAVIRET"",
  ""medicinal_ingredients"": ""Pibrentasvir / Glecaprevir"",
  ""reason_for_submission"": ""To shorten treatment duration in treatment-naïve patients with compensated cirrhosis and HCV genotype 3 infection from 12 weeks to 8 weeks."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 40mg / 100mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,E195768,234362,"October 30, 2020",MAVIRET,Pibrentasvir / Glecaprevir,To shorten treatment duration in treatment-naïve patients with compensated cirrhosis and HCV genotype 3 infection from 12 weeks to 8 weeks.,,"N/A, Oral, Tablet, 40mg / 100mg",,AbbVie Corporation,8401 Trans Canada Highway,Saint-Laurent,Quebec,Canada,H4S 1Z1,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031499.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e235195"",
  ""submission_no"": ""235195"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""November 9, 2020"",
  ""product_name"": ""AMIODARONE HYDROCHLORIDE FOR INJECTION"",
  ""medicinal_ingredients"": ""Amiodarone hydrochloride"",
  ""reason_for_submission"": ""abbreviated new drug submission"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02423227, Intravenous, Solution, 50 mg / mL"",
  ""canadian_reference_product"": ""Amiodarone Hydrochloride for injection, Sandoz Canada Incorporated, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e235195,235195,"November 9, 2020",AMIODARONE HYDROCHLORIDE FOR INJECTION,Amiodarone hydrochloride,abbreviated new drug submission,,"02423227, Intravenous, Solution, 50 mg / mL","Amiodarone Hydrochloride for injection, Sandoz Canada Incorporated, Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000031564.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""242584"",
  ""submission_no"": ""242584"",
  ""manufacturer"": {
    ""name"": ""Emergent Travel Health Inc."",
    ""street"": ""555 Twin Dolphin Drive, Suite 360"",
    ""city"": ""Redwood City"",
    ""province"": ""California"",
    ""country"": ""USA"",
    ""postal_code"": ""94065""
  },
  ""date"": ""November 13, 2020"",
  ""product_name"": ""VIVOTIF"",
  ""medicinal_ingredients"": ""Typhoid vaccine live oral attenuated TY21A / Vaccin antityphoïdique vivant oral atténué TY21A"",
  ""reason_for_submission"": ""Administrative – Change in Product Ownership"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00885975, ORL, ECC, 2-10 × 10⁹ CFU"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,242584,242584,"November 13, 2020",VIVOTIF,Typhoid vaccine live oral attenuated TY21A / Vaccin antityphoïdique vivant oral atténué TY21A,Administrative – Change in Product Ownership,,"00885975, ORL, ECC, 2-10 × 10⁹ CFU",,Emergent Travel Health Inc.,"555 Twin Dolphin Drive, Suite 360",Redwood City,California,USA,94065,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000031581.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E185905"",
  ""submission_no"": ""244145"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite #402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""November 6, 2020"",
  ""product_name"": ""AURO-VORICONAZOLE"",
  ""medicinal_ingredients"": ""Voriconazole"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 50mg; N/A, Oral, Tablet, 200mg"",
  ""canadian_reference_product"": ""Vfend, Pfizer Canada, Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Scott Appleton, PhD"",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E185905,244145,"November 6, 2020",AURO-VORICONAZOLE,Voriconazole,Safety updates to the Product Monograph.,,"N/A, Oral, Tablet, 50mg; N/A, Oral, Tablet, 200mg","Vfend, Pfizer Canada, Inc., Canada",Auro Pharma Inc.,"3700 Steeles Avenue West, Suite #402",Woodbridge,Ontario,Canada,L4L 8K8,"Scott Appleton, PhD",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000031634.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e233779"",
  ""submission_no"": ""233779"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""November 20, 2020"",
  ""product_name"": ""JAMP AMOXI CLAV"",
  ""medicinal_ingredients"": ""Amoxicillin (as Amoxicillin Trihydrate), Clavulanic Acid (as Clavulanate Potassium)"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02508249, Oral, Tablet, 250 mg / 125 mg; 02508257, Oral, Tablet, 500 mg / 125 mg; 02508265, Oral, Tablet, 875 mg / 125 mg"",
  ""canadian_reference_product"": ""CLAVULIN, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e233779,233779,"November 20, 2020",JAMP AMOXI CLAV,"Amoxicillin (as Amoxicillin Trihydrate), Clavulanic Acid (as Clavulanate Potassium)",This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,,"02508249, Oral, Tablet, 250 mg / 125 mg; 02508257, Oral, Tablet, 500 mg / 125 mg; 02508265, Oral, Tablet, 875 mg / 125 mg","CLAVULIN, GlaxoSmithKline Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000031709.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e149943"",
  ""submission_no"": ""245239"",
  ""manufacturer"": {
    ""name"": ""Glenwood GmbH Pharmazeutische Erzeugnisse"",
    ""street"": ""Arabellastr. 17"",
    ""city"": ""Munich"",
    ""province"": """",
    ""country"": ""Germany"",
    ""postal_code"": ""81925""
  },
  ""date"": ""November 30, 2020"",
  ""product_name"": ""PERSANTINE"",
  ""medicinal_ingredients"": ""Dipyridamole"",
  ""reason_for_submission"": ""Administrative: Change in Product Ownership"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""00637734, intravenous, solution, 5 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e149943,245239,"November 30, 2020",PERSANTINE,Dipyridamole,Administrative: Change in Product Ownership,,"00637734, intravenous, solution, 5 mg/mL",,Glenwood GmbH Pharmazeutische Erzeugnisse,Arabellastr. 17,Munich,,Germany,81925,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031732.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e192925"",
  ""submission_no"": ""237870"",
  ""manufacturer"": {
    ""name"": ""Ferrer Internacional, S.A."",
    ""street"": ""Gran Via Carlos III, 94"",
    ""city"": ""Barcelona"",
    ""province"": """",
    ""country"": ""Spain"",
    ""postal_code"": ""08028""
  },
  ""date"": ""December 10, 2020"",
  ""product_name"": ""OZANEX"",
  ""medicinal_ingredients"": ""Ozenoxacin"",
  ""reason_for_submission"": ""Addition of drug substance manufacturing sites"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Topical, Cream, 1% w/w"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e192925,237870,"December 10, 2020",OZANEX,Ozenoxacin,Addition of drug substance manufacturing sites,,"N/A, Topical, Cream, 1% w/w",,"Ferrer Internacional, S.A.","Gran Via Carlos III, 94",Barcelona,,Spain,08028,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031733.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e149436"",
  ""submission_no"": ""238174"",
  ""manufacturer"": {
    ""name"": ""Gilead Sciences Canada Inc."",
    ""street"": ""6711 Mississauga Rd, Suite 600"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 2W3""
  },
  ""date"": ""December 4, 2020"",
  ""product_name"": ""STRIBILD"",
  ""medicinal_ingredients"": ""Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate"",
  ""reason_for_submission"": ""To update the Contraindication and Consumer Information sections of the Product Monograph with the drug-drug interaction with lomitapide (JUXTAPID), as per Advisement Letter dated April 17, 2020."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 150 mg / 150 mg / 200 mg / 300 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e149436,238174,"December 4, 2020",STRIBILD,Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate,"To update the Contraindication and Consumer Information sections of the Product Monograph with the drug-drug interaction with lomitapide (JUXTAPID), as per Advisement Letter dated April 17, 2020.",,"N/A, Oral, Tablet, 150 mg / 150 mg / 200 mg / 300 mg",,Gilead Sciences Canada Inc.,"6711 Mississauga Rd, Suite 600",Mississauga,Ontario,Canada,L5N 2W3,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000031746.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e172953"",
  ""submission_no"": ""241017"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Inc."",
    ""street"": ""1165 Creditstone Road, Unit #1"",
    ""city"": ""Vaughan"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 4N7""
  },
  ""date"": ""December 7, 2020"",
  ""product_name"": ""AA-TELMISARTAN-AMLODIPINE"",
  ""medicinal_ingredients"": ""Telmisartan / Amlodipine (as Amlodipine Besylate)"",
  ""reason_for_submission"": ""Relaxation of acceptance criterion for a test in the drug product specifications"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 40 mg/ 5 mg; N/A, Oral, Tablet, 40 mg/ 10 mg; N/A, Oral, Tablet, 80 mg/ 5 mg; N/A, Oral, Tablet, 80 mg/ 10 mg"",
  ""canadian_reference_product"": ""TWYNSTA, Boehringer Ingelheim (Canada) Ltd./Ltee, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e172953,241017,"December 7, 2020",AA-TELMISARTAN-AMLODIPINE,Telmisartan / Amlodipine (as Amlodipine Besylate),Relaxation of acceptance criterion for a test in the drug product specifications,,"N/A, Oral, Tablet, 40 mg/ 5 mg; N/A, Oral, Tablet, 40 mg/ 10 mg; N/A, Oral, Tablet, 80 mg/ 5 mg; N/A, Oral, Tablet, 80 mg/ 10 mg","TWYNSTA, Boehringer Ingelheim (Canada) Ltd./Ltee, Canada",AA Pharma Inc.,"1165 Creditstone Road, Unit #1",Vaughan,Ontario,Canada,L4K 4N7,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000031851.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e162307"",
  ""submission_no"": ""242469"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Incorporated"",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""December 16, 2020"",
  ""product_name"": ""SANDOZ OLANZAPINE; OLANZAPINE FOR INJECTION"",
  ""medicinal_ingredients"": ""Olanzapine; Olanzapine (supplied as olanzapine tartrate)"",
  ""reason_for_submission"": ""Updated labelling materials"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 2.5 mg; N/A, Oral, Tablet, 5 mg; N/A, Oral, Tablet, 7.5 mg; N/A, Oral, Tablet, 10 mg; N/A, Oral, Tablet, 15 mg; N/A, Intramuscular, Powder for Solution, 10 mg/vial"",
  ""canadian_reference_product"": ""Zyprexa and Zyprexa Intramuscular, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e162307,242469,"December 16, 2020",SANDOZ OLANZAPINE; OLANZAPINE FOR INJECTION,Olanzapine; Olanzapine (supplied as olanzapine tartrate),Updated labelling materials,,"N/A, Oral, Tablet, 2.5 mg; N/A, Oral, Tablet, 5 mg; N/A, Oral, Tablet, 7.5 mg; N/A, Oral, Tablet, 10 mg; N/A, Oral, Tablet, 15 mg; N/A, Intramuscular, Powder for Solution, 10 mg/vial","Zyprexa and Zyprexa Intramuscular, Eli Lilly Canada Inc., Canada",Sandoz Canada Incorporated,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000032270.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""242036"",
  ""submission_no"": ""242036"",
  ""manufacturer"": {
    ""name"": ""Isologic Innovative Radiopharmaceuticals Ltd"",
    ""street"": ""11215 Chemin de la Côte-De-Liesse"",
    ""city"": ""Dorval"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9P 1B1""
  },
  ""date"": ""March 19, 2021"",
  ""product_name"": ""Kit for the Preparation of Technetium (99mTc) Pyrophosphate Injection / Trousse pour la préparation du pyrophosphate de technétium (99mTc) injectable"",
  ""medicinal_ingredients"": ""Sodium pyrophosphate / pyrophosphate de sodium"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02513870 - IV, PWSO, 12 mg/vial"",
  ""canadian_reference_product"": ""Technescan PYP, Mallinckrodt Canada ULC, Canada"",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,242036,242036,"March 19, 2021",Kit for the Preparation of Technetium (99mTc) Pyrophosphate Injection / Trousse pour la préparation du pyrophosphate de technétium (99mTc) injectable,Sodium pyrophosphate / pyrophosphate de sodium,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02513870 - IV, PWSO, 12 mg/vial","Technescan PYP, Mallinckrodt Canada ULC, Canada",Isologic Innovative Radiopharmaceuticals Ltd,11215 Chemin de la Côte-De-Liesse,Dorval,QC,Canada,H9P 1B1,,,,
https://pdf.hres.ca/noc_pm/0000032722.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e235384"",
  ""submission_no"": ""243865"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""May 18, 2021"",
  ""product_name"": ""JAMP PIRFENIDONE"",
  ""medicinal_ingredients"": ""Pirfenidone"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02514702, Oral, Tablet, 267 mg; 02514710, Oral, Tablet, 801 mg"",
  ""canadian_reference_product"": ""ESBRIET, Roche Registration GmbH, Germany"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e235384,243865,"May 18, 2021",JAMP PIRFENIDONE,Pirfenidone,This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,,"02514702, Oral, Tablet, 267 mg; 02514710, Oral, Tablet, 801 mg","ESBRIET, Roche Registration GmbH, Germany",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Quebec,Canada,J4B 5H3,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000032950.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e157025"",
  ""submission_no"": ""247816"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""May 5, 2021"",
  ""product_name"": ""AURO-CLOPIDOGREL"",
  ""medicinal_ingredients"": ""Clopidogrel (supplied as Clopidogrel Bisulfate)"",
  ""reason_for_submission"": ""Updates to labelling materials"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 75 mg"",
  ""canadian_reference_product"": ""PLAVIX, Sanofi-Aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e157025,247816,"May 5, 2021",AURO-CLOPIDOGREL,Clopidogrel (supplied as Clopidogrel Bisulfate),Updates to labelling materials,,"N/A, Oral, Tablet, 75 mg","PLAVIX, Sanofi-Aventis Canada Inc., Canada",Auro Pharma Inc.,"3700 Steeles Avenue West, Suite 402",Woodbridge,Ontario,Canada,L4L 8K8,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000032995.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e130761"",
  ""submission_no"": ""247160"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""385 Bouchard Boulevard"",
    ""city"": ""Dorval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""April 22, 2021"",
  ""product_name"": ""SANDOSTATIN / SANDOSTATIN LAR"",
  ""medicinal_ingredients"": ""Octreotide (supplied as octreotide acetate)"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Subcutaneous, Intravenous, Solution, 50 mcg/mL; N/A, Subcutaneous, Intravenous, Solution, 100 mcg/mL; N/A, Subcutaneous, Intravenous, Solution, 200 mcg/mL; N/A, Intramuscular, Powder for Suspension, Sustained-Release, 10 mg/vial; N/A, Intramuscular, Powder for Suspension, Sustained-Release, 20 mg/vial; N/A, Intramuscular, Powder for Suspension, Sustained-Release, 30 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e130761,247160,"April 22, 2021",SANDOSTATIN / SANDOSTATIN LAR,Octreotide (supplied as octreotide acetate),Safety updates to the Product Monograph.,,"N/A, Subcutaneous, Intravenous, Solution, 50 mcg/mL; N/A, Subcutaneous, Intravenous, Solution, 100 mcg/mL; N/A, Subcutaneous, Intravenous, Solution, 200 mcg/mL; N/A, Intramuscular, Powder for Suspension, Sustained-Release, 10 mg/vial; N/A, Intramuscular, Powder for Suspension, Sustained-Release, 20 mg/vial; N/A, Intramuscular, Powder for Suspension, Sustained-Release, 30 mg/vial",,Novartis Pharmaceuticals Canada Inc.,385 Bouchard Boulevard,Dorval,Quebec,Canada,H9S 1A9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000033029.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""247709"",
  ""submission_no"": ""247709"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""385 Bouchard Blvd"",
    ""city"": ""Dorval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""April 14, 2021"",
  ""product_name"": ""Lucentis"",
  ""medicinal_ingredients"": ""Ranibizumab"",
  ""reason_for_submission"": ""Additional manufacturing site / site de fabrication additionnel"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IVL, SOL, 10 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,247709,247709,"April 14, 2021",Lucentis,Ranibizumab,Additional manufacturing site / site de fabrication additionnel,,"N/A, IVL, SOL, 10 mg / mL",,Novartis Pharmaceuticals Canada Inc.,385 Bouchard Blvd,Dorval,Quebec,Canada,H9S 1A9,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,
https://pdf.hres.ca/noc_pm/0000033045.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e195538"",
  ""submission_no"": ""247489"",
  ""manufacturer"": {
    ""name"": ""Indivior UK Limited"",
    ""street"": ""The Chapleo Building, Henry Boot Way"",
    ""city"": ""Hull"",
    ""province"": """",
    ""country"": ""United Kingdom"",
    ""postal_code"": ""HU4 7DY""
  },
  ""date"": ""April 13, 2021"",
  ""product_name"": ""SUBLOCADE"",
  ""medicinal_ingredients"": ""Buprenorphine"",
  ""reason_for_submission"": ""Update to the outer carton and pouch labels"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Subcutaneous, Solution (extended-release), 100 mg / 0.5 ml; N/A, Subcutaneous, Solution (extended-release), 300 mg / 1.5 ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e195538,247489,"April 13, 2021",SUBLOCADE,Buprenorphine,Update to the outer carton and pouch labels,,"N/A, Subcutaneous, Solution (extended-release), 100 mg / 0.5 ml; N/A, Subcutaneous, Solution (extended-release), 300 mg / 1.5 ml",,Indivior UK Limited,"The Chapleo Building, Henry Boot Way",Hull,,United Kingdom,HU4 7DY,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000033063.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e165395"",
  ""submission_no"": ""249784"",
  ""manufacturer"": {
    ""name"": ""Pro Doc Ltée"",
    ""street"": ""2925, boul. Industriel"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 3W9""
  },
  ""date"": ""April 8, 2021"",
  ""product_name"": ""DILTIAZEM TZ"",
  ""medicinal_ingredients"": ""Diltiazem Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral, capsule (extended release), 120 mg; N/A, oral, capsule (extended release), 180 mg; N/A, oral, capsule (extended release), 240 mg; N/A, oral, capsule (extended release), 300 mg; N/A, oral, capsule (extended release), 360 mg"",
  ""canadian_reference_product"": ""Tiazac, Crystaal Corporation, Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e165395,249784,"April 8, 2021",DILTIAZEM TZ,Diltiazem Hydrochloride,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral, capsule (extended release), 120 mg; N/A, oral, capsule (extended release), 180 mg; N/A, oral, capsule (extended release), 240 mg; N/A, oral, capsule (extended release), 300 mg; N/A, oral, capsule (extended release), 360 mg","Tiazac, Crystaal Corporation, Canada",Pro Doc Ltée,"2925, boul. Industriel",Laval,Quebec,Canada,H7L 3W9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000033126.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""246916"",
  ""submission_no"": ""246916"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""385 Bouchard Blvd."",
    ""city"": ""Dorval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9S 1A9""
  },
  ""date"": ""March 23, 2021"",
  ""product_name"": ""AIMOVIG"",
  ""medicinal_ingredients"": ""erenumab / érénumab"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 70 mg/mL (prefilled syringe); N/A, SC, SOL, 70 mg/mL (prefilled auto-injector); N/A, SC, SOL, 140 mg/mL (prefilled syringe); N/A, SC, SOL, 140 mg/mL (prefilled auto-injector)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,246916,246916,"March 23, 2021",AIMOVIG,erenumab / érénumab,Update to the Product Monograph / Mise à jour de la monographie de produit,,"N/A, SC, SOL, 70 mg/mL (prefilled syringe); N/A, SC, SOL, 70 mg/mL (prefilled auto-injector); N/A, SC, SOL, 140 mg/mL (prefilled syringe); N/A, SC, SOL, 140 mg/mL (prefilled auto-injector)",,Novartis Pharmaceuticals Canada Inc.,385 Bouchard Blvd.,Dorval,Quebec,Canada,H9S 1A9,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000033142.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e135833"",
  ""submission_no"": ""249154"",
  ""manufacturer"": {
    ""name"": ""Organon Canada Inc."",
    ""street"": ""16766 route Transcanadienne"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""March 22, 2021"",
  ""product_name"": ""ESTROGEL"",
  ""medicinal_ingredients"": ""Estradiol supplied as Estradiol Hemihydrate"",
  ""reason_for_submission"": ""Administrative: Change in Product Ownership"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02238704, transdermal, gel, 0.06%"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e135833,249154,"March 22, 2021",ESTROGEL,Estradiol supplied as Estradiol Hemihydrate,Administrative: Change in Product Ownership,,"02238704, transdermal, gel, 0.06%",,Organon Canada Inc.,16766 route Transcanadienne,Kirkland,Quebec,Canada,H9H 4M7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000033254.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e142951"",
  ""submission_no"": ""247530"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L9""
  },
  ""date"": ""July 6, 2021"",
  ""product_name"": ""CAELYX"",
  ""medicinal_ingredients"": ""Doxorubicin Hydrochloride"",
  ""reason_for_submission"": ""Addition of drug substance manufacturing site."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Suspension, 2 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e142951,247530,"July 6, 2021",CAELYX,Doxorubicin Hydrochloride,Addition of drug substance manufacturing site.,,"N/A, Intravenous, Suspension, 2 mg/mL",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M3C 1L9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000033279.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e225686"",
  ""submission_no"": ""232449"",
  ""manufacturer"": {
    ""name"": ""Dutch Ophthalmic Research Center International BV"",
    ""street"": ""PO Box 43"",
    ""city"": ""Zuidland"",
    ""province"": ""South Holland"",
    ""country"": ""Netherlands"",
    ""postal_code"": ""3214 ZG""
  },
  ""date"": ""January 15, 2021"",
  ""product_name"": ""TISSUEBLUE"",
  ""medicinal_ingredients"": ""Brilliant Blue G"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02510995, Intravitreal, Solution, 0.25 mg/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e225686,232449,"January 15, 2021",TISSUEBLUE,Brilliant Blue G,"This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02510995, Intravitreal, Solution, 0.25 mg/ml",,Dutch Ophthalmic Research Center International BV,PO Box 43,Zuidland,South Holland,Netherlands,3214 ZG,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000033312.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e119036"",
  ""submission_no"": ""241745"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 Rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""February 9, 2021"",
  ""product_name"": ""SANDOZ CANDESARTAN PLUS"",
  ""medicinal_ingredients"": ""Candesartan cilexetil / hydrochlorothiazide"",
  ""reason_for_submission"": ""Alternate manufacturing site for the active pharmaceutical ingredient (candesartan cilexetil)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 16 mg / 12.5 mg; N/A, Oral, Tablet, 32 mg / 12.5 mg; N/A, Oral, Tablet, 32 mg / 25 mg"",
  ""canadian_reference_product"": ""ATACAND PLUS, ASTRAZENECA CANADA INC., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e119036,241745,"February 9, 2021",SANDOZ CANDESARTAN PLUS,Candesartan cilexetil / hydrochlorothiazide,Alternate manufacturing site for the active pharmaceutical ingredient (candesartan cilexetil),,"N/A, Oral, Tablet, 16 mg / 12.5 mg; N/A, Oral, Tablet, 32 mg / 12.5 mg; N/A, Oral, Tablet, 32 mg / 25 mg","ATACAND PLUS, ASTRAZENECA CANADA INC., Canada",Sandoz Canada Inc.,110 Rue de Lauzon,Boucherville,Quebec,Canada,J4B 1E6,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000033377.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E116647"",
  ""submission_no"": ""244369"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""February 17, 2021"",
  ""product_name"": ""ACT FLUCONAZOLE"",
  ""medicinal_ingredients"": ""Fluconazole"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 50mg; N/A, Oral, Tablet, 100mg"",
  ""canadian_reference_product"": ""Diflucan, Pfizer Canada, Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Scott Appleton, PhD"",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E116647,244369,"February 17, 2021",ACT FLUCONAZOLE,Fluconazole,Safety updates to the Product Monograph,,"N/A, Oral, Tablet, 50mg; N/A, Oral, Tablet, 100mg","Diflucan, Pfizer Canada, Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,"Scott Appleton, PhD",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000033449.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e207120"",
  ""submission_no"": ""250541"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""April 8, 2021"",
  ""product_name"": ""APO-ABIRATERONE FILM COATED TABLETS"",
  ""medicinal_ingredients"": ""Abiraterone Acetate"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 250mg; N/A, Oral, Tablet, 500mg"",
  ""canadian_reference_product"": ""Zytiga, Janssen Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Leslie Vrooman, M.Sc."",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e207120,250541,"April 8, 2021",APO-ABIRATERONE FILM COATED TABLETS,Abiraterone Acetate,Safety updates to the Product Monograph.,,"N/A, Oral, Tablet, 250mg; N/A, Oral, Tablet, 500mg","Zytiga, Janssen Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,"Leslie Vrooman, M.Sc.",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000033619.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""250276"",
  ""submission_no"": ""250276"",
  ""manufacturer"": {
    ""name"": ""Novo Nordisk Canada Inc."",
    ""street"": ""101-2476 Argentia Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6M1""
  },
  ""date"": ""July 23, 2021"",
  ""product_name"": ""Tresiba"",
  ""medicinal_ingredients"": ""insulin degludec"",
  ""reason_for_submission"": ""Product Monograph update / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 100 U/mL (Penfill); N/A, SC, SOL, 100 U/mL (FlexTouch); N/A, SC, SOL, 200 U/mL (FlexTouch)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,250276,250276,"July 23, 2021",Tresiba,insulin degludec,Product Monograph update / Mise à jour de la monographie de produit,,"N/A, SC, SOL, 100 U/mL (Penfill); N/A, SC, SOL, 100 U/mL (FlexTouch); N/A, SC, SOL, 200 U/mL (FlexTouch)",,Novo Nordisk Canada Inc.,101-2476 Argentia Road,Mississauga,Ontario,Canada,L5N 6M1,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000033710.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E137526"",
  ""submission_no"": ""238421"",
  ""manufacturer"": {
    ""name"": ""Bausch Health, Canada Inc."",
    ""street"": ""2150 St-Elzear West"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 4A8""
  },
  ""date"": ""September 30, 2020"",
  ""product_name"": ""VITAMIN A ACID"",
  ""medicinal_ingredients"": ""Tretinoin"",
  ""reason_for_submission"": ""Administrative: Change in Product Ownership\nUpdates to labelling material to reflect change in ownership, change in brand name and comply with PLL requirements"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""01926462, Topical, Gel, 0.01%\n01926470, Topical, Gel, 0.025%\n01926489, Topical, Gel, 0.05%"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,E137526,238421,"September 30, 2020",VITAMIN A ACID,Tretinoin,"Administrative: Change in Product Ownership
Updates to labelling material to reflect change in ownership, change in brand name and comply with PLL requirements",,"01926462, Topical, Gel, 0.01%
01926470, Topical, Gel, 0.025%
01926489, Topical, Gel, 0.05%",,"Bausch Health, Canada Inc.",2150 St-Elzear West,Laval,Quebec,Canada,H7L 4A8,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000033941.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e203536"",
  ""submission_no"": ""230928"",
  ""manufacturer"": {
    ""name"": ""Dr. Reddy’s Laboratories Ltd."",
    ""street"": ""Survey Nos. 42, 45, 46 & 54"",
    ""city"": ""Hyderabad"",
    ""province"": ""Telangana"",
    ""country"": ""India"",
    ""postal_code"": ""500090""
  },
  ""date"": ""September 1, 2021"",
  ""product_name"": ""REDDY-LENALIDOMIDE"",
  ""medicinal_ingredients"": ""Lenalidomide"",
  ""reason_for_submission"": ""Addition of New Indication and addition of previously approved strength"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02484714, Oral, Capsule, 2.5 mg; N/A, Oral, Capsule, 5 mg; N/A, Oral, Capsule, 10 mg; N/A, Oral, Capsule, 15 mg; N/A, Oral, Capsule, 20 mg; N/A, Oral, Capsule, 25 mg"",
  ""canadian_reference_product"": ""Revlimid, Celgene Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e203536,230928,"September 1, 2021",REDDY-LENALIDOMIDE,Lenalidomide,Addition of New Indication and addition of previously approved strength,,"02484714, Oral, Capsule, 2.5 mg; N/A, Oral, Capsule, 5 mg; N/A, Oral, Capsule, 10 mg; N/A, Oral, Capsule, 15 mg; N/A, Oral, Capsule, 20 mg; N/A, Oral, Capsule, 25 mg","Revlimid, Celgene Inc., Canada",Dr. Reddy’s Laboratories Ltd.,"Survey Nos. 42, 45, 46 & 54",Hyderabad,Telangana,India,500090,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000033990.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e123442"",
  ""submission_no"": ""249146"",
  ""manufacturer"": {
    ""name"": ""Elvium Life Sciences"",
    ""street"": ""3381 Steeles Avenue East, Suite 310"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2H 3S7""
  },
  ""date"": ""September 2, 2021"",
  ""product_name"": ""BIPHENTIN"",
  ""medicinal_ingredients"": ""methylphenidate hydrochloride"",
  ""reason_for_submission"": ""Safety updates to the product monograph and to convert the product monograph to 2020 format."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Capsule (extended-release), 10 mg; N/A, Oral, Capsule (extended-release), 15 mg; N/A, Oral, Capsule (extended-release), 20 mg; N/A, Oral, Capsule (extended-release), 30 mg; N/A, Oral, Capsule (extended-release), 40 mg; N/A, Oral, Capsule (extended-release), 50 mg; N/A, Oral, Capsule (extended-release), 60 mg; N/A, Oral, Capsule (extended-release), 80 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e123442,249146,"September 2, 2021",BIPHENTIN,methylphenidate hydrochloride,Safety updates to the product monograph and to convert the product monograph to 2020 format.,,"N/A, Oral, Capsule (extended-release), 10 mg; N/A, Oral, Capsule (extended-release), 15 mg; N/A, Oral, Capsule (extended-release), 20 mg; N/A, Oral, Capsule (extended-release), 30 mg; N/A, Oral, Capsule (extended-release), 40 mg; N/A, Oral, Capsule (extended-release), 50 mg; N/A, Oral, Capsule (extended-release), 60 mg; N/A, Oral, Capsule (extended-release), 80 mg",,Elvium Life Sciences,"3381 Steeles Avenue East, Suite 310",Toronto,Ontario,Canada,M2H 3S7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000034318.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e248884"",
  ""submission_no"": ""248884"",
  ""manufacturer"": {
    ""name"": ""Sivem Pharmaceuticals ULC"",
    ""street"": ""4705 Dobrin Street"",
    ""city"": ""Saint-Laurent"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4R 2P7""
  },
  ""date"": ""October 13, 2021"",
  ""product_name"": ""IMATINIB"",
  ""medicinal_ingredients"": ""Imatinib (as Imatinib Mesylate) / Imatinib (comme Mésylate d'imatinib)"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif : Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02521202, Oral, Tablet, 100 mg / 02521210, Oral, Tablet, 400 mg"",
  ""canadian_reference_product"": ""GLEEVEC, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e248884,248884,"October 13, 2021",IMATINIB,Imatinib (as Imatinib Mesylate) / Imatinib (comme Mésylate d'imatinib),Administrative: Licensing Agreement Between Two Companies / Administratif : Accord de licence entre deux sociétés,,"02521202, Oral, Tablet, 100 mg / 02521210, Oral, Tablet, 400 mg","GLEEVEC, Novartis Pharmaceuticals Canada Inc., Canada",Sivem Pharmaceuticals ULC,4705 Dobrin Street,Saint-Laurent,Québec,Canada,H4R 2P7,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000034377.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""252312"",
  ""submission_no"": ""252312"",
  ""manufacturer"": {
    ""name"": ""Novo Nordisk Canada Inc."",
    ""street"": ""101-2476 Argentia Road"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 6M1""
  },
  ""date"": ""October 19, 2021"",
  ""product_name"": ""OZEMPIC"",
  ""medicinal_ingredients"": ""Semaglutide injection"",
  ""reason_for_submission"": ""Modifications to the Drug Product manufacturing process / Modifications au processus de fabrication du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 1.34 mg/mL (fixed dose pen / stylo prérempli permettant une dose)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,252312,252312,"October 19, 2021",OZEMPIC,Semaglutide injection,Modifications to the Drug Product manufacturing process / Modifications au processus de fabrication du produit médicamenteux,,"N/A, SC, SOL, 1.34 mg/mL (fixed dose pen / stylo prérempli permettant une dose)",,Novo Nordisk Canada Inc.,101-2476 Argentia Road,Mississauga,ON,Canada,L5N 6M1,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000034436.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e249136"",
  ""submission_no"": ""249136"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""October 29, 2021"",
  ""product_name"": ""JAMP AMBRISENTAN"",
  ""medicinal_ingredients"": ""Ambrisentan"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02521938, Oral / Orale, Tablet / Comprimé, 5 mg; 02521946, Oral / Orale, Tablet / Comprimé, 10 mg"",
  ""canadian_reference_product"": ""VOLIBRIS, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e249136,249136,"October 29, 2021",JAMP AMBRISENTAN,Ambrisentan,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02521938, Oral / Orale, Tablet / Comprimé, 5 mg; 02521946, Oral / Orale, Tablet / Comprimé, 10 mg","VOLIBRIS, GlaxoSmithKline Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000034452.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""251117"",
  ""submission_no"": ""251117"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 5M8""
  },
  ""date"": ""November 1, 2021"",
  ""product_name"": ""HERCEPTIN"",
  ""medicinal_ingredients"": ""trastuzumab"",
  ""reason_for_submission"": ""New drug product manufacturing site/ nouveau site de fabrication pour le produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, PWSO, 440 mg/vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,251117,251117,"November 1, 2021",HERCEPTIN,trastuzumab,New drug product manufacturing site/ nouveau site de fabrication pour le produit médicamenteux,,"N/A, IV, PWSO, 440 mg/vial",,Hoffmann-La Roche Limited,7070 Mississauga Road,Mississauga,Ontario,Canada,L5N 5M8,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,
https://pdf.hres.ca/noc_pm/0000034458.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e176234"",
  ""submission_no"": ""253528"",
  ""manufacturer"": {
    ""name"": ""Medexus Pharmaceuticals Inc."",
    ""street"": ""1 Place du Commerce, Suite 225"",
    ""city"": ""Verdun"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H3E 1A2""
  },
  ""date"": ""November 2, 2021"",
  ""product_name"": ""Pediapharm Naproxen Suspension"",
  ""medicinal_ingredients"": ""Naproxen"",
  ""reason_for_submission"": ""Update to the Product Monograph to reflect safety concerns during pregnancy as per Advisement Letter and serious skin reactions"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Suspension, 25 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e176234,253528,"November 2, 2021",Pediapharm Naproxen Suspension,Naproxen,Update to the Product Monograph to reflect safety concerns during pregnancy as per Advisement Letter and serious skin reactions,,"N/A, Oral, Suspension, 25 mg / mL",,Medexus Pharmaceuticals Inc.,"1 Place du Commerce, Suite 225",Verdun,Quebec,Canada,H3E 1A2,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000034546.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e137776"",
  ""submission_no"": ""253508"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave., Suite 100"",
    ""city"": ""Montreal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""November 16, 2021"",
  ""product_name"": ""PMS-PAROXETINE"",
  ""medicinal_ingredients"": ""Paroxetine (as paroxetine hydrochloride) / Paroxétine (sous forme de chlorhydrate de paroxétine)"",
  ""reason_for_submission"": ""Update to labels / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 10 mg; N/A, Oral / Orale, Tablet / Comprimé, 20 mg; N/A, Oral / Orale, Tablet / Comprimé, 30 mg"",
  ""canadian_reference_product"": ""PAXIL, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e137776,253508,"November 16, 2021",PMS-PAROXETINE,Paroxetine (as paroxetine hydrochloride) / Paroxétine (sous forme de chlorhydrate de paroxétine),Update to labels / Mise à jour des étiquettes,,"N/A, Oral / Orale, Tablet / Comprimé, 10 mg; N/A, Oral / Orale, Tablet / Comprimé, 20 mg; N/A, Oral / Orale, Tablet / Comprimé, 30 mg","PAXIL, GlaxoSmithKline Inc., Canada",Pharmascience Inc.,"6111 Royalmount Ave., Suite 100",Montreal,Québec,Canada,H4P 2T4,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000034858.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e138463"",
  ""submission_no"": ""259429"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Inc."",
    ""street"": ""1165 Creditstone Road, Unit 1"",
    ""city"": ""Vaughan"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 4N7""
  },
  ""date"": ""January 5, 2022"",
  ""product_name"": ""FENOFIBRATE"",
  ""medicinal_ingredients"": ""Fenofibrate/Fénofibrate"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02225980, oral/orale, capsule, 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e138463,259429,"January 5, 2022",FENOFIBRATE,Fenofibrate/Fénofibrate,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02225980, oral/orale, capsule, 100 mg",,AA Pharma Inc.,"1165 Creditstone Road, Unit 1",Vaughan,Ontario,Canada,L4K 4N7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035006.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e213708"",
  ""submission_no"": ""251374"",
  ""manufacturer"": {
    ""name"": ""Bayer Inc."",
    ""street"": ""2920 Matheson Boulevard East"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 5R6""
  },
  ""date"": ""January 26, 2022"",
  ""product_name"": ""VITRAKVI"",
  ""medicinal_ingredients"": ""Larotrectinib Sulfate / Sulfate de Larotrectinib"",
  ""reason_for_submission"": ""To fulfill Commitment #1 of the Letter of Undertaking."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Solution, 20 mg/ml; N/A, Oral/Orale, Capsule, 25 mg; N/A, Oral/Orale, Capsule, 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e213708,251374,"January 26, 2022",VITRAKVI,Larotrectinib Sulfate / Sulfate de Larotrectinib,To fulfill Commitment #1 of the Letter of Undertaking.,,"N/A, Oral/Orale, Solution, 20 mg/ml; N/A, Oral/Orale, Capsule, 25 mg; N/A, Oral/Orale, Capsule, 100 mg",,Bayer Inc.,2920 Matheson Boulevard East,Mississauga,Ontario,Canada,L4W 5R6,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035048.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e259251"",
  ""submission_no"": ""259251"",
  ""manufacturer"": {
    ""name"": ""Sanis Health Inc."",
    ""street"": ""1 President’s Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""February 2, 2022"",
  ""product_name"": ""CINACALCET"",
  ""medicinal_ingredients"": ""Cinacalcet supplied as Cinacalcet Hydrochloride / Cinacalcet sous forme de chlorhydrate de cinacalcet"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02524880, oral / orale, tablet / comprimé, 30 mg; 02524899, oral / orale, tablet / comprimé, 60 mg; 02524902, oral / orale, tablet / comprimé, 90 mg"",
  ""canadian_reference_product"": ""Sensipar, Amgen Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e259251,259251,"February 2, 2022",CINACALCET,Cinacalcet supplied as Cinacalcet Hydrochloride / Cinacalcet sous forme de chlorhydrate de cinacalcet,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02524880, oral / orale, tablet / comprimé, 30 mg; 02524899, oral / orale, tablet / comprimé, 60 mg; 02524902, oral / orale, tablet / comprimé, 90 mg","Sensipar, Amgen Canada Inc., Canada",Sanis Health Inc.,1 President’s Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035065.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v251674"",
  ""submission_no"": ""251674"",
  ""manufacturer"": {
    ""name"": ""Dechra Veterinary Products Inc."",
    ""street"": ""1 Holiday Avenue, East Tower, Suite 345"",
    ""city"": ""Pointe-Claire"",
    ""province"": ""QC"",
    ""country"": """",
    ""postal_code"": ""H9R 5N3""
  },
  ""date"": ""February 7, 2022"",
  ""product_name"": ""Dexmedesed"",
  ""medicinal_ingredients"": ""Dexmedetomidine Hydrochloride/Chlorhydrate de dexmédétomidine"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of section C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": ""Dogs, Cats/Chiens, Chats"",
  ""drug_identification_number_route_form_strength"": ""02524945, Intramuscular (dogs, cats), Intravenous (dog), Solution, 0.5 mg/mL/02524945, Intramusculaire (chiens, chats), Intraveineuse (chiens), Solution, 0.5 mg/mL"",
  ""canadian_reference_product"": ""Dexdomitor (DIN 02333929, Orion Corporation)"",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v251674,251674,"February 7, 2022",Dexmedesed,Dexmedetomidine Hydrochloride/Chlorhydrate de dexmédétomidine,This is to notify you that the above abbreviated new drug submission complies with the requirements of section C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,"Dogs, Cats/Chiens, Chats","02524945, Intramuscular (dogs, cats), Intravenous (dog), Solution, 0.5 mg/mL/02524945, Intramusculaire (chiens, chats), Intraveineuse (chiens), Solution, 0.5 mg/mL","Dexdomitor (DIN 02333929, Orion Corporation)",Dechra Veterinary Products Inc.,"1 Holiday Avenue, East Tower, Suite 345",Pointe-Claire,QC,,H9R 5N3,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000035149.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e158025"",
  ""submission_no"": ""256286"",
  ""manufacturer"": {
    ""name"": ""AA Pharma Inc."",
    ""street"": ""Unit 1 - 1165 Creditstone Road"",
    ""city"": ""Vaughan"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""L4K 4N7""
  },
  ""date"": ""February 16, 2022"",
  ""product_name"": ""BROMOCRIPTINE"",
  ""medicinal_ingredients"": ""Bromocriptine (supplied as: bromocriptine mesylate) / Bromocriptine (fourni comme: mésylate de bromocriptine)"",
  ""reason_for_submission"": ""To update the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 2.5 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e158025,256286,"February 16, 2022",BROMOCRIPTINE,Bromocriptine (supplied as: bromocriptine mesylate) / Bromocriptine (fourni comme: mésylate de bromocriptine),To update the Product Monograph.,,"N/A, Oral/Orale, Tablet/Comprimé, 2.5 mg",,AA Pharma Inc.,Unit 1 - 1165 Creditstone Road,Vaughan,Ontario,,L4K 4N7,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035157.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e204031"",
  ""submission_no"": ""252954"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""February 17, 2022"",
  ""product_name"": ""APO-TAPENTADOL"",
  ""medicinal_ingredients"": ""Tapentadol (supplied as Tapentadol Hydrochloride)"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 50mg; N/A, Oral, Tablet, 75mg; N/A, Oral, Tablet, 100mg"",
  ""canadian_reference_product"": ""Nucynta IR, Janssen Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur générale"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e204031,252954,"February 17, 2022",APO-TAPENTADOL,Tapentadol (supplied as Tapentadol Hydrochloride),Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la monographie de produit,,"N/A, Oral, Tablet, 50mg; N/A, Oral, Tablet, 75mg; N/A, Oral, Tablet, 100mg","Nucynta IR, Janssen Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur générale,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035188.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e148690"",
  ""submission_no"": ""255167"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada ULC"",
    ""street"": ""17300 Trans-Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""February 23, 2022"",
  ""product_name"": ""VYNDAQEL"",
  ""medicinal_ingredients"": ""Tafamidis meglumine"",
  ""reason_for_submission"": ""Update to the Product Monograph as per Advisement Letter Conversion of the Product Monograph to 2020 format"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Capsule, 20 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e148690,255167,"February 23, 2022",VYNDAQEL,Tafamidis meglumine,Update to the Product Monograph as per Advisement Letter Conversion of the Product Monograph to 2020 format,,"N/A, Oral / Orale, Capsule, 20 mg",,Pfizer Canada ULC,17300 Trans-Canada Highway,Kirkland,Québec,Canada,H9J 2M5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000035301.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e109347"",
  ""submission_no"": ""257117"",
  ""manufacturer"": {
    ""name"": ""Allergan Inc."",
    ""street"": ""85 Enterprise Blvd, Suite 500"",
    ""city"": ""Markham"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6G 0B5""
  },
  ""date"": ""March 11, 2022"",
  ""product_name"": ""ZYMAR"",
  ""medicinal_ingredients"": ""Gatifloxacin / Gatifloxacine"",
  ""reason_for_submission"": ""To update the Product Monograph (PM) to the 2020 format, and to update the labels to meet Plain Language Labelling (PLL) requirements."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Ophthalmic/Ophtalmique, Solution, 0.3%"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e109347,257117,"March 11, 2022",ZYMAR,Gatifloxacin / Gatifloxacine,"To update the Product Monograph (PM) to the 2020 format, and to update the labels to meet Plain Language Labelling (PLL) requirements.",,"N/A, Ophthalmic/Ophtalmique, Solution, 0.3%",,Allergan Inc.,"85 Enterprise Blvd, Suite 500",Markham,Ontario,Canada,L6G 0B5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035369.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e185943"",
  ""submission_no"": ""250064"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc"",
    ""street"": ""3700 Steeles Avenue West, Suite # 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""August 13, 2021"",
  ""product_name"": ""Tranexamic Acid Injection"",
  ""medicinal_ingredients"": ""Tranexamic Acid"",
  ""reason_for_submission"": ""Updates to Labelling Material / Mises à jour du matériel d'étiquetage"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous, Solution, 100 mg / mL"",
  ""canadian_reference_product"": ""CYKLOKAPRON®, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e185943,250064,"August 13, 2021",Tranexamic Acid Injection,Tranexamic Acid,Updates to Labelling Material / Mises à jour du matériel d'étiquetage,,"N/A, Intravenous, Solution, 100 mg / mL","CYKLOKAPRON®, Pfizer Canada Inc., Canada",Auro Pharma Inc,"3700 Steeles Avenue West, Suite # 402",Woodbridge,Ontario,Canada,L4L 8K8,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,Therapeutic Products Directorate / Direction des produits thérapeutiques
https://pdf.hres.ca/noc_pm/0000035453.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e183969"",
  ""submission_no"": ""255995"",
  ""manufacturer"": {
    ""name"": ""Generic Medical Partners Inc."",
    ""street"": ""1500 Don Mills Road, Suite 711"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3B 3K4""
  },
  ""date"": ""March 25, 2022"",
  ""product_name"": ""MED-MOXIFLOXACIN"",
  ""medicinal_ingredients"": ""Moxifloxacin (supplied as moxifloxacin hydrochloride) / moxifloxacine (sous forme de chlorhydrate de moxifloxacine)"",
  ""reason_for_submission"": ""Addition of primary container closure system / Ajout du système de fermeture du conteneur primaire Updated product monograph and labelling materials / Monographie de produit et matériel d'étiquetage mis à jour"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / orale, Tablet / comprimé, 400 mg"",
  ""canadian_reference_product"": ""Avalox, Bayer Schering Pharma AG, Germany"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e183969,255995,"March 25, 2022",MED-MOXIFLOXACIN,Moxifloxacin (supplied as moxifloxacin hydrochloride) / moxifloxacine (sous forme de chlorhydrate de moxifloxacine),Addition of primary container closure system / Ajout du système de fermeture du conteneur primaire Updated product monograph and labelling materials / Monographie de produit et matériel d'étiquetage mis à jour,N/A,"N/A, Oral / orale, Tablet / comprimé, 400 mg","Avalox, Bayer Schering Pharma AG, Germany",Generic Medical Partners Inc.,"1500 Don Mills Road, Suite 711",Toronto,Ontario,Canada,M3B 3K4,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000035474.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e134345"",
  ""submission_no"": ""257792"",
  ""manufacturer"": {
    ""name"": ""Takeda Canada Inc."",
    ""street"": ""Suite 3800 - 22 Adelaide Street West"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5H 4E3""
  },
  ""date"": ""March 25, 2022"",
  ""product_name"": ""FOSRENOL"",
  ""medicinal_ingredients"": ""Lanthanum (supplied as: lanthanum carbonate hydrate) / Lanthane (fourni comme: Carbonate de lanthane hydraté)"",
  ""reason_for_submission"": ""To update the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 250 mg; N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 500 mg; N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 750 mg; N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 1000mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e134345,257792,"March 25, 2022",FOSRENOL,Lanthanum (supplied as: lanthanum carbonate hydrate) / Lanthane (fourni comme: Carbonate de lanthane hydraté),To update the Product Monograph.,,"N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 250 mg; N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 500 mg; N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 750 mg; N/A, Oral/Orale, Tablet (chewable)/Comprimé (à mâcher), 1000mg",,Takeda Canada Inc.,Suite 3800 - 22 Adelaide Street West,Toronto,Ontario,Canada,M5H 4E3,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035511.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e136346"",
  ""submission_no"": ""257491"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""March 30, 2022"",
  ""product_name"": ""SANDOZ LISINOPRIL HCT"",
  ""medicinal_ingredients"": ""Lisinopril (as Lisinopril Dihydrate) and Hydrochlorothiazide"",
  ""reason_for_submission"": ""Updating the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 10 mg / 12.5 mg; N/A, Oral / Orale, Tablet / Comprimé, 20 mg / 12.5 mg; N/A, Oral / Orale, Tablet / Comprimé, 20 mg / 25 mg"",
  ""canadian_reference_product"": ""ZESTORETIC, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e136346,257491,"March 30, 2022",SANDOZ LISINOPRIL HCT,Lisinopril (as Lisinopril Dihydrate) and Hydrochlorothiazide,Updating the Product Monograph,,"N/A, Oral / Orale, Tablet / Comprimé, 10 mg / 12.5 mg; N/A, Oral / Orale, Tablet / Comprimé, 20 mg / 12.5 mg; N/A, Oral / Orale, Tablet / Comprimé, 20 mg / 25 mg","ZESTORETIC, AstraZeneca Canada Inc., Canada",Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000035546.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e177304"",
  ""submission_no"": ""256359"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Ave. West, Suite 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""March 31, 2022"",
  ""product_name"": ""AURO-TRAMADOL/ACETAMINOPHEN"",
  ""medicinal_ingredients"": ""Tramadol hydrochloride / Acetaminophen / chlorhydrate de tramadol / Acétaminophène"",
  ""reason_for_submission"": ""Update to the product monograph as per advisement letter / Mise à jour de la monographie de produit comme la lettre d'annonce Update to package labels / Mise à jour des étiquettes du paquet"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 37.5 mg tramadol hydrochloride / 325 mg acetaminophen"",
  ""canadian_reference_product"": ""TRAMACET, Janssen Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP (EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques""
  }
}",TRUE,NA,e177304,256359,"March 31, 2022",AURO-TRAMADOL/ACETAMINOPHEN,Tramadol hydrochloride / Acetaminophen / chlorhydrate de tramadol / Acétaminophène,Update to the product monograph as per advisement letter / Mise à jour de la monographie de produit comme la lettre d'annonce Update to package labels / Mise à jour des étiquettes du paquet,,"N/A, Oral / Orale, Tablet / Comprimé, 37.5 mg tramadol hydrochloride / 325 mg acetaminophen","TRAMACET, Janssen Inc., Canada",Auro Pharma Inc.,"3700 Steeles Ave. West, Suite 402",Woodbridge,Ontario,Canada,L4L 8K8,"Dr. J. Patrick Stewart, MD, CCFP (EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,NA
https://pdf.hres.ca/noc_pm/0000035740.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e256440"",
  ""submission_no"": ""261288"",
  ""manufacturer"": {
    ""name"": ""Pfizer Canada ULC"",
    ""street"": ""17300 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": """",
    ""postal_code"": ""H9J 2M5""
  },
  ""date"": ""April 14, 2022"",
  ""product_name"": ""PAXLOVID"",
  ""medicinal_ingredients"": ""Ritonavir / Nirmatrelvir"",
  ""reason_for_submission"": ""Addition of Drug Product Manufacturing site"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 100mg / 150 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Therapeutic Products Directorate / Direction des produits thérapeutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e256440,261288,"April 14, 2022",PAXLOVID,Ritonavir / Nirmatrelvir,Addition of Drug Product Manufacturing site,,"N/A, Oral/Orale, Tablet/Comprimé, 100mg / 150 mg",,Pfizer Canada ULC,17300 Trans Canada Highway,Kirkland,Quebec,,H9J 2M5,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Therapeutic Products Directorate / Direction des produits thérapeutiques,
https://pdf.hres.ca/noc_pm/0000035993.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e149092"",
  ""submission_no"": ""262912"",
  ""manufacturer"": {
    ""name"": ""Marcan Pharmaceuticals Inc."",
    ""street"": ""2 Gurdwara Road, Suite #112"",
    ""city"": ""Ottawa"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""K2E 1A2""
  },
  ""date"": ""May 5, 2022"",
  ""product_name"": ""MAR-RISPERIDONE"",
  ""medicinal_ingredients"": ""Risperidone / Rispéridone"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 0.25 mg; N/A, oral / orale, tablet / comprimé, 0.5 mg; N/A, oral / orale, tablet / comprimé, 1 mg; N/A, oral / orale, tablet / comprimé, 2 mg; N/A, oral / orale, tablet / comprimé, 3 mg; N/A, oral / orale, tablet / comprimé, 4 mg"",
  ""canadian_reference_product"": ""Risperdal, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Dr. J. Patrick Stewart, MD, CCFP(EM)"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e149092,262912,"May 5, 2022",MAR-RISPERIDONE,Risperidone / Rispéridone,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, tablet / comprimé, 0.25 mg; N/A, oral / orale, tablet / comprimé, 0.5 mg; N/A, oral / orale, tablet / comprimé, 1 mg; N/A, oral / orale, tablet / comprimé, 2 mg; N/A, oral / orale, tablet / comprimé, 3 mg; N/A, oral / orale, tablet / comprimé, 4 mg","Risperdal, Janssen-Ortho Inc., Canada",Marcan Pharmaceuticals Inc.,"2 Gurdwara Road, Suite #112",Ottawa,Ontario,Canada,K2E 1A2,"Dr. J. Patrick Stewart, MD, CCFP(EM)",Director General / Directeur général,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000036022.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e130033"",
  ""submission_no"": ""259228"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Avenue, Suite 100"",
    ""city"": ""Montréal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""May 11, 2022"",
  ""product_name"": ""PMS-SUMATRIPTAN"",
  ""medicinal_ingredients"": ""Sumatriptan (supplied as sumatriptan succinate) / Sumatriptan (sous forme de succinate de sumatriptan)"",
  ""reason_for_submission"": ""Update to product monograph to match CRP / Mise à jour de la monographie de produit pour correspondre au CRP"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / orale, Tablet / comprimé, 25 mg; N/A, Oral / orale, Tablet / comprimé, 50 mg; N/A, Oral / orale, Tablet / comprimé, 100 mg"",
  ""canadian_reference_product"": ""Imitrex DF, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Bruce Randall"",
    ""title"": ""Acting Director General / Directeur général par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e130033,259228,"May 11, 2022",PMS-SUMATRIPTAN,Sumatriptan (supplied as sumatriptan succinate) / Sumatriptan (sous forme de succinate de sumatriptan),Update to product monograph to match CRP / Mise à jour de la monographie de produit pour correspondre au CRP,,"N/A, Oral / orale, Tablet / comprimé, 25 mg; N/A, Oral / orale, Tablet / comprimé, 50 mg; N/A, Oral / orale, Tablet / comprimé, 100 mg","Imitrex DF, GlaxoSmithKline Inc., Canada",Pharmascience Inc.,"6111 Royalmount Avenue, Suite 100",Montréal,Québec,Canada,H4P 2T4,Bruce Randall,Acting Director General / Directeur général par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000036055.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e105800"",
  ""submission_no"": ""258995"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""May 13, 2022"",
  ""product_name"": ""APO-VERAP"",
  ""medicinal_ingredients"": ""Verapamil hydrochloride / Chlorhydrate de vérapamil"",
  ""reason_for_submission"": ""Update to the Product Monograph\nConversion of the Product Monograph to the 2020 format"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/ Orale, Tablet/ Comprimé, 80 mg\nN/A, Oral/ Orale, Tablet/ Comprimé, 120 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Mandy Collier"",
    ""title"": ""Acting Director General"",
    ""division"": ""Pharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e105800,258995,"May 13, 2022",APO-VERAP,Verapamil hydrochloride / Chlorhydrate de vérapamil,"Update to the Product Monograph
Conversion of the Product Monograph to the 2020 format",,"N/A, Oral/ Orale, Tablet/ Comprimé, 80 mg
N/A, Oral/ Orale, Tablet/ Comprimé, 120 mg",,Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Mandy Collier,Acting Director General,Pharmaceutical Drugs Directorate,Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000036072.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e232901"",
  ""submission_no"": ""246943"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Avenue, Suite #100"",
    ""city"": ""Montréal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""May 16, 2022"",
  ""product_name"": ""pms-TERIFLUNOMIDE"",
  ""medicinal_ingredients"": ""Teriflunomide"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 14mg"",
  ""canadian_reference_product"": ""Aubagio, Genzyme Canada, a division of sanofi-aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Bruce Randall"",
    ""title"": ""Acting Director General"",
    ""division"": ""Pharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e232901,246943,"May 16, 2022",pms-TERIFLUNOMIDE,Teriflunomide,Safety updates to the Product Monograph.,,"N/A, Oral, Tablet, 14mg","Aubagio, Genzyme Canada, a division of sanofi-aventis Canada Inc., Canada",Pharmascience Inc.,"6111 Royalmount Avenue, Suite #100",Montréal,Québec,Canada,H4P 2T4,Bruce Randall,Acting Director General,Pharmaceutical Drugs Directorate,Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000036255.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e227544"",
  ""submission_no"": ""259738"",
  ""manufacturer"": {
    ""name"": ""Sanis Health Inc."",
    ""street"": ""243 Consumers Road"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2J 4W8""
  },
  ""date"": ""May 27, 2022"",
  ""product_name"": ""DULOXETINE"",
  ""medicinal_ingredients"": ""Duloxetine (supplied as duloxetine hydrochloride) / Duloxétine (sous forme de chlorhydrate de duloxétine)"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant) AND / ET Update to product monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / orale, Capsule (delayed-release) / capsule (à libération retardée), 30 mg / N/A, Oral / orale, Capsule (delayed-release) / Capsule (à libération retardée), 60 mg"",
  ""canadian_reference_product"": ""Cymbalta, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Bruce Randall"",
    ""title"": ""Acting Director General / Directeur général par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e227544,259738,"May 27, 2022",DULOXETINE,Duloxetine (supplied as duloxetine hydrochloride) / Duloxétine (sous forme de chlorhydrate de duloxétine),Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant) AND / ET Update to product monograph / Mise à jour de la monographie de produit,,"N/A, Oral / orale, Capsule (delayed-release) / capsule (à libération retardée), 30 mg / N/A, Oral / orale, Capsule (delayed-release) / Capsule (à libération retardée), 60 mg","Cymbalta, Eli Lilly Canada Inc., Canada",Sanis Health Inc.,243 Consumers Road,Toronto,Ontario,Canada,M2J 4W8,Bruce Randall,Acting Director General / Directeur général par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000036296.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e198960"",
  ""submission_no"": ""252766"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L9""
  },
  ""date"": ""June 1, 2022"",
  ""product_name"": ""ERLEADA"",
  ""medicinal_ingredients"": ""Apalutamide"",
  ""reason_for_submission"": ""To update the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 60mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General"",
    ""division"": ""Pharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e198960,252766,"June 1, 2022",ERLEADA,Apalutamide,To update the Product Monograph.,,"N/A, Oral/Orale, Tablet/Comprimé, 60mg",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M3C 1L9,Melissa Hunt,Acting Director General,Pharmaceutical Drugs Directorate,Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000036353.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e136763"",
  ""submission_no"": ""259791"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""June 7, 2022"",
  ""product_name"": ""TEVA-DICLOFENAC EC and TEVA-DICLOFENAC SR"",
  ""medicinal_ingredients"": ""Diclofenac Sodium / Diclofenac sodique"",
  ""reason_for_submission"": ""Update to the Product Monograph as per Advisement Letter / Mise à jour de la monographie de produit comme la lettre d'annonce"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 25 mg; N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 50 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 75 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General / Directeur général par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e136763,259791,"June 7, 2022",TEVA-DICLOFENAC EC and TEVA-DICLOFENAC SR,Diclofenac Sodium / Diclofenac sodique,Update to the Product Monograph as per Advisement Letter / Mise à jour de la monographie de produit comme la lettre d'annonce,,"N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 25 mg; N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 50 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 75 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 100 mg",,Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,,M1B 2K9,Melissa Hunt,Acting Director General / Directeur général par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000036711.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e243433"",
  ""submission_no"": ""254495"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""16750 route Transcanadienne"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""July 11, 2022"",
  ""product_name"": ""WELIREG"",
  ""medicinal_ingredients"": ""Belzutifan"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02528908, Oral/Orale, Tablet/Comprimé, 40 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e243433,254495,"July 11, 2022",WELIREG,Belzutifan,"This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02528908, Oral/Orale, Tablet/Comprimé, 40 mg",,Merck Canada Inc.,16750 route Transcanadienne,Kirkland,Quebec,Canada,H9H 4M7,Melissa Hunt,Acting Director General / Directrice générale par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000036792.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e144609"",
  ""submission_no"": ""261888"",
  ""manufacturer"": {
    ""name"": ""Bausch Health, Canada Inc."",
    ""street"": ""2150 Boul. St-Elzear, Ouest"",
    ""city"": ""Laval"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 4A8""
  },
  ""date"": ""July 18, 2022"",
  ""product_name"": ""WELLBUTRIN SR"",
  ""medicinal_ingredients"": ""Bupropion Hydrochloride / Chlorhydrate de bupropion"",
  ""reason_for_submission"": ""Safety Update to the post-market ADR section of the Product Monograph (PM)."",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet (Extended-Release)/Comprimé (à libération prolongée), 150 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e144609,261888,"July 18, 2022",WELLBUTRIN SR,Bupropion Hydrochloride / Chlorhydrate de bupropion,Safety Update to the post-market ADR section of the Product Monograph (PM).,N/A,"N/A, Oral/Orale, Tablet (Extended-Release)/Comprimé (à libération prolongée), 150 mg",,"Bausch Health, Canada Inc.","2150 Boul. St-Elzear, Ouest",Laval,Québec,Canada,H7L 4A8,Melissa Hunt,Acting Director General / Directrice générale par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000036894.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v218386"",
  ""submission_no"": ""257671"",
  ""manufacturer"": {
    ""name"": ""Dechra Regulatory BV"",
    ""street"": ""Handelsweg 25"",
    ""city"": ""Bladel"",
    ""province"": ""5531 AE"",
    ""country"": ""Netherlands"",
    ""postal_code"": """"
  },
  ""date"": ""July 29, 2022"",
  ""product_name"": ""Emavert"",
  ""medicinal_ingredients"": ""Maropitant / Maropitant"",
  ""reason_for_submission"": ""abbreviated new drug submission"",
  ""species"": ""Dogs, Cats / Chiens, Chats"",
  ""drug_identification_number_route_form_strength"": ""02529564, Intravenous, Subcutaneous, Solution, 10 mg/mL"",
  ""canadian_reference_product"": ""CERENIA (DIN 02299542, Zoetis Canada Inc.)"",
  ""authorizing_official"": {
    ""name"": ""Jennifer Geduld"",
    ""title"": ""Acting Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v218386,257671,"July 29, 2022",Emavert,Maropitant / Maropitant,abbreviated new drug submission,"Dogs, Cats / Chiens, Chats","02529564, Intravenous, Subcutaneous, Solution, 10 mg/mL","CERENIA (DIN 02299542, Zoetis Canada Inc.)",Dechra Regulatory BV,Handelsweg 25,Bladel,5531 AE,Netherlands,,Jennifer Geduld,Acting Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000037011.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e169564"",
  ""submission_no"": ""255153"",
  ""manufacturer"": {
    ""name"": ""Tillotts Pharma AG"",
    ""street"": ""Baslerstrasse 15"",
    ""city"": ""Rheinfelden"",
    ""province"": ""Aargau"",
    ""country"": ""Switzerland"",
    ""postal_code"": ""4310""
  },
  ""date"": ""August 8, 2022"",
  ""product_name"": ""OCTASA"",
  ""medicinal_ingredients"": ""Mesalazine/Mésalazine"",
  ""reason_for_submission"": ""New strength and treatment regimen for moderate active ulcerative colitis (UC)."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02529610, Oral/Orale, Tablet (Delayed-Release)/Comprimé (à libération retardée), 1600 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General"",
    ""division"": ""Pharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e169564,255153,"August 8, 2022",OCTASA,Mesalazine/Mésalazine,New strength and treatment regimen for moderate active ulcerative colitis (UC).,,"02529610, Oral/Orale, Tablet (Delayed-Release)/Comprimé (à libération retardée), 1600 mg",,Tillotts Pharma AG,Baslerstrasse 15,Rheinfelden,Aargau,Switzerland,4310,Melissa Hunt,Acting Director General,Pharmaceutical Drugs Directorate,Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000037120.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e222662"",
  ""submission_no"": ""265965"",
  ""manufacturer"": {
    ""name"": ""Angita Pharma Inc."",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""August 19, 2022"",
  ""product_name"": ""AG-ALENDRONATE"",
  ""medicinal_ingredients"": ""Alendronic Acid supplied as Alendronate Sodium / Acide alendronique sous forme d'alendronate sodique"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 5 mg; N/A, oral / orale, tablet / comprimé, 10 mg; N/A, oral / orale, tablet / comprimé, 70 mg"",
  ""canadian_reference_product"": ""Fosamax, Merck Frosst Canada Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""A/Director General – Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e222662,265965,"August 19, 2022",AG-ALENDRONATE,Alendronic Acid supplied as Alendronate Sodium / Acide alendronique sous forme d'alendronate sodique,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, tablet / comprimé, 5 mg; N/A, oral / orale, tablet / comprimé, 10 mg; N/A, oral / orale, tablet / comprimé, 70 mg","Fosamax, Merck Frosst Canada Ltd., Canada",Angita Pharma Inc.,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,Melissa Hunt,A/Director General – Directrice générale par intérim,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037122.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e169077"",
  ""submission_no"": ""266565"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""August 18, 2022"",
  ""product_name"": ""APO-TRAMADOL"",
  ""medicinal_ingredients"": ""Tramadol hydrochloride / Chlorhydrate de tramadol"",
  ""reason_for_submission"": ""Safety updates to the product monograph / Mise à jour de l'innocuité dans la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 50 mg"",
  ""canadian_reference_product"": ""ULTRAM, Janssen Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Leslie Vrooman, M.Sc."",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e169077,266565,"August 18, 2022",APO-TRAMADOL,Tramadol hydrochloride / Chlorhydrate de tramadol,Safety updates to the product monograph / Mise à jour de l'innocuité dans la monographie de produit,,"N/A, Oral/Orale, Tablet/Comprimé, 50 mg","ULTRAM, Janssen Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,"Leslie Vrooman, M.Sc.",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000037127.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""260589"",
  ""submission_no"": ""260589"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Incorporated"",
    ""street"": ""110 Rue De La Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""August 18, 2022"",
  ""product_name"": ""Inclunox, Inclunox HP"",
  ""medicinal_ingredients"": ""Enoxaparin sodium / énoxaparine sodique"",
  ""reason_for_submission"": ""Additional drug substance manufacturing site / Site de fabrication additionnel pour la substance médicamenteuse"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""Inclunox: N/A – SC, IV, SOL, 30 mg/0.3 mL; N/A – SC, IV, SOL, 40 mg/0.4 mL; N/A – SC, IV, SOL, 60 mg/0.6 mL; N/A – SC, IV, SOL, 80 mg/0.8 mL; N/A – SC, IV, SOL, 100 mg/mL; Indunox HP: N/A – SC, IV, SOL, 120 mg/0.8 mL; N/A – SC, IV, SOL, 150 mg/mL"",
  ""canadian_reference_product"": ""Lovenox, Lovenox HP"",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,260589,260589,"August 18, 2022","Inclunox, Inclunox HP",Enoxaparin sodium / énoxaparine sodique,Additional drug substance manufacturing site / Site de fabrication additionnel pour la substance médicamenteuse,,"Inclunox: N/A – SC, IV, SOL, 30 mg/0.3 mL; N/A – SC, IV, SOL, 40 mg/0.4 mL; N/A – SC, IV, SOL, 60 mg/0.6 mL; N/A – SC, IV, SOL, 80 mg/0.8 mL; N/A – SC, IV, SOL, 100 mg/mL; Indunox HP: N/A – SC, IV, SOL, 120 mg/0.8 mL; N/A – SC, IV, SOL, 150 mg/mL","Lovenox, Lovenox HP",Sandoz Canada Incorporated,110 Rue De La Lauzon,Boucherville,Quebec,Canada,J4B 1E6,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000037218.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e122158"",
  ""submission_no"": ""266495"",
  ""manufacturer"": {
    ""name"": ""AbbVie Corporation"",
    ""street"": ""8401 Trans-Canada Highway"",
    ""city"": ""Saint-Laurent"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 1Z1""
  },
  ""date"": ""August 29, 2022"",
  ""product_name"": ""ALPHAGAN P"",
  ""medicinal_ingredients"": ""Brimonidine Tartrate / Tartrate de brimonidine"",
  ""reason_for_submission"": ""Administrative: Merger/Buy-out / Administratif: Fusion/rachat"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02248151, ophthalmic / ophtalmique, solution, 0.15 % w/v / p/v"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""A/Director General – Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e122158,266495,"August 29, 2022",ALPHAGAN P,Brimonidine Tartrate / Tartrate de brimonidine,Administrative: Merger/Buy-out / Administratif: Fusion/rachat,,"02248151, ophthalmic / ophtalmique, solution, 0.15 % w/v / p/v",,AbbVie Corporation,8401 Trans-Canada Highway,Saint-Laurent,Quebec,Canada,H4S 1Z1,Melissa Hunt,A/Director General – Directrice générale par intérim,Pharmaceutical Drugs Directorate,Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000037219.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e249329"",
  ""submission_no"": ""249329"",
  ""manufacturer"": {
    ""name"": ""Sanis Health Inc."",
    ""street"": ""1 President's Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""August 30, 2022"",
  ""product_name"": ""MODAFINIL"",
  ""medicinal_ingredients"": ""Modafinil"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02530244, oral / orale, tablet / comprimé, 100 mg"",
  ""canadian_reference_product"": ""Alertec, Shire Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""A/Director General – Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e249329,249329,"August 30, 2022",MODAFINIL,Modafinil,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02530244, oral / orale, tablet / comprimé, 100 mg","Alertec, Shire Canada Inc., Canada",Sanis Health Inc.,1 President's Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,Melissa Hunt,A/Director General – Directrice générale par intérim,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037220.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e203827"",
  ""submission_no"": ""251033"",
  ""manufacturer"": {
    ""name"": ""Natco Pharma (Canada) Inc."",
    ""street"": ""2000 Argentia Road, Plaza 1, Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 1P7""
  },
  ""date"": ""August 29, 2022"",
  ""product_name"": ""NAT-EVEROLIMUS"",
  ""medicinal_ingredients"": ""Everolimus / Évérolimus"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02530090, Oral / Orale, Tablet / Comprimé, 2.5 mg; 02530104, Oral / Orale, Tablet / Comprimé, 5 mg; 02530112, Oral / Orale, Tablet / Comprimé, 7.5 mg; 02530120, Oral / Orale, Tablet / Comprimé, 10 mg"",
  ""canadian_reference_product"": ""AFINITOR, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General / Directeur général par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e203827,251033,"August 29, 2022",NAT-EVEROLIMUS,Everolimus / Évérolimus,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02530090, Oral / Orale, Tablet / Comprimé, 2.5 mg; 02530104, Oral / Orale, Tablet / Comprimé, 5 mg; 02530112, Oral / Orale, Tablet / Comprimé, 7.5 mg; 02530120, Oral / Orale, Tablet / Comprimé, 10 mg","AFINITOR, Novartis Pharmaceuticals Canada Inc., Canada",Natco Pharma (Canada) Inc.,"2000 Argentia Road, Plaza 1, Suite 200",Mississauga,Ontario,Canada,L5N 1P7,Melissa Hunt,Acting Director General / Directeur général par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037382.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""263895"",
  ""submission_no"": ""263895"",
  ""manufacturer"": {
    ""name"": ""Merck Canada Inc."",
    ""street"": ""16750 Route Transcanadienne"",
    ""city"": ""Kirkland"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""September 14, 2022"",
  ""product_name"": ""Keytruda"",
  ""medicinal_ingredients"": ""Pembrolizumab"",
  ""reason_for_submission"": ""Product Monograph update / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 25 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Celia Lourenco, Ph.D."",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,263895,263895,"September 14, 2022",Keytruda,Pembrolizumab,Product Monograph update / Mise à jour de la monographie de produit,,"N/A, IV, SOL, 25 mg / mL",,Merck Canada Inc.,16750 Route Transcanadienne,Kirkland,Quebec,Canada,H9H 4M7,"Celia Lourenco, Ph.D.",Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000037486.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e265050"",
  ""submission_no"": ""265050"",
  ""manufacturer"": {
    ""name"": ""Mantra Pharma Inc."",
    ""street"": ""9150 Leduc Blvd., Suite 201"",
    ""city"": ""Brossard"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4Y 0E3""
  },
  ""date"": ""September 20, 2022"",
  ""product_name"": ""M-APIXABAN"",
  ""medicinal_ingredients"": ""Apixaban"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02529009, oral / orale, tablet / comprimé, 2.5 mg; 02529017, oral / orale, tablet / comprimé, 5 mg"",
  ""canadian_reference_product"": ""ELIQUIS, Bristol-Myers Squibb Canada, Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e265050,265050,"September 20, 2022",M-APIXABAN,Apixaban,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02529009, oral / orale, tablet / comprimé, 2.5 mg; 02529017, oral / orale, tablet / comprimé, 5 mg","ELIQUIS, Bristol-Myers Squibb Canada, Canada",Mantra Pharma Inc.,"9150 Leduc Blvd., Suite 201",Brossard,Quebec,Canada,J4Y 0E3,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037493.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e124878"",
  ""submission_no"": ""260911"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": """",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""September 22, 2022"",
  ""product_name"": ""APO-DICLO and APO-DICLO SR"",
  ""medicinal_ingredients"": ""Diclofenac Sodium / Diclofenac sodique"",
  ""reason_for_submission"": ""Update to the Product Monograph as per Advisement Letter"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 25 mg; N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 50 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 75 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e124878,260911,"September 22, 2022",APO-DICLO and APO-DICLO SR,Diclofenac Sodium / Diclofenac sodique,Update to the Product Monograph as per Advisement Letter,,"N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 25 mg; N/A, Oral / Orale, Tablet (Enteric-Coated) / Comprimé (entérosoluble), 50 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 75 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 100 mg",,Apotex Inc.,150 Signet Drive,Toronto,Ontario,,M9L 1T9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000037656.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e139311"",
  ""submission_no"": ""267374"",
  ""manufacturer"": {
    ""name"": ""Sanis Health Inc."",
    ""street"": ""1 President’s Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""October 4, 2022"",
  ""product_name"": ""SERTRALINE"",
  ""medicinal_ingredients"": ""Sertraline supplied as Sertraline Hydrochloride"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, capsule, 25 mg; N/A, oral / orale, capsule, 50 mg; N/A, oral / orale, capsule, 100 mg"",
  ""canadian_reference_product"": ""Zoloft, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e139311,267374,"October 4, 2022",SERTRALINE,Sertraline supplied as Sertraline Hydrochloride,Administrative: Labelling Update (to Match Licensor),,"N/A, oral / orale, capsule, 25 mg; N/A, oral / orale, capsule, 50 mg; N/A, oral / orale, capsule, 100 mg","Zoloft, Pfizer Canada Inc., Canada",Sanis Health Inc.,1 President’s Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037791.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e136813"",
  ""submission_no"": ""264069"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L9""
  },
  ""date"": ""October 7, 2022"",
  ""product_name"": ""SPORANOX"",
  ""medicinal_ingredients"": ""Itraconazole"",
  ""reason_for_submission"": ""Updates to the Product Monograph (PM) with drug-drug interactions and PM conversion to the 2020 master template."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Capsule, 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e136813,264069,"October 7, 2022",SPORANOX,Itraconazole,Updates to the Product Monograph (PM) with drug-drug interactions and PM conversion to the 2020 master template.,,"N/A, Oral/Orale, Capsule, 100 mg",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M3C 1L9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037824.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e132233"",
  ""submission_no"": ""264359"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""October 20, 2022"",
  ""product_name"": ""ACT CLOPIDOGREL"",
  ""medicinal_ingredients"": ""Clopidogrel (as Clopidogrel Bisulfate) / Clopidogrel (sous forme de bisulfate de clopidogrel)"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie du produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 75 mg"",
  ""canadian_reference_product"": ""PLAVIX, Sanofi-Synthelabo., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e132233,264359,"October 20, 2022",ACT CLOPIDOGREL,Clopidogrel (as Clopidogrel Bisulfate) / Clopidogrel (sous forme de bisulfate de clopidogrel),Update to the Product Monograph / Mise à jour de la monographie du produit,,"N/A, Oral / Orale, Tablet / Comprimé, 75 mg","PLAVIX, Sanofi-Synthelabo., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000037896.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v159938"",
  ""submission_no"": ""262863"",
  ""manufacturer"": {
    ""name"": ""Intervet Canada Corp"",
    ""street"": ""16750 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""October 26, 2022"",
  ""product_name"": ""BRAVECTO"",
  ""medicinal_ingredients"": ""Fluralaner / Fluralaner"",
  ""reason_for_submission"": ""Addition of an alternate pork liver flavour excipient supplier / Ajout du fournisseur alternatif d’excipients d’arôme de foie de porc"",
  ""species"": ""Dogs / Chiens"",
  ""drug_identification_number_route_form_strength"": ""02425068, Oral, Chewable Tablet, 112.5 mg/tab / 02425068, Orale, Comprimé à croquer, 112.5 mg/tab; 02425076, Oral, Chewable Tablet, 250 mg/tab / 02425076, Orale, Comprimé à croquer, 250 mg/tab; 02425084, Oral, Chewable Tablet, 500 mg/tab / 02425084, Orale, Comprimé à croquer, 500 mg/tab; 02425092, Oral, Chewable Tablet, 1000 mg/tab / 02425092, Orale, Comprimé à croquer, 1000 mg/tab; 02425106, Oral, Chewable Tablet, 1400 mg/tab / 02425106, Orale, Comprimé à croquer, 1400 mg/tab"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v159938,262863,"October 26, 2022",BRAVECTO,Fluralaner / Fluralaner,Addition of an alternate pork liver flavour excipient supplier / Ajout du fournisseur alternatif d’excipients d’arôme de foie de porc,Dogs / Chiens,"02425068, Oral, Chewable Tablet, 112.5 mg/tab / 02425068, Orale, Comprimé à croquer, 112.5 mg/tab; 02425076, Oral, Chewable Tablet, 250 mg/tab / 02425076, Orale, Comprimé à croquer, 250 mg/tab; 02425084, Oral, Chewable Tablet, 500 mg/tab / 02425084, Orale, Comprimé à croquer, 500 mg/tab; 02425092, Oral, Chewable Tablet, 1000 mg/tab / 02425092, Orale, Comprimé à croquer, 1000 mg/tab; 02425106, Oral, Chewable Tablet, 1400 mg/tab / 02425106, Orale, Comprimé à croquer, 1400 mg/tab",,Intervet Canada Corp,16750 Trans Canada Highway,Kirkland,QC,Canada,H9H 4M7,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000038152.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e124319"",
  ""submission_no"": ""263071"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""November 16, 2022"",
  ""product_name"": ""SANDOZ ANASTROZOLE"",
  ""medicinal_ingredients"": ""Anastrozole / Anastrozole"",
  ""reason_for_submission"": ""Addition of manufacturing site of the drug substance / Ajout d'un site de fabrication de la substance médicamenteuse"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 1 mg"",
  ""canadian_reference_product"": ""ARIMIDEX, AstraZeneca UK Ltd., France"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e124319,263071,"November 16, 2022",SANDOZ ANASTROZOLE,Anastrozole / Anastrozole,Addition of manufacturing site of the drug substance / Ajout d'un site de fabrication de la substance médicamenteuse,,"N/A, Oral / Orale, Tablet / Comprimé, 1 mg","ARIMIDEX, AstraZeneca UK Ltd., France",Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000038201.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e157025"",
  ""submission_no"": ""264971"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Ave. West, Suite # 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""November 17, 2022"",
  ""product_name"": ""AURO-CLOPIDOGREL"",
  ""medicinal_ingredients"": ""Clopidogrel (supplied as Clopidogrel Bisulfate) / (forme comme Bisulfate de clopidogrel)"",
  ""reason_for_submission"": ""Update to The Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 75 mg"",
  ""canadian_reference_product"": ""PLAVIX by Sanofi-Aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e157025,264971,"November 17, 2022",AURO-CLOPIDOGREL,Clopidogrel (supplied as Clopidogrel Bisulfate) / (forme comme Bisulfate de clopidogrel),Update to The Product Monograph / Mise à jour de la monographie de produit,,"N/A, Oral/Orale, Tablet/Comprimé, 75 mg","PLAVIX by Sanofi-Aventis Canada Inc., Canada",Auro Pharma Inc.,"3700 Steeles Ave. West, Suite # 402",Woodbridge,Ontario,Canada,L4L 8K8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000038237.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e170837"",
  ""submission_no"": ""265069"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""November 24, 2022"",
  ""product_name"": ""APO-DARIFENACIN"",
  ""medicinal_ingredients"": ""Darifenacin (as darifenacin hydrobromide) / Darifénacine (forme comme bromhydrate de darifénacine)"",
  ""reason_for_submission"": ""Update to Labels / Mise à jour des étiquettes Update to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 7.5 mg N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 15 mg"",
  ""canadian_reference_product"": ""ENABLEX, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e170837,265069,"November 24, 2022",APO-DARIFENACIN,Darifenacin (as darifenacin hydrobromide) / Darifénacine (forme comme bromhydrate de darifénacine),Update to Labels / Mise à jour des étiquettes Update to the Package Insert / Mise à jour de l'encart,,"N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 7.5 mg N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 15 mg","ENABLEX, Novartis Pharmaceuticals Canada Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000038252.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e190063"",
  ""submission_no"": ""269353"",
  ""manufacturer"": {
    ""name"": ""Pro Doc Ltée"",
    ""street"": ""2925 boul. Industriel"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7L 3W9""
  },
  ""date"": ""November 22, 2022"",
  ""product_name"": ""OMEPRAZOLE"",
  ""medicinal_ingredients"": ""Omeprazole / Oméprazole"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, capsule (delayed release) / capsule (à libération retardée), 20 mg"",
  ""canadian_reference_product"": ""Losec, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e190063,269353,"November 22, 2022",OMEPRAZOLE,Omeprazole / Oméprazole,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, capsule (delayed release) / capsule (à libération retardée), 20 mg","Losec, AstraZeneca Canada Inc., Canada",Pro Doc Ltée,2925 boul. Industriel,Laval,Quebec,Canada,H7L 3W9,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000038271.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e205052"",
  ""submission_no"": ""255298"",
  ""manufacturer"": {
    ""name"": ""Marcan Pharmaceuticals Inc."",
    ""street"": ""2 Gurdwara Road, Suite # 112"",
    ""city"": ""Ottawa"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""K2E 1A2""
  },
  ""date"": ""November 25, 2022"",
  ""product_name"": ""MAR-CINACALCET"",
  ""medicinal_ingredients"": ""Cinacalcet (supplied as Cinacalcet Hydrochloride) / Cinacalcet (sous forme de chlorhydrate de Cinacalcet)"",
  ""reason_for_submission"": ""Addition of a manufacturing site of the drug substance / Ajout d'un site de fabrication de la substance médicamenteuse"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 30 mg; N/A, Oral / Orale, Tablet / Comprimé, 60 mg; N/A, Oral / Orale, Tablet / Comprimé, 90 mg"",
  ""canadian_reference_product"": ""SENSIPAR, Amgen Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e205052,255298,"November 25, 2022",MAR-CINACALCET,Cinacalcet (supplied as Cinacalcet Hydrochloride) / Cinacalcet (sous forme de chlorhydrate de Cinacalcet),Addition of a manufacturing site of the drug substance / Ajout d'un site de fabrication de la substance médicamenteuse,,"N/A, Oral / Orale, Tablet / Comprimé, 30 mg; N/A, Oral / Orale, Tablet / Comprimé, 60 mg; N/A, Oral / Orale, Tablet / Comprimé, 90 mg","SENSIPAR, Amgen Canada Inc., Canada",Marcan Pharmaceuticals Inc.,"2 Gurdwara Road, Suite # 112",Ottawa,Ontario,Canada,K2E 1A2,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000038382.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e172769"",
  ""submission_no"": ""269424"",
  ""manufacturer"": {
    ""name"": ""Laboratoire Riva Inc."",
    ""street"": ""660, boul. Industriel"",
    ""city"": ""Blainville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7C 3V4""
  },
  ""date"": ""November 30, 2022"",
  ""product_name"": ""RIVA-ATORVASTATIN"",
  ""medicinal_ingredients"": ""Atorvastatin supplied as Atorvastatin Calcium / Atorvastatine sous forme d'atorvastatine calcique"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02422751, oral / orale, tablet / comprimé, 10 mg; 02422778, oral / orale, tablet / comprimé, 20 mg; 02422786, oral / orale, tablet / comprimé, 40 mg; 02422794, oral / orale, tablet / comprimé, 80 mg"",
  ""canadian_reference_product"": ""Lipitor, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e172769,269424,"November 30, 2022",RIVA-ATORVASTATIN,Atorvastatin supplied as Atorvastatin Calcium / Atorvastatine sous forme d'atorvastatine calcique,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02422751, oral / orale, tablet / comprimé, 10 mg; 02422778, oral / orale, tablet / comprimé, 20 mg; 02422786, oral / orale, tablet / comprimé, 40 mg; 02422794, oral / orale, tablet / comprimé, 80 mg","Lipitor, Pfizer Canada Inc., Canada",Laboratoire Riva Inc.,"660, boul. Industriel",Blainville,Quebec,Canada,J7C 3V4,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000038414.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e233002"",
  ""submission_no"": ""259796"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 5M8""
  },
  ""date"": ""December 7, 2022"",
  ""product_name"": ""EVRYSDI"",
  ""medicinal_ingredients"": ""Risdiplam / Risdiplam"",
  ""reason_for_submission"": ""Update to the Product Monograph."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Powder for Solution/Poudre pour solution, .75 mg / ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e233002,259796,"December 7, 2022",EVRYSDI,Risdiplam / Risdiplam,Update to the Product Monograph.,,"N/A, Oral/Orale, Powder for Solution/Poudre pour solution, .75 mg / ml",,Hoffmann-La Roche Limited,7070 Mississauga Road,Mississauga,Ontario,Canada,L5N 5M8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000038681.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e269891"",
  ""submission_no"": ""269891"",
  ""manufacturer"": {
    ""name"": ""Angita Pharma Inc."",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""January 3, 2023"",
  ""product_name"": ""AG-ANASTROZOLE"",
  ""medicinal_ingredients"": ""Anastrozole"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02534118, oral / orale, tablet / comprimé, 1 mg"",
  ""canadian_reference_product"": ""Arimidex, AstraZeneca Pharmaceuticals LP, USA"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e269891,269891,"January 3, 2023",AG-ANASTROZOLE,Anastrozole,Administrative: Licensing Agreement Between Two Companies / Administratif: Accord de licence entre deux sociétés,,"02534118, oral / orale, tablet / comprimé, 1 mg","Arimidex, AstraZeneca Pharmaceuticals LP, USA",Angita Pharma Inc.,1310 rue Nobel,Boucherville,Quebec,Canada,J4B 5H3,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000038833.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e185943"",
  ""submission_no"": ""266686"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""January 16, 2023"",
  ""product_name"": ""TRANEXAMIC ACID INJECTION"",
  ""medicinal_ingredients"": ""Tranexamic Acid / Acide tranexamique"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit\nProduct Monograph reformatted to the Master Template / Remise en forme de la monographie de produit selon le modèle principal\nUpdate to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous / Intraveineuse, Solution, 100 mg/mL"",
  ""canadian_reference_product"": ""CYKLOKAPRON, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e185943,266686,"January 16, 2023",TRANEXAMIC ACID INJECTION,Tranexamic Acid / Acide tranexamique,"Update to the Product Monograph / Mise à jour de la monographie de produit
Product Monograph reformatted to the Master Template / Remise en forme de la monographie de produit selon le modèle principal
Update to the Package Insert / Mise à jour de l'encart",,"N/A, Intravenous / Intraveineuse, Solution, 100 mg/mL","CYKLOKAPRON, Pfizer Canada Inc., Canada",Auro Pharma Inc.,"3700 Steeles Avenue West, Suite 402",Woodbridge,Ontario,Canada,L4L 8K8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000039091.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e220439"",
  ""submission_no"": ""271223"",
  ""manufacturer"": {
    ""name"": ""Altamed Pharma"",
    ""street"": ""1565, boul. Lionel-Boulet"",
    ""city"": ""Varennes"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J3X 1P7""
  },
  ""date"": ""February 6, 2023"",
  ""product_name"": ""DULOXETINE"",
  ""medicinal_ingredients"": ""Duloxetine supplied as Duloxetine Hydrochloride / Duloxétine sous forme de chlorhydrate de duloxétine"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02481952, oral / orale, capsule (delayed release) / capsule (à libération retardée), 30 mg; 02481960, oral / orale, capsule (delayed release) / capsule (à libération retardée), 60 mg"",
  ""canadian_reference_product"": ""Cymbalta, Eli Lilly Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e220439,271223,"February 6, 2023",DULOXETINE,Duloxetine supplied as Duloxetine Hydrochloride / Duloxétine sous forme de chlorhydrate de duloxétine,Administrative: Labelling Update (to Match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"02481952, oral / orale, capsule (delayed release) / capsule (à libération retardée), 30 mg; 02481960, oral / orale, capsule (delayed release) / capsule (à libération retardée), 60 mg","Cymbalta, Eli Lilly Canada Inc., Canada",Altamed Pharma,"1565, boul. Lionel-Boulet",Varennes,Quebec,Canada,J3X 1P7,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000039113.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""261020"",
  ""submission_no"": ""261020"",
  ""manufacturer"": {
    ""name"": ""Sanofi Pasteur Limited"",
    ""street"": ""1755 Steeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2R 3T4""
  },
  ""date"": ""February 9, 2023"",
  ""product_name"": ""PENTACEL"",
  ""medicinal_ingredients"": ""Pertussis toxoid / anatoxine coquelucheuse, filamentous haemagglutinin / hémagglutinine filamenteuse, pertactin / pertactine, fimbriae types 2 and 3 / Fimbriae de types 2 et 3, diphtheria toxoid / anatoxine diphtérique, tetanus toxoid / anatoxine tétanique, Haemophilus type b polysaccharide / haemophilus influenzae de type B, tetanus protein / protéine tétanique, inactivated poliomyelitis vaccine type 1 (Mahoney), Type 2 (M.E.F.1), Type 3 (Saukett) / vaccin antipoliomyélitique inactivé de type 1 (Mahoney), Type 2 (M.E.F.1), Type 3 (Saukett)"",
  ""reason_for_submission"": ""Change in formulation / Changement à la formulation Additional facility for filling and packaging of the drug product / Site additionnel pour l’emballage et le remplissage du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02534797, IM, SUS, 20 µg / 0.5 mL pertussis toxoid / anatoxine coquelucheuse, 20 µg / 0.5 mL filamentous haemagglutinin / hémagglutinine filamenteuse, 3 µg / 0.5 mL pertactin / pertactine, 5 µg / 0.5 mL, fimbriae types 2 and 3 / fimbriae de types 2 et 3, 15 Lf / 0.5 mL diphtheria toxoid / anatoxine diphtérique, 5 Lf / 0.5 mL tetanus toxoid / anatoxine tétanique, 10 µg / 0.5 mL Haemophilus type b polysaccharide / haemophilus influenzae type B; 18-30 µg / 0.5 mL tetanus protein / protéine tétanique, inactivated poliomyelitis vaccine / vaccin inactivé contre la poliomyélite: 29 DU / 0.5 mL type 1 (Mahoney), 7 DU / 0.5 mL Type 2 (M.E.F.1), 26 DU / 0.5 mL Type 3 (Saukett)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Michael Rosu-Myles, Ph.D."",
    ""title"": ""Acting Director General / Directeur général par intérim"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,261020,261020,"February 9, 2023",PENTACEL,"Pertussis toxoid / anatoxine coquelucheuse, filamentous haemagglutinin / hémagglutinine filamenteuse, pertactin / pertactine, fimbriae types 2 and 3 / Fimbriae de types 2 et 3, diphtheria toxoid / anatoxine diphtérique, tetanus toxoid / anatoxine tétanique, Haemophilus type b polysaccharide / haemophilus influenzae de type B, tetanus protein / protéine tétanique, inactivated poliomyelitis vaccine type 1 (Mahoney), Type 2 (M.E.F.1), Type 3 (Saukett) / vaccin antipoliomyélitique inactivé de type 1 (Mahoney), Type 2 (M.E.F.1), Type 3 (Saukett)",Change in formulation / Changement à la formulation Additional facility for filling and packaging of the drug product / Site additionnel pour l’emballage et le remplissage du produit médicamenteux,,"02534797, IM, SUS, 20 µg / 0.5 mL pertussis toxoid / anatoxine coquelucheuse, 20 µg / 0.5 mL filamentous haemagglutinin / hémagglutinine filamenteuse, 3 µg / 0.5 mL pertactin / pertactine, 5 µg / 0.5 mL, fimbriae types 2 and 3 / fimbriae de types 2 et 3, 15 Lf / 0.5 mL diphtheria toxoid / anatoxine diphtérique, 5 Lf / 0.5 mL tetanus toxoid / anatoxine tétanique, 10 µg / 0.5 mL Haemophilus type b polysaccharide / haemophilus influenzae type B; 18-30 µg / 0.5 mL tetanus protein / protéine tétanique, inactivated poliomyelitis vaccine / vaccin inactivé contre la poliomyélite: 29 DU / 0.5 mL type 1 (Mahoney), 7 DU / 0.5 mL Type 2 (M.E.F.1), 26 DU / 0.5 mL Type 3 (Saukett)",,Sanofi Pasteur Limited,1755 Steeles Avenue West,Toronto,ON,Canada,M2R 3T4,"Michael Rosu-Myles, Ph.D.",Acting Director General / Directeur général par intérim,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000039204.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e234814"",
  ""submission_no"": ""234814"",
  ""manufacturer"": {
    ""name"": ""Dr. Reddy's Laboratories Limited"",
    ""street"": ""Survey Nos. 42, 45, 46 & 54, Bachupally"",
    ""city"": ""Quthbullapur"",
    ""province"": ""Hyderabad, Telangana"",
    ""country"": ""India"",
    ""postal_code"": ""500090""
  },
  ""date"": ""February 20, 2023"",
  ""product_name"": ""REDDY-POMALIDOMIDE"",
  ""medicinal_ingredients"": ""Pomalidomide"",
  ""reason_for_submission"": ""abbreviated new drug submission"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": [
    ""02504073, Oral / Orale, Capsule / Capsule, 1 mg"",
    ""02504081, Oral / Orale, Capsule / Capsule, 2 mg"",
    ""02504103, Oral / Orale, Capsule / Capsule, 3 mg"",
    ""02504111, Oral / Orale, Capsule / Capsule, 4 mg""
  ],
  ""canadian_reference_product"": ""POMALYST, Celgene Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e234814,234814,"February 20, 2023",REDDY-POMALIDOMIDE,Pomalidomide,abbreviated new drug submission,,"02504073, Oral / Orale, Capsule / Capsule, 1 mg | 02504081, Oral / Orale, Capsule / Capsule, 2 mg | 02504103, Oral / Orale, Capsule / Capsule, 3 mg | 02504111, Oral / Orale, Capsule / Capsule, 4 mg","POMALYST, Celgene Inc., Canada",Dr. Reddy's Laboratories Limited,"Survey Nos. 42, 45, 46 & 54, Bachupally",Quthbullapur,"Hyderabad, Telangana",India,500090,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000039234.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e117576"",
  ""submission_no"": ""264700"",
  ""manufacturer"": {
    ""name"": ""Lantheus MI Canada Inc."",
    ""street"": ""1111 Dr. Frederik-Philips Blvd., Suite 600"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4M 2X6""
  },
  ""date"": ""February 17, 2023"",
  ""product_name"": ""DEFINITY"",
  ""medicinal_ingredients"": ""Perflutren / Perflutrène"",
  ""reason_for_submission"": ""A new drug product manufacturing site and a change in the drug product manufacturing process."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous/Intraveineuse, Suspension, 150 mcl/ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e117576,264700,"February 17, 2023",DEFINITY,Perflutren / Perflutrène,A new drug product manufacturing site and a change in the drug product manufacturing process.,,"N/A, Intravenous/Intraveineuse, Suspension, 150 mcl/ml",,Lantheus MI Canada Inc.,"1111 Dr. Frederik-Philips Blvd., Suite 600",Montreal,Quebec,Canada,H4M 2X6,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000039240.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e153082"",
  ""submission_no"": ""267700"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave., Suite 100"",
    ""city"": ""Montréal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""February 22, 2023"",
  ""product_name"": ""PMS-NIFEDIPINE ER"",
  ""medicinal_ingredients"": ""Nifedipine / Nifédipine"",
  ""reason_for_submission"": ""Update to labels to align with Plain Language Labelling Regulations / Mise à jour de l'étiquetage devant respecter les exigence de l'étiquetage en langage clair"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 20 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 30 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 60 mg"",
  ""canadian_reference_product"": ""ADALAT XL, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e153082,267700,"February 22, 2023",PMS-NIFEDIPINE ER,Nifedipine / Nifédipine,Update to labels to align with Plain Language Labelling Regulations / Mise à jour de l'étiquetage devant respecter les exigence de l'étiquetage en langage clair,,"N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 20 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 30 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 60 mg","ADALAT XL, Bayer Inc., Canada",Pharmascience Inc.,"6111 Royalmount Ave., Suite 100",Montréal,Québec,Canada,H4P 2T4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000039388.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e144767"",
  ""submission_no"": ""272254"",
  ""manufacturer"": {
    ""name"": ""Sante Health Inc."",
    ""street"": ""1 President's Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""March 7, 2023"",
  ""product_name"": ""SIMVASTATIN"",
  ""medicinal_ingredients"": ""Simvastatin / Simvastatine"",
  ""reason_for_submission"": ""Administrative: Labeling Update (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 5 mg\nN/A, oral / orale, tablet / comprimé, 10 mg\nN/A, oral / orale, tablet / comprimé, 20 mg\nN/A, oral / orale, tablet / comprimé, 40 mg\nN/A, oral / orale, tablet / comprimé, 80 mg"",
  ""canadian_reference_product"": ""ZOCOR, Merck Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Laura Durno, MSc"",
    ""title"": ""A/Director / Directrice par intérim"",
    ""division"": ""Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e144767,272254,"March 7, 2023",SIMVASTATIN,Simvastatin / Simvastatine,Administrative: Labeling Update (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),N/A,"N/A, oral / orale, tablet / comprimé, 5 mg
N/A, oral / orale, tablet / comprimé, 10 mg
N/A, oral / orale, tablet / comprimé, 20 mg
N/A, oral / orale, tablet / comprimé, 40 mg
N/A, oral / orale, tablet / comprimé, 80 mg","ZOCOR, Merck Canada Inc., Canada",Sante Health Inc.,1 President's Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,"Laura Durno, MSc",A/Director / Directrice par intérim,"Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales",Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000039431.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e259748"",
  ""submission_no"": ""259748"",
  ""manufacturer"": {
    ""name"": ""Accord Healthcare Inc."",
    ""street"": ""3535 Boulevard St. Charles, Suite 704"",
    ""city"": ""Kirkland"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 5B9""
  },
  ""date"": ""March 9, 2023"",
  ""product_name"": ""ACH-FESOTERODINE"",
  ""medicinal_ingredients"": ""Fesoterodine Fumarate / Fumarate de fésotérodine"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02535998, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 4 mg; 02536005, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 8 mg"",
  ""canadian_reference_product"": ""TOVIAZ, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e259748,259748,"March 9, 2023",ACH-FESOTERODINE,Fesoterodine Fumarate / Fumarate de fésotérodine,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02535998, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 4 mg; 02536005, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 8 mg","TOVIAZ, Pfizer Canada Inc., Canada",Accord Healthcare Inc.,"3535 Boulevard St. Charles, Suite 704",Kirkland,Québec,Canada,H9H 5B9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000039547.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e106525"",
  ""submission_no"": ""269764"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""March 23, 2023"",
  ""product_name"": ""APO-SUMATRIPTAN"",
  ""medicinal_ingredients"": ""Sumatriptan (supplied as sumatriptan hemisulfate) / Sumatriptan (sous forme d'hémisulfate de sumatriptan)"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit\nUpdate to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Nasal / Nasale, Spray / Pulvérisation, 5 mg\nN/A, Nasal / Nasale, Spray / Pulvérisation, 20 mg"",
  ""canadian_reference_product"": ""IMITREX, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e106525,269764,"March 23, 2023",APO-SUMATRIPTAN,Sumatriptan (supplied as sumatriptan hemisulfate) / Sumatriptan (sous forme d'hémisulfate de sumatriptan),"Update to the Product Monograph / Mise à jour de la monographie de produit
Update to the Package Insert / Mise à jour de l'encart",,"N/A, Nasal / Nasale, Spray / Pulvérisation, 5 mg
N/A, Nasal / Nasale, Spray / Pulvérisation, 20 mg","IMITREX, GlaxoSmithKline Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000039617.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e222951"",
  ""submission_no"": ""267547"",
  ""manufacturer"": {
    ""name"": ""Hoffmann-La Roche Limited"",
    ""street"": ""7070 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 5M8""
  },
  ""date"": ""March 27, 2023"",
  ""product_name"": ""XOFLUZA"",
  ""medicinal_ingredients"": ""Baloxavir Marboxil"",
  ""reason_for_submission"": ""Addition of a drug product manufacturer. Change in the drug product manufacturing process."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 80 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e222951,267547,"March 27, 2023",XOFLUZA,Baloxavir Marboxil,Addition of a drug product manufacturer. Change in the drug product manufacturing process.,,"N/A, Oral/Orale, Tablet/Comprimé, 80 mg",,Hoffmann-La Roche Limited,7070 Mississauga Road,Mississauga,Ontario,Canada,L5N 5M8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000039929.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e241709"",
  ""submission_no"": ""274031"",
  ""manufacturer"": {
    ""name"": ""Sanie Health Inc."",
    ""street"": ""1 President's Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""April 28, 2023"",
  ""product_name"": ""MATINIB"",
  ""medicinal_ingredients"": ""Imatinib supplied as Imatinib Mesylate / sous forme de méylate d'imatinib"",
  ""reason_for_submission"": ""Administrative Labeling Update (to match License) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 100 mg / 400 mg"",
  ""canadian_reference_product"": ""Gleevec, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Laura Durno, MSc"",
    ""title"": ""A/Director / Directrice par intérim"",
    ""division"": ""Bureau de Gastroentérologie, Infection et Maladies Infectieuses et Virales"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e241709,274031,"April 28, 2023",MATINIB,Imatinib supplied as Imatinib Mesylate / sous forme de méylate d'imatinib,Administrative Labeling Update (to match License) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),N/A,"N/A, oral / orale, tablet / comprimé, 100 mg / 400 mg","Gleevec, Novartis Pharmaceuticals Canada Inc., Canada",Sanie Health Inc.,1 President's Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,"Laura Durno, MSc",A/Director / Directrice par intérim,"Bureau de Gastroentérologie, Infection et Maladies Infectieuses et Virales",Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000040061.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e142626"",
  ""submission_no"": ""269955"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""May 5, 2023"",
  ""product_name"": ""TEVA-SERTRALINE"",
  ""medicinal_ingredients"": ""Sertraline HCL (sertraline as sertraline hydrochloride)"",
  ""reason_for_submission"": ""Safety updates to the product monograph / Mise à jour de l'innocuité dans la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Capsule, 25 mg; N/A, Oral / Orale, Capsule, 50 mg; N/A, Oral / Orale, Capsule, 100 mg"",
  ""canadian_reference_product"": ""Zoloft, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Leslie Vrooman, M.Sc."",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e142626,269955,"May 5, 2023",TEVA-SERTRALINE,Sertraline HCL (sertraline as sertraline hydrochloride),Safety updates to the product monograph / Mise à jour de l'innocuité dans la monographie de produit,,"N/A, Oral / Orale, Capsule, 25 mg; N/A, Oral / Orale, Capsule, 50 mg; N/A, Oral / Orale, Capsule, 100 mg","Zoloft, Pfizer Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,"Leslie Vrooman, M.Sc.",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000040126.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e235155"",
  ""submission_no"": ""270525"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave, Suite 100"",
    ""city"": ""Montréal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""May 12, 2023"",
  ""product_name"": ""DIACETYLMORPHINE HYDROCHLORIDE"",
  ""medicinal_ingredients"": ""Diamorphine hydrochloride / Chlorhydrate de diamorphine"",
  ""reason_for_submission"": ""Labelling update on the reconstitution of the product"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intramuscular, Intravenous/ Intramusculaire, Intraveineuse, Powder for solution/ Poudre pour solution, 200 mg / Vial; N/A, Intramuscular, Intravenous/ Intramusculaire, Intraveineuse, Powder for solution/ Poudre pour solution, 5 g / Vial"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e235155,270525,"May 12, 2023",DIACETYLMORPHINE HYDROCHLORIDE,Diamorphine hydrochloride / Chlorhydrate de diamorphine,Labelling update on the reconstitution of the product,,"N/A, Intramuscular, Intravenous/ Intramusculaire, Intraveineuse, Powder for solution/ Poudre pour solution, 200 mg / Vial; N/A, Intramuscular, Intravenous/ Intramusculaire, Intraveineuse, Powder for solution/ Poudre pour solution, 5 g / Vial",,Pharmascience Inc.,"6111 Royalmount Ave, Suite 100",Montréal,Québec,Canada,H4P 2T4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000040238.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e131247"",
  ""submission_no"": ""270394"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""May 25, 2023"",
  ""product_name"": ""APO-METOPROLOL (Type L)"",
  ""medicinal_ingredients"": ""Metoprolol tartrate / Tartrate de métoprolol"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit\nUpdate to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 25 mg\nN/A, Oral / Orale, Tablet / Comprimé, 50 mg\nN/A, Oral / Orale, Tablet / Comprimé, 100 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e131247,270394,"May 25, 2023",APO-METOPROLOL (Type L),Metoprolol tartrate / Tartrate de métoprolol,"Update to the Product Monograph / Mise à jour de la monographie de produit
Update to the Package Insert / Mise à jour de l'encart",,"N/A, Oral / Orale, Tablet / Comprimé, 25 mg
N/A, Oral / Orale, Tablet / Comprimé, 50 mg
N/A, Oral / Orale, Tablet / Comprimé, 100 mg",,Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000040456.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e180156"",
  ""submission_no"": ""271947"",
  ""manufacturer"": {
    ""name"": ""SteriMax Inc."",
    ""street"": ""2770 Portland Dr."",
    ""city"": ""Oakville"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6H 6R4""
  },
  ""date"": ""June 6, 2023"",
  ""product_name"": ""BUPIVACAINE INJECTION BP"",
  ""medicinal_ingredients"": ""Bupivacaine Hydrochloride / Chlorhydrate de bupivacaïne"",
  ""reason_for_submission"": ""Update to Labels / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Block/Infiltration / Bloc/Infiltration, Epidural / Épidurale, Solution, 2.5 mg/mL; N/A, Block/Infiltration / Bloc/Infiltration, Epidural / Épidurale, Solution, 5 mg/mL"",
  ""canadian_reference_product"": ""SENSORCAINE, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e180156,271947,"June 6, 2023",BUPIVACAINE INJECTION BP,Bupivacaine Hydrochloride / Chlorhydrate de bupivacaïne,Update to Labels / Mise à jour des étiquettes,,"N/A, Block/Infiltration / Bloc/Infiltration, Epidural / Épidurale, Solution, 2.5 mg/mL; N/A, Block/Infiltration / Bloc/Infiltration, Epidural / Épidurale, Solution, 5 mg/mL","SENSORCAINE, AstraZeneca Canada Inc., Canada",SteriMax Inc.,2770 Portland Dr.,Oakville,Ontario,Canada,L6H 6R4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000040475.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e119553"",
  ""submission_no"": ""267551"",
  ""manufacturer"": {
    ""name"": ""Fresenius Kabi Canada Ltd."",
    ""street"": ""165 Galaxy Blvd, Suite 100"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9W 0C8""
  },
  ""date"": ""June 9, 2023"",
  ""product_name"": ""TOBRAMYCIN FOR INJECTION"",
  ""medicinal_ingredients"": ""Tobramycin (supplied as Tobramycin Sulfate) / Tobramycine (sous forme de Sulfate de Tobramycine)"",
  ""reason_for_submission"": ""Change in specification for the drug substance"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous/Intraveineuse, Powder for Solution/Poudre pour solution, 1.2 g / vial/fiole"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e119553,267551,"June 9, 2023",TOBRAMYCIN FOR INJECTION,Tobramycin (supplied as Tobramycin Sulfate) / Tobramycine (sous forme de Sulfate de Tobramycine),Change in specification for the drug substance,,"N/A, Intravenous/Intraveineuse, Powder for Solution/Poudre pour solution, 1.2 g / vial/fiole",,Fresenius Kabi Canada Ltd.,"165 Galaxy Blvd, Suite 100",Toronto,Ontario,Canada,M9W 0C8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000040572.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e263078"",
  ""submission_no"": ""263078"",
  ""manufacturer"": {
    ""name"": ""Natco Pharma (Canada) Inc."",
    ""street"": ""2000 Argentia Road, Plaza 1, Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 1P7""
  },
  ""date"": ""June 27, 2023"",
  ""product_name"": ""NAT-ERIBULIN"",
  ""medicinal_ingredients"": ""Eribulin Mesylate / Mésylate d'Éribuline"",
  ""reason_for_submission"": ""abbreviated new drug submission"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02539136, Intravenous / Intraveineuse, Solution, 0.5 mg/mL"",
  ""canadian_reference_product"": ""HALAVEN, Eisai Limited, Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e263078,263078,"June 27, 2023",NAT-ERIBULIN,Eribulin Mesylate / Mésylate d'Éribuline,abbreviated new drug submission,,"02539136, Intravenous / Intraveineuse, Solution, 0.5 mg/mL","HALAVEN, Eisai Limited, Canada",Natco Pharma (Canada) Inc.,"2000 Argentia Road, Plaza 1, Suite 200",Mississauga,Ontario,Canada,L5N 1P7,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000040580.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e132614"",
  ""submission_no"": ""269696"",
  ""manufacturer"": {
    ""name"": ""Pendopharm, Division of Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave, Suite 100"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""June 23, 2023"",
  ""product_name"": ""AXID"",
  ""medicinal_ingredients"": ""Nizatidine"",
  ""reason_for_submission"": ""Addition of a test for an impurity NDMA"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Capsule, 150 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e132614,269696,"June 23, 2023",AXID,Nizatidine,Addition of a test for an impurity NDMA,,"N/A, Oral/Orale, Capsule, 150 mg",,"Pendopharm, Division of Pharmascience Inc.","6111 Royalmount Ave, Suite 100",Montreal,Quebec,Canada,H4P 2T4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000040589.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""271667"",
  ""submission_no"": ""271667"",
  ""manufacturer"": {
    ""name"": ""Biogen Canada Inc."",
    ""street"": ""3250 Bloor Street West, East Tower, Suite 1200"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M8X 2X9""
  },
  ""date"": ""June 26, 2023"",
  ""product_name"": ""Plegridy"",
  ""medicinal_ingredients"": ""Peginterferon beta-1a"",
  ""reason_for_submission"": ""Updates to the Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, LIQ, 63 mcg / 0.5 mL; N/A, SC, LIQ, 94 mcg / 0.5 mL; N/A, SC, LIQ, 125 mcg / 0.5 mL; N/A, SC, LIQ, 63 mcg / 0.5 mL, 94 mcg / 0.5 mL (starter pack)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,271667,271667,"June 26, 2023",Plegridy,Peginterferon beta-1a,Updates to the Product Monograph / Mise à jour de la monographie de produit,,"N/A, SC, LIQ, 63 mcg / 0.5 mL; N/A, SC, LIQ, 94 mcg / 0.5 mL; N/A, SC, LIQ, 125 mcg / 0.5 mL; N/A, SC, LIQ, 63 mcg / 0.5 mL, 94 mcg / 0.5 mL (starter pack)",,Biogen Canada Inc.,"3250 Bloor Street West, East Tower, Suite 1200",Toronto,Ontario,Canada,M8X 2X9,Sophie Sommerer,Acting Director General / Directrice générale par intérim,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000040844.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e158216"",
  ""submission_no"": ""272305"",
  ""manufacturer"": {
    ""name"": ""Marcan Pharmaceuticals Inc."",
    ""street"": ""2 Gurdwara Road, Suite # 112"",
    ""city"": ""Ottawa"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""K2E 1A2""
  },
  ""date"": ""July 20, 2023"",
  ""product_name"": ""IPG-PREGABALIN"",
  ""medicinal_ingredients"": ""Pregabalin / Prégabaline"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit\nUpdate to Labels / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Capsule / Capsule, 25 mg\nN/A, Oral / Orale, Capsule / Capsule, 50 mg\nN/A, Oral / Orale, Capsule / Capsule, 75 mg\nN/A, Oral / Orale, Capsule / Capsule, 100 mg\nN/A, Oral / Orale, Capsule / Capsule, 150 mg\nN/A, Oral / Orale, Capsule / Capsule, 200 mg\nN/A, Oral / Orale, Capsule / Capsule, 225 mg\nN/A, Oral / Orale, Capsule / Capsule, 300 mg"",
  ""canadian_reference_product"": ""LYRICA, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e158216,272305,"July 20, 2023",IPG-PREGABALIN,Pregabalin / Prégabaline,"Update to the Product Monograph / Mise à jour de la monographie de produit
Update to Labels / Mise à jour des étiquettes",,"N/A, Oral / Orale, Capsule / Capsule, 25 mg
N/A, Oral / Orale, Capsule / Capsule, 50 mg
N/A, Oral / Orale, Capsule / Capsule, 75 mg
N/A, Oral / Orale, Capsule / Capsule, 100 mg
N/A, Oral / Orale, Capsule / Capsule, 150 mg
N/A, Oral / Orale, Capsule / Capsule, 200 mg
N/A, Oral / Orale, Capsule / Capsule, 225 mg
N/A, Oral / Orale, Capsule / Capsule, 300 mg","LYRICA, Pfizer Canada Inc., Canada",Marcan Pharmaceuticals Inc.,"2 Gurdwara Road, Suite # 112",Ottawa,Ontario,Canada,K2E 1A2,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000040966.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""272485"",
  ""submission_no"": ""272485"",
  ""manufacturer"": {
    ""name"": ""Alexion Pharma GMBH"",
    ""street"": ""Giesshubelstrasse 30"",
    ""city"": ""Zurich"",
    ""province"": ""Switzerland"",
    ""country"": ""Switzerland"",
    ""postal_code"": ""8045""
  },
  ""date"": ""July 28, 2023"",
  ""product_name"": ""Ultomiris"",
  ""medicinal_ingredients"": ""ravulizumab"",
  ""reason_for_submission"": ""Alternate drug product manufacturing site"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 10mg/ml; N/A, IV, SOL, 300mg/3ml; N/A, IV, SOL 1100mg/ 11ml"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Acting Director General"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate""
  }
}",TRUE,NA,272485,272485,"July 28, 2023",Ultomiris,ravulizumab,Alternate drug product manufacturing site,,"N/A, IV, SOL, 10mg/ml; N/A, IV, SOL, 300mg/3ml; N/A, IV, SOL 1100mg/ 11ml",,Alexion Pharma GMBH,Giesshubelstrasse 30,Zurich,Switzerland,Switzerland,8045,Sophie Sommerer,Acting Director General,Biologic and Radiopharmaceutical Drugs Directorate,Biologic and Radiopharmaceutical Drugs Directorate
https://pdf.hres.ca/noc_pm/0000041100.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""272284"",
  ""submission_no"": ""272284"",
  ""manufacturer"": {
    ""name"": ""Alexion Pharma GmbH"",
    ""street"": ""Giesshübelstrasse 30"",
    ""city"": ""Zürich"",
    ""province"": ""Switzerland"",
    ""country"": ""Switzerland"",
    ""postal_code"": ""8045""
  },
  ""date"": ""August 21, 2023"",
  ""product_name"": ""Strensiq"",
  ""medicinal_ingredients"": ""Asfotase alfa"",
  ""reason_for_submission"": ""Addition of a new drug product manufacturing site / Ajout d’un nouveau site de fabrication pour le produit médicamenteux"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 12mg/0.3mL (40mg/mL); N/A, SC, SOL, 18mg/0.45mL (40mg/mL); N/A, SC, SOL, 28mg/0.7mL (40mg/mL); N/A, SC, SOL, 40mg/1mL (40mg/mL); N/A, SC, SOL, 80mg/0.8mL (100mg/mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,272284,272284,"August 21, 2023",Strensiq,Asfotase alfa,Addition of a new drug product manufacturing site / Ajout d’un nouveau site de fabrication pour le produit médicamenteux,N/A,"N/A, SC, SOL, 12mg/0.3mL (40mg/mL); N/A, SC, SOL, 18mg/0.45mL (40mg/mL); N/A, SC, SOL, 28mg/0.7mL (40mg/mL); N/A, SC, SOL, 40mg/1mL (40mg/mL); N/A, SC, SOL, 80mg/0.8mL (100mg/mL)",,Alexion Pharma GmbH,Giesshübelstrasse 30,Zürich,Switzerland,Switzerland,8045,Sophie Sommerer,Acting Director General / Directrice générale par intérim,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000041143.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e182623"",
  ""submission_no"": ""273193"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""August 28, 2023"",
  ""product_name"": ""JAMP-SILDENAFIL R"",
  ""medicinal_ingredients"": ""Sildenafil (supplied as Sildenafil Citrate) / Sildénafil (fourni comme citrate de sildénafil)"",
  ""reason_for_submission"": ""Update to Labels / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 20 mg"",
  ""canadian_reference_product"": ""REVATIO, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e182623,273193,"August 28, 2023",JAMP-SILDENAFIL R,Sildenafil (supplied as Sildenafil Citrate) / Sildénafil (fourni comme citrate de sildénafil),Update to Labels / Mise à jour des étiquettes,,"N/A, Oral / Orale, Tablet / Comprimé, 20 mg","REVATIO, Pfizer Canada Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000041420.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e265385"",
  ""submission_no"": ""275438"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""September 21, 2023"",
  ""product_name"": ""APO-DAPAGLIFLOZIN-METFORMIN"",
  ""medicinal_ingredients"": ""Dapagliflozin / Metformin Hydrochloride / Dapagliflozine/Chlorhydrate de metformine"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit Update to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 5 mg/850 mg N/A, Oral / Orale, Tablet / Comprimé, 5 mg/1000 mg"",
  ""canadian_reference_product"": ""XIGDUO, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e265385,275438,"September 21, 2023",APO-DAPAGLIFLOZIN-METFORMIN,Dapagliflozin / Metformin Hydrochloride / Dapagliflozine/Chlorhydrate de metformine,Update to the Product Monograph / Mise à jour de la monographie de produit Update to the Package Insert / Mise à jour de l'encart,,"N/A, Oral / Orale, Tablet / Comprimé, 5 mg/850 mg N/A, Oral / Orale, Tablet / Comprimé, 5 mg/1000 mg","XIGDUO, AstraZeneca Canada Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000041455.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e230497"",
  ""submission_no"": ""275480"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""September 08, 2021"",
  ""product_name"": ""JAMP LEVETIRACETAM TABLETS"",
  ""medicinal_ingredients"": ""Levetiracetam / Lévétiracétam"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la Monographie de Produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 250 mg; N/A, Oral / Orale, Tablet / Comprimé, 500 mg; N/A, Oral / Orale, Tablet / Comprimé, 750 mg"",
  ""canadian_reference_product"": ""KEPPRA, UCB Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Sophie Gaudreault, PhD"",
    ""title"": ""A/Manager / Gestionnaire, par interim"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e230497,275480,"September 08, 2021",JAMP LEVETIRACETAM TABLETS,Levetiracetam / Lévétiracétam,Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la Monographie de Produit,,"N/A, Oral / Orale, Tablet / Comprimé, 250 mg; N/A, Oral / Orale, Tablet / Comprimé, 500 mg; N/A, Oral / Orale, Tablet / Comprimé, 750 mg","KEPPRA, UCB Canada Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,"Sophie Gaudreault, PhD","A/Manager / Gestionnaire, par interim",Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000041779.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e117334"",
  ""submission_no"": ""275866"",
  ""manufacturer"": {
    ""name"": ""Servier Canada Inc."",
    ""street"": ""3224 Avenue Jean-Béraud, Suite 270"",
    ""city"": ""Laval"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7T 2S4""
  },
  ""date"": ""October 25, 2023"",
  ""product_name"": ""VIACORAM"",
  ""medicinal_ingredients"": ""Perindopril arginine / Périndopril arginine Amlodipine (supplied as amlodipine besylate / fourni comme bésylate d'amlodipine)"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph Update to the Package Insert"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 3.5 mg / 2.5 mg N/A, Oral/Orale, Tablet/Comprimé, 7 mg / 5 mg N/A, Oral/Orale, Tablet/Comprimé, 14 mg / 10 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e117334,275866,"October 25, 2023",VIACORAM,Perindopril arginine / Périndopril arginine Amlodipine (supplied as amlodipine besylate / fourni comme bésylate d'amlodipine),Safety updates to the Product Monograph Update to the Package Insert,,"N/A, Oral/Orale, Tablet/Comprimé, 3.5 mg / 2.5 mg N/A, Oral/Orale, Tablet/Comprimé, 7 mg / 5 mg N/A, Oral/Orale, Tablet/Comprimé, 14 mg / 10 mg",,Servier Canada Inc.,"3224 Avenue Jean-Béraud, Suite 270",Laval,Québec,Canada,H7T 2S4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000041838.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""E198316"",
  ""submission_no"": ""242215"",
  ""manufacturer"": {
    ""name"": ""Taro Pharmaceuticals Inc."",
    ""street"": ""130 East Drive"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6T 1C1""
  },
  ""date"": ""November 1, 2023"",
  ""product_name"": ""TARO-RIVAROXABAN"",
  ""medicinal_ingredients"": ""Rivaroxaban"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 10 mg; N/A, Oral, Tablet, 15 mg; N/A, Oral, Tablet, 20 mg"",
  ""canadian_reference_product"": ""XARELTO, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,E198316,242215,"November 1, 2023",TARO-RIVAROXABAN,Rivaroxaban,Safety updates to the Product Monograph,,"N/A, Oral, Tablet, 10 mg; N/A, Oral, Tablet, 15 mg; N/A, Oral, Tablet, 20 mg","XARELTO, Bayer Inc., Canada",Taro Pharmaceuticals Inc.,130 East Drive,Brampton,Ontario,Canada,L6T 1C1,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000041976.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""273937"",
  ""submission_no"": ""273937"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""700 Saint-Hubert St., Suite 100"",
    ""city"": ""Montreal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H2Y 0C1""
  },
  ""date"": ""November 10, 2023"",
  ""product_name"": ""Zolgensma"",
  ""medicinal_ingredients"": ""Onasemnogene abeparvovec / Onasemnogène abéparvovec"",
  ""reason_for_submission"": ""Addition of a new drug product and drug substance manufacturing site. New manufacturing process. / Addition d’un nouveau site de fabrication pour la substance médicamenteuse et le produit médicamenteux. Nouveau processus de fabrication."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 2.0 × 10¹³ vector genomes (vg)/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,273937,273937,"November 10, 2023",Zolgensma,Onasemnogene abeparvovec / Onasemnogène abéparvovec,Addition of a new drug product and drug substance manufacturing site. New manufacturing process. / Addition d’un nouveau site de fabrication pour la substance médicamenteuse et le produit médicamenteux. Nouveau processus de fabrication.,,"N/A, IV, SOL, 2.0 × 10¹³ vector genomes (vg)/mL",,Novartis Pharmaceuticals Canada Inc.,"700 Saint-Hubert St., Suite 100",Montreal,Quebec,Canada,H2Y 0C1,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000042024.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-271312"",
  ""submission_no"": ""271312"",
  ""manufacturer"": {
    ""name"": ""Accel Pharma Inc."",
    ""street"": ""119 Labrosse Ave."",
    ""city"": ""Pointe-Claire"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9R 1A3""
  },
  ""date"": ""November 17, 2023"",
  ""product_name"": ""ACCEL-DAPAGLIFLOZIN"",
  ""medicinal_ingredients"": ""Dapagliflozin / Dapagliflozine"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02543184, Oral / Orale, Tablet / Comprimé, 5 mg; 02543192, Oral / Orale, Tablet / Comprimé, 10 mg"",
  ""canadian_reference_product"": ""FORXIGA, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-271312,271312,"November 17, 2023",ACCEL-DAPAGLIFLOZIN,Dapagliflozin / Dapagliflozine,This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,,"02543184, Oral / Orale, Tablet / Comprimé, 5 mg; 02543192, Oral / Orale, Tablet / Comprimé, 10 mg","FORXIGA, AstraZeneca Canada Inc., Canada",Accel Pharma Inc.,119 Labrosse Ave.,Pointe-Claire,Québec,Canada,H9R 1A3,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000042030.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""276004"",
  ""submission_no"": ""276004"",
  ""manufacturer"": {
    ""name"": ""Advanced Accelerator Applications USA Inc."",
    ""street"": ""57 East Willow Street"",
    ""city"": ""Millburn"",
    ""province"": ""NJ"",
    ""country"": ""USA"",
    ""postal_code"": ""07041""
  },
  ""date"": ""November 17, 2023"",
  ""product_name"": ""Lutathera"",
  ""medicinal_ingredients"": ""lutetium (177Lu) oxodotreotide / lutécium (177Lu) oxodotréotide"",
  ""reason_for_submission"": ""Labelling updates / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 370 MBq/mL at calibration"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,276004,276004,"November 17, 2023",Lutathera,lutetium (177Lu) oxodotreotide / lutécium (177Lu) oxodotréotide,Labelling updates / Mise à jour des étiquettes,,"N/A, IV, SOL, 370 MBq/mL at calibration",,Advanced Accelerator Applications USA Inc.,57 East Willow Street,Millburn,NJ,USA,07041,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000042076.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e102963"",
  ""submission_no"": ""274895"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""November 24, 2023"",
  ""product_name"": ""APO-IBUPROFEN"",
  ""medicinal_ingredients"": ""Ibuprofen / Ibuprofène"",
  ""reason_for_submission"": ""Update to the Product Monograph as per Advisement Letter / Mise à jour de la monographie de produit comme la lettre d'annonce"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 600 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,HC6-024-e102963,274895,"November 24, 2023",APO-IBUPROFEN,Ibuprofen / Ibuprofène,Update to the Product Monograph as per Advisement Letter / Mise à jour de la monographie de produit comme la lettre d'annonce,,"N/A, Oral / Orale, Tablet / Comprimé, 600 mg",,Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000042082.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e235195"",
  ""submission_no"": ""277332"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""November 24, 2023"",
  ""product_name"": ""AMIODARONE HYDROCHLORIDE FOR INJECTION"",
  ""medicinal_ingredients"": ""Amiodarone Hydrochloride / Chlorhydrate d’amiodarone"",
  ""reason_for_submission"": ""Update to Labels / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous / Intraveineuse, Solution / Solution, 50 mg/mL"",
  ""canadian_reference_product"": ""AMIODARONE HYDROCHLORIDE FOR INJECTION, Sandoz Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,HC6-024-e235195,277332,"November 24, 2023",AMIODARONE HYDROCHLORIDE FOR INJECTION,Amiodarone Hydrochloride / Chlorhydrate d’amiodarone,Update to Labels / Mise à jour des étiquettes,,"N/A, Intravenous / Intraveineuse, Solution / Solution, 50 mg/mL","AMIODARONE HYDROCHLORIDE FOR INJECTION, Sandoz Canada Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000042116.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024- e153673"",
  ""submission_no"": ""273575"",
  ""manufacturer"": {
    ""name"": ""Vertex Pharmaceuticals (Canada) Incorporated"",
    ""street"": ""20 Bay Street, Suite 1520"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5J 2N8""
  },
  ""date"": ""November 28, 2023"",
  ""product_name"": ""KALYDECO"",
  ""medicinal_ingredients"": ""Ivacaftor"",
  ""reason_for_submission"": ""Expansion of indication\nAddition of new strength\nUpdates to the Product Monograph\nUpdates to labels\nUpdates to package insert"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02543451, Oral/Orale, Granules, 13.4 mg / sachet\nN/A, Oral/Orale, Granules, 25 mg / sachet\nN/A, Oral/Orale, Granules, 50 mg / sachet\nN/A, Oral/Orale, Granules, 75 mg / sachet\nN/A, Oral/Orale, Tablet/Comprimé , 150 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024- e153673,273575,"November 28, 2023",KALYDECO,Ivacaftor,"Expansion of indication
Addition of new strength
Updates to the Product Monograph
Updates to labels
Updates to package insert",,"02543451, Oral/Orale, Granules, 13.4 mg / sachet
N/A, Oral/Orale, Granules, 25 mg / sachet
N/A, Oral/Orale, Granules, 50 mg / sachet
N/A, Oral/Orale, Granules, 75 mg / sachet
N/A, Oral/Orale, Tablet/Comprimé , 150 mg",,Vertex Pharmaceuticals (Canada) Incorporated,"20 Bay Street, Suite 1520",Toronto,Ontario,Canada,M5J 2N8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000042254.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e139279"",
  ""submission_no"": ""281034"",
  ""manufacturer"": {
    ""name"": ""Sanis Health Inc."",
    ""street"": ""1 President's Choice Circle"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6Y 5S5""
  },
  ""date"": ""December 7, 2023"",
  ""product_name"": ""LEVETIRACETAM"",
  ""medicinal_ingredients"": ""Levetiracetam"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to match Licensor)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 250 mg; N/A, oral / orale, tablet / comprimé, 500 mg; N/A, oral / orale, tablet / comprimé, 750 mg; N/A, oral / orale, tablet / comprimé, 1000 mg"",
  ""canadian_reference_product"": ""Keppra, UCB Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Tanya Ramsamy, Ph.D."",
    ""title"": ""Director / Directrice"",
    ""division"": ""Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e139279,281034,"December 7, 2023",LEVETIRACETAM,Levetiracetam,Administrative: Labelling Update (to match Licensor),,"N/A, oral / orale, tablet / comprimé, 250 mg; N/A, oral / orale, tablet / comprimé, 500 mg; N/A, oral / orale, tablet / comprimé, 750 mg; N/A, oral / orale, tablet / comprimé, 1000 mg","Keppra, UCB Canada Inc., Canada",Sanis Health Inc.,1 President's Choice Circle,Brampton,Ontario,Canada,L6Y 5S5,"Tanya Ramsamy, Ph.D.",Director / Directrice,"Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales",Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000042353.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e216035"",
  ""submission_no"": ""269878"",
  ""manufacturer"": {
    ""name"": ""Bristol-Myers Squibb Canada"",
    ""street"": ""2344 Boul. Alfred-Nobel, Suite 300"",
    ""city"": ""St. Laurent"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 0A4""
  },
  ""date"": ""December 20, 2023"",
  ""product_name"": ""ZEPOSIA"",
  ""medicinal_ingredients"": ""Ozanimod (supplied as Ozanimod Hydrochloride) / Ozanimod (sous forme Chlorhydrate d'ozanimod)"",
  ""reason_for_submission"": ""To add new data on the use in patients with hepatic impairment and to propose dosing recommendations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Capsule/Capsule (Kit/Trousse), 0.23 mg / 0.46 mg; N/A, Oral/Orale, Capsule/Capsule, 0.92 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e216035,269878,"December 20, 2023",ZEPOSIA,Ozanimod (supplied as Ozanimod Hydrochloride) / Ozanimod (sous forme Chlorhydrate d'ozanimod),To add new data on the use in patients with hepatic impairment and to propose dosing recommendations.,,"N/A, Oral/Orale, Capsule/Capsule (Kit/Trousse), 0.23 mg / 0.46 mg; N/A, Oral/Orale, Capsule/Capsule, 0.92 mg",,Bristol-Myers Squibb Canada,"2344 Boul. Alfred-Nobel, Suite 300",St. Laurent,Québec,Canada,H4S 0A4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000042379.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e222010"",
  ""submission_no"": ""281767"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""January 2, 2024"",
  ""product_name"": ""JAMP DUTASTERIDE"",
  ""medicinal_ingredients"": ""Dutasteride / Dutastéride"",
  ""reason_for_submission"": ""Administrative: Labelling Update (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, capsule, 0.5 mg"",
  ""canadian_reference_product"": ""Avodart, GlaxoSmithKline Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques"",
    ""directorate"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e222010,281767,"January 2, 2024",JAMP DUTASTERIDE,Dutasteride / Dutastéride,Administrative: Labelling Update (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, capsule, 0.5 mg","Avodart, GlaxoSmithKline Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Quebec,Canada,J4B 5H3,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000042406.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e143995"",
  ""submission_no"": ""277533"",
  ""manufacturer"": {
    ""name"": ""Vita Health Products Inc."",
    ""street"": ""150 Beghin Ave."",
    ""city"": ""Winnipeg"",
    ""province"": ""MB"",
    ""country"": ""Canada"",
    ""postal_code"": ""R2J 3W2""
  },
  ""date"": ""2023-12-29"",
  ""product_name"": ""24 HOUR ALLERGY REMEDY"",
  ""medicinal_ingredients"": ""Loratadine"",
  ""reason_for_submission"": ""Addition of private retailer label / Ajout de marques privées"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet, 10 mg"",
  ""canadian_reference_product"": ""CLARITIN ALLERGY, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Natalie Page"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Natural and Non-prescription Health Products Directorate / Direction des produits de santé naturels et sans ordonnance""
  }
}",TRUE,NA,e143995,277533,2023-12-29,24 HOUR ALLERGY REMEDY,Loratadine,Addition of private retailer label / Ajout de marques privées,,"N/A, Oral, Tablet, 10 mg","CLARITIN ALLERGY, Bayer Inc., Canada",Vita Health Products Inc.,150 Beghin Ave.,Winnipeg,MB,Canada,R2J 3W2,Natalie Page,Director General / Directrice générale,Natural and Non-prescription Health Products Directorate / Direction des produits de santé naturels et sans ordonnance,NA
https://pdf.hres.ca/noc_pm/0000042440.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e234182"",
  ""submission_no"": ""277441"",
  ""manufacturer"": {
    ""name"": ""Accord Healthcare Inc."",
    ""street"": ""3535 boulevard St. Charles, Suite 704"",
    ""city"": ""Kirkland"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 5B9""
  },
  ""date"": ""January 09, 2024"",
  ""product_name"": ""ACH-TERIFLUNOMIDE"",
  ""medicinal_ingredients"": ""Teriflunomide / Tériflunomide"",
  ""reason_for_submission"": ""Updates to Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 14 mg"",
  ""canadian_reference_product"": ""AUBAGIO, Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Sophie Gaudreault"",
    ""title"": ""Acting Manager / Gestionnaire par intérim"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e234182,277441,"January 09, 2024",ACH-TERIFLUNOMIDE,Teriflunomide / Tériflunomide,Updates to Product Monograph / Mise à jour de la monographie de produit,,"N/A, Oral / Orale, Tablet / Comprimé, 14 mg","AUBAGIO, Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc., Canada",Accord Healthcare Inc.,"3535 boulevard St. Charles, Suite 704",Kirkland,Québec,Canada,H9H 5B9,Sophie Gaudreault,Acting Manager / Gestionnaire par intérim,Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000042631.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e109960"",
  ""submission_no"": ""278404"",
  ""manufacturer"": {
    ""name"": ""Glenmark Pharmaceuticals Canada Inc."",
    ""street"": ""1600 Steeles Avenue West, Suite 407"",
    ""city"": ""Concord"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4K 4M2""
  },
  ""date"": ""January 24, 2024"",
  ""product_name"": ""GLN-TOPIRAMATE"",
  ""medicinal_ingredients"": ""Topiramate / Topiramate"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit Update to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 25 mg N/A, Oral / Orale, Tablet / Comprimé, 100 mg N/A, Oral / Orale, Tablet / Comprimé, 200 mg"",
  ""canadian_reference_product"": ""TOPAMAX, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e109960,278404,"January 24, 2024",GLN-TOPIRAMATE,Topiramate / Topiramate,Update to the Product Monograph / Mise à jour de la monographie de produit Update to the Package Insert / Mise à jour de l'encart,,"N/A, Oral / Orale, Tablet / Comprimé, 25 mg N/A, Oral / Orale, Tablet / Comprimé, 100 mg N/A, Oral / Orale, Tablet / Comprimé, 200 mg","TOPAMAX, Janssen-Ortho Inc., Canada",Glenmark Pharmaceuticals Canada Inc.,"1600 Steeles Avenue West, Suite 407",Concord,Ontario,Canada,L4K 4M2,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000042657.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v190913"",
  ""submission_no"": ""277223"",
  ""manufacturer"": {
    ""name"": ""Zoetis Canada Inc."",
    ""street"": ""16740 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""February 1, 2024"",
  ""product_name"": ""REVOLUTION PLUS"",
  ""medicinal_ingredients"": ""Sarolaner, Selamectin"",
  ""reason_for_submission"": ""Additional claim / Indication supplémentaire"",
  ""species"": ""Cats / Chats"",
  ""drug_identification_number_route_form_strength"": ""N/A, Topical, Solution, Sarolaner 10 mg/mL, Selamectin 60 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v190913,277223,"February 1, 2024",REVOLUTION PLUS,"Sarolaner, Selamectin",Additional claim / Indication supplémentaire,Cats / Chats,"N/A, Topical, Solution, Sarolaner 10 mg/mL, Selamectin 60 mg/mL",,Zoetis Canada Inc.,16740 Trans Canada Highway,Kirkland,QC,Canada,H9H 4M7,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000042837.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""278877"",
  ""submission_no"": ""278877"",
  ""manufacturer"": {
    ""name"": ""Advanced Accelerator Applications USA, Inc."",
    ""street"": ""57 East Willow Street"",
    ""city"": ""Millburn"",
    ""province"": ""New Jersey"",
    ""country"": ""United States of America"",
    ""postal_code"": ""07041""
  },
  ""date"": ""February 22, 2024"",
  ""product_name"": ""Locametz"",
  ""medicinal_ingredients"": ""Gallium (68Ga) gozetotide / Gallium (68Ga) gozétotide"",
  ""reason_for_submission"": ""Labelling update / Mise à jour de l’étiquetage"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, PWSO, 25 mcg/vial / N/A, IV, PWSO, 25 mcg/fiole"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Cynthia Colapinto, PhD"",
    ""title"": ""Acting Director General"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,278877,278877,"February 22, 2024",Locametz,Gallium (68Ga) gozetotide / Gallium (68Ga) gozétotide,Labelling update / Mise à jour de l’étiquetage,,"N/A, IV, PWSO, 25 mcg/vial / N/A, IV, PWSO, 25 mcg/fiole",,"Advanced Accelerator Applications USA, Inc.",57 East Willow Street,Millburn,New Jersey,United States of America,07041,"Cynthia Colapinto, PhD",Acting Director General,Biologic and Radiopharmaceutical Drugs Directorate,Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000043127.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e170376"",
  ""submission_no"": ""281759"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite # 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""April 2, 2024"",
  ""product_name"": ""AURO-RIVASTIGMINE"",
  ""medicinal_ingredients"": ""Rivastigmine (supplied as Rivastigmine Hydrogen Tartrate) / Rivastigmine (sous forme de tartrate hydrogéné de rivastigmine)"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit Update to the Package Insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Capsule / Capsule, 1.5 mg N/A, Oral / Orale, Capsule / Capsule, 3 mg N/A, Oral / Orale, Capsule / Capsule, 4.5 mg N/A, Oral / Orale, Capsule / Capsule, 6 mg"",
  ""canadian_reference_product"": ""EXELON, Novartis Pharmaceuticals Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e170376,281759,"April 2, 2024",AURO-RIVASTIGMINE,Rivastigmine (supplied as Rivastigmine Hydrogen Tartrate) / Rivastigmine (sous forme de tartrate hydrogéné de rivastigmine),Update to the Product Monograph / Mise à jour de la monographie de produit Update to the Package Insert / Mise à jour de l'encart,,"N/A, Oral / Orale, Capsule / Capsule, 1.5 mg N/A, Oral / Orale, Capsule / Capsule, 3 mg N/A, Oral / Orale, Capsule / Capsule, 4.5 mg N/A, Oral / Orale, Capsule / Capsule, 6 mg","EXELON, Novartis Pharmaceuticals Canada Inc., Canada",Auro Pharma Inc.,"3700 Steeles Avenue West, Suite # 402",Woodbridge,Ontario,Canada,L4L 8K8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043139.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e172363"",
  ""submission_no"": ""279783"",
  ""manufacturer"": {
    ""name"": ""JAMP PHARMA CORPORATION"",
    ""street"": ""1310 Rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""March 28, 2024"",
  ""product_name"": ""JAMP-AMOXICILLIN"",
  ""medicinal_ingredients"": ""Amoxicillin (supplied as amoxicillin trihydrate) / Amoxicilline (sous forme d'amoxicilline trihydratée)"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit\nUpdate to the Package Insert / Mise à jour de l'encart\nUpdate to labels / Mise à jour des étiquettes"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Capsule / Capsule, 250 mg\nN/A, Oral / Orale, Capsule / Capsule, 500 mg"",
  ""canadian_reference_product"": ""APO-AMOXI, Apotex Inc, Canada"",
  ""authorizing_official"": {
    ""name"": ""Mandy Collier"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,HC6-024-e172363,279783,"March 28, 2024",JAMP-AMOXICILLIN,Amoxicillin (supplied as amoxicillin trihydrate) / Amoxicilline (sous forme d'amoxicilline trihydratée),"Update to the Product Monograph / Mise à jour de la monographie de produit
Update to the Package Insert / Mise à jour de l'encart
Update to labels / Mise à jour des étiquettes",,"N/A, Oral / Orale, Capsule / Capsule, 250 mg
N/A, Oral / Orale, Capsule / Capsule, 500 mg","APO-AMOXI, Apotex Inc, Canada",JAMP PHARMA CORPORATION,1310 Rue Nobel,Boucherville,Québec,Canada,J4B 5H3,Mandy Collier,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000043151.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e250471"",
  ""submission_no"": ""250471"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""April 3, 2024"",
  ""product_name"": ""SANDOZ RIOCIGUAT"",
  ""medicinal_ingredients"": ""Riociguat"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02533545, Oral/Orale, Tablet/Comprimé, 0.5 mg; 02533561, Oral/Orale, Tablet/Comprimé, 1 mg; 02533588, Oral/Orale, Tablet/Comprimé, 1.5 mg; 02533596, Oral/Orale, Tablet/Comprimé, 2 mg; 02533618, Oral/Orale, Tablet/Comprimé, 2.5 mg"",
  ""canadian_reference_product"": ""ADEMPAS, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e250471,250471,"April 3, 2024",SANDOZ RIOCIGUAT,Riociguat,This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,,"02533545, Oral/Orale, Tablet/Comprimé, 0.5 mg; 02533561, Oral/Orale, Tablet/Comprimé, 1 mg; 02533588, Oral/Orale, Tablet/Comprimé, 1.5 mg; 02533596, Oral/Orale, Tablet/Comprimé, 2 mg; 02533618, Oral/Orale, Tablet/Comprimé, 2.5 mg","ADEMPAS, Bayer Inc., Canada",Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043156.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e153872"",
  ""submission_no"": ""279919"",
  ""manufacturer"": {
    ""name"": ""Taro Pharmaceuticals Inc."",
    ""street"": ""130 East Drive"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6T 1C1""
  },
  ""date"": ""April 4, 2024"",
  ""product_name"": ""TARO-LATANOPROST"",
  ""medicinal_ingredients"": ""Latanoprost"",
  ""reason_for_submission"": ""Product Monograph reformatted to the Master Template/Remise en forme de la monographie de produit selon le modèle principal"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Ophthalmic/Ophtalmique, Solution, 50 mcg/mL"",
  ""canadian_reference_product"": ""XALATAN, PFIZER CANADA INC, Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e153872,279919,"April 4, 2024",TARO-LATANOPROST,Latanoprost,Product Monograph reformatted to the Master Template/Remise en forme de la monographie de produit selon le modèle principal,,"N/A, Ophthalmic/Ophtalmique, Solution, 50 mcg/mL","XALATAN, PFIZER CANADA INC, Canada",Taro Pharmaceuticals Inc.,130 East Drive,Brampton,Ontario,Canada,L6T 1C1,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043214.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e166790"",
  ""submission_no"": ""277582"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""April 11, 2024"",
  ""product_name"": ""TEVA-ESOMEPRAZOLE"",
  ""medicinal_ingredients"": ""Esomeprazole (supplied as Esomeprazole Magnesium Dihydrate)"",
  ""reason_for_submission"": ""Update to Labels"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet (Delayed-Release)/Comprimé (à libération retardée), 20 mg; N/A, Oral/Orale, Tablet (Delayed-Release)/Comprimé (à libération retardée), 40 mg"",
  ""canadian_reference_product"": ""NEXIUM, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e166790,277582,"April 11, 2024",TEVA-ESOMEPRAZOLE,Esomeprazole (supplied as Esomeprazole Magnesium Dihydrate),Update to Labels,,"N/A, Oral/Orale, Tablet (Delayed-Release)/Comprimé (à libération retardée), 20 mg; N/A, Oral/Orale, Tablet (Delayed-Release)/Comprimé (à libération retardée), 40 mg","NEXIUM, AstraZeneca Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043303.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""283128"",
  ""submission_no"": ""283128"",
  ""manufacturer"": {
    ""name"": ""10445517 Canada Inc / North Pharmaceuticals / DAC Pharmaceuticals"",
    ""street"": ""3030 Le Carrefour, Suite 903"",
    ""city"": ""Laval"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H7T 2P5""
  },
  ""date"": ""April 19, 2024"",
  ""product_name"": ""CIPROFLOXACIN"",
  ""medicinal_ingredients"": ""Ciprofloxacin supplied as Ciprofloxacin Hydrochloride / Ciprofloxacine sous forme de chlorhydrate de ciprofloxacine"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement Between Two Manufacturers / Administratif: Accord de licence entre deux fabricants"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02547139, oral / orale, tablet / comprimé, 250 mg; 02547147, oral / orale, tablet / comprimé, 500 mg; 02547155, oral / orale, tablet / comprimé, 750 mg"",
  ""canadian_reference_product"": ""ZITHROMAX, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,283128,283128,"April 19, 2024",CIPROFLOXACIN,Ciprofloxacin supplied as Ciprofloxacin Hydrochloride / Ciprofloxacine sous forme de chlorhydrate de ciprofloxacine,Administrative: Licensing Agreement Between Two Manufacturers / Administratif: Accord de licence entre deux fabricants,,"02547139, oral / orale, tablet / comprimé, 250 mg; 02547147, oral / orale, tablet / comprimé, 500 mg; 02547155, oral / orale, tablet / comprimé, 750 mg","ZITHROMAX, Pfizer Canada Inc., Canada",10445517 Canada Inc / North Pharmaceuticals / DAC Pharmaceuticals,"3030 Le Carrefour, Suite 903",Laval,Quebec,Canada,H7T 2P5,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043320.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e227269"",
  ""submission_no"": ""281575"",
  ""manufacturer"": {
    ""name"": ""Janssen Inc."",
    ""street"": ""19 Green Belt Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3C 1L9""
  },
  ""date"": ""April 26, 2024"",
  ""product_name"": ""OPSYNVI"",
  ""medicinal_ingredients"": ""Macitentan, Tadalafil"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph, Updates to the package insert"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 10 mg / 40 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,HC6-024-e227269,281575,"April 26, 2024",OPSYNVI,"Macitentan, Tadalafil","Safety updates to the Product Monograph, Updates to the package insert",,"N/A, Oral/Orale, Tablet/Comprimé, 10 mg / 40 mg",,Janssen Inc.,19 Green Belt Drive,Toronto,Ontario,Canada,M3C 1L9,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000043614.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e272462"",
  ""submission_no"": ""272462"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""May 28, 2024"",
  ""product_name"": ""JAMP FLUCONAZOLE 150 MG"",
  ""medicinal_ingredients"": ""Fluconazole"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02547864, Oral, Capsule, 150 mg"",
  ""canadian_reference_product"": ""Diflucan One, Pfizer Canada ULC, Canada"",
  ""authorizing_official"": {
    ""name"": ""Stephen Norman"",
    ""title"": ""Director General / Directeur général"",
    ""division"": ""Natural and Non-prescription Health Products Directorate / Direction des produits de santé naturels et sans ordonnance""
  }
}",TRUE,NA,e272462,272462,"May 28, 2024",JAMP FLUCONAZOLE 150 MG,Fluconazole,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02547864, Oral, Capsule, 150 mg","Diflucan One, Pfizer Canada ULC, Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,QC,Canada,J4B 5H3,Stephen Norman,Director General / Directeur général,Natural and Non-prescription Health Products Directorate / Direction des produits de santé naturels et sans ordonnance,NA
https://pdf.hres.ca/noc_pm/0000043659.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e257296"",
  ""submission_no"": ""265912"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""June 3, 2024"",
  ""product_name"": ""SANDOZ LISDEXAMFETAMINE CAPSULES"",
  ""medicinal_ingredients"": ""Lisdexamfetamine Dimesylate / Dimésylate de lisdexamfétamine"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": [
    ""02546248, Oral / Orale, Capsule / Capsule, 10 mg"",
    ""02546256, Oral / Orale, Capsule / Capsule, 20 mg"",
    ""02546264, Oral / Orale, Capsule / Capsule, 30 mg"",
    ""02546272, Oral / Orale, Capsule / Capsule, 40 mg"",
    ""02546280, Oral / Orale, Capsule / Capsule, 50 mg"",
    ""02546299, Oral / Orale, Capsule / Capsule, 60 mg"",
    ""02546302, Oral / Orale, Capsule / Capsule, 70 mg""
  ],
  ""canadian_reference_product"": ""VYVANSE, Takeda Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e257296,265912,"June 3, 2024",SANDOZ LISDEXAMFETAMINE CAPSULES,Lisdexamfetamine Dimesylate / Dimésylate de lisdexamfétamine,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02546248, Oral / Orale, Capsule / Capsule, 10 mg | 02546256, Oral / Orale, Capsule / Capsule, 20 mg | 02546264, Oral / Orale, Capsule / Capsule, 30 mg | 02546272, Oral / Orale, Capsule / Capsule, 40 mg | 02546280, Oral / Orale, Capsule / Capsule, 50 mg | 02546299, Oral / Orale, Capsule / Capsule, 60 mg | 02546302, Oral / Orale, Capsule / Capsule, 70 mg","VYVANSE, Takeda Canada Inc., Canada",Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043821.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""282933"",
  ""submission_no"": ""282933"",
  ""manufacturer"": {
    ""name"": ""Gilead Sciences Canada Inc."",
    ""street"": ""6925 Century Avenue, Suite 400"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": """",
    ""postal_code"": ""L5N 7K2""
  },
  ""date"": ""June 17, 2024"",
  ""product_name"": ""Tecartus"",
  ""medicinal_ingredients"": ""brexucabtagene autoleucel / brexucabtagène autoleucel"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SUS, 1 × 10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg body weight with a maximum of 1 × 10^8 CAR-positive viable T cells / N/A, IV, SUS, 2 × 10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg body weight with a maximum of 2 × 10^6 CAR-positive viable T cells"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Co Pham"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,282933,282933,"June 17, 2024",Tecartus,brexucabtagene autoleucel / brexucabtagène autoleucel,Update to the Product Monograph / Mise à jour de la monographie de produit,,"N/A, IV, SUS, 1 × 10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg body weight with a maximum of 1 × 10^8 CAR-positive viable T cells / N/A, IV, SUS, 2 × 10^6 chimeric antigen receptor (CAR)-positive viable T cells per kg body weight with a maximum of 2 × 10^6 CAR-positive viable T cells",,Gilead Sciences Canada Inc.,"6925 Century Avenue, Suite 400",Mississauga,ON,,L5N 7K2,Co Pham,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,
https://pdf.hres.ca/noc_pm/0000043843.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""285994"",
  ""submission_no"": ""285994"",
  ""manufacturer"": {
    ""name"": ""Mantra Pharma Inc."",
    ""street"": ""1000 rue Du Lux, Suite 201"",
    ""city"": ""Brossard"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4Y 0E3""
  },
  ""date"": ""June 20, 2024"",
  ""product_name"": ""M-RIZATRIPTAN ODT"",
  ""medicinal_ingredients"": ""Rizatriptan supplied as Rizatriptan Benzoate / sous forme de benzoate de rizatriptan"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02548801, oral / orale, tablet (orally disintegrating) / comprimé (à désintégration orale), 5 mg; 02548828, oral / orale, tablet (orally disintegrating) / comprimé (à désintégration orale), 10 mg"",
  ""canadian_reference_product"": ""Maxalt Smelt, Merck Sharp & Dohme BV, Netherlands"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,285994,285994,"June 20, 2024",M-RIZATRIPTAN ODT,Rizatriptan supplied as Rizatriptan Benzoate / sous forme de benzoate de rizatriptan,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants,,"02548801, oral / orale, tablet (orally disintegrating) / comprimé (à désintégration orale), 5 mg; 02548828, oral / orale, tablet (orally disintegrating) / comprimé (à désintégration orale), 10 mg","Maxalt Smelt, Merck Sharp & Dohme BV, Netherlands",Mantra Pharma Inc.,"1000 rue Du Lux, Suite 201",Brossard,Quebec,Canada,J4Y 0E3,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043854.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e275519"",
  ""submission_no"": ""281421"",
  ""manufacturer"": {
    ""name"": ""Accord Healthcare Inc."",
    ""street"": ""3535 Boulevard St. Charles, Suite 704"",
    ""city"": ""Kirkland"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 5B9""
  },
  ""date"": ""June 25, 2024"",
  ""product_name"": ""ACH-PROGESTERONE"",
  ""medicinal_ingredients"": ""Progesterone / Progestérone"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02549158, Oral / Orale, Capsule / Capsule, 100 mg"",
  ""canadian_reference_product"": ""PROMETRIUM, Organon Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Chris Rose for Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e275519,281421,"June 25, 2024",ACH-PROGESTERONE,Progesterone / Progestérone,This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,,"02549158, Oral / Orale, Capsule / Capsule, 100 mg","PROMETRIUM, Organon Canada Inc., Canada",Accord Healthcare Inc.,"3535 Boulevard St. Charles, Suite 704",Kirkland,Québec,Canada,H9H 5B9,Chris Rose for Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000043959.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e127236"",
  ""submission_no"": ""282415"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""July 5, 2024"",
  ""product_name"": ""ARGATROBAN"",
  ""medicinal_ingredients"": ""Argatroban"",
  ""reason_for_submission"": ""Product Monograph reformatted to the Master Template / Reformatage de la monographie de produit vers le modèle principal\nAddition of new strength: 1 mg/mL / Ajout de nouvelle concentration: 1 mg/mL\nAddition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication ou d'un fabricant impliquant la fabrication de la substance médicamenteuse\nChange in the composition of a dosage form / Changement apporté à la composition de la forme pharmaceutique\nAddition of a drug product manufacturing site and/or manufacturer involving production / Ajout d'un site de fabrication ou d'un fabricant pour le produit médicamenteux impliquant la production\nAddition of a drug product manufacturing site and/or manufacturer involving testing / Ajout d'un site de fabrication ou d'un fabricant pour le produit médicamenteux impliquant les essais\nAddition of a primary container closure system / Ajout d'un dispositif de fermeture de l'emballage immédiat\nNew package insert / Nouvel encart\nUpdate to Patient Medication Information / Mise à jour des renseignements sur le médicament pour le patient\nUpdate to package insert / Mise à jour de l'encart"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02548968, Intravenous/Intraveineuse, Solution, 1 mg / mL\nN/A, Intravenous/Intraveineuse, Solution, 100 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {}
}",TRUE,NA,HC6-024-e127236,282415,"July 5, 2024",ARGATROBAN,Argatroban,"Product Monograph reformatted to the Master Template / Reformatage de la monographie de produit vers le modèle principal
Addition of new strength: 1 mg/mL / Ajout de nouvelle concentration: 1 mg/mL
Addition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication ou d'un fabricant impliquant la fabrication de la substance médicamenteuse
Change in the composition of a dosage form / Changement apporté à la composition de la forme pharmaceutique
Addition of a drug product manufacturing site and/or manufacturer involving production / Ajout d'un site de fabrication ou d'un fabricant pour le produit médicamenteux impliquant la production
Addition of a drug product manufacturing site and/or manufacturer involving testing / Ajout d'un site de fabrication ou d'un fabricant pour le produit médicamenteux impliquant les essais
Addition of a primary container closure system / Ajout d'un dispositif de fermeture de l'emballage immédiat
New package insert / Nouvel encart
Update to Patient Medication Information / Mise à jour des renseignements sur le médicament pour le patient
Update to package insert / Mise à jour de l'encart",,"02548968, Intravenous/Intraveineuse, Solution, 1 mg / mL
N/A, Intravenous/Intraveineuse, Solution, 100 mg / mL",,Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,NA,NA,NA,NA
https://pdf.hres.ca/noc_pm/0000043965.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e286201"",
  ""submission_no"": ""286201"",
  ""manufacturer"": {
    ""name"": ""Mantra Pharma Inc."",
    ""street"": ""1000 rue Du Lux, Suite 201"",
    ""city"": ""Brossard"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4Y 0E3""
  },
  ""date"": ""July 5, 2024"",
  ""product_name"": ""M-FEBUXOSTAT"",
  ""medicinal_ingredients"": ""Febuxostat supplied as Febuxostat Hemihydrate / Fébuxostat sous forme de hémihydrate de fébuxostat"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02549425, oral / orale, tablet / comprimé, 80 mg"",
  ""canadian_reference_product"": ""Uloric, Takeda Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e286201,286201,"July 5, 2024",M-FEBUXOSTAT,Febuxostat supplied as Febuxostat Hemihydrate / Fébuxostat sous forme de hémihydrate de fébuxostat,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants,,"02549425, oral / orale, tablet / comprimé, 80 mg","Uloric, Takeda Canada Inc., Canada",Mantra Pharma Inc.,"1000 rue Du Lux, Suite 201",Brossard,Quebec,Canada,J4Y 0E3,Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000044195.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e251588"",
  ""submission_no"": ""283876"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""Suite 100 – 700 Saint-Hubert Street"",
    ""city"": ""Montréal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H2Y 0C1""
  },
  ""date"": ""July 29, 2024"",
  ""product_name"": ""TABRECTA"",
  ""medicinal_ingredients"": ""Capmatinib (supplied as capmatinib hydrochloride / sous forme de chlorhydrate de capmatinib)"",
  ""reason_for_submission"": ""Addition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication ou d'un fabricant impliquant la fabrication de la substance médicamenteuse. Change in the manufacturing process for the drug substance / Changement apporté au procédé de fabrication de la substance médicamenteuse. Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 150 mg; N/A, Oral/Orale, Tablet/Comprimé, 200 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e251588,283876,"July 29, 2024",TABRECTA,Capmatinib (supplied as capmatinib hydrochloride / sous forme de chlorhydrate de capmatinib),Addition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication ou d'un fabricant impliquant la fabrication de la substance médicamenteuse. Change in the manufacturing process for the drug substance / Changement apporté au procédé de fabrication de la substance médicamenteuse. Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux.,,"N/A, Oral/Orale, Tablet/Comprimé, 150 mg; N/A, Oral/Orale, Tablet/Comprimé, 200 mg",,Novartis Pharmaceuticals Canada Inc.,Suite 100 – 700 Saint-Hubert Street,Montréal,Québec,Canada,H2Y 0C1,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044412.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v286927"",
  ""submission_no"": ""286927"",
  ""manufacturer"": {
    ""name"": ""BIMEDA-MTC ANIMAL HEALTH INC"",
    ""street"": ""420 Beaverdale Rd"",
    ""city"": ""Cambridge"",
    ""province"": ""ON"",
    ""country"": """",
    ""postal_code"": ""N3C 2W4""
  },
  ""date"": ""August 26, 2024"",
  ""product_name"": ""SOLMECTIN INJECTION FOR CATTLE AND SWINE"",
  ""medicinal_ingredients"": ""Ivermectin / Ivermectin"",
  ""reason_for_submission"": ""Administrative - Additional Product Name / Administratif - Nom complémentaire de produit"",
  ""species"": ""Cattle, Swine / Bovins, Porcs"",
  ""drug_identification_number_route_form_strength"": ""02551179, Subcutaneous, Solution, 10 mg/mL"",
  ""canadian_reference_product"": ""IVOMEC (DIN 00630470, Merial Canada Inc.)"",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v286927,286927,"August 26, 2024",SOLMECTIN INJECTION FOR CATTLE AND SWINE,Ivermectin / Ivermectin,Administrative - Additional Product Name / Administratif - Nom complémentaire de produit,"Cattle, Swine / Bovins, Porcs","02551179, Subcutaneous, Solution, 10 mg/mL","IVOMEC (DIN 00630470, Merial Canada Inc.)",BIMEDA-MTC ANIMAL HEALTH INC,420 Beaverdale Rd,Cambridge,ON,,N3C 2W4,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000044440.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e269453"",
  ""submission_no"": ""288891"",
  ""manufacturer"": {
    ""name"": ""Eugia Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""August 27, 2024"",
  ""product_name"": ""HYDRALAZINE HYDROCHLORIDE INJECTION, USP / CHLORHYDRATE D'HYDRALAZINE INJECTION, USP"",
  ""medicinal_ingredients"": ""Hydralazine Hydrochloride / Chlorhydrate d'hydralazine"",
  ""reason_for_submission"": ""Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, intravenous / intraveineuse, solution, 20 mg/mL"",
  ""canadian_reference_product"": ""Apresoline, SteriMax Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Mandy Collier"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e269453,288891,"August 27, 2024","HYDRALAZINE HYDROCHLORIDE INJECTION, USP / CHLORHYDRATE D'HYDRALAZINE INJECTION, USP",Hydralazine Hydrochloride / Chlorhydrate d'hydralazine,Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, intravenous / intraveineuse, solution, 20 mg/mL","Apresoline, SteriMax Inc., Canada",Eugia Pharma Inc.,"3700 Steeles Avenue West, Suite 402",Woodbridge,Ontario,Canada,L4L 8K8,Mandy Collier,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044452.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""262990"",
  ""submission_no"": ""262990"",
  ""manufacturer"": {
    ""name"": ""Lupin Pharma Canada Limited"",
    ""street"": ""550-1111 Rue St-Charles Ouest"",
    ""city"": ""Longueuil"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4K 5G4""
  },
  ""date"": ""August 16, 2024"",
  ""product_name"": ""Armlupeg"",
  ""medicinal_ingredients"": ""Pegfilgrastim"",
  ""reason_for_submission"": ""Armlupeg (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02550857, SC, SOL, 6 mg / 0.6 mL (10mg/mL)"",
  ""canadian_reference_product"": ""Neulasta (pegfilgrastim)"",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,262990,262990,"August 16, 2024",Armlupeg,Pegfilgrastim,"Armlupeg (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.",,"02550857, SC, SOL, 6 mg / 0.6 mL (10mg/mL)",Neulasta (pegfilgrastim),Lupin Pharma Canada Limited,550-1111 Rue St-Charles Ouest,Longueuil,Quebec,Canada,J4K 5G4,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044552.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e261716"",
  ""submission_no"": ""283462"",
  ""manufacturer"": {
    ""name"": ""Auro Pharma Inc."",
    ""street"": ""3700 Steeles Avenue West, Suite 402"",
    ""city"": ""Woodbridge"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4L 8K8""
  },
  ""date"": ""September 10, 2024"",
  ""product_name"": ""AURO-BRIVARACETAM"",
  ""medicinal_ingredients"": ""Brivaracetam / Brivaracétam"",
  ""reason_for_submission"": ""Updates to the Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 50 mg; N/A, Oral / Orale, Tablet / Comprimé, 100 mg"",
  ""canadian_reference_product"": ""BRIVLERA, UCB Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e261716,283462,"September 10, 2024",AURO-BRIVARACETAM,Brivaracetam / Brivaracétam,Updates to the Product Monograph / Mise à jour de la monographie de produit,,"N/A, Oral / Orale, Tablet / Comprimé, 50 mg; N/A, Oral / Orale, Tablet / Comprimé, 100 mg","BRIVLERA, UCB Canada Inc., Canada",Auro Pharma Inc.,"3700 Steeles Avenue West, Suite 402",Woodbridge,Ontario,Canada,L4L 8K8,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044578.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e188501"",
  ""submission_no"": ""289479"",
  ""manufacturer"": {
    ""name"": ""Laboratoire Riva Inc."",
    ""street"": ""660 Boul. Industriel"",
    ""city"": ""Blainville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7C 3V4""
  },
  ""date"": ""September 09, 2024"",
  ""product_name"": ""RIVA-GABAPENTIN"",
  ""medicinal_ingredients"": ""Gabapentin / Gabapentine"",
  ""reason_for_submission"": ""Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, capsule, 100 mg; N/A, oral / orale, capsule, 300 mg; N/A, oral / orale, capsule, 400 mg; N/A, oral / orale, tablet / comprimé, 600 mg; N/A, oral / orale, tablet / comprimé, 800 mg"",
  ""canadian_reference_product"": ""NEURONTIN (Capsule), Parke-Davis, Division of Warner-Lambert Canada Inc., Canada; NEURONTIN (Tablet / Comprimé), Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Tanya Ramsamy, Ph.D."",
    ""title"": ""Director / Directrice"",
    ""division"": ""Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e188501,289479,"September 09, 2024",RIVA-GABAPENTIN,Gabapentin / Gabapentine,Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, capsule, 100 mg; N/A, oral / orale, capsule, 300 mg; N/A, oral / orale, capsule, 400 mg; N/A, oral / orale, tablet / comprimé, 600 mg; N/A, oral / orale, tablet / comprimé, 800 mg","NEURONTIN (Capsule), Parke-Davis, Division of Warner-Lambert Canada Inc., Canada; NEURONTIN (Tablet / Comprimé), Pfizer Canada Inc., Canada",Laboratoire Riva Inc.,660 Boul. Industriel,Blainville,Quebec,Canada,J7C 3V4,"Tanya Ramsamy, Ph.D.",Director / Directrice,"Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales",Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000044631.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""287904"",
  ""submission_no"": ""287904"",
  ""manufacturer"": {
    ""name"": ""Moderna Biopharma Canada Corporation"",
    ""street"": ""155 Wellington St, West Suite 3130"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5V 3L3""
  },
  ""date"": ""September 17, 2024"",
  ""product_name"": ""Spikevax"",
  ""medicinal_ingredients"": ""mRNA encoding SARS-CoV-2 spike protein, 5’(m7G-5’-ppp-5’-Gm) cap, 100-nucleotide 3' poly(A) tail / ARNm codant pour la protéine de spicule du SRAS-CoV-2, protégé par une coiffe en 5’ (m7G-5’-ppp-5’-Gm) et terminé par une queue poly(A) de 100 nucléotides en 3’"",
  ""reason_for_submission"": ""Update to antigen composition (Omicron KP.2 variant) / mise à jour de la composition antigénique (variant Omicron KP.2)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IM, DISP, 0.1 mg / mL (multiple doses (5 doses of 0.5 mL per vial))"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,287904,287904,"September 17, 2024",Spikevax,"mRNA encoding SARS-CoV-2 spike protein, 5’(m7G-5’-ppp-5’-Gm) cap, 100-nucleotide 3' poly(A) tail / ARNm codant pour la protéine de spicule du SRAS-CoV-2, protégé par une coiffe en 5’ (m7G-5’-ppp-5’-Gm) et terminé par une queue poly(A) de 100 nucléotides en 3’",Update to antigen composition (Omicron KP.2 variant) / mise à jour de la composition antigénique (variant Omicron KP.2),,"N/A, IM, DISP, 0.1 mg / mL (multiple doses (5 doses of 0.5 mL per vial))",,Moderna Biopharma Canada Corporation,"155 Wellington St, West Suite 3130",Toronto,Ontario,Canada,M5V 3L3,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044714.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e157878"",
  ""submission_no"": ""287372"",
  ""manufacturer"": {
    ""name"": ""Laboratoire Riva Inc."",
    ""street"": ""660 Boul. Industriel"",
    ""city"": ""Blainville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7C 3V4""
  },
  ""date"": ""June 25, 2024"",
  ""product_name"": ""RIVA-ANASTROZOLE"",
  ""medicinal_ingredients"": ""Anastrozole"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02392259, oral / orale, tablet / comprimé, 1 mg"",
  ""canadian_reference_product"": ""ARIMIDEX, AstraZeneca Pharmaceuticals LP, USA"",
  ""authorizing_official"": {
    ""name"": ""Chris Rose for Karen Reynolds"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e157878,287372,"June 25, 2024",RIVA-ANASTROZOLE,Anastrozole,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants,,"02392259, oral / orale, tablet / comprimé, 1 mg","ARIMIDEX, AstraZeneca Pharmaceuticals LP, USA",Laboratoire Riva Inc.,660 Boul. Industriel,Blainville,Quebec,Canada,J7C 3V4,Chris Rose for Karen Reynolds,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044765.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""288077"",
  ""submission_no"": ""288077"",
  ""manufacturer"": {
    ""name"": ""Novavax Inc."",
    ""street"": ""700 Quince Orchard Rd."",
    ""city"": ""Gaithersburg"",
    ""province"": ""MD"",
    ""country"": ""USA"",
    ""postal_code"": ""20878""
  },
  ""date"": ""September 19, 2024"",
  ""product_name"": ""Nuvaxovid"",
  ""medicinal_ingredients"": ""SARS-CoV-2 recombinant spike protein"",
  ""reason_for_submission"": ""Update to antigen composition (Omicron JN.1 variant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IM, SUS, 5 mcg / 0.5 mL (vial contains 5 doses of 0.5 mL)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate"",
    ""directorate"": ""Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,288077,288077,"September 19, 2024",Nuvaxovid,SARS-CoV-2 recombinant spike protein,Update to antigen composition (Omicron JN.1 variant),,"N/A, IM, SUS, 5 mcg / 0.5 mL (vial contains 5 doses of 0.5 mL)",,Novavax Inc.,700 Quince Orchard Rd.,Gaithersburg,MD,USA,20878,Sophie Sommerer,Director General,Biologic and Radiopharmaceutical Drugs Directorate,Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000044818.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""286502"",
  ""submission_no"": ""286502"",
  ""manufacturer"": {
    ""name"": ""Regeneron Canada Company"",
    ""street"": ""868 - 2425 Matheson Boulevard East"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L4W 5K4""
  },
  ""date"": ""September 25, 2024"",
  ""product_name"": ""Libtayo"",
  ""medicinal_ingredients"": ""Cemiplimab / Cémiplimab"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 350 mg / 7mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,286502,286502,"September 25, 2024",Libtayo,Cemiplimab / Cémiplimab,Update to the Product Monograph / Mise à jour de la monographie de produit,,"N/A, IV, SOL, 350 mg / 7mL",,Regeneron Canada Company,868 - 2425 Matheson Boulevard East,Mississauga,Ontario,Canada,L4W 5K4,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000044831.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e127448"",
  ""submission_no"": ""278353"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""700 Rue Saint-Hubert, Suite 100"",
    ""city"": ""Montréal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H2Y 0C1""
  },
  ""date"": ""September 24, 2024"",
  ""product_name"": ""TRILEPTAL"",
  ""medicinal_ingredients"": ""Oxcarbazepine / Oxcarbazépine"",
  ""reason_for_submission"": ""Update to the Product Monograph with new safety information / Mise à jour de la monographie de produit avec de nouveaux renseignements relatifs à l'innocuité"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Suspension, 60 mg / mL; N/A, Oral/Orale, Tablet/Comprimé, 300 mg; N/A, Oral/Orale, Tablet/Comprimé, 600 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e127448,278353,"September 24, 2024",TRILEPTAL,Oxcarbazepine / Oxcarbazépine,Update to the Product Monograph with new safety information / Mise à jour de la monographie de produit avec de nouveaux renseignements relatifs à l'innocuité,,"N/A, Oral/Orale, Suspension, 60 mg / mL; N/A, Oral/Orale, Tablet/Comprimé, 300 mg; N/A, Oral/Orale, Tablet/Comprimé, 600 mg",,Novartis Pharmaceuticals Canada Inc.,"700 Rue Saint-Hubert, Suite 100",Montréal,Quebec,Canada,H2Y 0C1,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000044891.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e267932"",
  ""submission_no"": ""267932"",
  ""manufacturer"": {
    ""name"": ""JAMP Pharma Corporation"",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""October 4, 2024"",
  ""product_name"": ""JAMP FLUDROCORTISONE"",
  ""medicinal_ingredients"": ""Fludrocortisone Acetate / Acétate de fludrocortisone"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02552248, Oral / Orale, Tablet (Immediate Release) / Comprimé (à libération immédiate), 0.1 mg"",
  ""canadian_reference_product"": ""FLORINEF, Paladin Labs Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,HC6-024-e267932,267932,"October 4, 2024",JAMP FLUDROCORTISONE,Fludrocortisone Acetate / Acétate de fludrocortisone,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02552248, Oral / Orale, Tablet (Immediate Release) / Comprimé (à libération immédiate), 0.1 mg","FLORINEF, Paladin Labs Inc., Canada",JAMP Pharma Corporation,1310 rue Nobel,Boucherville,Québec,Canada,J4B 5H3,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000044895.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e126216"",
  ""submission_no"": ""285880"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""October 4, 2024"",
  ""product_name"": ""ACT LEVOFLOXACIN"",
  ""medicinal_ingredients"": ""Levofloxacin (supplied as levofloxacin hemihydrate) / Lévofloxacine (sous forme de hémihydrate de lévofloxacine)"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la Monographie de Produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 250 mg; N/A, Oral/Orale, Tablet/Comprimé, 500 mg; N/A, Oral/Orale, Tablet/Comprimé, 750 mg"",
  ""canadian_reference_product"": ""Levaquin, Janssen-Ortho Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Scott Appleton, PhD"",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1"",
    ""directorate"": ""Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,HC6-024-e126216,285880,"October 4, 2024",ACT LEVOFLOXACIN,Levofloxacin (supplied as levofloxacin hemihydrate) / Lévofloxacine (sous forme de hémihydrate de lévofloxacine),Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la Monographie de Produit,,"N/A, Oral/Orale, Tablet/Comprimé, 250 mg; N/A, Oral/Orale, Tablet/Comprimé, 500 mg; N/A, Oral/Orale, Tablet/Comprimé, 750 mg","Levaquin, Janssen-Ortho Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,"Scott Appleton, PhD",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1,Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000045153.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""HC6-024-e139182"",
  ""submission_no"": ""280628"",
  ""manufacturer"": {
    ""name"": ""Pharmascience Inc."",
    ""street"": ""6111 Royalmount Ave., Suite 100"",
    ""city"": ""Montréal"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""October 28, 2024"",
  ""product_name"": ""PMS-NAPROXEN"",
  ""medicinal_ingredients"": ""Naproxen / Naproxène"",
  ""reason_for_submission"": ""Update to the Product Monograph as per advisement letter / Mise à jour de la monographie de produit conformément à la lettre d'avis"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Rectal / Rectale, Suppository / Suppositoire, 500 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,HC6-024-e139182,280628,"October 28, 2024",PMS-NAPROXEN,Naproxen / Naproxène,Update to the Product Monograph as per advisement letter / Mise à jour de la monographie de produit conformément à la lettre d'avis,,"N/A, Rectal / Rectale, Suppository / Suppositoire, 500 mg",,Pharmascience Inc.,"6111 Royalmount Ave., Suite 100",Montréal,Québec,Canada,H4P 2T4,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000045296.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e283688"",
  ""submission_no"": ""283688"",
  ""manufacturer"": {
    ""name"": ""Taro Pharmaceuticals Inc."",
    ""street"": ""130 East Drive"",
    ""city"": ""Brampton"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L6T 1C1""
  },
  ""date"": ""November 13, 2024"",
  ""product_name"": ""TARO-DEFERIPRONE"",
  ""medicinal_ingredients"": ""Deferiprone / Défériprone"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02553112, Oral / Orale, Tablet / Comprimé, 1000 mg"",
  ""canadian_reference_product"": ""FERRIPROX, Chiesi Canada Corp., Canada"",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e283688,283688,"November 13, 2024",TARO-DEFERIPRONE,Deferiprone / Défériprone,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02553112, Oral / Orale, Tablet / Comprimé, 1000 mg","FERRIPROX, Chiesi Canada Corp., Canada",Taro Pharmaceuticals Inc.,130 East Drive,Brampton,Ontario,Canada,L6T 1C1,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000045859.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e135426"",
  ""submission_no"": ""289933"",
  ""manufacturer"": {
    ""name"": ""Jazz Pharmaceuticals Ireland Limited"",
    ""street"": ""5th Floor, Waterloo Exchange, Waterloo Rd."",
    ""city"": ""Dublin"",
    ""province"": ""Ireland"",
    ""country"": ""Ireland"",
    ""postal_code"": ""D04 E5W7""
  },
  ""date"": ""January 23, 2025"",
  ""product_name"": ""XYREM"",
  ""medicinal_ingredients"": ""Sodium Oxybate / Oxybate de sodium"",
  ""reason_for_submission"": ""Update to the Product Monograph with new safety information"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Solution, 500 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Karen Reynolds"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e135426,289933,"January 23, 2025",XYREM,Sodium Oxybate / Oxybate de sodium,Update to the Product Monograph with new safety information,,"N/A, Oral/Orale, Solution, 500 mg / mL",,Jazz Pharmaceuticals Ireland Limited,"5th Floor, Waterloo Exchange, Waterloo Rd.",Dublin,Ireland,Ireland,D04 E5W7,Karen Reynolds,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000046087.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e120166"",
  ""submission_no"": ""287053"",
  ""manufacturer"": {
    ""name"": ""Sanofi-Aventis Canada Inc"",
    ""street"": ""1755 Steeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2R 3T4""
  },
  ""date"": ""February 21, 2025"",
  ""product_name"": ""PLAQUENIL"",
  ""medicinal_ingredients"": ""Hydroxychloroquine sulfate / Sulfate d'hydroxychloroquine"",
  ""reason_for_submission"": ""Update to the Product Monograph with new safety information / Mise à jour de la monographie de produit avec de nouveaux renseignements relatifs à l'innocuité"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 200 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e120166,287053,"February 21, 2025",PLAQUENIL,Hydroxychloroquine sulfate / Sulfate d'hydroxychloroquine,Update to the Product Monograph with new safety information / Mise à jour de la monographie de produit avec de nouveaux renseignements relatifs à l'innocuité,,"N/A, Oral / Orale, Tablet / Comprimé, 200 mg",,Sanofi-Aventis Canada Inc,1755 Steeles Avenue West,Toronto,Ontario,Canada,M2R 3T4,Melissa Hunt,Acting Director General / Directrice générale par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000046096.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e120841"",
  ""submission_no"": ""293827"",
  ""manufacturer"": {
    ""name"": ""Apotex Inc."",
    ""street"": ""150 Signet Drive"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M9L 1T9""
  },
  ""date"": ""February 20, 2025"",
  ""product_name"": ""APO-ROSUVASTATIN"",
  ""medicinal_ingredients"": ""Rosuvastatin (supplied as rosuvastatin calcium) / Rosuvastatine (sous forme de rosuvastatine calcique)"",
  ""reason_for_submission"": ""Update to Product Monograph / Mise à jour de la monographie de produit."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 5 mg; N/A, Oral/Orale, Tablet/Comprimé, 10 mg; N/A, Oral/Orale, Tablet/Comprimé, 20 mg; N/A, Oral/Orale, Tablet/Comprimé, 40 mg"",
  ""canadian_reference_product"": ""CRESTOR, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Scott Appleton, PhD"",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e120841,293827,"February 20, 2025",APO-ROSUVASTATIN,Rosuvastatin (supplied as rosuvastatin calcium) / Rosuvastatine (sous forme de rosuvastatine calcique),Update to Product Monograph / Mise à jour de la monographie de produit.,,"N/A, Oral/Orale, Tablet/Comprimé, 5 mg; N/A, Oral/Orale, Tablet/Comprimé, 10 mg; N/A, Oral/Orale, Tablet/Comprimé, 20 mg; N/A, Oral/Orale, Tablet/Comprimé, 40 mg","CRESTOR, AstraZeneca Canada Inc., Canada",Apotex Inc.,150 Signet Drive,Toronto,Ontario,Canada,M9L 1T9,"Scott Appleton, PhD",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000046098.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e144088"",
  ""submission_no"": ""293550"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 Rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""February 20, 2025"",
  ""product_name"": ""SANDOZ TELMISARTAN HCT"",
  ""medicinal_ingredients"": ""Telmisartan / Hydrochlorothiazide"",
  ""reason_for_submission"": ""Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la Monographie de Produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 80 mg / 12.5 mg; N/A, Oral/Orale, Tablet/Comprimé, 80 mg / 25 mg"",
  ""canadian_reference_product"": ""MICARDIS PLUS, Boehringer Ingelheim (Canada) Ltd., Canada"",
  ""authorizing_official"": {
    ""name"": ""Scott Appleton, PhD"",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1"",
    ""directorate"": ""Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e144088,293550,"February 20, 2025",SANDOZ TELMISARTAN HCT,Telmisartan / Hydrochlorothiazide,Safety updates to the Product Monograph / Mise à jour de l'innocuité dans la Monographie de Produit,,"N/A, Oral/Orale, Tablet/Comprimé, 80 mg / 12.5 mg; N/A, Oral/Orale, Tablet/Comprimé, 80 mg / 25 mg","MICARDIS PLUS, Boehringer Ingelheim (Canada) Ltd., Canada",Sandoz Canada Inc.,110 Rue de Lauzon,Boucherville,Quebec,Canada,J4B 1E6,"Scott Appleton, PhD",Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 1 / Division de l'évaluation biopharmaceutique 1,Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000046102.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e120247"",
  ""submission_no"": ""290185"",
  ""manufacturer"": {
    ""name"": ""PENDOPHARM, Division of Pharmascience Inc"",
    ""street"": ""6111 Royalmount Ave 100"",
    ""city"": ""Montreal"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4P 2T4""
  },
  ""date"": ""February 25, 2025"",
  ""product_name"": ""ENTROPHEN"",
  ""medicinal_ingredients"": ""Acetylsalicylic acid"",
  ""reason_for_submission"": ""Update to Product Monograph (to align with CRP approved PM)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral, Tablet (Delayed-Release), 81 mg"",
  ""canadian_reference_product"": ""ASPIRIN 81MG, Bayer Inc, Canada"",
  ""authorizing_official"": {
    ""name"": ""Stephen Norman"",
    ""title"": ""Director General"",
    ""division"": ""Natural and Non-prescription Health Products Directorate"",
    ""directorate"": ""Direction des produits de santé naturels et sans ordonnance""
  }
}",TRUE,NA,e120247,290185,"February 25, 2025",ENTROPHEN,Acetylsalicylic acid,Update to Product Monograph (to align with CRP approved PM),,"N/A, Oral, Tablet (Delayed-Release), 81 mg","ASPIRIN 81MG, Bayer Inc, Canada","PENDOPHARM, Division of Pharmascience Inc",6111 Royalmount Ave 100,Montreal,QC,Canada,H4P 2T4,Stephen Norman,Director General,Natural and Non-prescription Health Products Directorate,Direction des produits de santé naturels et sans ordonnance
https://pdf.hres.ca/noc_pm/0000046151.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e118900"",
  ""submission_no"": ""288541"",
  ""manufacturer"": {
    ""name"": ""Baxter corporation"",
    ""street"": ""7125 Mississauga Road"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 0C2""
  },
  ""date"": ""March 4, 2025"",
  ""product_name"": ""OLIMEL 4.4%, OLIMEL 5.7%, OLIMEL 7.6%"",
  ""medicinal_ingredients"": ""Amino Acids/Acides Aminés, Dextrose, Lipids/Lipides"",
  ""reason_for_submission"": ""Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux"",
  ""species"": ""N/A"",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous/Intraveineuse, Emulsion/Émulsion, 4.4% w/v / 14% w/v / 4% w/v / 11% w/v / 4% w/v / 7.3% w/v / 3.5% w/v"",
  ""canadian_reference_product"": ""N/A"",
  ""authorizing_official"": {
    ""name"": ""Melissa Hunt"",
    ""title"": ""Acting Director General / Directrice générale par intérim"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e118900,288541,"March 4, 2025","OLIMEL 4.4%, OLIMEL 5.7%, OLIMEL 7.6%","Amino Acids/Acides Aminés, Dextrose, Lipids/Lipides",Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux,N/A,"N/A, Intravenous/Intraveineuse, Emulsion/Émulsion, 4.4% w/v / 14% w/v / 4% w/v / 11% w/v / 4% w/v / 7.3% w/v / 3.5% w/v",N/A,Baxter corporation,7125 Mississauga Road,Mississauga,Ontario,Canada,L5N 0C2,Melissa Hunt,Acting Director General / Directrice générale par intérim,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000046327.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e255389"",
  ""submission_no"": ""271972"",
  ""manufacturer"": {
    ""name"": ""Formative Pharma Inc."",
    ""street"": ""4145 North Service Road, Suite 200"",
    ""city"": ""Burlington"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L7L 6A3""
  },
  ""date"": ""March 20, 2025"",
  ""product_name"": ""XFUSOR"",
  ""medicinal_ingredients"": ""Ropivacaine Hydrochloride / Chlorhydrate de ropivacaïne"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02556472, Block/Infiltration / Bloc/Infiltration, Solution, 2 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e255389,271972,"March 20, 2025",XFUSOR,Ropivacaine Hydrochloride / Chlorhydrate de ropivacaïne,This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations.,,"02556472, Block/Infiltration / Bloc/Infiltration, Solution, 2 mg / mL",,Formative Pharma Inc.,"4145 North Service Road, Suite 200",Burlington,Ontario,Canada,L7L 6A3,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000046393.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e294456"",
  ""submission_no"": ""294456"",
  ""manufacturer"": {
    ""name"": ""Angita Pharma Inc."",
    ""street"": ""1310 rue Nobel"",
    ""city"": ""Boucherville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 5H3""
  },
  ""date"": ""March 31, 2025"",
  ""product_name"": ""AG-PERINDOPRIL / INDAPAMIDE"",
  ""medicinal_ingredients"": ""Perindopril Erbumine / Périndopril erbumine, Indapamide"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02447991, oral / orale, tablet / comprimé, 2 mg / 0.625 mg; 02448009, oral / orale, tablet / comprimé, 4 mg /1.25 mg; 02448017, oral / orale, tablet / comprimé, 8 mg / 2.5 mg"",
  ""canadian_reference_product"": ""COVERSYL PLUS HD, Servier Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e294456,294456,"March 31, 2025",AG-PERINDOPRIL / INDAPAMIDE,"Perindopril Erbumine / Périndopril erbumine, Indapamide",Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants,,"02447991, oral / orale, tablet / comprimé, 2 mg / 0.625 mg; 02448009, oral / orale, tablet / comprimé, 4 mg /1.25 mg; 02448017, oral / orale, tablet / comprimé, 8 mg / 2.5 mg","COVERSYL PLUS HD, Servier Canada Inc., Canada",Angita Pharma Inc.,1310 rue Nobel,Boucherville,Quebec,Canada,J4B 5H3,Kelly Robinson,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000046444.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e284229"",
  ""submission_no"": ""295075"",
  ""manufacturer"": {
    ""name"": ""NB Pharma Inc."",
    ""street"": ""2700 Jean-Perrin, Ste 208"",
    ""city"": ""Québec"",
    ""province"": ""G2C 1S9"",
    ""country"": ""Canada"",
    ""postal_code"": ""G2C 1S9""
  },
  ""date"": ""April 2, 2025"",
  ""product_name"": ""NB-AMLODIPINE"",
  ""medicinal_ingredients"": ""Amlodipine supplied as Amlodipine Besylate / Amlodipine sous forme de bésylate d’amlodipine"",
  ""reason_for_submission"": ""Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02556707, oral / orale, tablet / comprimé, 2.5 mg; 02556715, oral / orale, tablet / comprimé, 5 mg; 02556723, oral / orale, tablet / comprimé, 10 mg"",
  ""canadian_reference_product"": ""NORVASC, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e284229,295075,"April 2, 2025",NB-AMLODIPINE,Amlodipine supplied as Amlodipine Besylate / Amlodipine sous forme de bésylate d’amlodipine,Administrative: Licensing Agreement between two manufacturers / Administratif: Accord de licence entre deux fabricants,,"02556707, oral / orale, tablet / comprimé, 2.5 mg; 02556715, oral / orale, tablet / comprimé, 5 mg; 02556723, oral / orale, tablet / comprimé, 10 mg","NORVASC, Pfizer Canada Inc., Canada",NB Pharma Inc.,"2700 Jean-Perrin, Ste 208",Québec,G2C 1S9,Canada,G2C 1S9,Kelly Robinson,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000046521.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e140647"",
  ""submission_no"": ""294917"",
  ""manufacturer"": {
    ""name"": ""Generic Medical Partners Inc."",
    ""street"": ""1500 Don Mills Road, Suite 711"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M3B 3K4""
  },
  ""date"": ""April 11, 2025"",
  ""product_name"": ""MED-ANASTROZOLE"",
  ""medicinal_ingredients"": ""Anastrozole"",
  ""reason_for_submission"": ""Update to Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 1 mg"",
  ""canadian_reference_product"": ""ARIMIDEX, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Sophie Gaudreault"",
    ""title"": ""Manager / Gestionnaire"",
    ""division"": ""Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2"",
    ""directorate"": ""Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e140647,294917,"April 11, 2025",MED-ANASTROZOLE,Anastrozole,Update to Product Monograph / Mise à jour de la monographie de produit,,"N/A, Oral / Orale, Tablet / Comprimé, 1 mg","ARIMIDEX, AstraZeneca Canada Inc., Canada",Generic Medical Partners Inc.,"1500 Don Mills Road, Suite 711",Toronto,Ontario,Canada,M3B 3K4,Sophie Gaudreault,Manager / Gestionnaire,Division of Biopharmaceutics Evaluation 2 / Division de l'évaluation biopharmaceutique 2,Pharmaceutical Drugs Directorate/ Direction des médicaments pharmaceutiques
https://pdf.hres.ca/noc_pm/0000046616.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e128061"",
  ""submission_no"": ""292241"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""April 25, 2025"",
  ""product_name"": ""TEVA-ROSUVASTATIN"",
  ""medicinal_ingredients"": ""Rosuvastatin Calcium / Rosuvastatine calcique"",
  ""reason_for_submission"": ""Update to Package Labels / Mise à jour de l'étiquetage"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral/Orale, Tablet/Comprimé, 5 mg; N/A, Oral/Orale, Tablet/Comprimé, 10 mg; N/A, Oral/Orale, Tablet/Comprimé, 20 mg; N/A, Oral/Orale, Tablet/Comprimé, 40 mg"",
  ""canadian_reference_product"": ""CRESTOR, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e128061,292241,"April 25, 2025",TEVA-ROSUVASTATIN,Rosuvastatin Calcium / Rosuvastatine calcique,Update to Package Labels / Mise à jour de l'étiquetage,,"N/A, Oral/Orale, Tablet/Comprimé, 5 mg; N/A, Oral/Orale, Tablet/Comprimé, 10 mg; N/A, Oral/Orale, Tablet/Comprimé, 20 mg; N/A, Oral/Orale, Tablet/Comprimé, 40 mg","CRESTOR, AstraZeneca Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000046727.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e271421"",
  ""submission_no"": ""284373"",
  ""manufacturer"": {
    ""name"": ""Bristol-Myers Squibb Canada"",
    ""street"": ""2344 Boul. Alfred-Nobel, Suite 300"",
    ""city"": ""St-Laurent"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H4S 0A4""
  },
  ""date"": ""May 7, 2025"",
  ""product_name"": ""AUGTYRO"",
  ""medicinal_ingredients"": ""Repotrectinib"",
  ""reason_for_submission"": ""This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02557444, Oral / Orale, Capsule, 40 mg; 02557452, Oral / Orale, Capsule, 160 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e271421,284373,"May 7, 2025",AUGTYRO,Repotrectinib,This is to notify you that the above new drug submission complies with the requirements of sections C.08.002 and C.08.005.1 of the Food and Drug Regulations.,,"02557444, Oral / Orale, Capsule, 40 mg; 02557452, Oral / Orale, Capsule, 160 mg",,Bristol-Myers Squibb Canada,"2344 Boul. Alfred-Nobel, Suite 300",St-Laurent,Quebec,Canada,H4S 0A4,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000046957.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v170635"",
  ""submission_no"": ""296147"",
  ""manufacturer"": {
    ""name"": ""Phibro Animal Health Corporation"",
    ""street"": ""300 Frank W Burr Blvd."",
    ""city"": ""Teaneck"",
    ""province"": ""NJ"",
    ""country"": ""USA"",
    ""postal_code"": ""07666""
  },
  ""date"": ""June 2, 2025"",
  ""product_name"": ""DECCOX 6%"",
  ""medicinal_ingredients"": ""Decoquinate"",
  ""reason_for_submission"": ""Administrative - Change in Product Ownership"",
  ""species"": ""Broiler chickens, Cattle, Sheep"",
  ""drug_identification_number_route_form_strength"": ""00867349, Oral, Drug premix, 60 g/kg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v170635,296147,"June 2, 2025",DECCOX 6%,Decoquinate,Administrative - Change in Product Ownership,"Broiler chickens, Cattle, Sheep","00867349, Oral, Drug premix, 60 g/kg",,Phibro Animal Health Corporation,300 Frank W Burr Blvd.,Teaneck,NJ,USA,07666,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000047067.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e252284"",
  ""submission_no"": ""252284"",
  ""manufacturer"": {
    ""name"": ""Mint Pharmaceuticals Inc."",
    ""street"": ""6575 Davand Drive"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5T 2M3""
  },
  ""date"": ""June 17, 2025"",
  ""product_name"": ""MINT-LEVETIRACETAM SOLUTION"",
  ""medicinal_ingredients"": ""Levetiracetam / Lévétiracétam"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""02558416, Oral / Orale, Solution / Solution, 100 mg/mL"",
  ""canadian_reference_product"": ""pdp-levETIRAcetam, PENDOPHARM, Division of Pharmascience Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Chris Rose for Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e252284,252284,"June 17, 2025",MINT-LEVETIRACETAM SOLUTION,Levetiracetam / Lévétiracétam,"This is to notify you that the above abbreviated new drug submission complies with the requirements of sections C.08.002.1 and C.08.005.1 of the Food and Drug Regulations. Pursuant to section C.08.004 of the Food and Drug Regulations, this Notice of Compliance is issued.",,"02558416, Oral / Orale, Solution / Solution, 100 mg/mL","pdp-levETIRAcetam, PENDOPHARM, Division of Pharmascience Inc., Canada",Mint Pharmaceuticals Inc.,6575 Davand Drive,Mississauga,Ontario,Canada,L5T 2M3,Chris Rose for Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000047231.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""289770"",
  ""submission_no"": ""289770"",
  ""manufacturer"": {
    ""name"": ""GlaxoSmithKline Inc."",
    ""street"": ""100 Milverton Drive, Suite 800"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5R 4H1""
  },
  ""date"": ""July 2, 2025"",
  ""product_name"": ""Boostrix"",
  ""medicinal_ingredients"": ""Diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin / Anatoxine diphtérique, anatoxine tétanique, anatoxine coquelucheuse, hémagglutinine filamenteuse, pertactin"",
  ""reason_for_submission"": ""Additional manufacturing site / Addition d’un site de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IM, SUS, 0.5 mL (single dose / dose unique)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,289770,289770,"July 2, 2025",Boostrix,"Diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin / Anatoxine diphtérique, anatoxine tétanique, anatoxine coquelucheuse, hémagglutinine filamenteuse, pertactin",Additional manufacturing site / Addition d’un site de fabrication,,"N/A, IM, SUS, 0.5 mL (single dose / dose unique)",,GlaxoSmithKline Inc.,"100 Milverton Drive, Suite 800",Mississauga,Ontario,Canada,L5R 4H1,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000047240.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e126730"",
  ""submission_no"": ""292967"",
  ""manufacturer"": {
    ""name"": ""Novartis Pharmaceuticals Canada Inc."",
    ""street"": ""100, 700 Rue Saint-Hubert"",
    ""city"": ""Montréal"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""H2Y 0C1""
  },
  ""date"": ""July 4, 2025"",
  ""product_name"": ""TOBREX"",
  ""medicinal_ingredients"": ""Tobramycin / Tobramycine"",
  ""reason_for_submission"": ""Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Ophthalmic/Ophtalmique, Solution, 0.3% w/v"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e126730,292967,"July 4, 2025",TOBREX,Tobramycin / Tobramycine,Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux,,"N/A, Ophthalmic/Ophtalmique, Solution, 0.3% w/v",,Novartis Pharmaceuticals Canada Inc.,"100, 700 Rue Saint-Hubert",Montréal,Quebec,Canada,H2Y 0C1,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000047310.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""293410"",
  ""submission_no"": ""293410"",
  ""manufacturer"": {
    ""name"": ""Amgen Canada Inc."",
    ""street"": ""6775 Financial Drive, Suite 300"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 0A4""
  },
  ""date"": ""June 27, 2025"",
  ""product_name"": ""Aranesp"",
  ""medicinal_ingredients"": ""darbepoetin alfa"",
  ""reason_for_submission"": ""drug substance manufacturing process change / changement au processus de fabrication de la substance médicamenteuse"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC/IV, SOL, 15 µg/mL (single-use vials) / N/A, SC/IV, SOL, 60 µg/mL (single-use vials) / N/A, SC/IV, SOL, 325 µg/mL (single-use vials) / N/A, SC/IV, SOL, 200 µg/mL (130 µg/0.65 mL Prefilled Syringe) / N/A, SC/IV, SOL, 500 µg/mL (300 µg/0.6 mL Prefilled Syringe) / N/A, SC/IV, SOL, 500 µg/mL (400 µg/0.8 mL Prefilled Syringe) / N/A, SC/IV, SOL, 500 µg/mL (500 µg/mL Prefilled Syringe)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,293410,293410,"June 27, 2025",Aranesp,darbepoetin alfa,drug substance manufacturing process change / changement au processus de fabrication de la substance médicamenteuse,,"N/A, SC/IV, SOL, 15 µg/mL (single-use vials) / N/A, SC/IV, SOL, 60 µg/mL (single-use vials) / N/A, SC/IV, SOL, 325 µg/mL (single-use vials) / N/A, SC/IV, SOL, 200 µg/mL (130 µg/0.65 mL Prefilled Syringe) / N/A, SC/IV, SOL, 500 µg/mL (300 µg/0.6 mL Prefilled Syringe) / N/A, SC/IV, SOL, 500 µg/mL (400 µg/0.8 mL Prefilled Syringe) / N/A, SC/IV, SOL, 500 µg/mL (500 µg/mL Prefilled Syringe)",,Amgen Canada Inc.,"6775 Financial Drive, Suite 300",Mississauga,Ontario,Canada,L5N 0A4,,,,
https://pdf.hres.ca/noc_pm/0000047341.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e233861"",
  ""submission_no"": ""289289"",
  ""manufacturer"": {
    ""name"": ""Loxo Oncology Inc"",
    ""street"": ""Fl 9, 281 Tresser Blvd"",
    ""city"": ""Stamford"",
    ""province"": ""Connecticut"",
    ""country"": ""United States"",
    ""postal_code"": ""06901""
  },
  ""date"": ""July 22, 2025"",
  ""product_name"": ""RETEVMO"",
  ""medicinal_ingredients"": ""Selpercatinib"",
  ""reason_for_submission"": ""Update to the Product Monograph with new safety and efficacy information"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Capsule, 40 mg; N/A, Oral / Orale, Capsule, 80 mg"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e233861,289289,"July 22, 2025",RETEVMO,Selpercatinib,Update to the Product Monograph with new safety and efficacy information,,"N/A, Oral / Orale, Capsule, 40 mg; N/A, Oral / Orale, Capsule, 80 mg",,Loxo Oncology Inc,"Fl 9, 281 Tresser Blvd",Stamford,Connecticut,United States,06901,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000047356.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e220985"",
  ""submission_no"": ""296914"",
  ""manufacturer"": {
    ""name"": ""Mantra Pharma Inc."",
    ""street"": ""1000 rue Du Lux, Suite 201"",
    ""city"": ""Brossard"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4Y 0E3""
  },
  ""date"": ""July 22, 2025"",
  ""product_name"": ""M-PERINDOPRIL ERBUMINE"",
  ""medicinal_ingredients"": ""Perindopril Erbumine / Périndopril erbumine"",
  ""reason_for_submission"": ""Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 2 mg; N/A, oral / orale, tablet / comprimé, 4 mg; N/A, oral / orale, tablet / comprimé, 8 mg"",
  ""canadian_reference_product"": ""Coversyl, Servier Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General – Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e220985,296914,"July 22, 2025",M-PERINDOPRIL ERBUMINE,Perindopril Erbumine / Périndopril erbumine,Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, tablet / comprimé, 2 mg; N/A, oral / orale, tablet / comprimé, 4 mg; N/A, oral / orale, tablet / comprimé, 8 mg","Coversyl, Servier Canada Inc., Canada",Mantra Pharma Inc.,"1000 rue Du Lux, Suite 201",Brossard,Quebec,Canada,J4Y 0E3,Kelly Robinson,Director General – Directrice générale,Pharmaceutical Drugs Directorate – Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000047372.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e150833"",
  ""submission_no"": ""293373"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 Rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""July 23, 2025"",
  ""product_name"": ""CIPROFLOXACIN INTRAVENOUS INFUSION BP"",
  ""medicinal_ingredients"": ""Ciprofloxacin / Ciprofloxacine"",
  ""reason_for_submission"": ""Addition of a manufacturing site and/or manufacturer involving production of the drug substance intermediate"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous/Intraveineuse, Solution, 2 mg / mL"",
  ""canadian_reference_product"": ""CIPRO I.V. MINIBAGS, Bayer Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e150833,293373,"July 23, 2025",CIPROFLOXACIN INTRAVENOUS INFUSION BP,Ciprofloxacin / Ciprofloxacine,Addition of a manufacturing site and/or manufacturer involving production of the drug substance intermediate,,"N/A, Intravenous/Intraveineuse, Solution, 2 mg / mL","CIPRO I.V. MINIBAGS, Bayer Inc., Canada",Sandoz Canada Inc.,110 Rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000047416.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""296139"",
  ""submission_no"": ""296139"",
  ""manufacturer"": {
    ""name"": ""EMD Serono, A Division of EMD Inc. Canada"",
    ""street"": ""200-2695 North Sheridan Way"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5K 2N6""
  },
  ""date"": ""July 28, 2025"",
  ""product_name"": ""Bavencio"",
  ""medicinal_ingredients"": ""Avelumab / Avélumab"",
  ""reason_for_submission"": ""Update to the Product Monograph / Mise à jour de la monographie de produit"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, IV, SOL, 20 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,296139,296139,"July 28, 2025",Bavencio,Avelumab / Avélumab,Update to the Product Monograph / Mise à jour de la monographie de produit,,"N/A, IV, SOL, 20 mg/mL",,"EMD Serono, A Division of EMD Inc. Canada",200-2695 North Sheridan Way,Mississauga,Ontario,Canada,L5K 2N6,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,
https://pdf.hres.ca/noc_pm/0000047492.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e119041"",
  ""submission_no"": ""293764"",
  ""manufacturer"": {
    ""name"": ""Sandoz Canada Inc."",
    ""street"": ""110 rue de Lauzon"",
    ""city"": ""Boucherville"",
    ""province"": ""Québec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J4B 1E6""
  },
  ""date"": ""August 8, 2025"",
  ""product_name"": ""SANDOZ IRBESARTAN"",
  ""medicinal_ingredients"": ""Irbesartan"",
  ""reason_for_submission"": ""Addition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication ou d'un fabricant impliquant la fabrication de la substance médicamenteuse\nAddition of a drug product manufacturing site and/or manufacturer involving production / Ajout d'un site de fabrication ou d'un fabricant pour le produit médicamenteux impliquant la production\nChange in the batch size for the drug product / Changement apporté à la taille des lots du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet / Comprimé, 75 mg\nN/A, Oral / Orale, Tablet / Comprimé, 150 mg\nN/A, Oral / Orale, Tablet / Comprimé, 300 mg"",
  ""canadian_reference_product"": ""AVAPRO, Sanofi-aventis Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e119041,293764,"August 8, 2025",SANDOZ IRBESARTAN,Irbesartan,"Addition of a manufacturing site and/or manufacturer involving production of the drug substance / Ajout d'un site de fabrication ou d'un fabricant impliquant la fabrication de la substance médicamenteuse
Addition of a drug product manufacturing site and/or manufacturer involving production / Ajout d'un site de fabrication ou d'un fabricant pour le produit médicamenteux impliquant la production
Change in the batch size for the drug product / Changement apporté à la taille des lots du produit médicamenteux",,"N/A, Oral / Orale, Tablet / Comprimé, 75 mg
N/A, Oral / Orale, Tablet / Comprimé, 150 mg
N/A, Oral / Orale, Tablet / Comprimé, 300 mg","AVAPRO, Sanofi-aventis Canada Inc., Canada",Sandoz Canada Inc.,110 rue de Lauzon,Boucherville,Québec,Canada,J4B 1E6,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000047584.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v284183"",
  ""submission_no"": ""284183"",
  ""manufacturer"": {
    ""name"": ""Parnell Technologies PTY Ltd"",
    ""street"": ""4/476 Gardners Road"",
    ""city"": ""Alexandria"",
    ""province"": ""New South Wales"",
    ""country"": ""Australia"",
    ""postal_code"": ""2015""
  },
  ""date"": ""August 20 2025"",
  ""product_name"": ""VACASAN"",
  ""medicinal_ingredients"": ""Tulathromycin / tulathromycine"",
  ""reason_for_submission"": ""This is to notify you that the above abbreviated new drug submission complies with the requirements of section C.08.002.1 and C.08.005.1 of the Food and Drug Regulations."",
  ""species"": ""Cattle (beef cattle, replacement heifers, calves), Swine, Sheep / Bovins (bovins de boucherie, génisses de remplacement, veaux), porcs, moutons"",
  ""drug_identification_number_route_form_strength"": ""02560348, Subcutaneous (cattle), Intramuscular (swine, sheep), Solution, 100 mg/mL / 02560348, sous-cutanée (bovins), intramusculaire (moutons, porcs), solution, 100 mg/mL"",
  ""canadian_reference_product"": ""DRAXXIN (DIN 02285452, Zoetis Canada Inc.)"",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires""
  }
}",TRUE,NA,v284183,284183,August 20 2025,VACASAN,Tulathromycin / tulathromycine,This is to notify you that the above abbreviated new drug submission complies with the requirements of section C.08.002.1 and C.08.005.1 of the Food and Drug Regulations.,"Cattle (beef cattle, replacement heifers, calves), Swine, Sheep / Bovins (bovins de boucherie, génisses de remplacement, veaux), porcs, moutons","02560348, Subcutaneous (cattle), Intramuscular (swine, sheep), Solution, 100 mg/mL / 02560348, sous-cutanée (bovins), intramusculaire (moutons, porcs), solution, 100 mg/mL","DRAXXIN (DIN 02285452, Zoetis Canada Inc.)",Parnell Technologies PTY Ltd,4/476 Gardners Road,Alexandria,New South Wales,Australia,2015,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,NA
https://pdf.hres.ca/noc_pm/0000047618.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e141946"",
  ""submission_no"": ""297312"",
  ""manufacturer"": {
    ""name"": ""Eisai Limited"",
    ""street"": ""6925 Century Ave, Suite 701"",
    ""city"": ""Mississauga"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5N 7K2""
  },
  ""date"": ""August 21, 2025"",
  ""product_name"": ""HALAVEN"",
  ""medicinal_ingredients"": ""Eribulin Mesylate / Mésylate d'Éribuline"",
  ""reason_for_submission"": ""Update to package labels / Mise à jour de l'étiquetage"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intravenous / Intraveineuse, Solution, 0.5 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e141946,297312,"August 21, 2025",HALAVEN,Eribulin Mesylate / Mésylate d'Éribuline,Update to package labels / Mise à jour de l'étiquetage,,"N/A, Intravenous / Intraveineuse, Solution, 0.5 mg/mL",,Eisai Limited,"6925 Century Ave, Suite 701",Mississauga,Ontario,Canada,L5N 7K2,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000047673.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""v167721"",
  ""submission_no"": ""292836"",
  ""manufacturer"": {
    ""name"": ""Zoetis Canada Inc."",
    ""street"": ""16740 Trans Canada Highway"",
    ""city"": ""Kirkland"",
    ""province"": ""QC"",
    ""country"": ""Canada"",
    ""postal_code"": ""H9H 4M7""
  },
  ""date"": ""August 28, 2025"",
  ""product_name"": ""SYNOVEX CHOICE"",
  ""medicinal_ingredients"": ""Trenbolone Acetate, Estradiol Benzoate"",
  ""reason_for_submission"": ""Additional indication"",
  ""species"": ""Cattle / Bovins"",
  ""drug_identification_number_route_form_strength"": ""N/A, Subcutaneous, Implant, Trenbolone Acetate 100 mg/implant, Estradiol Benzoate 14 mg/implant"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Marilena Bassi"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Veterinary Drugs Directorate / Direction des médicaments vétérinaires"",
    ""directorate"": """"
  }
}",TRUE,NA,v167721,292836,"August 28, 2025",SYNOVEX CHOICE,"Trenbolone Acetate, Estradiol Benzoate",Additional indication,Cattle / Bovins,"N/A, Subcutaneous, Implant, Trenbolone Acetate 100 mg/implant, Estradiol Benzoate 14 mg/implant",,Zoetis Canada Inc.,16740 Trans Canada Highway,Kirkland,QC,Canada,H9H 4M7,Marilena Bassi,Director General / Directrice générale,Veterinary Drugs Directorate / Direction des médicaments vétérinaires,
https://pdf.hres.ca/noc_pm/0000048112.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e183428"",
  ""submission_no"": ""295576"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""October 10, 2025"",
  ""product_name"": ""TEVA-DESVENLAFAXINE"",
  ""medicinal_ingredients"": ""Desvenlafaxine (supplied as Desvenlafaxine Succinate) / Desvenlafaxine (sous forme de succinate de desvenlafaxine)"",
  ""reason_for_submission"": ""Change in the drug product manufacturing process / Changement apporté au procédé de fabrication du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 50 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 100 mg"",
  ""canadian_reference_product"": ""PRISTIQ, Pfizer Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e183428,295576,"October 10, 2025",TEVA-DESVENLAFAXINE,Desvenlafaxine (supplied as Desvenlafaxine Succinate) / Desvenlafaxine (sous forme de succinate de desvenlafaxine),Change in the drug product manufacturing process / Changement apporté au procédé de fabrication du produit médicamenteux,,"N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 50 mg; N/A, Oral / Orale, Tablet (Extended-Release) / Comprimé (à libération prolongée), 100 mg","PRISTIQ, Pfizer Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,NA
https://pdf.hres.ca/noc_pm/0000048154.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""295842"",
  ""submission_no"": ""295842"",
  ""manufacturer"": {
    ""name"": ""Sanofi-aventis Canada Inc."",
    ""street"": ""1755 Steeles Avenue West"",
    ""city"": ""Toronto"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""M2R 3T4""
  },
  ""date"": ""October 11, 2025"",
  ""product_name"": ""SOLIQUA"",
  ""medicinal_ingredients"": ""Insulin Glargine / Insuline glargine, Lixisenatide / Lixisénatide"",
  ""reason_for_submission"": ""Changes to the manufacturing process / Changements au processus de fabrication"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 100 unit / mL + 33 mcg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,295842,295842,"October 11, 2025",SOLIQUA,"Insulin Glargine / Insuline glargine, Lixisenatide / Lixisénatide",Changes to the manufacturing process / Changements au processus de fabrication,,"N/A, SC, SOL, 100 unit / mL + 33 mcg / mL",,Sanofi-aventis Canada Inc.,1755 Steeles Avenue West,Toronto,ON,Canada,M2R 3T4,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000048211.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e134887"",
  ""submission_no"": ""298127"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""October 16, 2025"",
  ""product_name"": ""TEVA-BUDESONIDE"",
  ""medicinal_ingredients"": ""Budesonide"",
  ""reason_for_submission"": ""Update to package labels / Mise à jour de l'étiquetage"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Inhalation/Inhalation, Suspension/Suspension, 0.125 mg/ mL; N/A, Inhalation/Inhalation, Suspension/Suspension, 0.25 mg/ mL; N/A, Inhalation/Inhalation, Suspension/Suspension, 0.5 mg/ mL"",
  ""canadian_reference_product"": ""PULMICORT NEBUAMP, AstraZeneca Canada Inc., Canada"",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e134887,298127,"October 16, 2025",TEVA-BUDESONIDE,Budesonide,Update to package labels / Mise à jour de l'étiquetage,,"N/A, Inhalation/Inhalation, Suspension/Suspension, 0.125 mg/ mL; N/A, Inhalation/Inhalation, Suspension/Suspension, 0.25 mg/ mL; N/A, Inhalation/Inhalation, Suspension/Suspension, 0.5 mg/ mL","PULMICORT NEBUAMP, AstraZeneca Canada Inc., Canada",Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000048349.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""288758"",
  ""submission_no"": ""288758"",
  ""manufacturer"": {
    ""name"": ""Eli Lilly Canada Inc."",
    ""street"": ""Exchange Tower, 130 King Street West"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M5X 1B1""
  },
  ""date"": ""October 30, 2025"",
  ""product_name"": ""Omvoh"",
  ""medicinal_ingredients"": ""Mirikizumab"",
  ""reason_for_submission"": ""1. New formulation\n2. New presentations\n3. New indication: Omvoh is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment."",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 100 mg/mL (pre-filled syringe)\nN/A, SC, SOL, 100 mg/mL (pre-filled pen)\n02559226, SC, SOL, 200 mg/2 mL (pre-filled syringe)\n02559218, SC, SOL, 200 mg/2 mL (pre-filled pen)\n02559234, SC, KIT, 200 mg/2 mL & 100 mg/mL (pre-filled syringe)\n02559242, SC, KIT, 200 mg/2 mL & 100 mg/mL (pre-filled pen)\nN/A, IV, SOL, 20 mg/mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": """",
    ""title"": """",
    ""division"": """",
    ""directorate"": """"
  }
}",TRUE,NA,288758,288758,"October 30, 2025",Omvoh,Mirikizumab,"1. New formulation
2. New presentations
3. New indication: Omvoh is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment.",,"N/A, SC, SOL, 100 mg/mL (pre-filled syringe)
N/A, SC, SOL, 100 mg/mL (pre-filled pen)
02559226, SC, SOL, 200 mg/2 mL (pre-filled syringe)
02559218, SC, SOL, 200 mg/2 mL (pre-filled pen)
02559234, SC, KIT, 200 mg/2 mL & 100 mg/mL (pre-filled syringe)
02559242, SC, KIT, 200 mg/2 mL & 100 mg/mL (pre-filled pen)
N/A, IV, SOL, 20 mg/mL",,Eli Lilly Canada Inc.,"Exchange Tower, 130 King Street West",Toronto,Ontario,Canada,M5X 1B1,,,,
https://pdf.hres.ca/noc_pm/0000048613.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""295676"",
  ""submission_no"": ""295676"",
  ""manufacturer"": {
    ""name"": ""EMD Serono, a Division of EMD Inc., Canada"",
    ""street"": ""2695 North Sheridan Way, Suite 200"",
    ""city"": ""Mississauga"",
    ""province"": ""ON"",
    ""country"": ""Canada"",
    ""postal_code"": ""L5K 2N6""
  },
  ""date"": ""December 2, 2025"",
  ""product_name"": ""Pergoveris"",
  ""medicinal_ingredients"": ""Follitropin alfa and lutropin alfa / Follitropine alfa et lutropine alfa"",
  ""reason_for_submission"": ""Changes to the drug product manufacturing process / Changements au processus de fabrication du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, SC, SOL, 900 IU/1.44 mL (follitropin alfa); 450 IU/1.44 mL (lutropin alfa) / N/A, SC, SOL, 450 IU/0.72 mL (follitropin alfa); 225 IU/0.72 mL (lutropin alfa) / N/A, SC, SOL, 300 IU/0.48 mL (follitropin alfa); 150 IU/0.48 mL (lutropin alfa)"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Sophie Sommerer"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques"",
    ""directorate"": ""Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques""
  }
}",TRUE,NA,295676,295676,"December 2, 2025",Pergoveris,Follitropin alfa and lutropin alfa / Follitropine alfa et lutropine alfa,Changes to the drug product manufacturing process / Changements au processus de fabrication du produit médicamenteux,,"N/A, SC, SOL, 900 IU/1.44 mL (follitropin alfa); 450 IU/1.44 mL (lutropin alfa) / N/A, SC, SOL, 450 IU/0.72 mL (follitropin alfa); 225 IU/0.72 mL (lutropin alfa) / N/A, SC, SOL, 300 IU/0.48 mL (follitropin alfa); 150 IU/0.48 mL (lutropin alfa)",,"EMD Serono, a Division of EMD Inc., Canada","2695 North Sheridan Way, Suite 200",Mississauga,ON,Canada,L5K 2N6,Sophie Sommerer,Director General / Directrice générale,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques,Biologic and Radiopharmaceutical Drugs Directorate / Direction des médicaments biologiques et radiopharmaceutiques
https://pdf.hres.ca/noc_pm/0000048717.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e062902"",
  ""submission_no"": ""295630"",
  ""manufacturer"": {
    ""name"": ""Teva Canada Limited"",
    ""street"": ""30 Novopharm Court"",
    ""city"": ""Toronto"",
    ""province"": ""Ontario"",
    ""country"": ""Canada"",
    ""postal_code"": ""M1B 2K9""
  },
  ""date"": ""December 11, 2025"",
  ""product_name"": ""LEUCOVORIN CALCIUM INJECTION"",
  ""medicinal_ingredients"": ""Leucovorin calcium / Leucovorine calcique"",
  ""reason_for_submission"": ""Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux\nChange in the controls (in-process tests and/or criteria) applied during the drug product manufacturing process / Changement des controles (tests en cours et/ou critères d'acceptation) apporté au procédé de fabrication du produit médicamenteux"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, Intramuscular / Intramusculaire, Intravenous / Intraveineuse, 10 mg / mL"",
  ""canadian_reference_product"": """",
  ""authorizing_official"": {
    ""name"": ""Kelly Robinson"",
    ""title"": ""Director General / Directrice générale"",
    ""division"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques"",
    ""directorate"": """"
  }
}",TRUE,NA,e062902,295630,"December 11, 2025",LEUCOVORIN CALCIUM INJECTION,Leucovorin calcium / Leucovorine calcique,"Change in the specification for the drug product / Changement apporté aux spécifications du produit médicamenteux
Change in the controls (in-process tests and/or criteria) applied during the drug product manufacturing process / Changement des controles (tests en cours et/ou critères d'acceptation) apporté au procédé de fabrication du produit médicamenteux",,"N/A, Intramuscular / Intramusculaire, Intravenous / Intraveineuse, 10 mg / mL",,Teva Canada Limited,30 Novopharm Court,Toronto,Ontario,Canada,M1B 2K9,Kelly Robinson,Director General / Directrice générale,Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques,
https://pdf.hres.ca/noc_pm/0000048870.PDF,"{
  ""data_found"": true,
  ""dossier_id"": ""e260843"",
  ""submission_no"": ""301458"",
  ""manufacturer"": {
    ""name"": ""Laboratoire RIVA Inc."",
    ""street"": ""660 Boul. Industriel"",
    ""city"": ""Blainville"",
    ""province"": ""Quebec"",
    ""country"": ""Canada"",
    ""postal_code"": ""J7C 3V4""
  },
  ""date"": ""December 23, 2025"",
  ""product_name"": ""RIVA APIXABAN"",
  ""medicinal_ingredients"": ""Apixaban"",
  ""reason_for_submission"": ""Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant)"",
  ""species"": """",
  ""drug_identification_number_route_form_strength"": ""N/A, oral / orale, tablet / comprimé, 2.5 mg; N/A, oral / orale, tablet / comprimé, 5 mg"",
  ""canadian_reference_product"": ""ELIQUIS, Bristol-Myers Squibb Canada, Canada"",
  ""authorizing_official"": {
    ""name"": ""Laura Durno, MSc"",
    ""title"": ""A/Director / Directrice par intérim"",
    ""division"": ""Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales"",
    ""directorate"": ""Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques""
  }
}",TRUE,NA,e260843,301458,"December 23, 2025",RIVA APIXABAN,Apixaban,Administrative: Update to labelling (to match Licensor) / Administratif: Mise à jour de l'étiquetage (pour correspondre au concédant),,"N/A, oral / orale, tablet / comprimé, 2.5 mg; N/A, oral / orale, tablet / comprimé, 5 mg","ELIQUIS, Bristol-Myers Squibb Canada, Canada",Laboratoire RIVA Inc.,660 Boul. Industriel,Blainville,Quebec,Canada,J7C 3V4,"Laura Durno, MSc",A/Director / Directrice par intérim,"Bureau of Gastroenterology, Infection and Viral Diseases / Bureau de la gastroentérologie et des maladies infectieuses et virales",Pharmaceutical Drugs Directorate / Direction des médicaments pharmaceutiques
